WO2008109155A2 - Compositions and methods for treatment of cervical cancer - Google Patents
Compositions and methods for treatment of cervical cancer Download PDFInfo
- Publication number
- WO2008109155A2 WO2008109155A2 PCT/US2008/003067 US2008003067W WO2008109155A2 WO 2008109155 A2 WO2008109155 A2 WO 2008109155A2 US 2008003067 W US2008003067 W US 2008003067W WO 2008109155 A2 WO2008109155 A2 WO 2008109155A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- another embodiment
- present
- protein
- listeria strain
- antigen
- Prior art date
Links
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract description 56
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract description 55
- 201000010881 cervical cancer Diseases 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims description 143
- 238000000034 method Methods 0.000 title abstract description 228
- 238000011282 treatment Methods 0.000 title description 5
- 241000186781 Listeria Species 0.000 claims abstract description 237
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 221
- 239000000427 antigen Substances 0.000 claims abstract description 206
- 108091007433 antigens Proteins 0.000 claims abstract description 200
- 102000036639 antigens Human genes 0.000 claims abstract description 200
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 154
- 101150082952 ACTA1 gene Proteins 0.000 claims abstract description 110
- 101710164436 Listeriolysin O Proteins 0.000 claims abstract description 101
- 210000004898 n-terminal fragment Anatomy 0.000 claims abstract description 71
- 230000001939 inductive effect Effects 0.000 claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 155
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 102
- 229920001184 polypeptide Polymers 0.000 claims description 98
- 210000004027 cell Anatomy 0.000 claims description 74
- 230000028993 immune response Effects 0.000 claims description 39
- 239000013612 plasmid Substances 0.000 claims description 39
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 22
- 230000035899 viability Effects 0.000 claims description 20
- 238000010257 thawing Methods 0.000 claims description 17
- 230000005867 T cell response Effects 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 230000002503 metabolic effect Effects 0.000 claims description 11
- 241000186779 Listeria monocytogenes Species 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 102000040945 Transcription factor Human genes 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 50
- 208000024891 symptom Diseases 0.000 abstract description 37
- 201000010099 disease Diseases 0.000 abstract description 29
- 230000001404 mediated effect Effects 0.000 abstract description 25
- 208000035475 disorder Diseases 0.000 abstract description 21
- 230000004044 response Effects 0.000 abstract description 15
- 239000012634 fragment Substances 0.000 description 137
- 235000018102 proteins Nutrition 0.000 description 129
- 102000004169 proteins and genes Human genes 0.000 description 129
- 150000001413 amino acids Chemical class 0.000 description 77
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 65
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 64
- 239000002671 adjuvant Substances 0.000 description 64
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 61
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 60
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 60
- 229960005486 vaccine Drugs 0.000 description 59
- 238000003860 storage Methods 0.000 description 58
- 230000002906 microbiologic effect Effects 0.000 description 54
- 239000010941 cobalt Substances 0.000 description 45
- 229910017052 cobalt Inorganic materials 0.000 description 45
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 45
- 150000007523 nucleic acids Chemical group 0.000 description 43
- 229960003495 thiamine Drugs 0.000 description 43
- 230000012010 growth Effects 0.000 description 42
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 41
- 206010028980 Neoplasm Diseases 0.000 description 41
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 40
- 238000005138 cryopreservation Methods 0.000 description 40
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 40
- 235000019157 thiamine Nutrition 0.000 description 40
- 239000011721 thiamine Substances 0.000 description 40
- 238000004108 freeze drying Methods 0.000 description 39
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 37
- 150000001720 carbohydrates Chemical class 0.000 description 37
- 235000014633 carbohydrates Nutrition 0.000 description 37
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 34
- 229960000643 adenine Drugs 0.000 description 34
- 229930024421 Adenine Natural products 0.000 description 32
- 150000003839 salts Chemical class 0.000 description 32
- 229960002685 biotin Drugs 0.000 description 31
- 235000020958 biotin Nutrition 0.000 description 31
- 239000011616 biotin Substances 0.000 description 31
- 229960003966 nicotinamide Drugs 0.000 description 31
- 235000005152 nicotinamide Nutrition 0.000 description 31
- 239000011570 nicotinamide Substances 0.000 description 31
- 239000011575 calcium Substances 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 30
- 125000003729 nucleotide group Chemical group 0.000 description 30
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 29
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 29
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 29
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 29
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 29
- 229960005069 calcium Drugs 0.000 description 29
- 229910052791 calcium Inorganic materials 0.000 description 29
- 229910052802 copper Inorganic materials 0.000 description 29
- 239000010949 copper Substances 0.000 description 29
- 229910052750 molybdenum Inorganic materials 0.000 description 29
- 239000011733 molybdenum Substances 0.000 description 29
- 229940014662 pantothenate Drugs 0.000 description 29
- 235000019161 pantothenic acid Nutrition 0.000 description 29
- 239000011713 pantothenic acid Substances 0.000 description 29
- 229960003581 pyridoxal Drugs 0.000 description 29
- 235000008164 pyridoxal Nutrition 0.000 description 29
- 239000011674 pyridoxal Substances 0.000 description 29
- 239000011701 zinc Substances 0.000 description 29
- 229910052725 zinc Inorganic materials 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
- 208000009889 Herpes Simplex Diseases 0.000 description 26
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 26
- 102000039446 nucleic acids Human genes 0.000 description 26
- 108020004707 nucleic acids Proteins 0.000 description 26
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 24
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 24
- 241000607479 Yersinia pestis Species 0.000 description 24
- 229910052796 boron Inorganic materials 0.000 description 24
- 150000001768 cations Chemical class 0.000 description 24
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 24
- 239000011573 trace mineral Substances 0.000 description 24
- 235000013619 trace mineral Nutrition 0.000 description 24
- 229940088594 vitamin Drugs 0.000 description 24
- 229930003231 vitamin Natural products 0.000 description 24
- 235000013343 vitamin Nutrition 0.000 description 24
- 239000011782 vitamin Substances 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 23
- 239000004475 Arginine Substances 0.000 description 22
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 22
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 22
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 22
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 22
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 22
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 22
- 235000018417 cysteine Nutrition 0.000 description 22
- 230000002163 immunogen Effects 0.000 description 22
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 22
- 229960000310 isoleucine Drugs 0.000 description 22
- 239000004474 valine Substances 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 21
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 21
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 21
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 21
- 230000004927 fusion Effects 0.000 description 21
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 21
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 21
- 239000002028 Biomass Substances 0.000 description 20
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 20
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 20
- 108010029485 Protein Isoforms Proteins 0.000 description 20
- 102000001708 Protein Isoforms Human genes 0.000 description 20
- 102100040396 Transcobalamin-1 Human genes 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 19
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 19
- 230000003247 decreasing effect Effects 0.000 description 19
- 229910001447 ferric ion Inorganic materials 0.000 description 19
- 229910001448 ferrous ion Inorganic materials 0.000 description 19
- 235000019136 lipoic acid Nutrition 0.000 description 19
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 19
- 229960002663 thioctic acid Drugs 0.000 description 19
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 18
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 101150024289 hly gene Proteins 0.000 description 18
- 239000006174 pH buffer Substances 0.000 description 18
- 229960002477 riboflavin Drugs 0.000 description 18
- 235000019192 riboflavin Nutrition 0.000 description 18
- 239000002151 riboflavin Substances 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 238000002255 vaccination Methods 0.000 description 17
- 230000010076 replication Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 14
- -1 fatty acid monoglycerides Chemical class 0.000 description 14
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 13
- 230000002238 attenuated effect Effects 0.000 description 13
- 229910052742 iron Inorganic materials 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 12
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 11
- 241000700584 Simplexvirus Species 0.000 description 11
- 229960005091 chloramphenicol Drugs 0.000 description 11
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 210000004988 splenocyte Anatomy 0.000 description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 239000000654 additive Substances 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 10
- 238000007710 freezing Methods 0.000 description 10
- 230000008014 freezing Effects 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 229910052748 manganese Inorganic materials 0.000 description 10
- 239000011572 manganese Substances 0.000 description 10
- 238000011740 C57BL/6 mouse Methods 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 101150013359 E7 gene Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 101800000716 Tumor necrosis factor, membrane form Proteins 0.000 description 8
- 102400000700 Tumor necrosis factor, membrane form Human genes 0.000 description 8
- 230000005809 anti-tumor immunity Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960002413 ferric citrate Drugs 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical group [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 101150093386 prfA gene Proteins 0.000 description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229930182817 methionine Natural products 0.000 description 7
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 210000001685 thyroid gland Anatomy 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 6
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 101150023527 actA gene Proteins 0.000 description 6
- 159000000007 calcium salts Chemical class 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 150000001868 cobalt Chemical class 0.000 description 6
- 150000001879 copper Chemical class 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 6
- YHGPYBQVSJBGHH-UHFFFAOYSA-H iron(3+);trisulfate;pentahydrate Chemical group O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O YHGPYBQVSJBGHH-UHFFFAOYSA-H 0.000 description 6
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 6
- 150000002696 manganese Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 150000003751 zinc Chemical class 0.000 description 6
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 5
- 102100038358 Prostate-specific antigen Human genes 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 239000003125 aqueous solvent Substances 0.000 description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 5
- 229960002079 calcium pantothenate Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 210000003679 cervix uteri Anatomy 0.000 description 5
- 150000001860 citric acid derivatives Chemical class 0.000 description 5
- MPTQRFCYZCXJFQ-UHFFFAOYSA-L copper(II) chloride dihydrate Chemical group O.O.[Cl-].[Cl-].[Cu+2] MPTQRFCYZCXJFQ-UHFFFAOYSA-L 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 108010075210 streptolysin O Proteins 0.000 description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 5
- 206010008263 Cervical dysplasia Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 101000746457 Neisseria gonorrhoeae UPF0213 protein in glnA 3'region Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 150000001642 boronic acid derivatives Chemical class 0.000 description 4
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 4
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 4
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 4
- 229910001431 copper ion Inorganic materials 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical group 0.000 description 4
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- KVMMLFSIULLRDK-UHFFFAOYSA-L zinc dichloride heptahydrate Chemical compound O.O.O.O.O.O.O.[Cl-].[Cl-].[Zn+2] KVMMLFSIULLRDK-UHFFFAOYSA-L 0.000 description 4
- 108010053481 Antifreeze Proteins Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002528 anti-freeze Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 101150030499 lnt gene Proteins 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 3
- 101150027417 recU gene Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 208000020077 squamous cell intraepithelial neoplasia Diseases 0.000 description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical group [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 108010000916 Fimbriae Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- 102100034867 Kallikrein-7 Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 241000186806 Listeria grayi Species 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010015724 Prephenate Dehydratase Proteins 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003776 Vitamin B4 Natural products 0.000 description 2
- 229930003571 Vitamin B5 Natural products 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 108010051081 dopachrome isomerase Proteins 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000008979 vitamin B4 Nutrition 0.000 description 2
- 239000011579 vitamin B4 Substances 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical group OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- YBJHBAHKTGYVGT-OOZYFLPDSA-N 5-[(3as,4r,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-OOZYFLPDSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010041525 Alanine racemase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 201000007155 CD40 ligand deficiency Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000613 Cathepsin S Proteins 0.000 description 1
- 102100035654 Cathepsin S Human genes 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108050004635 D-amino acid aminotransferases Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012422 Derealisation Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101710140958 Formimidoyltetrahydrofolate cyclodeaminase Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 241000197200 Gallinago media Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000807938 Human papillomavirus 31 Protein E6 Proteins 0.000 description 1
- 101000767614 Human papillomavirus 31 Protein E7 Proteins 0.000 description 1
- 101000807948 Human papillomavirus 45 Protein E6 Proteins 0.000 description 1
- 101000622270 Human papillomavirus 45 Protein E7 Proteins 0.000 description 1
- 101000807958 Human papillomavirus 52 Protein E6 Proteins 0.000 description 1
- 101000622278 Human papillomavirus 52 Protein E7 Proteins 0.000 description 1
- 101000742671 Human papillomavirus 58 Protein E6 Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
- 101000767629 Human papillomavirus type 18 Protein E7 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101000743006 Lactococcus lactis subsp. cremoris UPF0177 protein in abiGi 5'region Proteins 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 241000186780 Listeria ivanovii Species 0.000 description 1
- 241000866438 Listeria monocytogenes 10403S Species 0.000 description 1
- 241000186807 Listeria seeligeri Species 0.000 description 1
- 241000186814 Listeria welshimeri Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical group OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010061308 Neonatal infection Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010038707 Respiratory papilloma Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 190014017285 Satraplatin Chemical compound 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 108010090851 Simplexvirus DNA polymerase Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007156 Spondylarthritis Diseases 0.000 description 1
- 241001219481 Spongospora subterranea Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical group N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940063013 borate ion Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 125000001547 cellobiose group Chemical group 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical group [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229950006799 crisantaspase Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 101150012893 dat gene Proteins 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- VXWSFRMTBJZULV-UHFFFAOYSA-H iron(3+) sulfate hydrate Chemical compound O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VXWSFRMTBJZULV-UHFFFAOYSA-H 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical group [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical group O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 101150053431 phaZ gene Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical group OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical group [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 208000016367 transient hypogammaglobulinemia of infancy Diseases 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1285—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention provides a recombinant Listeria strain, comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N- terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a
- PEST-like sequence-containing peptide for uses related to treating and protecting against cervical cancer.
- the present invention also provides use of the recombinant Listeria strain in methods for inducing an anti-E7 CTL response in a human subject and for treating HPV-mediated diseases, disorders, and symptoms.
- Cervical cancer begins in the lining of the cervix.
- Normal cervical cells gradually develop pre-cancerous changes that turn into cancer.
- Several terms are used to describe these pre- cancerous changes, including cervical intraepithelial neoplasia (CIN), squamous intraepithelial lesion (SIL), and neoplasia in situ, dysplasia.
- cervical cancers There are 2 major types of cervical cancers: squamous cell carcinoma and adenocarcinoma. Cervical cancers and cervical precancers are classified by microscopic appearance. About 80%-90% of cervical cancers are squamous cell carcinomas, which are composed of cells that resemble the flat, thin cells called squamous cells that cover the surface of the endocervix. Squamous cell carcinomas most often begin where the ectocervix joins the endocervix.
- cervical cancers are adenocarcinomas. Adenocarcinomas are becoming more common in women born in the last 20 to 30 years. Cervical adenocarcinoma develops from the mucus-producing gland cells of the endocervix. Less commonly, cervical cancers have features of both squamous cell carcinomas and adenocarcinomas. These are called “adenosquamous carcinomas" or “mixed carcinomas.”
- the present invention provides a recombinant Listeria strain, comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N- P-7771-PC3 terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide for uses related to treating and protecting against cervical cancer.
- HPV Human Papilloma Virus
- the present invention also provides use of the recombinant Listeria strain in methods for inducing an anti-E7 CTL response in a human subject and for treating HPV-mediated diseases, disorders, and symptoms.
- a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for treating a cervical cancer in a human subject, whereby said recombinant Listeria strain induces an immune response against said E7 antigen and wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 10 9 - 3.31 x 10 9 organisms.
- HPV Human Papilloma virus
- a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for protecting a human subject against a cervical cancer, whereby said recombinant Listeria strain induces an immune response against said E7 antigen, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 10 9 -
- a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and a PEST-like sequence-containing peptide for the preparation of a composition for inducing an immune response against a cervical cancer in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a
- a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, P-7771-PC3 for the preparation of a composition for inducing an anti-E7 cytotoxic T cell response in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 10 9 - 3.31 x 10 10 organisms.
- HPV Human Papilloma Virus
- Lm-E7 and Lm-LLO-E7 use different expression systems to express and secrete E7.
- Lm-E7 was generated by introducing a gene cassette into the orfZ domain of the L. monocytogenes genome (A) The hly promoter drives expression of the hly signal sequence and the first five amino acids (AA) of LLO followed by HPV- 16 E7.
- B Lm-LL0-E7 was generated by transforming the prfA- strain XFL-7 with the plasmid pGG-55.
- pGG-55 has the hly promoter driving expression of a nonhemolytic fusion of LLO-E7.
- pGG-55 also contains the prfA gene to select for retention of the plasmid by XFL-7 in vivo.
- FIG. 3 Tumor immunotherapeutic efficacy of LLO-E7 fusions. Tumor size in millimeters in mice is shown at 7, 14, 21, 28 and 56 days post tumor-inoculation. Naive mice: open-circles; Lm- LLO-E7: filled circles; Lm-E7: squares; Lm-Gag: open diamonds; and Lm-LLO-NP: filled triangles.
- FIG. 4 Splenocytes from Lm-LL0-E7-immunized mice proliferate when exposed to TC-I cells.
- C57BL/6 mice were immunized and boosted with Lm-LLO-E7, Lm-E7, or control rLm strains.
- Splenocytes were harvested 6 days after the boost and plated with irradiated TC-I cells at the ratios shown. The cells were pulsed with 3 H thymidine and harvested.
- Cpm is defined as (experimental cpm) - (no-TC-1 control).
- FIG. 5 [0015] Figure 5.
- Lane 1 Lm-LLO-E7;
- lane 2 Lm-ActA-E7.001 ;
- lane 3 Lm-ActA-E7-2.5.3;
- lane 4 Lm-ActA-E7-2.5.4.
- FIG. 1 A schematic representation of the plasmid inserts used to create 4 LM vaccines.
- Lm-LL0-E7 insert contains all of the Listeria genes used. It contains the hly promoter, the first P-7771-PC3
- hly gene which encodes the protein LLO
- HPV-16 E7 gene The first 1.3 kb of hly includes the signal sequence (ss) and the PEST region.
- Lm-PEST-E7 includes the hly promoter, the signal sequence, and PEST and E7 sequences but excludes the remainder of the truncated LLO gene.
- Lm- ⁇ PEST-E7 excludes the PEST region, but contains the hly promoter, the signal sequence, E7, and the remainder of the truncated LLO.
- Lm-E7epi has only the hly promoter, the signal sequence, and E7.
- Bottom panel Average tumor sizes at day 28 post-tumor challenge in 2 separate experiments.
- C Listeria constructs containing PEST regions induce a higher percentage of E7-specific lymphocytes in the spleen. Average and SE of data from 3 experiments are depicted.
- FIG. 7 (A) Induction of E7-specific IFN-gamma-secreting CD8 + T cells in the spleens and the numbers penetrating the tumors, in mice administered TC-I tumor cells and subsequently administered Lm-E7, Lm-LLO-E7, Lm-ActA-E7, or no vaccine (naive). (B) Induction and penetration of E7 specific CD8 + cells in the spleens and tumors of the mice described for (A).
- FIG. 8 Listeria constructs containing PEST regions induce a higher percentage of E7- specific lymphocytes within the tumor.
- FIG. 9 E6/E7 transgenic mice develop tumors in their thyroid, where the E7 gene is expressed. Mice were sacrificed at 3 months and had their thyroids removed, sectioned, and stained by hematoxylin and eosin.
- E7 message is expressed in the thyroid and medullary thymic epithelial cells of the E6/E7 transgenic mouse.
- A Tissue-specific expression of the E7 transgene is detected in the thyroid only but not the liver, spleen, or whole thymus.
- Lane 1 Liver; Lane 2: Spleen; Lane 3: Thyroid; Lane 4: Whole Thymus.
- B Medullary thymic epithelial cells (mTECs) express E7. RT-PCR results are as shown for equivalent amounts of cDNA loaded for 40 cycles. Lane 5: Cathepsin S; Lane 6: E7; Lane 7: Actin; Lane 8: Negative Control.
- mice A third group of wild type C57B1/6 control mice received E7 peptide plus adjuvant. The mice were vaccinated twice intraperitoneally (i.p.), 7 days apart and challenged with 5 x 10 4 TC -1 cells 7 P-7771-PC3 days later. Tumors were measured every 5 days until unimmunized mice needed to be sacrificed. Error bars: standard deviations from the mean value.
- Vaccines of the present invention induce regression of solid tumors in the E6/E7 transgenic mice in wild-type mice and transgenic mice immunized with LM-LLO-E7 (A), or LM- ActA-E7 (B), left naive, or treated with LM-NP (control).
- FIG. 13 (A) IV immunization of LM-LLO-E7 is effective at inducing the regression of established tumors at doses as low as 1 x 10 6 CFU per mouse. (B) Tumor loads for the 2 cohorts in the LM-LLO-E7 clinical trial.
- Figure 14 Effect of passaging on bacterial load (virulence) of recombinant Listeria vaccine vectors. Top panel. Lm-Gag. Bottom panel. Lm-LL0-E7. (B) Effect of passaging on bacterial load of recombinant Lm-E7 in the spleen. Average CFU of live bacteria per milliliter of spleen homogenate from four mice is depicted.
- FIG. 15 Induction of antigen-specific CD8 + T-cells for HIV-Gag and LLO after administration of passaged Lm-Gag versus unpassaged Lm-Gag.
- Mice were immunized with 10 (A, B, E, F) or 10 5 (C, D, G, H) CFU passaged Listeria vaccine vectors, and antigen-specific T-cells were analyzed.
- B, D, F, H unpassaged Listeria vaccine vectors.
- E-H immune response to an LLO peptide.
- I splenocytes from mice immunized with 10 5 CFU passaged Lm-Gag stimulated with a control peptide from HPV E7.
- Figure 16 (A) Plasmid isolation throughout LB stability study. (B) Plasmid isolation throughout TB stability study. (C) Quantitation of TB stability study.
- Figure 17 Numbers of viable bacteria chloramphenicol (CAP)-resistant and CAP-sensitive colony-forming units (CFU) from bacteria grown in LB. Dark bars: CAP + ; white bars: CAP " . The two dark bars and two white bars for each time point represent duplicate samples.
- CAP chloramphenicol
- CFU colony-forming units
- Figure 18 Numbers of viable bacteria CAP-resistant and CAP-sensitive CFU from bacteria grown in TB. Dark bars: CAP + ; white bars: CAP. The two dark bars and two white bars for each time point represent duplicate samples.
- Figure 20 Viability of LB RWCB following storage at -70 0 C.
- Figure 21 Viability of TB RWCB following storage at -70 0 C.
- Figure 22 Growth curve of 200 mL LB and TB cultures of Lm-LL0-E7.
- FIG. 23 Growth of Lm-LL0-E7 in 4 defined media with and without AA, vitamins and trace elements, at the 50 mL stage.
- AA + Vits + TE + denotes bulk medium, essential components, AA, vitamins and trace elements
- AA + Vits + TE - denotes bulk medium, essential components, AA, and vitamins
- AA + Vits - TE - denotes bulk medium, essential components, and AA
- AA - Vits - TE - denotes bulk medium and essential components.
- Figure 24 Growth of Lm-LLO-E7 in 4 defined media with and without amino acids, vitamins and trace elements, at the 200 mL stage. Groups are labeled as for Figure 23.
- Figure 25 Growth of Lm-LLO-E7 in 200 mL cultures of defined media with different concentrations of supplements, with and without inorganic nitrogen.
- Figure 26 Growth of Lm-LLO-E7 in 200 mL cultures of defined media supplemented with different concentrations of supplements, with and without glutamine and iron.
- FIG. 27 (A) Growth curves of Lm-LLO-E7 in 5 L fermenters in TB and defined media. B. Viability of Lm-LLO-E7 grown in 5 L fermenters in TB to different densities. C. Viability of Lm- LLO-E7 grown in 5 L fermenters in defined media to different densities.
- Figure 28 Percentage of viable cells remaining after storage at -20 0 C for 3 days.
- Figure 30 (A) Percentage of viable cells remaining following snap freezing in liquid nitrogen and storage at -70 0 C for 3 days. (B) Summary of viability studies for several conditions. C. Growth kinetics of cryopreserved samples after thawing.
- FIG. 31 Listeria vaccine vectors grown in defined media effectively protect mice against growth of established tumors.
- "BHI cultured”- vectors cultured in Brain-Heart Infusion media "Terrific Broth cultured” and “defined media cultured”- vectors cultured in indicated media.
- the present invention provides methods of treating, protecting against, and inducing an immune response against cervical cancer, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprising a listeriolysin O (LLO) P-7771-PC3 fragment and an E7 antigen.
- the present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.
- the present invention provides a method of treating, inhibiting, suppressing, or preventing a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an Human Papilloma Virus (HPV) E7 antigen, whereby the recombinant Listeria strain induces an immune response against the E7 antigen, thereby treating a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention.
- the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen.
- the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen.
- the N-terminal LLO protein fragment and HPV E7 antigen are, in another embodiment, fused directly to one another.
- the genes encoding the N-terminal LLO protein fragment and HPV E7 antigen are fused directly to one another.
- the N- terminal LLO protein fragment and HPV E7 antigen are attached via a linker peptide.
- the N-terminal LLO protein fragment and HPV E7 antigen are attached via a heterologous peptide.
- the N-terminal LLO protein fragment is N-terminal to the HPV E7 antigen.
- the N-terminal LLO protein fragment is the N-terminal- most portion of the fusion protein.
- the present invention provides a method for inducing an immune response against a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing an immune response against a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen.
- a method for inducing an anti-E7 cytotoxic T cell response in a human subject comprising the step of administering to said subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing an anti-E7 cytotoxic T cell response in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen.
- the N-terminal fragment of an LLO protein and HPV E7 antigen are, in another embodiment, fused directly to one another.
- the genes encoding the N-terminal fragment of an LLO protein and HPV E7 antigen are fused directly to one another.
- the N- terminal fragment of an LLO protein and HPV E7 antigen are attached via a linker peptide.
- the N-terminal fragment of an LLO protein and HPV E7 antigen are attached via a heterologous peptide.
- the N-terminal fragment of an LLO protein is N- terminal to the HPV E7 antigen.
- the N-terminal fragment of an LLO protein is the N-terminal-most portion of the fusion protein.
- Each possibility represents a separate embodiment of the present invention.
- recombinant Listeria strains expressing LLO-antigen fusions induce anti- tumor immunity (Example 1 ), elicit antigen-specific T cell proliferation (Example 2), generate antigen-specific, tumor-infiltrating T cells (Example 4), and abrogate central and peripheral tolerance to antigens such as E6 and E7 (Examples 5-9).
- vaccines of the present invention are efficacious at inducing immune responses against E7 and E6.
- the recombinant Listeria strains are safe and P-7771-PC3 improve disease indicators in human subjects (Example 10).
- the present invention provides a method of treating, inhibiting, suppressing, or preventing a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an ActA protein and an HPV E7 antigen, whereby the recombinant Listeria strain induces an immune response against the E7 antigen, thereby treating a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the present invention provides a method for inducing an immune response against a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an ActA protein and an HPV E7 antigen, thereby inducing an immune response against a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- a method for inducing an anti-E7 cytotoxic T cell response in a human subject comprising the step of administering to the subject a recombinant
- the recombinant Listeria strain comprising a recombinant polypeptide comprising an
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention.
- the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen.
- the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen.
- the N-terminal ActA protein fragment and HPV E7 antigen are, in another embodiment, fused P-7771-PC3 directly to one another.
- the genes encoding the N-terminal ActA protein fragment and HPV E7 antigen are fused directly to one another.
- the N- terminal ActA protein fragment and HPV E7 antigen are attached via a linker peptide.
- the N-terminal ActA protein fragment and HPV E7 antigen are attached via a heterologous peptide.
- the N-terminal ActA protein fragment is N-terminal to the HPV E7 antigen.
- the N-terminal ActA protein fragment is the N-terminal- most portion of the fusion protein.
- recombinant Listeria strains expressing ActA-antigen fusions induce anti- tumor immunity (Example 3), generate antigen-specific, tumor-infiltrating T cells (Example 4), and abrogate central and peripheral tolerance to antigens such as E6 and E7 (Examples 5-9). Further, recombinant Listeria strains of the present invention are safe and improve disease indicators in human subjects (Example 10).
- the present invention provides a method of treating, inhibiting, suppressing, or preventing a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising a PEST-like sequence-containing peptide and an HPV E7 antigen, whereby the recombinant Listeria strain induces an immune response against the E7 antigen, thereby treating a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention.
- the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen.
- the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen.
- the present invention provides a method for inducing an immune response against a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising a PEST-like sequence-containing peptide and an HPV E7 antigen, thereby inducing an immune response against a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the P-7771-PC3 recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- a method for inducing an anti-E7 cytotoxic T cell response in a human subject comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising a PEST-like sequence-containing peptide and an HPV E7 antigen, thereby inducing an anti-E7 cytotoxic T cell response in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen.
- the PEST sequence and HPV E7 antigen are, in another embodiment, fused directly to one another.
- the genes encoding the PEST sequence and HPV E7 antigen are fused directly to one another.
- the PEST sequence and HPV E7 antigen are attached via a linker peptide.
- the PEST sequence and HPV E7 antigen are attached via a heterologous peptide.
- the PEST sequence is N-terminal to the HPV E7 antigen.
- the PEST sequence is the N-terminal-most portion of the fusion protein.
- recombinant Listeria strains expressing PEST-like sequence-antigen fusions induce anti-tumor immunity (Example 3) and generate antigen-specific, tumor-infiltrating T cells (Example 4). Further, recombinant Listeria strains of the present invention are safe and improve disease indicators in human subjects (Example 10).
- a method for inducing an anti-E7 cytotoxic T cell response in a human subject comprising the step of administering to said subject a recombinant Listeria strain.
- said recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen.
- said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, P-7771-PC3 thereby inducing an anti-E7 cytotoxic T cell response in a human subject.
- the present invention provides a recombinant Listeria strain, comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N- terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide for uses related to treating and protecting against cervical cancer.
- HPV Human Papilloma Virus
- the present invention also provides use of the recombinant Listeria strain in methods for inducing an anti-E7 CTL response in a human subject and for treating HPV-mediated diseases, disorders, and symptoms.
- a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for treating a cervical cancer in a human subject, whereby said recombinant Listeria strain induces an immune response against said E7 antigen and wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 10 - 3.31 x 10 organisms.
- HPV Human Papilloma virus
- a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for protecting a human subject against a cervical cancer, whereby said recombinant Listeria strain induces an immune response against said E7 antigen, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 10 9 - 3.31 x 10 9 organisms.
- HPV Human Papilloma virus
- a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and a PEST-like sequence-containing peptide for the preparation of a composition for inducing an immune response against a cervical cancer in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 10 9 - 3.31 x 10 10 organisms.
- HPV Human Papilloma Virus
- a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for inducing an anti-E7 cytotoxic T cell response in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 10 9 - 3.31 x 10 10 organisms.
- HPV Human Papilloma Virus
- provided herein is a method of treating a cervical cancer in a human subject, comprising the step of administering to the subject an attenuated, auxotrophic Listeria strain.
- a method of protecting a human subject against a cervical cancer comprising the step of administering to the subject an attenuated, auxotrophic Listeria strain.
- a method for inducing an immune response against a cervical cancer in a human subject comprising the step of administering to the subject an attenuated, auxotrophic Listeria strain.
- a method of treating, inhibiting, preventing, or suppressing a cervical cancer in a human subject, or inducing an immune response against a cervical cancer in a human subject comprising the step of administering to the subject an attenuated, auxotrophic Listeria monocytogenes strain.
- the attenuated, auxotrophic Listeria strain comprises a mutation in dal gene.
- the attenuated, auxotrophic Listeria strain comprises a mutation in the dat gene.
- the attenuated auxotrophic Listeria strain comprises a mutation in the dal and the dat genes.
- the attenuated, auxotrophic Listeria comprises a mutation in prephenate dehydratase.
- the enzyme prephenate dehydratase is an enzyme acting late in the pathway of biosynthesis of phenylalanine.
- the recombinant Listeria requires exogenous phenylalanine for growth.
- the attenuated, auxotrophic Listeria strain requires exogenous alanine for growth.
- the attenuated, auxotrophic Listeria strain requires exogenous D-alanine for growth.
- the attenuated, auxotrophic Listeria strain requires exogenous threonine for growth.
- the recombinant Listeria strain expresses a recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the attenuated, auxotrophic Listeria strain Listeria strain comprises a recombinant polypeptide.
- the attenuated, auxotrophic Listeria strain comprises an antigen.
- the recombinant Listeria strain comprises a PEST-like sequence-containing peptide and an HPV E7 antigen.
- the recombinant Listeria strain induces an immune response against the E7 antigen.
- an induced immune response against the E7 antigen treats a P-7771-PC3 cervical cancer in a human subject.
- the present invention provides a method for vaccinating a human subject against an HPV, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N- terminal fragment of an LLO protein and an HPV E7 antigen, thereby vaccinating a human subject against an HPV.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the present invention provides a method for vaccinating a human subject against an HPV, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N- terminal fragment of an ActA protein and an HPV E7 antigen, thereby vaccinating a human subject against an HPV.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the present invention provides a method for vaccinating a human subject against an HPV, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising a PEST-like sequence-containing peptide and an HPV E7 antigen, thereby vaccinating a human subject against an HPV.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- recombinant Listeria strains expressing fusions of an antigen to LLO, ActA, or a PEST-like sequence-containing peptide induce anti-E6 and E7 immunity (Example 3), and abrogate central and peripheral tolerance to antigens such as E6 and E7 (Examples 5-9). Further, recombinant Listeria strains of the present invention are safe and improve disease indicators in human subjects (Example 10). Thus, Listeria strains of the present invention can be used to vaccinate a subject against an HPV, thereby preventing or inhibiting HPV-mediated carcinogenesis.
- the subject is at risk for developing an HPV-mediated carcinogenesis, which in one embodiment is cervical cancer.
- human papillomavirus DNA can be P-7771-PC3 detected in over 90% of cervical cances lesions.
- the subject is at risk for developing an HPV-mediated carcinogenesis, which in one embodiment, is a non-cervical anogenital tract cancer, which in one embodiment is an anal, vulvar, or vaginal tumour.
- the HPV-mediated carcinogenesis is penile intraepithelial neoplasia, which in one embodiment, is found in high prevalence in the sexual partners of women with cervical intraepithelial neoplasia.
- the HPV-mediated carcinogenesis is a cancer of the non-cervical anogenital epithelium.
- the subject is HPV-positive.
- the subject's sexual partner is HPV-positive.
- the subject exhibits cervical intraepithelial neoplasia.
- the subject exhibits a squamous intraepithelial lesion.
- the subject exhibits a dysplasia in the cervix.
- the HPV that is the target of methods of the present invention is, in another embodiment, an HPV 16.
- the HPV is an HPV-18.
- the HPV is selected from HPV-16 and HPV-18.
- the HPV is an HPV-31.
- the HPV is an HPV-35.
- the HPV is an HPV-39.
- the HPV is an HPV-45.
- the HPV is an HPV-51.
- the HPV is an HPV-52.
- the HPV is an HPV-58.
- the HPV is a high-risk HPV type.
- the HPV is a mucosal HPV type.
- Each possibility represents a separate embodiment of the present invention.
- the present invention provides a method for inducing a regression of a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing a regression of a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the present invention provides a method for reducing an incidence of relapse of a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby reducing an incidence of relapse of a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
- the present invention provides a method for suppressing a formation of a cervical tumor in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby suppressing a formation of a cervical tumor in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the present invention provides a method for inducing a remission of a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing a remission of a cervical cancer in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the present invention provides a method for impeding a growth of a cervical tumor in a human subject, comprising the step of administering to the subject a recombinant
- the recombinant Listeria strain comprising a recombinant polypeptide comprising an
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the present invention provides a method for reducing a size of a cervical tumor in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby reducing a size of a cervical tumor in a human subject.
- the recombinant Listeria strain expresses the recombinant polypeptide.
- the recombinant Listeria strain comprises a plasmid P-7771-PC3 that encodes the recombinant polypeptide.
- the cervical tumor targeted by methods of the present invention is, in another embodiment, a squamous cell carcinoma.
- methods of the present invention may be used to prevent, treat, inhibit or suppress a progressive squamous cell cancer of the cervix. In another embodiment, methods of the present invention may be used to prevent, treat, inhibit or suppress a recurrent squamous cell cancer of the cervix. In another embodiment, methods of the present invention may be used to prevent, treat, inhibit or suppress an advanced squamous cell cancer of the cervix. In another embodiment, methods of the present invention may be used to prevent, treat, inhibit or suppress any other form or type of cervical cancer known in the art.
- the cervical tumor is an adenocarcinoma. In another embodiment, the cervical tumor is an adenosquamous carcinoma. In another embodiment, the cervical tumor is a small cell carcinoma. In another embodiment, the cervical tumor is any other type of cervical tumor known in the art. Each possibility represents a separate embodiment of the present invention.
- an HPV E6 antigen is utilized instead of or in addition to an E7 antigen in a method of the present invention for treating, protecting against, or inducing an immune response against a cervical cancer.
- an ActA protein fragment is utilized instead of or in addition to an LLO fragment in a method of the present invention for treating, protecting against, or inducing an immune response against a cervical cancer.
- a PEST-like sequence-containing protein fragment is utilized instead of or in addition to an LLO fragment in a method of the present invention for treating, protecting against, or inducing an immune response against a cervical cancer.
- the present invention provides a method for inducing an anti-E7 cytotoxic T cell (CTL) response in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing an anti-E7 CTL response in a human subject.
- the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide.
- the method further comprises the step of boosting the subject with a recombinant Listeria strain of P-7771-PC3 the present invention.
- the method further comprises the step of boosting the subject with an immunogenic composition comprising an E7 antigen.
- the method further comprises the step of boosting the subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen.
- the CTL response is capable of therapeutic efficacy against an HPV-mediated disease, disorder, or symptom.
- the CTL response is capable of prophylactic efficacy against an HPV-mediated disease, disorder, or symptom.
- the present invention provides a method of treating or ameliorating an HPV-mediated disease, disorder, or symptom in a subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, whereby the recombinant Listeria strain induces an immune response against the E7 antigen, thereby treating or ameliorating an HPV-mediated disease, disorder, or symptom in a subject.
- the subject is a human subject.
- the subject is any other type of subject known in the art. Each possibility represents a separate embodiment of the present invention.
- the HPV causing the disease, disorder, or symptom is, in another embodiment, an HPV 16.
- the HPV is an HPV- 18.
- the HPV is an HPV-31.
- the HPV is an HPV-35.
- the HPV is an HPV-39.
- the HPV is an HPV-45.
- the HPV is an HPV-51.
- the HPV is an HPV-52.
- the HPV is an HPV-58.
- the HPV is a high-risk HPV type.
- the HPV is a mucosal HPV type.
- Each possibility represents a separate embodiment of the present invention.
- the HPV-mediated disease, disorder, or symptom is genital warts. In another embodiment, the HPV-mediated disease, disorder, or symptom is non-genital warts. In another embodiment, the HPV-mediated disease, disorder, or symptom is a respiratory papilloma. In another embodiment, the HPV-mediated disease, disorder, or symptom is any other HPV-mediated disease, disorder, or symptom known in the art. Each possibility represents a separate embodiment of the present invention.
- an HPV E6 antigen is utilized instead of or in addition to an E7 antigen in a method of the present invention for treating or ameliorating an HPV-mediated disease, disorder, or symptom.
- an ActA protein fragment is utilized instead of or in addition to an P-7771-PC3
- LLO fragment in a method of the present invention for treating or ameliorating an HPV-mediated disease, disorder, or symptom.
- a PEST-like sequence-containing protein fragment is utilized instead of or in addition to an LLO fragment in a method of the present invention for treating or ameliorating an HPV-mediated disease, disorder, or symptom.
- an HPV E6 antigen is utilized instead of or in addition to an E7 antigen in a method of the present invention for treating or ameliorating an HPV-mediated disease, disorder, or symptom.
- the antigen of methods and compositions of the present invention is, in another embodiment, an HPV E7 protein.
- the antigen is an HPV E6 protein.
- the antigen is any other HPV protein known in the art. Each possibility represents a separate embodiment of the present invention.
- E7 antigen refers, in another embodiment, to an E7 protein. In another embodiment, the term refers to an E7 fragment. In another embodiment, the term refers to an E7 peptide. In another embodiment, the term refers to any other type of E7 antigen known in the art. Each possibility represents a separate embodiment of the present invention.
- the E7 protein of methods and compositions of the present invention is, in another embodiment, an HPV 16 E7 protein.
- the E7 protein is an HPV- 18 E7 protein.
- the E7 protein is an HPV-31 E7 protein.
- the E7 protein is an HPV-35 E7 protein.
- the E7 protein is an HPV-39 E7 protein.
- the E7 protein is an HPV-45 E7 protein.
- the E7 protein is an HPV-51 E7 protein.
- the E7 protein is an HPV-52 E7 protein.
- the E7 protein is an HPV-58 E7 protein.
- the E7 protein is an E7 protein of a high-risk HPV type.
- the E7 protein is an E7 protein of a mucosal HPV type.
- Each possibility represents a separate embodiment of the present invention.
- E6 antigen refers, in another embodiment, to an E6 protein. In another embodiment, the term refers to an E6 fragment. In another embodiment, the term refers to an E6 peptide. In another embodiment, the term refers to any other type of E6 antigen known in the art. Each possibility represents a separate embodiment of the present invention.
- the E6 protein of methods and compositions of the present invention is, in another embodiment, an HPV 16 E6 protein.
- the E6 protein is an HPV- 18 E6 P-7771-PC3 protein.
- the E6 protein is an HPV-31 E6 protein.
- the E6 protein is an HPV-35 E6 protein.
- the E6 protein is an HPV-39 E6 protein.
- the E6 protein is an HPV-45 E6 protein.
- the E6 protein is an HPV-51 E6 protein.
- the E6 protein is an HPV-52 E6 protein.
- the E6 protein is an HPV-58 E6 protein.
- the E6 protein is an E6 protein of a high-risk HPV type.
- the E6 protein is an E6 protein of a mucosal HPV type.
- Each possibility represents a separate embodiment of the present invention.
- the present invention provides a method of vaccinating a human subject against an antigen of interest, the method comprising the step of administering intravenously to the human subject a recombinant Listeria strain comprising or expressing the antigen of interest, wherein the first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, thereby vaccinating a human subject against an antigen of interest.
- the present invention provides a method of vaccinating a human subject against an antigen of interest, the method comprising the step of administering intravenously to the human subject an immunogenic composition, comprising a fusion of a first peptide to the antigen of interest, wherein the first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, thereby vaccinating a human subject against an antigen of interest.
- the present invention provides a method of vaccinating a human subject against an antigen of interest, the method comprising the step of administering intravenously to the human subject a recombinant Listeria strain comprising a recombinant polypeptide, the recombinant polypeptide comprising a first peptide fused to the antigen of interest, wherein the first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N- terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, thereby vaccinating a human subject against an antigen of interest.
- compositions for use in the methods of the present invention are administered intravenously.
- the vaccine is administered orally, whereas in another embodiment, the vaccine is administered parenterally (e.g., subcutaneously, intramuscularly, and the like).
- compositions or vaccines are administered as a suppository, for example a rectal suppository or a urethral suppository.
- pharmaceutical compositions are administered by subcutaneous implantation of a pellet.
- the pellet provides for controlled release of an agent over a period of time.
- pharmaceutical compositions are administered in the form of a capsule.
- the route of administration may be parenteral.
- the route may be intra-ocular, conjunctival, topical, transdermal, intradermal, subcutaneous, intraperitoneal, intravenous, intra-arterial, vaginal, rectal, intratumoral, parcanceral, transmucosal, intramuscular, intravascular, intraventricular, intracranial, inhalation (aerosol), nasal aspiration (spray), intranasal (drops), sublingual, oral, aerosol or suppository or a combination thereof.
- solutions or suspensions of the compounds mixed and aerosolized or nebulized in the presence of the appropriate carrier suitable for intranasal administration or application by inhalation, solutions or suspensions of the compounds mixed and aerosolized or nebulized in the presence of the appropriate carrier suitable.
- Such an aerosol may comprise any agent described herein.
- the compositions as set forth herein may be in a form suitable for intracranial administration, which in one embodiment, is intrathecal and intracerebroventricular administration.
- the regimen of administration will be determined by skilled clinicians, based on factors such as exact nature of the condition being treated, the severity of the condition, the age and general physical condition of the patient, body weight, and response of the individual patient, etc.
- injectable, sterile solutions preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories and enemas.
- Ampoules are convenient unit dosages.
- Such a suppository may comprise any agent described herein.
- Sustained or directed release compositions can be formulated, e.g., liposomes or those wherein the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. Such compositions may be formulated for immediate or slow release. It is also possible to freeze-dry the new compounds and use the lyophilisates obtained, for example, for the preparation of products for injection.
- pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, emulsions or oils.
- non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.
- compositions of this invention are pharmaceutically acceptable.
- pharmaceutically acceptable refers to any formulation which is safe, and provides the appropriate delivery for the desired route of administration of an effective amount of at least one compound for use in the present invention. This term refers to the use of buffered formulations as well, wherein the pH is maintained at a particular desired value, ranging from pH 4.0 to pH 9.0, in accordance with the stability of the compounds and route of administration.
- compositions of or used in the methods of this invention may be administered alone or within a composition.
- compositions of this invention admixture with conventional excipients i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, enteral (e.g., oral) or topical application which do not deleteriously react with the active compounds may be used.
- suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatine, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, white paraffin, glycerol, alginates, hyaluronic acid, collagen, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc.
- the pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- they can also be combined where desired with other active
- compositions for use in the methods of the present invention may be administered with a carrier/diluent.
- Solid carriers/diluents include, but are not limited to, a gum, a starch (e.g., corn starch, pregeletanized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g., microcrystalline cellulose), an acrylate (e.g., polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
- compositions of the present invention may comprise the composition of this invention and one or more additional compounds effective in preventing or treating cervical cancer.
- the additional compound may comprise a compound useful in chemotherapy, which in one embodiment, is Cisplatin.
- Ifosfamide, Fluorouracilor5-FU, Irinotecan, Paclitaxel (Taxol), Docetaxel, Gemcitabine, Topotecan or a combination thereof may be administered with a composition of the present invention for use in the methods of the present invention.
- the present invention provides a method of inducing a CTL response in a human subject against an antigen of interest, the method comprising the step of administering to the human subject a recombinant Listeria strain comprising or expressing the antigen of interest, thereby inducing a CTL response in a human subject against an antigen of interest.
- the step of administering is intravenous administration.
- recombinant Listeria strains expressing LLO-antigen fusions induce antitumor immunity (Example 1), elicit antigen-specific T cell proliferation (Example 2), generate antigen-specific, tumor-infiltrating T cells (Example 4), and abrogate peripheral tolerance to antigens such as E6 and E7 (Examples 5-9).
- vaccines of the present invention are efficacious at inducing immune responses against E7 and E6.
- the recombinant Listeria strains are safe and improve disease indicators in human subjects (Example 10).
- the antigen of interest is HPV-E7. In another embodiment, the antigen is HPV-E6. In another embodiment, the antigen is Her-2. In another embodiment, the antigen is NY- ESO-I . In another embodiment, the antigen is telomerase. In another embodiment, the antigen is SCCE. In another embodiment, the antigen is HMW-MAA. In another embodiment, the antigen is WT-I . In another embodiment, the antigen is HIV-I Gag. In another embodiment, the antigen is Proteinase 3. In another embodiment, the antigen is Tyrosinase related protein 2. In another embodiment, the antigen is PSA (prostate-specific antigen).
- the antigen is selected from E7, E6, Her-2, NY-ESO-I , telomerase, SCCE, HMW-MAA, WT-I , HIV-I Gag, Proteinase 3, Tyrosinase related protein 2, Mucl, PSA (prostate-specific antigen), or a combination thereof.
- the antigen is a tumor-associated antigen, which in one embodiment, P-7771-PC3 is one of the following tumor antigens: a MAGE (Melanoma-Associated Antigen E) protein, e.g.
- CEA carcinoembryonic antigen
- the antigen for the compositions and methods of the present invention are melanoma-associated antigens, which in one embodiment are TRP-2, MAGE-I, MAGE-3, gp-100, tyrosinase, HSP-70, beta-HCG, or a combination thereof.
- the antigen is an infectious disease antigen.
- the antigen is derived from a fungal pathogen, bacteria, parasite, helminth, or viruses.
- the antigen is selected from tetanus toxoid, hemagglutinin molecules from influenza virus, diphtheria toxoid, HIV gpl20, HIV gag protein, IgA protease, insulin peptide B, Spongospora subterranea antigen, vibriose antigens, Salmonella antigens, pneumococcus antigens, respiratory syncytial virus antigens, Haemophilus influenza outer membrane proteins, Helicobacter pylori urease, Neisseria meningitidis pilins, N.
- gonorrhoeae pilins human papilloma virus antigens El and E2 from type HPV-16, -18, -31, -33, -35 or -45 human papilloma viruses, or a combination thereof.
- the antigen is associated with one of the following diseases; cholera, diphtheria, Haemophilus, hepatitis A, hepatitis B, influenza, measles, meningitis, mumps, pertussis, small pox, pneumococcal pneumonia, polio, rabies, rubella, tetanus, tuberculosis, typhoid, Varicella- zoster, whooping cough3 yellow fever, the immunogens and antigens from Addison's disease, allergies, anaphylaxis, Bruton's syndrome, cancer, including solid and blood borne tumors, eczema, Hashimoto's thyroiditis, polymyositis, dermatomyositis, type 1 diabetes mellitus, acquired immune deficiency syndrome, transplant rejection, such as kidney, heart, pancreas, lung, bone, and liver transplants, Graves' disease, polyen
- Each antigen represents a separate embodiment of the present invention.
- the immune response induced by methods and compositions of the present invention is, in another embodiment, a T cell response.
- the immune response comprises a T cell response.
- the response is a CD8 + T cell response.
- the response comprises a CD8 + T cell response.
- the N-terminal LLO protein fragment of methods and compositions of the present invention comprises, in another embodiment, SEQ ID NO: 1.
- the fragment comprises an LLO signal peptide.
- the fragment comprises SEQ ID NO: 25.
- the fragment consists approximately of SEQ ID NO: 25.
- the fragment consists essentially of SEQ ID NO: 25.
- the fragment corresponds to SEQ ID NO: 25.
- the fragment is homologous to SEQ ID NO: 25.
- the fragment is homologous to a fragment of SEQ ID NO: 25.
- the ⁇ LLO used in some of the Examples was 416 AA long (exclusive of the signal sequence), as 88 residues from the amino terminus which is inclusive of the activation domain containing cysteine 484 were truncated. It will be clear to those skilled in the art that any ⁇ LLO without the activation domain, and in particular without cysteine 484, are suitable for methods and compositions of the present invention.
- fusion of an E7 or E6 antigen to any ⁇ LLO including the PEST-like AA sequence, SEQ ID NO: 1, enhances cell mediated and anti-tumor immunity of the antigen. Each possibility represents a separate embodiment of the present invention.
- the LLO protein utilized to construct vaccines of the present invention has, in another embodiment, the sequence:
- NRETPGVPIAYTTNFLKDNELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVN YDPEGNEIVQHKNWSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEWWRTVIDDRN LPLVKNRNISIWGTTLYPKYSNKVDNPIE (GenBank Accession No. P13128; SEQ ID NO: 27; nucleic acid sequence is set forth in GenBank Accession No. Xl 5127).
- the first 25 AA of the proprotein corresponding to this sequence are the signal sequence and are cleaved from LLO when it is secreted by the bacterium.
- the full length active LLO protein is 504 residues long.
- the above LLO fragment is used as the source of the LLO fragment incorporated in a vaccine of the present invention. Each possibility represents a separate embodiment of the present invention.
- N-terminal fragment of an LLO protein utilized in compositions and methods of the present invention has the sequence:
- the LLO fragment corresponds to about AA 20-442 of an LLO protein utilized herein.
- the LLO fragment has the sequence:
- truncated LLO or " ⁇ LLO” refers to a fragment of LLO that comprises the PEST-like domain.
- the terms refer to an LLO fragment that P-7771-PC3 comprises a PEST sequence.
- the terms refer to an LLO fragment that does not contain the activation domain at the amino terminus and does not include cysteine 484. In another embodiment, the terms refer to an LLO fragment that is not hemolytic. In another embodiment, the LLO fragment is rendered non-hemolytic by deletion or mutation of the activation domain. In another embodiment, the LLO fragment is rendered non-hemolytic by deletion or mutation of cysteine 484. In another embodiment, the LLO fragment is rendered non-hemolytic by deletion or mutation at another location. Each possibility represents a separate embodiment of the present invention.
- the LLO fragment consists of about the first 441 AA of the LLO protein. In another embodiment, the LLO fragment consists of about the first 420 AA of LLO. In another embodiment, the LLO fragment is a non-hemolytic form of the LLO protein.
- the LLO fragment contains residues of a homologous LLO protein that correspond to one of the above AA ranges.
- the residue numbers need not, in another embodiment, correspond exactly with the residue numbers enumerated above; e.g. if the homologous LLO protein has an insertion or deletion, relative to an LLO protein utilized herein, then the residue numbers can be adjusted accordingly.
- the LLO fragment is any other LLO fragment known in the art. Each possibility represents a separate embodiment of the present invention.
- the present invention provides a method of treating, suppressing, inhibiting, or reducing an incidence of an HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention.
- the HSV infection is an HSV-I infection.
- the HSV infection is an HSV-2 infection.
- the HSV infection is a primary HSV infection.
- the HSV infection is a flare, recurrence, or HSV labialis following a primary HSV infection.
- the HSV infection is HSV encephalitis.
- the HSV infection is an HSV neonatal infection.
- the subject is HIV-infected.
- the present invention provides a method of inhibiting an HSV labialis following a primary HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention.
- the present invention provides a method of preventing a recurrence of an HSV infection, the method comprising the step of administering to said subject a vaccine of the P-7771-PC3 present invention.
- the present invention provides a method of diminishing the severity of a recurrence of an HSV infection, the method comprising the step of administering to said subject a vaccine of the present invention.
- the present invention provides a method of reducing the frequency of a recurrence of an HSV infection, the method comprising the step of administering to said subject a vaccine of the present invention.
- the present invention provides any of the described methods in an HIV-infected subject.
- HSV-2 refers, in another embodiment, to a Herpes Simplex Virus-2.
- the term refers to an HSV-2 333 strain.
- the term refers to a 2.12 strain.
- the term refers to an HG52 strain.
- the term refers to an MS strain.
- the term refers to a G strain.
- the term refers to an 186 strain.
- the term refers to any other HSV-2 strain known in the art.
- the present invention provides a method of vaccinating a subject against an HSV infection, the method comprising the step of administering to said subject a vaccine of the present invention.
- the present invention provides a method of suppressing an HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention.
- the present invention provides a method of impeding an HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention.
- the present invention provides a method of impeding a primary HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention.
- the present invention provides a method of impeding neuronal HSV spread in a subject, the method comprising the step of administering to said subject a vaccine of the present invention.
- the terms impeding an infection refer to decreasing the titer of infectious virus by 90%.
- the titer is decreased by 50%.
- the titer is decreased by 55%.
- the titer is decreased by 60%.
- the titer is decreased by 65%.
- the titer is decreased by
- the titer is decreased by 75%. In another embodiment, the titer is decreased by 80%. In another embodiment, the titer is decreased by 85%. In another embodiment, the titer is decreased by 92%. In another embodiment, the titer is decreased by 95%. In another embodiment, the titer is decreased by 96%. In another embodiment, the titer is decreased by 97%. In another embodiment, the titer is decreased by 98%. In another embodiment, the titer is decreased by P-7771-PC3
- the titer is decreased by over 99%.
- the terms refer to decreasing the extent of viral replication by 90%. In another embodiment, replication is reduced by 50%. In another embodiment, replication is reduced by
- replication is reduced by 60%. In another embodiment, replication is reduced by 65%. In another embodiment, replication is reduced by 70%. In another embodiment, replication is reduced by 75%. In another embodiment, replication is reduced by 80%. In another embodiment, replication is reduced by 85%. In another embodiment, replication is reduced by 92%. In another embodiment, replication is reduced by 95%. In another embodiment, replication is reduced by
- replication is reduced by 96%. In another embodiment, replication is reduced by 97%. In another embodiment, replication is reduced by 98%. In another embodiment, replication is reduced by 99%. In another embodiment, replication is reduced by over 99%.
- the present invention provides a method of treating, reducing the pathogenesis of, ameliorating the symptoms of, ameliorating the secondary symptoms of, reducing the incidence of, prolonging the latency to a relapse of a Herpes Simplex Virus (HSV) infection in a subject, comprising the step of administering to the subject a vaccine of the present invention.
- HSV infection that is treated or ameliorated by methods and compositions of the present invention is, in another embodiment, a genital HSV infection.
- the methods of the present invention may be used to treat, inhibit, suppress, etc an HSV infection or primary or secondary symptoms related to such an infection following exposure of the subject to HSV.
- the subject has been infected with HSV before vaccination.
- the subject is at risk for HSV infection.
- vaccination by a method of the present invention is efficacious in treating, inhibiting, suppressing, etc an HSV infection or primary or secondary symptoms related to such an infection.
- symptoms are primary, while in another embodiment, symptoms are secondary.
- primary refers to a symptom that is a direct result of the subject viral infection
- secondary refers to a symptom that is derived from or consequent to a primary cause.
- compositions and strains for use in the present invention treat primary or secondary symptoms or secondary complications related to HSV infection.
- the recombinant Listeria strain is administered to the human subject at a dose of 1 x 10 9 - 3.31 x 10 10 CFU.
- the dose is 5-500 x 10 8 CFU.
- the dose is 7-500 x 10 8 CFU.
- the dose is 10-500 x 10 8 CFU.
- the dose is 20-500 x 10 8 CFU.
- the dose is 30-500 x 10 8 CFU.
- the dose is 50-500 x 10 8 CFU.
- the dose is 70- 500 x 10 8 CFU.
- the dose is 100-500 x 10 8 CFU.
- the dose is 150-500 x 10 8 CFU. In another embodiment, the dose is 5-300 x 10 8 CFU. In another embodiment, the dose is 5-200 x 10 8 CFU. In another embodiment, the dose is 5-150 x 10 8 CFU. In another embodiment, the dose is 5-100 x 10 8 CFU. In another embodiment, the dose is 5-70 x 10 8 CFU. In another embodiment, the dose is 5-50 x 10 8 CFU. In another embodiment, the dose is 5-30 x 10 8 CFU. In another embodiment, the dose is 5-20 x 10 8 CFU. In another embodiment, the dose is 1- 30 x 10 9 CFU. In another embodiment, the dose is 1-20 x 10 9 CFU.
- the dose is 2-30 x 10 9 CFU. In another embodiment, the dose is 1-10 x 10 9 CFU. In another embodiment, the dose is 2-10 x 10 9 CFU. In another embodiment, the dose is 3-10 x 10 9 CFU. In another embodiment, the dose is 2-7 x 10 9 CFU. In another embodiment, the dose is 2-5 x 10 9 CFU. In another embodiment, the dose is 3-5 x 10 9 CFU.
- the dose is 1 x 10 9 -3.31 x 10 9 organisms, which is an unexpectedly low dose of recombinant Listeria in view of pre-clinical data.
- the dose is 1.5 x 10 9 organisms. In another embodiment, the dose is 2 x 10 9 organisms. In another embodiment, the dose is 3 x 10 9 organisms. In another embodiment, the dose is 4 x 10 9 organisms. In another embodiment, the dose is 5 x 10 9 organisms. In another embodiment, the dose is 6 x 10 9 organisms. In another embodiment, the dose is 7 x 10 9 organisms. In another embodiment, the dose is 8 x 10 9 organisms. In another embodiment, the dose is 10 x 10 9 organisms. In another embodiment, the dose is 1.5 x 10 10 organisms. In another embodiment, the dose is 2 x l ⁇ '° organisms. In another embodiment, the dose is 2.5 x 10 10 organisms. In another embodiment, the dose is 3 x 10 10 organisms. In another embodiment, the dose is 3.3 x l ⁇ '° organisms.
- the dose is 4 x l ⁇ '° organisms. In another embodiment, the dose is 5 x 10 10 P-7771-PC3 organisms.
- the recombinant polypeptide of methods of the present invention is expressed by the recombinant Listeria strain.
- the expression is mediated by a nucleotide molecule carried by the recombinant Listeria strain.
- the recombinant Listeria strain expresses the recombinant polypeptide by means of a plasmid that encodes the recombinant polypeptide.
- the plasmid comprises a gene encoding a bacterial transcription factor.
- the plasmid encodes a Listeria transcription factor.
- the transcription factor is prfA.
- the transcription factor is any other transcription factor known in the art. Each possibility represents a separate embodiment of the present invention.
- the plasmid comprises a gene encoding a metabolic enzyme.
- the metabolic enzyme is a bacterial metabolic enzyme.
- the metabolic enzyme is a Listerial metabolic enzyme.
- the metabolic enzyme is an amino acid metabolism enzyme.
- the amino acid metabolism gene is involved in a cell wall synthesis pathway.
- the metabolic enzyme is the product of a D-amino acid aminotransferase gene (dat).
- the metabolic enzyme is the product of an alanine racemase gene (dal).
- the metabolic enzyme is any other metabolic enzyme known in the art. Each possibility represents a separate embodiment of the present invention.
- a method of present invention further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention.
- the recombinant Listeria strain used in the booster inoculation is the same as the strain used in the initial "priming" inoculation.
- the booster strain is different from the priming strain.
- the same doses are used in the priming and boosting inoculations.
- a larger dose is used in the booster.
- a smaller dose is used in the booster.
- a method of present invention further comprises the step of inoculating the human subject with an immunogenic composition comprising the E7 antigen.
- the immunogenic composition comprises a recombinant E7 protein or fragment P-7771-PC3 thereof.
- the immunogenic composition comprises a nucleotide molecule expressing a recombinant E7 protein or fragment thereof.
- the non-Listerial inoculation is administered after the Listerial inoculation.
- the non-Listerial inoculation is administered before the Listerial inoculation.
- Boosting refers, in another embodiment, to administration of an additional vaccine dose to a subject.
- 2 boosts or a total of 3 inoculations
- 3 boosts are administered.
- 4 boosts are administered.
- 5 boosts are administered.
- 6 boosts are administered.
- more than 6 boosts are administered.
- a vaccine boost is provided 21 days after the initial vaccination. In another embodiment, a boost is provided 7 days after the initial vaccination. In another embodiment, a boost is provided 14 days after the initial vaccination. In another embodiment, a boost is provided 28 days after the initial vaccination. In another embodiment, a boost is provided 10 days after the initial vaccination. In another embodiment, a boost is provided 25 days after the initial vaccination. In another embodiment, a boost is provided 1 month after the initial vaccination. In another embodiment, a boost is provided 6 weeks after the initial vaccination. In another embodiment, a boost is provided 2 months after the initial vaccination. In another embodiment, a boost is provided 3 months after the initial vaccination. In another embodiment, a boost is provided 4 months after the initial vaccination. In another embodiment, a boost is provided 5 months after the initial vaccination. In another embodiment, a boost is provided 6 months after the initial vaccination. In one embodiment, a boost is provided in any combination of the time periods described hereinabove.
- the recombinant Listeria strain of methods and compositions of the present invention is, in another embodiment, a recombinant Listeria monocytogenes strain. In another embodiment, the
- Listeria strain is a recombinant Listeria seeligeri strain. In another embodiment, the Listeria strain is a recombinant Listeria grayi strain. In another embodiment, the Listeria strain is a recombinant Listeria ivanovii strain. In another embodiment, the Listeria strain is a recombinant Listeria murrayi strain. In another embodiment, the Listeria strain is a recombinant Listeria welshimeri strain. In another embodiment, the Listeria strain is a recombinant strain of any other Listeria species known in the art.
- a recombinant Listeria strain of the present invention has been P-7771-PC3 passaged through an animal host.
- said passaging occurs prior to the step of administering the recombinant Listeria strain.
- the passaging maximizes efficacy of the strain as a vaccine vector.
- the passaging stabilizes the immunogenicity of the Listeria strain.
- the passaging stabilizes the virulence of the Listeria strain.
- the passaging increases the immunogenicity of the Listeria strain.
- the passaging increases the virulence of the Listeria strain.
- the passaging removes unstable sub-strains of the Listeria strain.
- the passaging reduces the prevalence of unstable sub-strains of the Listeria strain.
- the Listeria strain contains a genomic insertion of the gene encoding the antigen- containing recombinant peptide.
- the Listeria strain carries a plasmid comprising the gene encoding the antigen-containing recombinant peptide.
- the passaging is performed as described herein (e.g. in Example 12) or as described in WO 04/062597, which is incorporated herein by reference.
- the passaging is performed by any other method known in the art. Each possibility represents a separate embodiment of the present invention.
- the recombinant Listeria strain utilized in methods of the present invention has been stored in a frozen cell bank.
- the recombinant Listeria strain has been stored in a lyophilized cell bank.
- the cell bank is as described in WO 2007/061848, which is incorporated herein by reference.
- methods for cryopreservation and lyophilization of a Listeria strain are as described in WO 2007/061848, which is incorporated herein by reference in its entrirety.
- the cell bank of methods and compositions of the present invention is a master cell bank.
- the cell bank is a working cell bank.
- the cell bank is Good Manufacturing Practice (GMP) cell bank.
- the cell bank is intended for production of clinical-grade material.
- the cell bank conforms to regulatory practices for human use.
- the cell bank is any other type of cell bank known in the art. Each possibility represents a separate embodiment of the present invention.
- Good Manufacturing Practices are defined, in another embodiment, by (21 CFR 210-21 1 ) of P-7771-PC3 the United States Code of Federal Regulations. In another embodiment, "Good Manufacturing Practices” are defined by other standards for production of clinical-grade material or for human consumption; e.g. standards of a country other than the United States. Each possibility represents a separate embodiment of the present invention.
- a recombinant Listeria strain utilized in methods of the present invention is from a batch of vaccine doses.
- a recombinant Listeria strain utilized in methods of the present invention is from a frozen stock produced by a method disclosed herein.
- a recombinant Listeria strain utilized in methods of the present invention is from a lyophilized stock produced by a method disclosed herein.
- a cell bank, frozen stock, or batch of vaccine doses of the present invention exhibits viability upon thawing of greater than 90%.
- the thawing follows storage for cryopreservation or frozen storage for 24 hours.
- the storage is for 2 days.
- the storage is for 3 days.
- the storage is for 4 days.
- the storage is for 1 week.
- the storage is for 2 weeks.
- the storage is for 3 weeks.
- the storage is for 1 month.
- the storage is for 2 months.
- the storage is for 3 months.
- the storage is for 5 months.
- the storage is for 6 months.
- the storage is for 9 months.
- the storage is for 1 year.
- Each possibility represents a separate embodiment of the present invention.
- a cell bank, frozen stock, or batch of vaccine doses of the present invention is cryopreserved by a method that comprises growing a culture of the Listeria strain in a nutrient media, freezing the culture in a solution comprising glycerol, and storing the Listeria strain at below -20 degrees Celsius.
- the temperature is about -70 degrees Celsius. In another embodiment, the temperature is about " 70 - " 80 degrees Celsius.
- a cell bank, frozen stock, or batch of vaccine doses of the present invention is cryopreserved by a method that comprises growing a culture of the Listeria strain in a defined media of the present invention (as described below), freezing the culture in a solution comprising glycerol, and storing the Listeria strain at below -20 degrees Celsius.
- the temperature is about -70 degrees Celsius.
- the temperature is P-7771-PC3 about " 70 - " 80 degrees Celsius.
- any defined microbiological media of the present invention may be used in this method. Each defined microbiological media represents a separate embodiment of the present invention.
- the culture e.g. the culture of a Listeria vaccine strain that is used to produce a batch of Listeria vaccine doses
- the culture is inoculated from a cell bank.
- the culture is inoculated from a frozen stock.
- the culture is inoculated from a starter culture.
- the culture is inoculated from a colony.
- the culture is inoculated at mid-log growth phase.
- the culture is inoculated at approximately mid-log growth phase.
- the culture is inoculated at another growth phase.
- the solution used for freezing contains glycerol in an amount of 2-20%. In another embodiment, the amount is 2%. In another embodiment, the amount is 20%. In another embodiment, the amount is 1%. In another embodiment, the amount is 1.5%. In another embodiment, the amount is 3%. In another embodiment, the amount is 4%. In another embodiment, the amount is 5%. In another embodiment, the amount is 2%. In another embodiment, the amount is 2%. In another embodiment, the amount is 7%. In another embodiment, the amount is 9%. In another embodiment, the amount is 10%. In another embodiment, the amount is 12%. In another embodiment, the amount is 14%. In another embodiment, the amount is 16%.
- the amount is 18%. In another embodiment, the amount is 222%. In another embodiment, the amount is 25%. In another embodiment, the amount is 30%. In another embodiment, the amount is 35%. In another embodiment, the amount is 40%.
- the solution used for freezing contains another colligative additive or additive with anti-freeze properties, in place of glycerol.
- the solution used for freezing contains another colligative additive or additive with anti-freeze properties, in addition to glycerol.
- the additive is mannitol. In another embodiment, the additive is
- the additive is sucrose.
- the additive is any other colligative additive or additive with anti-freeze properties that is known in the art. Each possibility represents a separate embodiment of the present invention.
- the nutrient media utilized for growing a culture of a Listeria strain is LB.
- the nutrient media is TB.
- the nutrient media is a P-7771-PC3 defined media.
- the nutrient media is a defined media of the present invention.
- the nutrient media is any other type of nutrient media known in the art. Each possibility represents a separate embodiment of the present invention.
- the step of growing is performed with a shake flask.
- the flask is a baffled shake flask.
- the growing is performed with a batch fermenter.
- the growing is performed with a stirred tank or flask.
- the growing is performed with an airflit fermenter.
- the growing is performed with a fed batch.
- the growing is performed with a continuous cell reactor.
- the growing is performed with an immobilized cell reactor.
- the growing is performed with any other means of growing bacteria that is known in the art. Each possibility represents a separate embodiment of the present invention.
- a constant pH is maintained during growth of the culture (e.g. in a batch fermenter).
- the pH is maintained at about 7.0.
- the pH is about 6.
- the pH is about 6.5.
- the pH is about 7.5.
- the pH is about 8.
- the pH is 6.5-7.5.
- the pH is 6-8.
- the pH is 6-7.
- the pH is 7- 8.
- a constant temperature is maintained during growth of the culture.
- the temperature is maintained at about 37 0 C.
- the temperature is 37 0 C.
- the temperature is 25 0 C.
- the temperature is 27 °C.
- the temperature is 28 0 C.
- the temperature is 30 0 C.
- the temperature is 32 0 C.
- the temperature is 34 °C.
- the temperature is 35 °C.
- the temperature is 36 0 C.
- the temperature is 38 0 C.
- the temperature is 39 0 C.
- a constant dissolved oxygen concentration is maintained during growth of the culture.
- the dissolved oxygen concentration is maintained at 20% of saturation.
- the concentration is 15% of saturation.
- the concentration is 16% of saturation.
- the concentration is 18% of saturation.
- the concentration is 22% of saturation.
- the concentration is 25% of saturation.
- the concentration is 30% of saturation.
- the concentration is 35% of saturation.
- the concentration is 40% of saturation.
- the concentration is 45% of saturation.
- the concentration is 50% of saturation.
- the concentration is 55% of saturation.
- the concentration is 60% of saturation.
- the concentration is 65% of saturation. In another embodiment, the concentration is 70% of saturation. In another embodiment, the concentration is 75% of saturation. In another embodiment, the concentration is 80% of saturation. In another embodiment, the concentration is 85% of saturation. In another embodiment, the concentration is 90% of saturation. In another embodiment, the concentration is 95% of saturation. In another embodiment, the concentration is 100% of saturation. In another embodiment, the concentration is near 100% of saturation.
- the culture is grown in media having a maximum volume of 2 liters (L) per vessel.
- the media has a maximum volume of 200 ml per vessel.
- the media has a maximum volume of 300 ml per vessel.
- the media has a maximum volume of 500 ml per vessel.
- the media has a maximum volume of 750 ml per vessel.
- the media has a maximum volume of 1 L per vessel.
- the media has a maximum volume of 1.5 L per vessel.
- the media has a maximum volume of 2.5 L per vessel.
- the media has a maximum volume of 3 L per vessel.
- the media has a minimum volume of 2 L per vessel. In another embodiment, the media has a minimum volume of 500 ml per vessel. In another embodiment, the media has a minimum volume of 750 ml per vessel. In another embodiment, the media has a minimum volume of 1 L per vessel. In another embodiment, the media has a minimum volume of 1.5 L per vessel. In another embodiment, the media has a minimum volume of 2.5 L per vessel. In another embodiment, the media has a minimum volume of 3 L per vessel. In another embodiment, the media has a minimum volume of 4 L per vessel. In another embodiment, the media has a minimum volume of 5 L per vessel. In another embodiment, the media has a minimum volume of 6 L per vessel. In another embodiment, the media has a minimum volume of 8 L per vessel. In another embodiment, the media has a minimum volume of 10 L per vessel.
- Each volume represents a separate embodiment of the present invention.
- the step of P-7771-PC3 freezing or lyophilization is performed when the culture has an OD 600 of 0.7 units.
- the culture has an OD 600 of 0.8 units.
- the OD 600 is about 0.7 units.
- the OD 600 is about 0.8 units.
- the OD 600 is 0.6 units.
- the OD 600 is 0.65 units.
- the OD 6O0 is 0.75 units.
- the OD 600 is 0.85 units.
- the OD 60O is 0.9 units.
- the OD 60O is 1 unit.
- the OD 60O is 0.6-0.9 units.
- the OD 600 is 0.65-0.9 units. In another embodiment, the OD 600 is 0.7-0.9 units. In another embodiment, the OD 600 is 0.75-0.9 units. In another embodiment, the OD 600 is 0.8-0.9 units. In another embodiment, the OD 600 is 0.75-1 units. In another embodiment, the OD 600 is 0.9-1 units. In another embodiment, the OD 600 is greater than 1 unit.
- the OD 60O is significantly greater than 1 unit (e.g. when the culture is produced in a batch fermenter).
- the OD 600 is 7.5-8.5 units.
- the OD 600 is 1.2 units.
- the OD 600 is 1.5 units.
- the OD 600 is 2 units.
- the OD 600 is 2.5 units.
- the OD 600 is 3 units.
- the OD 600 is 3.5 units.
- the OD 600 is 4 units.
- the OD 600 is 4.5 units.
- the OD 600 is 5 units.
- the OD 600 is 5.5 units.
- the OD 600 is 6 units.
- the OD 600 is 6.5 units. In another embodiment, the OD 600 is 7 units. In another embodiment, the OD 600 is 7.5 units. In another embodiment, the OD 600 is 8 units. In another embodiment, the OD 600 is 8.5 units. In another embodiment, the OD 600 is 9 units. In another embodiment, the OD 600 is 9.5 units. In another embodiment, the OD 600 is 10 units. In another embodiment, the OD 600 is more than 10 units.
- the OD 600 is 1 -2 units. In another embodiment, the OD 600 is 1.5-2.5 units. In another embodiment, the OD 600 is 2-3 units. In another embodiment, the OD 600 is 2.5-3.5 units. In another embodiment, the OD 600 is 3-4 units. In another embodiment, the OD 600 is 3.5-4.5 units. In another embodiment, the OD 60O is 4-5 units. In another embodiment, the OD 600 is 4.5-5.5 units. In another embodiment, the OD 600 is 5-6 units. In another embodiment, the OD 600 is 5.5-6.5 units. In another embodiment, the OD 600 is 1 -3 units. In another embodiment, the OD 600 is 1.5-3.5 units. In another embodiment, the OD 600 is 2-4 units.
- the OD 600 is 2.5-4.5 units. In another embodiment, the OD 600 is 3-5 units. In another embodiment, the OD 600 is 4-6 units. In another embodiment, the OD 600 is 5-7 units. In another embodiment, the OD 6O0 is 2-5 units. In another embodiment, the OD 6 oo is 3-6 units. In another embodiment, the OD 600 is 4-7 units. In another embodiment, the OD 60O is 5-8 units. In another embodiment, the OD 600 is 1.2-7.5 units. In another embodiment, the OD 6O o >s 1.5-7.5 units. In another embodiment, the OD 600 is 2-7.5 units. In another P-7771-PC3 embodiment, the OD 600 is 2.5-7.5 units. In another embodiment, the OD 600 is 3-7.5 units.
- the OD 600 is 3.5-7.5 units. In another embodiment, the OD 600 is 4-7.5 units. In another embodiment, the OD 600 is 4.5-7.5 units. In another embodiment, the OD 600 is 5-7.5 units. In another embodiment, the OD 600 is 5.5-7.5 units. In another embodiment, the OD 600 is 6-7.5 units. In another embodiment, the OD 600 is 6.5-7.5 units. In another embodiment, the OD 600 is 7-7.5 units. In another embodiment, the OD 600 is more than 10 units. In another embodiment, the OD 600 is 1.2-8.5 units. In another embodiment, the OD 6O0 is 1.5-8.5 units. In another embodiment, the OD 600 is 2-8.5 units. In another embodiment, the OD 600 is 2.5-8.5 units.
- the OD 600 is 3-8.5 units. In another embodiment, the OD 600 is 3.5-8.5 units. In another embodiment, the OD 600 is 4-8.5 units. In another embodiment, the OD 60O is 4.5-8.5 units. In another embodiment, the OD 600 is 5-8.5 units. In another embodiment, the OD 6 oo is 5.5-8.5 units. In another embodiment, the OD 600 is 6-8.5 units. In another embodiment, the OD 6O0 is 6.5-8.5 units. In another embodiment, the OD 6O0 is 7-8.5 units. In another embodiment, the OD 600 is 7.5-8.5 units. In another embodiment, the OD 6O0 is 8-8.5 units. In another embodiment, the OD 6O0 is 9.5-8.5 units. In another embodiment, the OD 600 is 10 units.
- the step of freezing or lyophilization is performed when the culture has a biomass of 1 x 10 9 colony-forming units (CFU)/ml.
- the biomass is 1.5 x 10 9 CFR/ml.
- the biomass is 1.5 x 10 9 CFR/ml.
- the biomass is 2 x 10 9 CFR/ml.
- the biomass is 3 x 10 9 CFR/ml.
- the biomass is 4 x 10 9 CFR/ml.
- the biomass is 5 x 10 9 CFR/ml.
- the biomass is 7 x 10 9 CFR/ml.
- the biomass is 9 x 10 9 CFR/ml.
- the biomass is 10 x 10 9 CFR/ml. In another embodiment, the biomass is 12 x 10 9 CFR/ml. In another embodiment, the biomass is 15 x 10 9 CFR/ml. In another embodiment, the biomass is 20 x 10 CFR/ml. In another embodiment, the biomass is 25 x 10 CFR/ml. In another embodiment, the biomass is 30 x 10 9 CFR/ml. In another embodiment, the biomass is 33 x 10 9 CFR/ml. In another embodiment, the biomass is 4O x 10 9 CFR/ml. In another embodiment, the biomass is 50 x 10 9 CFR/ml. In another embodiment, the biomass is more than 50 x 10 9 CFR/ml.
- the Listeria culture is flash-frozen in liquid nitrogen, followed by storage at the final freezing temperature.
- the culture is frozen in a more gradual manner; e.g. by placing in a vial of the culture in the final storage temperature.
- the culture is frozen by any other method known in the art for freezing a bacterial culture. Each possibility represents a separate P-7771-PC3 embodiment of the present invention.
- the storage temperature of the culture is between “ 20 and " 80 degrees Celsius ( 0 C). In another embodiment, the temperature is significantly below “ 20 0 C. In another embodiment, the temperature is not warmer than “70 0 C. In another embodiment, the temperature is " 70 0 C. In another embodiment, the temperature is about “ 70 0 C. In another embodiment, the temperature is " 20 0 C. In another embodiment, the temperature is about “ 20 0 C. In another embodiment, the temperature is " 30 0 C. In another embodiment, the temperature is " 40 0 C. In another embodiment, the temperature is " 50 0 C. In another embodiment, the temperature is " 60 0 C. In another embodiment, the temperature is " 80 °C.
- the temperature is " 30 - " 70 0 C. In another embodiment, the temperature is “ 40 - “ 70 0 C. In another embodiment, the temperature is “ 50 - “ 70 0 C. In another embodiment, the temperature is “ 60 - “ 70 0 C. In another embodiment, the temperature is “ 30 - “ 80 0 C. In another embodiment, the temperature is “ 40 - “ 80 0 C. In another embodiment, the temperature is “ 50 - " 80 0 C. In another embodiment, the temperature is “ 60 - “ 80 0 C. In another embodiment, the temperature is “ 70 - " 80 0 C. In another embodiment, the temperature is colder than “ 70 0 C. In another embodiment, the temperature is colder than " 80 °C. Each possibility represents a separate embodiment of the present invention.
- the cryopreservation, frozen storage, or lyophilization is for a maximum of 24 hours. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 2 days. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 3 days. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 4 days. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 1 week. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 2 weeks.
- cryopreservation, frozen storage, or lyophilization is for maximum of 3 weeks. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 1 month. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 2 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 3 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 5 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 6 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 9 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 1 year. P-7771-PC3
- the cryopreservation, frozen storage, or lyophilization is for a minimum of 1 week. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 2 weeks. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 3 weeks. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 1 month. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 2 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 3 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 5 months.
- cryopreservation, frozen storage, or lyophilization is for minimum of 6 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 9 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 1 year. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 1.5 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 2 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 3 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 5 years.
- cryopreservation, frozen storage, or lyophilization is for minimum of 7 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 10 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for longer than 10 years.
- the Listeria bacteria exhibit exponential growth essentially immediately after thawing following an extended period of cryopreservation or frozen storage (Example 14).
- the Listeria bacteria exhibit exponential growth essentially immediately after reconstitution following an extended period of lyophilization.
- "essentially immediately” refers to within about 1 hour after inoculating fresh media with cells from the cell bank or starter culture.
- the bacteria exhibit exponential growth shortly after (e.g. in various embodiments, after 10 minutes (min), 20 min, 30 min, 40 min, 50 min, 1 hour, 75 min, 90 min, 105 min, or 2 hours) thawing following the period of cryopreservation or storage.
- Each possibility represents a separate embodiment of the present invention.
- the "extended period" of cryopreservation, frozen storage, or lyophilization is, in another P-7771-PC3 embodiment, 1 month.
- the period is 2 months.
- the period is 3 months.
- the period is 5 months.
- the period is 6 months.
- the period is 9 months.
- the period is 1 year.
- the period is 1.5 years.
- the period is 2 years.
- Each possibility represents a separate embodiment of the present invention.
- exposure growth refers to a doubling time that is close to the maximum observed for the conditions (e.g. media type, temperature, etc.) in which the culture is growing.
- exposure growth refers to a doubling time that is reasonable constant several hours (e.g. 1 hour, 1.5 hours, 2 hours, or 2.5 hours) after dilution of the culture; optionally following a brief recovery period.
- a Listeria vaccine strain of methods and compositions of the present invention retains a viability of over 90% after thawing following 14 days of cryopreservation (Example 14).
- the viability upon thawing is close to 100% following the period of cryopreservation.
- the viability upon thawing is about 90%.
- the viability upon thawing is close to 90%.
- the viability upon thawing is at least 90%.
- the viability upon thawing is over 80%.
- a Listeria vaccine strain of methods and compositions of the present invention retains a viability of over 90% after reconstitution following lyophilization.
- the viability upon thawing is close to 100% following the period of lyophilization.
- the viability upon thawing is about 90%.
- the viability upon thawing is close to 90%.
- the viability upon thawing is at least 90%.
- the viability upon thawing is over 80%.
- a cell bank, frozen stock, or batch of vaccine doses of the present invention is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L of methionine; and (2) effective amounts of: (a) cysteine; (b) a pH buffer; (c) a carbohydrate; (d) a divalent cation; (e) ferric or ferrous ions; (f) glutamine or another nitrogen source; (g) riboflavin; (h) thioctic acid (also known as lipoic acid); (i) another or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and P-7771-PC3 nicotinamide; and (k)
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L of cysteine; and (2) effective amounts of: (a) methionine; (b) a pH buffer; (c) a carbohydrate; (d) a divalent cation; (e) ferric or ferrous ions; (f) glutamine or another nitrogen source; (g) riboflavin; (h) thioctic acid; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, moly
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.00123 - 0.00246 moles of ferric or ferrous ions per liter; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) glutamine or another nitrogen source; (g) riboflavin; (h) thioctic acid; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron,
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 1.8 - 3.6 g/L of glutamine or another nitrogen source; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate: (c) a divalent cation; (d) methionine (e) cysteine; (f) ferric or ferrous ions (g) riboflavin (h); thioctic acid; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 15 and about 30 mg/L of riboflavin; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) thioctic acid; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para- P-7771-PC3 aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganes
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1) between about 0.3 and about 0.6 g/L of thioctic acid; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate (c) a divalent cation; (d) methionine
- cysteine cysteine
- ferric or ferrous ions glutamine or another nitrogen source
- riboflavin one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine
- j one or more components selected from adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide
- cobalt copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; and (6) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (e) one or more components selected from adenine, biotin, thiamine, pyridoxal, para- amino
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; and (6) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) leucine; (e) isoleucine; (f) valine; (g) arginine; (h) histidine; (i) tryptophan; (j) phenylalanine; (k) one or more components selected from adenine, biotin, thiouracil, 5-fluor
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1) between about 0.3 and about 0.6 g/L each of one or P-7771-PC3 more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper,
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1) between about 0.3 and about 0.6 g/L each of leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum,
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1) between about 0.2 and about 0.75 of one or more components selected from biotin and adenine; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (k) one or more components selected from thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (1) one or more components selected from cobalt, copper, boron, manganes
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1 ) between about 3 and about 6 mg/L each of one or more components selected from thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation;
- the cell bank, frozen stock, or batch of vaccine doses is grown in a P-7771-PC3 defined microbiological media, comprising: (1) between about 0.2 and about 0.75 mg/L each of one or more components selected from biotin and adenine; (2) between about 3 and about 6 mg/L each of one or more components selected from thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (3) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.005 and about 0.02 g/L each of one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, and calcium; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine;
- cysteine cysteine
- ferric or ferrous ions glutamine or another nitrogen source
- riboflavin riboflavin
- thioctic acid one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine
- adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine
- k one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide.
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.4 and about 1 g/L of citrate; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (0 ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, and calcium; and (1) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, panto
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1 ) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and about 0.6 g/L each of one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (7) between about 0.2 and about 0.75 mg/L each of one or more components selected from biotin and adenine; (8) between about 3 and about 6 mg/L each of one or more components selected from thionine and cysteine;
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and about 0.6 g/L each of leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (7) between about 0.2 and about 0.75 mg/L each of one or more components selected from biotin and adenine; (8) between about 3 and about 6 mg/L each of one or more components selected from thiamine, pyridoxal,
- the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and about 0.6 g/L each of leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (7) between about 0.2 and about 0.75 mg/L each of biotin and adenine; (8) between about 3 and about 6 mg/L each of thiamine, pyridoxal, para-aminobenzoic acid, panto
- a defined microbiological media of the present invention further comprises an aqueous solvent.
- the aqueous solvent is water.
- the aqueous solvent is any other aqueous solvent known in the art.
- the carbohydrate utilized in methods and compositions of the present invention is, in another embodiment, glucose.
- the carbohydrate is lactose.
- the carbohydrate is fructose.
- the carbohydrate is mannose.
- the carbohydrate is cellobiose.
- the carbohydrate is trehalose.
- the carbohydrate is maltose.
- the carbohydrate is glycerol.
- the carbohydrate is glucosamine.
- the carbohydrate is N-acetylglucosamine.
- the carbohydrate is N-acetylmuramic acid.
- the carbohydrate is any other carbohydrate that can be utilized by Listeria. Each possibility represents a separate embodiment of the present invention.
- the amount of a carbohydrate present in a defined microbiological media of methods and compositions of the present invention is between about 12-18 grams/liter (g/L). In another embodiment, the amount is 15 g/L. In another embodiment, the amount is 10 g/L. In another embodiment, the amount is 9 g/L. In another embodiment, the amount is 1 1 g/L. In another embodiment, the amount is 12 g/L. In another embodiment, the amount is 13 g/L. In another embodiment, the amount is 14 g/L. In another embodiment, the amount is 16 g/L. In another embodiment, the amount is 17 g/L. In another embodiment, the amount is 18 g/L. In another embodiment, the amount is 19 g/L. In another embodiment, the amount is 20 g/L. In another embodiment, the amount is more than 20 g/L.
- the amount is 9-15 g/L. In another embodiment, the amount is 10-15 g/L. In another embodiment, the amount is 11-15 g/L. In another embodiment, the amount is 12-16 g/L. In another embodiment, the amount is 13-17 g/L. In another embodiment, the amount is 14-18 g/L. In another embodiment, the amount is 16-19 g/L. In another embodiment, the amount is 17-20 g/L. In another embodiment, the amount is 10-20 g/L. In another embodiment, the amount is 12-20 g/L. In another embodiment, the amount is 15-20 g/L.
- the total amount of carbohydrate in the media is one of the above amounts. In another embodiment, the amount of one of the carbohydrates in the media is one of the above amounts. In another embodiment, the amount of each of the carbohydrates in the media is one of the above amounts.
- the cobalt present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a cobalt ion.
- the cobalt is present as a cobalt salt.
- the salt is cobalt chloride.
- the salt is any other cobalt salt known in the art.
- the cobalt is present as any other form of cobalt known in the art.
- the cobalt salt is a hydrate (e.g. cobalt chloride hexahydrate). In another embodiment, the cobalt salt is anhydrous. In another embodiment, the cobalt salt is any other form of a cobalt salt known in the art. Each of the above forms of cobalt represents a separate embodiment of the present invention.
- a hydrate of a component of a defined media of methods and compositions of the present invention is, in another embodiment, a monohydrate.
- the hydrate is a dihydrate.
- the hydrate is a trihydrate.
- the hydrate is a tetrahydrate.
- the hydrate is a pentahydrate.
- the hydrate is a hexahydrate.
- the hydrate is a heptahydrate.
- the hydrate is any other hydrate known in the art. Each possibility represents a separate embodiment of the present invention.
- the copper present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a copper ion.
- the copper ion is a copper (I) ion.
- the copper ion is a copper (II) ion.
- the copper ion is a copper (III) ion.
- the copper is present as a copper salt.
- the salt is copper chloride.
- the salt is any other copper salt known in the art.
- the copper is present as any other form of copper known. in the art.
- the copper salt is a hydrate (e.g. copper chloride dihydrate).
- the copper salt is anhydrous.
- the copper salt is any other form of a copper salt known in the art. Each of the above forms of copper represents a separate embodiment of the present invention.
- the boron present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a borate ion.
- the boron is present as a borate acid (e.g. boric acid, H 3 BO 3 ).
- the boron is present as any other form of boron known in the art.
- the borate salt or borate acid is a hydrate. In another embodiment, the borate salt or borate acid is anhydrous. In another embodiment, the borate salt or borate acid is any other form of a borate salt or borate acid known in the art. Each of the above forms of boron represents a separate embodiment of the present invention.
- the manganese present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a manganese ion.
- the manganese is present as a manganese salt.
- the salt is manganese sulfate.
- the salt is any other manganese salt known in the art.
- the manganese is present as any other form of manganese known in the art.
- the manganese salt is a hydrate (e.g. manganese sulfate monohydrate). In another embodiment, the manganese salt is anhydrous. In another embodiment, the manganese salt is any other form of a manganese salt known in the art. Each of the above forms of manganese represents a separate embodiment of the present invention.
- the molybdenum present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a molybdate ion.
- the molybdenum is present as a molybdate salt.
- the salt is sodium molybdate.
- the salt is any other molybdate salt known in the art.
- the molybdenum is present as any other form of molybdenum known in the art.
- the molybdate salt is a hydrate (e.g. sodium molybdate dihydrate). In another embodiment, the molybdate salt is anhydrous. In another embodiment, the molybdate salt is any other form of a molybdate salt known in the art. Each of the above forms of molybdenum represents a separate embodiment of the present invention.
- the zinc present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a zinc ion.
- the zinc is present as a zinc salt.
- the salt is zinc chloride.
- the salt is any other zinc salt known in the art.
- the zinc is present as any other form of zinc known in the art.
- the zinc salt is a hydrate (e.g. zinc chloride heptahydrate). In another embodiment, the zinc salt is anhydrous. In another embodiment, the zinc salt is any other form of a zinc salt known in the art. Each of the above forms of zinc represents a separate embodiment of the present invention.
- the iron present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a ferric ion. In another embodiment, the iron is present as a ferrous ion. In another embodiment, the iron is present as a ferric salt. In another embodiment, the iron is present as a ferrous salt. In another embodiment, the salt is ferric sulfate. In another embodiment, the salt is ferric citrate. In another embodiment, the salt is any other ferric salt known in the art. In another embodiment, the salt is any other ferrous salt known in the art. In another embodiment, the iron is present as any other form of iron known in the art.
- the ferric or ferrous salt is a hydrate (e.g. ferric sulfate monohydrate).
- the ferric or ferrous salt is anhydrous.
- the ferric or ferrous salt is any other form of a ferric or ferrous salt known in the art. Each of the above forms of iron represents a separate embodiment of the present invention.
- the calcium present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a calcium ion.
- the calcium is present as a calcium salt.
- the salt is calcium chloride.
- the salt is any other calcium salt known in the art.
- the calcium is present as any other form of calcium known in the art.
- the calcium salt is a hydrate (e.g. calcium chloride dihydrate).
- the calcium salt is anhydrous.
- the calcium salt is any other form of a calcium salt known in the art. Each of the above forms of calcium represents a separate embodiment of the present invention.
- the citrate present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a citrate ion.
- the citrate is present as a citrate salt.
- the citrate is present as a citrate acid (e.g. citric acid).
- the citrate is present as both ferric citrate and citric acid (Examples 15-16).
- the citrate is present as any other form of citrate known in the art.
- the citrate salt or citrate acid is a hydrate. In another embodiment, the citrate salt or citrate acid is anhydrous. In another embodiment, the citrate salt or citrate acid is any other form of a citrate salt or citrate acid known in the art. Each of the above forms of citrate represents a separate embodiment of the present invention.
- the cobalt present in defined microbiological media of methods and compositions of the P-7771-PC3 present invention is, in another embodiment, present in an amount of 0.02 g/L (Examples 15-16). In another embodiment, the amount is about 0.02 g/L. In another embodiment, the amount is 0.003 g/L. In another embodiment, the amount is 0.005 g/L. In another embodiment, the amount is 0.007 g/L. In another embodiment, the amount is 0.01 g/L. In another embodiment, the amount is 0.015 g/L. In another embodiment, the amount is 0.025 g/L. In another embodiment, the amount is 0.03 g/L. In another embodiment, the amount is 0.003-0.006 g/L.
- the amount is 0.005-0.01 g/L. In another embodiment, the amount is 0.01-0.02 g/L. In another embodiment, the amount is 0.02- 0.04 g/L. In another embodiment, the amount is 0.03-0.06 g/L.
- the cobalt is present in an amount that is the molar equivalent of 0.02 g/L of cobalt chloride hexahydrate. In another embodiment, the amount of cobalt present is the molar equivalent of about 0.02 g/L of cobalt chloride hexahydrate. In another embodiment, the amount of cobalt present is the molar equivalent of another of the above amounts or ranges of cobalt chloride hexahydrate. Each of the above amounts or ranges of cobalt represents a separate embodiment of the present invention.
- the copper present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.019 g/L (Examples 15-16). In another embodiment, the amount is about 0.019 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
- the copper is present in an amount that is the molar equivalent of 0.019 g/L of copper chloride dihydrate. In another embodiment, the amount of copper present is the molar equivalent of about 0.019 g/L of copper chloride dihydrate. In another embodiment, the amount of copper present is the molar equivalent of copper chloride dihydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of copper represents a separate embodiment of the present invention.
- the borate present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.016 g/L (Examples 15-16). In another embodiment, the amount is about 0.016 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
- the borate is present in an amount that is the molar equivalent of 0.016 g/L of boric acid. In another embodiment, the amount of borate present is the molar equivalent of about 0.016 g/L of boric acid. In another embodiment, the amount of borate present is the molar equivalent of boric acid in any of the amounts or ranges listed above for cobalt. Each of the above P-7771-PC3 amounts or ranges of borate represents a separate embodiment of the present invention.
- the manganese present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.016 g/L (Examples 15-16). In another embodiment, the amount is about 0.016 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
- the manganese is present in an amount that is the molar equivalent of 0.016 g/L of manganese sulfate monohydrate. In another embodiment, the amount of manganese present is the molar equivalent of about 0.016 g/L of manganese sulfate monohydrate. In another embodiment, the amount of manganese present is the molar equivalent of manganese sulfate monohydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of manganese represents a separate embodiment of the present invention.
- the molybdenum present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.02 g/L (Examples 15-16). In another embodiment, the amount is about 0.02 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
- the molybdenum is present in an amount that is the molar equivalent of 0.2 g/L of sodium molybdate dihydrate. In another embodiment, the amount of molybdenum present is the molar equivalent of about 0.02 g/L of sodium molybdate dihydrate. In another embodiment, the amount of molybdenum present is the molar equivalent of sodium molybdate dihydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of molybdenum represents a separate embodiment of the present invention.
- the zinc present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.02 g/L (Examples 15-16). In another embodiment, the amount is about 0.02 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
- the zinc is present in an amount that is the molar equivalent of 0.02 g/L of zinc chloride heptahydrate. In another embodiment, the amount of zinc present is the molar equivalent of about 0.02 g/L of zinc chloride heptahydrate. In another embodiment, the amount of zinc present is the molar equivalent of zinc chloride heptahydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of zinc represents a separate embodiment of the present invention.
- ferric sulfate or a related compound is present in defined microbiological media of methods and compositions of the present invention.
- the ferric sulfate or related compound is present in an amount of 0.01 g/L (Examples 15-16). In another embodiment, the amount is about 0.01 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
- the iron is present in an amount that is the molar equivalent of 0.01 g/L of ferric sulfate. In another embodiment, the amount of iron present is the molar equivalent of about
- the amount of iron present is the molar equivalent of ferric sulfate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of iron represents a separate embodiment of the present invention.
- the calcium present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.01 g/L (Examples 15-16). In another embodiment, the amount is about 0.01 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
- the calcium is present in an amount that is the molar equivalent of 0.01 g/L of calcium chloride dihydrate. In another embodiment, the amount of calcium present is the molar equivalent of about 0.01 g/L of calcium chloride dihydrate. In another embodiment, the amount of calcium present is the molar equivalent of calcium chloride dihydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of calcium represents a separate embodiment of the present invention.
- the citrate present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.9 g/L (Examples 15-16). In another embodiment, the amount is 0.6 g/L in the form of citric acid (Examples 15-16). In another embodiment, the amount is 0.4 g/L in the form of ferric citrate (Examples 15-16). In another embodiment, the amount is 0.6 g/L in the form of citric acid and 0.4 g/L in the form of ferric citrate (Examples 15-16). In another embodiment, the amount is about 0.6 g/L. In another embodiment, the amount is 0.1 g/L. In another embodiment, the amount is 0.2 g/L.
- the amount is 0.3 g/L. In another embodiment, the amount is 0.4 g/L. In. another embodiment, the amount is 0.5 g/L. In another embodiment, the amount is 0.7 g/L. In another embodiment, the amount is 0.8 g/L. In another embodiment, the amount is 1 g/L. In another embodiment, the amount is more than 1 g/L.
- the citrate is . present in an amount that is the molar equivalent of 0.6 g/L of citric acid.
- the amount of citrate present is the molar equivalent of P-7771-PC3 about 0.6 g/L of citric acid.
- the amount of citrate present is the molar equivalent of about 0.4 g/L of ferric citrate.
- the amount of citrate present is the molar equivalent of 0.4 g/L of ferric citrate.
- the amount of citrate present is the molar equivalent of 0.6 g/L of citric acid and 0.4 g/L of ferric citrate.
- the amount of citrate present is the about molar equivalent of 0.6 g/L of citric acid and 0.4 g/L of ferric citrate. In another embodiment, the amount of citrate present is the molar equivalent of citric acid in any of the amounts or ranges listed above for citrate. Each of the above amounts or ranges of citrate represents a separate embodiment of the present invention.
- One or more of the adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide present in defined microbiological media of methods and compositions of the present invention are, in another embodiment, present as the free compound.
- one of the above compounds is present as a salt thereof.
- one of the above compounds is present as a derivative thereof.
- one of the above compounds is present as a hydrate thereof.
- the salt, derivative, or hydrate can be any salt, derivative, or hydrate known in the art.
- Each of the above forms of adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide represents a separate embodiment of the present invention.
- the thiamine (vitamin Bl) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of thiamine HCl.
- the thiamine is present as any other salt, derivative, or hydrate of thiamine known in the art.
- another form of vitamin Bl is substituted for thiamine.
- the thiamine is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is about 0.5 mg/L. In another embodiment, the amount is 0.7 mg/L. In another embodiment, the amount is 1 mg/L. In another embodiment, the amount is 1.5 mg/L. In another embodiment, the amount is 2 mg/L. In another embodiment, the amount is 3 mg/L. In another embodiment, the amount is 5 mg/L. In another embodiment, the amount is 6 mg/L. In another embodiment, the amount is 8 mg/L. In another embodiment, the amount is more than 8 mg/L. In another embodiment, the thiamine is present in an amount that is the molar equivalent of 4 mg/L of thiamine HCl. In another embodiment, the thiamine is present in an amount that is the molar equivalent of thiamine HCl in one of the above amounts. Each possibility represents a separate embodiment of the present invention.
- the pyridoxal (vitamin B6) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of pyridoxal HCl.
- the pyridoxal is present as any other salt, derivative, or hydrate of pyridoxal known in the art.
- another form of vitamin B6 is substituted for pyridoxal.
- the pyridoxal is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of pyridoxal present is the molar equivalent of about 4 mg/L of pyridoxal HCl. In another embodiment, the amount of pyridoxal present is the molar equivalent of pyridoxal HCl in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the present invention.
- adenine (vitamin B4) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of free adenine.
- the adenine is present as any other salt, derivative, or hydrate of adenine known in the art.
- another form of vitamin B4 is substituted for adenine.
- the adenine is present in an amount of 0.25 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for cobalt. In another embodiment, the amount of adenine present is the molar equivalent of about 0.25 mg/L of free adenine. In another embodiment, the amount of adenine present is the molar equivalent of free adenine in any of the amounts or ranges listed above for cobalt. Each possibility represents a separate embodiment of the present invention.
- the biotin (vitamin B7) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of free biotin.
- the biotin is present as any other salt, derivative, or hydrate of biotin known in the art.
- another form of vitamin B7 is substituted for biotin.
- the biotin is present in an amount of 2 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of biotin present is the molar equivalent of about 2 mg/L of free biotin. In another embodiment, the amount of biotin present is the molar equivalent of free biotin in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the P-7771-PC3 present invention.
- the para-aminobenzoic acid (vitamin B-x) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of free para-aminobenzoic acid.
- the para-aminobenzoic acid is present as any other salt, derivative, or hydrate of para-aminobenzoic acid known in the art.
- another form of vitamin B-x is substituted for para-aminobenzoic acid.
- the para-aminobenzoic acid is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of para-aminobenzoic acid present is the molar equivalent of about 4 mg/L of free para-aminobenzoic acid. In another embodiment, the amount of para-aminobenzoic acid present is the molar equivalent of free para-aminobenzoic acid in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the present invention.
- pantothenate present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of calcium pantothenate.
- the pantothenate is present as any other salt, derivative, or hydrate of pantothenate known in the art.
- another form of vitamin B5 is substituted for pantothenate.
- the pantothenate is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of pantothenate present is the molar equivalent of about 4 mg/L of calcium pantothenate. In another embodiment, the amount of pantothenate present is the molar equivalent of calcium pantothenate in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the present invention.
- the nicotinamide (vitamin B3) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of free nicotinamide.
- the nicotinamide is present as any other salt, derivative, or hydrate of nicotinamide known in the art.
- another form of vitamin B3 is substituted for nicotinamide.
- the nicotinamide is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of nicotinamide present is the molar equivalent of about 4 mg/L of free nicotinamide. In another embodiment, the amount of nicotinamide present is the molar equivalent of free nicotinamide in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the present invention.
- One or more of the leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine present in defined microbiological media of methods and compositions of the present invention are, in another embodiment, present as free amino acids.
- one of the above compounds is present as a salt thereof.
- one of the above compounds is present as a derivative thereof.
- one of the above compounds is present as a hydrate thereof.
- the salt, derivative, or hydrate can be any salt, derivative, or hydrate known in the art.
- Each of the above forms of adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide represents a separate embodiment of the present invention.
- one or more of the leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine is present in an amount of 0.4 g/L (Examples 15-16).
- the amount is about 0.05 g/L.
- the amount is 0.07 g/L.
- the amount is 0.1 g/L.
- the amount is 0.15 g/L.
- the amount is 0.2 g/L.
- the amount is 0.3 g/L.
- the amount is 0.5 g/L.
- the amount is 0.6 g/L.
- the amount is 0.8 g/L. In another embodiment, the amount is more than 0.8 g/L. In another embodiment, one or more of these AA is present in an amount that is the molar equivalent of 0.4 g/L of the free AA. In another embodiment, the amount is the molar equivalent of thiamine the free AA in one of the above amounts.
- Each possibility represents a separate embodiment of the present invention.
- a defined media of methods and compositions of the present invention contains two of the amino acids (AA) listed in the second section of Table 3B, e.g. leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine.
- the defined media contains 3 of these AA.
- the media contains 4 of these AA.
- the media contains 3 of these AA.
- the media contains 5 of these P-7771-PC3
- the media contains 6 of these AA. In another embodiment, the media contains all of these AA. In another embodiment, the media contains at least 2 of these AA. In another embodiment, the media contains at least 3 of these AA. In another embodiment, the media contains at least 4 of these AA. In another embodiment, the media contains at least 5 of these AA. In another embodiment, the media contains at least 6 of these AA.
- Each possibility represents a separate embodiment of the present invention.
- a defined media of methods and compositions of the present invention contains 2 of the vitamins listed in the third section of Table 3B, e.g. adenine, biotin, thiamine, pyridoxal, para-ami nobenzoic acid, pantothenate, and nicotinamide.
- the defined media contains 3 of these vitamins.
- the media contains 4 of these vitamins.
- the media contains 3 of these vitamins.
- the media contains 5 of these vitamins.
- the media contains 6 of these vitamins.
- the media contains all of these vitamins.
- the media contains at least 2 of these vitamins.
- the media contains at least 3 of these vitamins.
- the media contains at least 4 of these vitamins.
- the media contains at least 5 of these vitamins.
- the media contains at least 6 of these vitamins.
- Each possibility represents a separate embodiment of the present invention.
- a defined media of methods and compositions of the present invention contains 2 of the trace elements listed in the fourth section of Table 3B, e.g. cobalt, copper, boron, manganese, molybdenum, zinc, iron, calcium, and citrate.
- the defined media contains 3 of these trace elements.
- the media contains 4 of these trace elements.
- the media contains 3 of these trace elements.
- the media contains 5 of these trace elements.
- the media contains 6 of these trace elements.
- the media contains 7 of these trace elements.
- the media contains 7 of these trace elements.
- the media contains all of these trace elements.
- the media contains at least 2 of these trace elements. In another embodiment, the media contains at least 3 of these trace elements. In another embodiment, the media contains at least 4 of these trace elements. In another embodiment, the media contains at least 5 of these trace elements. In another embodiment, the media contains at least 6 of these trace elements. In another embodiment, the media contains at least 7 of these trace elements. In another embodiment, the media contains at least 8 of these trace elements.
- P-7771-PC3 P-7771-PC3
- a defined media of methods and compositions of the present invention contains more than 1 component from 2 of the above classes of components; e.g more than one of the AA listed in the second section of Table 3B, and more than one of the vitamins listed in the third section.
- the media contains more than 2 components from 2 of the above classes of components; e.g more than 2 of the AA listed in the second section of Table 3B, and more than 2 of the trace elements listed in the fourth section.
- the media contains more than 3 components from 2 of the above classes.
- the media contains more than 4 components from 2 of the above classes.
- the media contains more than 5 components from 2 of the above classes.
- the media contains more than 6 components from 2 of the above classes.
- the media contains all of the components from 2 of the above classes.
- a defined media of methods and compositions of the present invention contains more than 1 component from all of the above classes of components (e.g. more than 1 component each from AA, vitamins and trace elements).
- the media contains more than 2 components from all of the above classes of components.
- the media contains more than 3 components from all of the above classes.
- the media contains more than 4 components from all of the above classes.
- the media contains more than all components from 2 of the above classes.
- the media contains more than 6 components from all of the above classes.
- the media contains all of the components from all of the above classes.
- the media contains any other combination of numbers of components from each of the above classes; e.g. 2 AA, 2 vitamins, and 3 trace elements; 3 AA, 3 vitamins, and 2 trace elements; 2 AA, 3 vitamins, and all of the trace elements, etc.
- a defined media of methods and compositions of the present invention consists of one of the above recipes, mixtures of components, lists of components in specified amounts, or combinations of numbers of components from each of the above classes. Each possibility represents a separate embodiment of the present invention.
- the divalent cation present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, Mg.
- the divalent cation is Ca.
- the divalent cation is any other divalent cation known in the art.
- Mg can, in P-7771-PC3 other embodiments, be present in any form of Mg known in the art, e.g. MgSO 4 (Examples 15-16).
- the divalent cation is present in an amount that is the molar equivalent of about 0.41 g/mL. In other embodiments, the divalent cation is present in another effective amount, as known to those skilled in the art.
- a nitrogen source other than glutamine is utilized in defined media of the present invention.
- the nitrogen source is another AA.
- the nitrogen source is another source of peptides or proteins (e.g. casitone or casamino acids).
- the nitrogen source is ammonium chloride.
- the nitrogen source is ammonium nitrate.
- the nitrogen source is ammonium sulfate.
- the nitrogen source is another ammonium salt.
- the nitrogen source is any other nitrogen source known in the art. Each possibility represents a separate embodiment of the present invention.
- a defined microbiological media of methods and compositions of the present invention does not contain a component derived from an animal source.
- the defined microbiological media does not contain an animal-derived component of incompletely defined composition (e.g. yeast extract, bacto-tryptone, etc.).
- yeast extract e.g. yeast extract, bacto-tryptone, etc.
- bacto-tryptone e.g. yeast extract, bacto-tryptone, etc.
- defined microbiological media refers to a media whose components are known.
- the term refers to a media that does not contain a component derived from an animal source.
- the term refers to a media whose components have been chemically characterized. Each possibility represents a separate embodiment of the present invention.
- a defined media of methods and compositions of the present invention supports growth of the Listeria strain to about 1.1 x 10 10 CFU/mL (e.g. when grown in flasks; Examples 13-16). In another embodiment, the defined media supports growth to about 1.1 x 10 10 CFU/mL (e.g. when grown in fermenters; Examples 13-16). In another embodiment, the defined media supports growth to about 5 x 10 9 CFU/mL (e.g. when grown in fermenters; Examples 13-16). In another embodiment, the defined media supports growth of viable bacteria (e.g. bacteria that can be cryopreserved without significant loss of viability) to about 3 x 10 10 CFU/mL (e.g.
- the defined media when grown in fermenters; Examples 13-16).
- the defined media supports growth to an OD ⁇ oo of about 4.5 (Examples 13-16).
- the defined media supports growth to another OD ⁇ oo value enumerated herein.
- the defined media supports growth to another P-7771-PC3
- the defined media supports growth to a density approximately equivalent to that obtained with TB. In another embodiment, the defined media supports growth to a density approximately equivalent to that obtained with LB.
- a defined media of methods and compositions of the present invention supports a growth rate of the Listeria strain of about 0.25 h "1 (Examples). In another embodiment, the growth rate is about 0.15 h "1 . In another embodiment, the growth rate is about 0.2 h "1 . In another embodiment, the growth rate is about 0.3 h '1 . In another embodiment, the growth rate is about 0.4 h "1 . In another embodiment, the growth rate is about 0.5 h "1 . In another embodiment, the growth rate is about 0.6 h "1 . In another embodiment, the defined media supports a growth rate approximately equivalent to that obtained with TB. In another embodiment, the defined media supports a growth rate approximately equivalent to that obtained with LB. Each possibility represents a separate embodiment of the present invention.
- a peptide of the present invention is a fusion peptide.
- "fusion peptide” refers to a peptide or polypeptide comprising 2 or more proteins linked together by peptide bonds or other chemical bonds.
- the proteins are linked together directly by a peptide or other chemical bond.
- the proteins are linked together with 1 or more AA (e.g. a "spacer") between the 2 or more proteins.
- AA e.g. a "spacer”
- a vaccine of the present invention further comprises an adjuvant.
- the adjuvant utilized in methods and compositions of the present invention is, in another embodiment, a granulocyte/macrophage colony-stimulating factor (GM-CSF) protein.
- the adjuvant comprises a GM-CSF protein.
- the adjuvant is a nucleotide molecule encoding GM-CSF.
- the adjuvant comprises a nucleotide molecule encoding GM-CSF.
- the adjuvant is saponin QS21.
- the adjuvant comprises saponin QS21.
- the adjuvant is monophosphoryl lipid A.
- the adjuvant comprises monophosphoryl lipid A. In another embodiment, the adjuvant is SBAS2. In another embodiment, the adjuvant comprises SBAS2. In another embodiment, the adjuvant is an unmethylated CpG-containing oligonucleotide. In another embodiment, the adjuvant comprises an unmethylated CpG-containing oligonucleotide. In another embodiment, the adjuvant is an immune- stimulating cytokine. In another embodiment, the adjuvant comprises an immune-stimulating cytokine. In another embodiment, the adjuvant is a nucleotide molecule encoding an immune- stimulating cytokine.
- the adjuvant comprises a nucleotide molecule encoding P-7771-PC3 an immune-stimulating cytokine.
- the adjuvant is or comprises a quill glycoside.
- the adjuvant is or comprises a bacterial mitogen.
- the adjuvant is or comprises a bacterial toxin.
- the adjuvant is or comprises any other adjuvant known in the art. Each possibility represents a separate embodiment of the present invention.
- a nucleotide of the present invention is operably linked to a promoter, regulatory sequence, or combination thereof that drives expression of the encoded peptide in the Listeria strain.
- Promoter, regulatory sequences, and combinations thereof useful for driving constitutive expression of a gene are well known in the art and include, but are not limited to, for example, the P h i yA , P A « A , hly, ActA, and p60 promoters of Listeria, the Streptococcus bac promoter, the Streptomyces griseus sgiA promoter, and the B. thuringiensis phaZ promoter.
- inducible and tissue specific expression of the nucleic acid encoding a peptide of the present invention is accomplished by placing the nucleic acid encoding the peptide under the control of an inducible or tissue specific promoter/regulatory sequence.
- tissue specific or inducible regulatory sequences, promoters, and combinations thereof which are useful for his purpose include, but are not limited to the MMTV LTR inducible promoter, and the SV40 late enhancer/promoter.
- a promoter that is induced in response to inducing agents such as metals, glucocorticoids, and the like, is utilized.
- a regulatory sequence is a promoter, while in another embodiment, a regulatory sequence is an enhancer, while in another embodiment, a regulatory sequence is a suppressor, while in another embodiment, a regulatory sequence is a repressor, while in another embodiment, a regulatory sequence is a silencer.
- the ActA sequence for use in the compositions and methods of the present invention is from Listeria monocytogenes, which in one embodiment, is the EGD strain, the 10403S strain (Genbank accession number: DQ054585) the NICPBP 54002 strain (Genbank accession number: EU394959, the S3 strain (Genbank accession number: EU394960), the NCTC 5348 strain (Genbank accession number: EU394961), the NICPBP 54006 strain (Genbank accession number: EU394962), the M7 strain (Genbank accession number: EU394963), the S 19 strain (Genbank accession number: EU394964), or any other strain of Listeria monocytogenes which is known in the art.
- an N-terminal fragment of an ActA protein utilized in methods and P-7771-PC3 compositions of the present invention comprises or consists of the first 390 AA of ActA, in another embodiment, the first 418 AA of ActA, in another embodiment, the first 50 AA of ActA, in another embodiment, the first 100 AA of ActA, which in one embodiment, comprise a PEST-like sequence such as that provided in SEQ ID NO: 2.
- an N-terminal fragment of an ActA protein utilized in methods and compositions of the present invention comprises or consists of the first 150 AA of ActA, in another embodiment, the first approximately 200 AA of ActA, which in one embodiment comprises 2 PEST-like sequences as described herein.
- an N- terminal fragment of an ActA protein utilized in methods and compositions of the present invention comprises or consists of the first 250 AA of ActA, in another embodiment, the first 300 AA of ActA.
- the ActA fragment contains residues of a homologous ActA protein that correspond to one of the above AA ranges.
- the residue numbers need not, in another embodiment, correspond exactly with the residue numbers enumerated above; e.g. if the homologous ActA protein has an insertion or deletion, relative to an ActA protein utilized herein, then the residue numbers can be adjusted accordingly, as would be routine to a skilled artisan using sequence alignment tools such as NCBI BLAST that are well-known in the art.
- the N-terminal portion of the ActA protein comprises 1, 2, 3, or 4 PEST-like sequences, which in one embodiment are SEQ ID NOs: 2-5, 38-40, or their homologs, as described herein or other PEST-like sequences as can be determined using the methods and algorithms described herein or by using alternative methods known in the art.
- N-terminal fragment of an ActA protein utilized in methods and compositions of the present invention has, in another embodiment, the sequence set forth in SEQ ID NO: 23:
- the ActA fragment comprises the sequence set forth in SEQ ID NO: 23. In another embodiment, the ActA fragment is any other ActA fragment known in the art. In another embodiment, the ActA protein is a homologue of SEQ ID NO: 23. In another embodiment, the ActA protein is a variant of SEQ ID NO: 23. In another embodiment, the ActA protein is an isoform of SEQ ID NO: 23. In another embodiment, the ActA protein is a fragment of SEQ ID NO: 23. In another embodiment, the ActA protein is a fragment of a homologue of SEQ ID P-7771-PC3
- the ActA protein is a fragment of a variant of SEQ ID NO: 23. In another embodiment, the ActA protein is a fragment of an isoform of SEQ ID NO: 23.
- each possibility represents a separate embodiment of the present invention. Each possibility represents a separate embodiment of the present invention.
- the recombinant nucleotide encoding a fragment of an ActA protein comprises the sequence set forth in SEQ ID NO: 24: atgcgtgcgatgatggtggttttcattactgccaattgcattacgattaaccccgacataatatttgcagcgacagatagcgaagattctagtctaaaca cagatgaatgggaagaagaaaaaacagaagagcaaccaagcgaggtaaatacgggaccaagatacgaaactgcacgtgaagtaagttcacgtg atattaaagaactagaaaaatcgaataaagtgagaaatacgaacaaagcagacctaatagcaatgttgaaagaaaaaaggtccaaata tcagtgaaa
- the recombinant nucleotide has the sequence set forth in SEQ ED NO: 24. In another embodiment, the recombinant nucleotide comprises any other sequence that encodes a fragment of an ActA protein. Each possibility represents a separate embodiment of the present invention.
- An N-terminal fragment of an ActA protein utilized in methods and compositions of the present invention has, in another embodiment, the sequence set forth in SEQ ID NO: 36: MRAMMVVFITANCITINPDIIFAATDSEDSSLNTDEWEEEKTEEQPSEVNTGPRYETAREVSSR DIEELEKSNKVKNTNKADLIAMLKAKAEKGPNNNNNNGEQTGNVAINEEASGVDRPTLQVE RRHPGLSSDSAAEIKKRRKAIASSDSELESLTYPDKPTKANKRKVAKESVVDASESDLDSSMQ SADESTPQPLKANQKPFFPKVFKKIKDAGKWVRDKIDENPEVKKAIVDKSAGLIDQLLTKKKS EEVNASDFPPPPTDEELRLALPETPMLLGFNAPTPSEPSSFEFPPPPTDEELRLALPETPMLLGFN APATSEPSSFEFPPPPTEDELEIMRETAPSLDSSFTSGDLASLRSAINRHSENFSDFPLIPTEEELN
- GRGGRP SEQ ID NO: 36
- the ActA fragment comprises the sequence set forth in SEQ ID NO: 36.
- the ActA fragment is any other ActA fragment known in the art.
- the ActA protein is a homologue of SEQ ID NO: 36.
- the ActA protein is a variant of SEQ ID NO: 36. In another embodiment, the ActA protein is an isoform of SEQ DD NO: 36. In another embodiment, the ActA protein is a fragment of SEQ ID NO: 36. In another embodiment, the ActA protein is a fragment of a homologue of SEQ ID NO: 36. In another embodiment, the ActA protein is a fragment of a variant of SEQ ID NO: 36. In another embodiment, the ActA protein is a fragment of an isoform of SEQ ID NO: 36.
- Each possibility represents a separate embodiment of the present invention. Each possibility represents a separate embodiment of the present invention.
- the recombinant nucleotide encoding a fragment of an ActA protein comprises the sequence set forth in SEQ ID NO: 37: atgcgtgcgatgatggtagttttcattactgccaactgcattacgattaaccccgacataatatttgcagcgacagatagcgaagattccagtctaaaca cagatgaatgggaagaagaaaaaacagaagagcagccaagcgaggtaaatacgggaccaagatacgaaactgcacgtgaagtagttcacgtgatgatgaaagttcacgtgatgatgaaaagttcacgtg attgaggaactagaaaaatcgaataaaaaaatacgaacaaagcagacctaatagcaatgttgaaaagcaaaacagagaaaggt
- the recombinant nucleotide has the sequence set forth in SEQ ID NO: 37. In another embodiment, the recombinant nucleotide comprises any other sequence that encodes a fragment of an ActA protein. Each possibility represents a separate embodiment of the present invention.
- a PEST-like AA sequence is fused to the antigen, which in one embodiment is the E7 or E6 antigen.
- a PEST sequence is fused to the antigen.
- a PEST-containing sequence is fused to the antigen.
- recombinant Listeria strains expressing PEST- like sequence-antigen fusions induce anti-tumor immunity (Example 3) and generate antigen-specific, tumor-infiltrating T cells (Example 4). Further, enhanced cell mediated immunity was demonstrated for fusion proteins comprising an antigen and LLO containing the PEST-like AA sequence P-7771-PC3
- KENSISSMAPPASPPASPKTPIEKKHADEIDK (SEQ ID NO: 1).
- fusion of an antigen to other LM PEST-like sequences and PEST-like sequences derived from other prokaryotic organisms will also enhance immunogenicity of the antigen.
- the PEST-like AA sequence has, in another embodiment, a sequence selected from SEQ ID NO: 2-7.
- the PEST-like sequence is a PEST-like sequence from an LM ActA protein.
- an ActA protein comprises PEST-like sequences as set forth in SEQ ID NO: 2, 3, and 4.
- an ActA protein comprises PEST-like sequences as set forth in SEQ ID NO: 2, 3, 4, and 5.
- the PEST-like sequences that the ActA protein comprises is set forth in SEQ ID NO: 2, 3, 4 or their combination. In another embodiment, the PEST- like sequences that the ActA protein comprises is set forth in SEQ ID NO: 2, 3, 4, 5, or their combination. In another embodiment, an ActA protein comprises a PEST-like sequence as set forth in SEQ ID NO: 2. In another embodiment, an ActA protein comprises a PEST-like sequence as set forth in SEQ ID NO: 3. In another embodiment, an ActA protein comprises a PEST-like sequence that is 82% homologous to the sequence as set forth in SEQ ID NO: 3. In another embodiment, an ActA protein comprises a PEST-like sequence as set forth in SEQ ID NO: 4.
- an ActA protein comprises a PEST-like sequence that is 95% homologous to the sequence as set forth in SEQ ID NO: 4. In another embodiment, an ActA protein comprises a PEST-like sequence as set forth in SEQ ID NO: 5. In another embodiment, an ActA fragment comprises a PEST-like sequence as set forth in SEQ ID NO: 2. In another embodiment, an ActA fragment comprises a PEST-like sequence as set forth in SEQ ID NO: 3. In another embodiment, an ActA fragment comprises a PEST-like sequence as set forth in SEQ ED NO: 4. In another embodiment, an ActA fragment comprises a PEST- like sequence as set forth in SEQ ID NO: 5.
- the ActA fragment comprises PEST-like sequences as set forth in SEQ ID NO: 2, 3, 4 or their combination. In another embodiment, the the ActA fragment comprises PEST-like sequences as set forth in SEQ ID NO: 2, 3, 4, 5 or their combination. In another embodiment, the PEST-like sequence is KTEEQPSEVNTGPR (SEQ ID NO: 2), KASVTDTSEGDLDSSMQSADESTPQPLK (SEQ ED NO: 3),
- the PEST-like sequence is from Streptolysin O protein of Streptococcus sp. In another embodiment, the PEST-like sequence is from Streptococcus pyogenes Streptolysin O, e.g.
- KQNTASTETTTTNEQPK (SEQ ID NO: 6), which in one embodiment is at AA 35-51 of Streptolysin O.
- the PEST-like sequence is from Streptococcus equisimilis Streptolysin O, e.g. P-7771-PC3
- KQNTANTETTTTNEQPK (SEQ ID NO: 7), which in one embodiment, is at AA 38-54 of Streptolysin O.
- the PEST-like sequence is another PEST-like AA sequence derived from a prokaryotic organism.
- the PEST-like sequence is any other PEST-Hke sequence known in the art. Each possibility represents a separate embodiment of the present invention.
- PEST-like sequences of other prokaryotic organism can be identified in accordance with methods such as described by, for example Rechsteiner and Rogers (1996, Trends Biochem. Sci. 21:267-271) for LM. Alternatively, PEST-like AA sequences from other prokaryotic organisms can also be identified based on this method. Other prokaryotic organisms wherein PEST-like AA sequences would be expected to include, but are not limited to, other Listeria species. In another embodiment, the PEST-like sequence is embedded within the antigenic protein. Thus, in another embodiment, "fusion" refers to an antigenic protein comprising both the antigen and the PEST-like amino acid sequence either linked at one end of the antigen or embedded within the antigen.
- the PEST-like sequence is identified using any other method or algorithm known in the art, e.g the CaSPredictor (Garay-Malpartida HM, Occhiucci JM, Alves J,
- a PEST index is calculated for each 30-35 AA stretch by assigning a value of 1 to the amino acids Ser, Thr, Pro, GIu, Asp, Asn, or GIn.
- the coefficient value (CV) for each of the PEST residue is 1 and for each of the other AA (non-PEST) is 0.
- a PEST-like sequence has a CV of 1. In another embodiment, a PEST-like sequence has a CV of 2. In another embodiment, a PEST-like sequence has a CV of 3. In another embodiment, a PEST-like sequence has a CV of 4. In another embodiment, a PEST-like sequence has a CV of 5. In another embodiment, a PEST-like sequence has a CV of 6. In another embodiment, a PEST-like sequence has a CV of 2. In another embodiment, a PEST-like sequence has a CV of 7. In another embodiment, a PEST-like sequence has a CV of 8. In another embodiment, a PEST-like sequence has a CV of 9. In another embodiment, a PEST-like sequence has a CV of 10.
- a PEST-like sequence has a CV of 1 1. In another embodiment, a PEST-like sequence P-7771-PC3 has a CV of 12. In another embodiment, a PEST-like sequence has a CV of 13. In another embodiment, a PEST-like sequence has a CV of 14. In another embodiment, a PEST-like sequence has a CV of 15. In another embodiment, a PEST-like sequence has a CV of 16. In another embodiment, a PEST-like sequence has a CV of 17. In another embodiment, a PEST-like sequence has a CV of 18. In another embodiment, a PEST-like sequence has a CV of 19. In another embodiment, a PEST-like sequence has a CV of 20.
- a PEST-like sequence has a CV of 20. In another embodiment, a PEST-like sequence has a CV of 21. In another embodiment, a PEST-like sequence has a CV of 22. In another embodiment, a PEST-like sequence has a CV of 23. In another embodiment, a PEST-like sequence has a CV of 24. In another embodiment, a PEST-like sequence has a CV of 25. In another embodiment, a PEST-like sequence has a CV of 26. In another embodiment, a PEST-like sequence has a CV of 27. In another embodiment, a PEST-like sequence has a CV of 28. In another embodiment, a PEST-like sequence has a CV of 29.
- a PEST-like sequence has a CV of 30. In another embodiment, a PEST-like sequence has a CV of 31. In another embodiment, a PEST-like sequence has a CV of 32. In another embodiment, a PEST-like sequence has a CV of 33. In another embodiment, a PEST-like sequence has a CV of 34. In another embodiment, a PEST-like sequence has a CV of 35.
- a PEST-like sequence is a PEST sequence identified using one of the algorithms described herein or known in the art.
- a PEST-like sequence is a sequence that is similar to a known PEST sequence in structure, while in another embodiment, a PEST-like sequence has a similar function to known PEST sequences, or in another embodiment, a PEST-like sequence is similar both structurally and functionally to known PEST sequences.
- a similar structure to a known PEST sequence is one that would receive a higher than threshold score, which in one embodiment, is 5 using one of the algorithms described hereinabove, which in one embodiment, is PESTf ⁇ nd.
- a PEST-like sequence is a sequence comprising a PEST motif.
- the LLO protein, ActA protein, or fragment thereof of the present invention need not be that which is set forth exactly in the sequences set forth herein, but rather other alterations, modifications, or changes can be made that retain the functional characteristics of an LLO or ActA protein fused to an antigen as set forth elsewhere herein.
- the present invention utilizes an analog of an LLO protein, ActA protein, or fragment thereof. Analogs differ, in another embodiment, from naturally occurring proteins or peptides by conservative AA sequence differences or by modifications which do not affect sequence, or by both. For example, P-7771-PC3 conservative amino acid changes may be made, which although they alter the primary sequence of the protein or peptide, do not normally alter its function.
- conservative amino acid substitutions include substitutions within the following groups: (a) glycine, alanine; (b) valine, isoleucine, leucine; (c) aspartic acid, glutamic acid; (d) asparagine, glutamine; (e) serine, threonine; (f) lysine, arginine; (g) phenylalanine, tyrosine.
- conservative AA substitution comprise substitutions of polar AAs with other polar AAs, non-polar AAs with other non-polar AAs, charged AAs with other charged AAs, non-charged AAs with other non-charged AAs, hydrophobic AAs with other hydrophobic AAs, basic AAs with other basic AAs, acidic AAs with other acidic AAs, or a combination thereof, as is well known in the art.
- modifications include in vivo, or in vitro chemical derealization of polypeptides, e.g., acetylation, or carboxylation.
- modifications of glycosylation e.g., those made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing or in further processing steps; e.g., by exposing the polypeptide to enzymes which affect glycosylation, e.g., mammalian glycosylating or deglycosylating enzymes.
- sequences which have phosphorylated amino acid residues e.g., phosphotyrosine, phosphoserine, or phosphothreonine.
- polypeptides which have been modified using ordinary molecular biological techniques so as to improve their resistance to proteolytic degradation or to optimize solubility properties or to render them more suitable as a therapeutic agent.
- Analogs of such polypeptides include those containing residues other than naturally occurring L-amino acids, e.g., D-amino acids or non- naturally occurring synthetic amino acids.
- the peptides of the invention are not limited to products of any of the specific exemplary processes listed herein.
- the vaccines of the present invention comprise an adjuvant, while in another embodiment, the vaccines do not comprise an adjuvant.
- adjuvant refers, in another embodiment, to compounds that, when administered to an individual or tested in vitro, increase the immune response to an antigen in the individual or test system to which the antigen is administered.
- an immune adjuvant enhances an immune response to an antigen that is weakly immunogenic when administered alone, i.e., inducing no or weak antibody titers or cell-mediated immune response.
- the adjuvant increases antibody titers to the antigen.
- the adjuvant lowers the dose of the antigen effective to achieve an immune response in the individual.
- the adjuvant utilized in methods and compositions of the present invention is, in another P-7771-PC3 embodiment, a CpG-containing nucleotide sequence.
- the adjuvant is a CpG- containing oligonucleotide.
- the adjuvant is a CpG-containing oligodeoxynucleotide (CpG ODN).
- the adjuvant is ODN 1826, which in one embodiment, is acquired from Coley Pharmaceutical Group.
- the adjuvant is an aluminum salt adjuvant.
- the adjuvant is a Montanide ISA adjuvant.
- the adjuvant is a trimer of complement component C3d.
- the trimer is covalently linked to the protein immunogen.
- the adjuvant is MF59.
- the adjuvant is a granulocyte/macrophage colony-stimulating factor (GM-CSF) protein.
- the adjuvant is a mixture comprising a GM-CSF protein.
- the adjuvant is a nucleotide molecule encoding GM-CSF.
- the adjuvant is a mixture comprising a nucleotide molecule encoding GM-CSF.
- the adjuvant is saponin QS21.
- the adjuvant is a mixture comprising saponin QS21.
- the adjuvant is monophosphoryl lipid A (MPL). In another embodiment, the adjuvant is a mixture comprising MPL. In another embodiment, the adjuvant is SBAS2. In another embodiment, the adjuvant is a mixture comprising SBAS2. In another embodiment, the adjuvant is an unmethylated CpG-containing oligonucleotide. In another embodiment, the adjuvant is a mixture comprising an unmethylated CpG-containing oligonucleotide. In another embodiment, the adjuvant is an immune-stimulating cytokine. In another embodiment, the adjuvant is a mixture comprising an immune-stimulating cytokine.
- the adjuvant is a nucleotide molecule encoding an immune-stimulating cytokine. In another embodiment, the adjuvant is a mixture comprising a nucleotide molecule encoding an immune-stimulating cytokine. In another embodiment, the adjuvant is a mixture comprising a quill glycoside. In another embodiment, the adjuvant is a mixture comprising a bacterial mitogen. In another embodiment, the adjuvant is a mixture comprising a bacterial toxin. In another embodiment, the adjuvant is a mixture comprising any other adjuvant known in the art. In another embodiment, the adjuvant is a mixture of one or more of the above adjuvants.
- CpG-containing nucleotide refers, in another embodiment, to a nucleotide molecule of 8-50 nucleotides in length that contains an unmethylated CpG moiety.
- nucleic acids or “nucleotide” refers to a string of at least 2 base- sugar-phosphate combinations.
- the term includes, in another embodiment, DNA and RNA.
- Nucleotides refers, in one embodiment, to the monomelic units of nucleic acid polymers.
- RNA is, in one embodiment, in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA
- DNA can be, in other embodiments, in form of plasmid DNA, viral DNA, linear DNA, or chromosomal DNA or derivatives of these groups.
- these forms of DNA and RNA can be single, double, triple, or quadruple stranded.
- the term also includes, in another embodiment, artificial nucleic acids that contain other types of backbones but the same bases.
- the artificial nucleic acid is a PNA (peptide nucleic acid).
- PNA peptide nucleic acid
- PNA contain peptide backbones and nucleotide bases and are able to bind, in one embodiment, to both DNA and RNA molecules.
- the nucleotide is oxetane modified.
- the nucleotide is modified by replacement of one or more phosphodiester bonds with a phosphorothioate bond.
- the artificial nucleic acid contains any other variant of the phosphate backbone of native nucleic acids known in the art.
- nucleic acids and PNA are known to those skilled in the art, and are described in, for example, Neilsen PE, Curr Opin Struct Biol 9:353-57; and Raz NK et al. Biochem Biophys Res Commun. 297:1075-84.
- the production and use of nucleic acids is known to those skilled in art and is described, for example, in Molecular Cloning, (2001), Sambrook and Russell, eds. and Methods in Enzymology: Methods for molecular cloning in eukaryotic cells (2003) Purchio and G. C. Fareed. Each nucleic acid derivative represents a separate embodiment of the present invention.
- Each type of modified oligonucleotide represents a separate embodiment of the present invention.
- E7 protein or a fragment thereof is fused to a LLO protein, ActA protein, or PEST-like sequence-containing peptide to generate a recombinant peptide of methods of the present invention.
- the E7 protein that is utilized (either whole or as the source of the fragments) has, in another embodiment, the sequence:
- the E7 protein is a homologue of SEQ ID NO: 30. In another embodiment, the E7 protein is a variant of SEQ ID NO: 30. In another embodiment, the E7 protein is an isoform of SEQ
- the E7 protein is a fragment of SEQ ID NO: 30.
- the E7 protein is a fragment of a homologue of SEQ ID NO: 30.
- the E7 protein is a fragment of a variant of SEQ ID NO: 30.
- the E7 protein is a fragment of an isoform of SEQ ID NO: 30.
- sequence of the E7 protein is:
- the E7 protein is a homologue of SEQ ID NO: 31.
- the E7 protein is a variant of SEQ ID NO: 31.
- the E7 protein is an isoform of SEQ ID NO: 31.
- the E7 protein is a fragment of SEQ ID NO: 31.
- the E7 protein is a fragment of a homologue of SEQ ID NO: 31.
- the E7 protein is a fragment of a variant of SEQ ID NO: 31.
- the E7 protein is a fragment of an isoform of SEQ ID NO: 31.
- the E7 protein is encoded by a nucleic acid sequence set forth in one of the following GenBank entries: M24215, NC_004500, VOl 116, X62843, M14119 or other sequences known in the art.
- the E7 protein has the sequence set forth in NCBFs Genbank Accession No.: NPJ775306.1, CAA24316.1, CAA44648.1, AAA46928.1, CAA75471, CAA63874, CAA63883.1, NP_932320.1, NP_043417.1, AAR13015.1 or other sequences known in the art.
- the E7 protein is a homologue of a sequence from one of the above GenBank entries.
- the E7 protein is a variant of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is an isoform of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a fragment of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a fragment of a homologue of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a fragment of a variant of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a fragment of an isoform of a sequence from one of the above GenBank entries. Each possibility represents a separate embodiment of the present invention..
- E6 protein or a fragment thereof is fused to a LLO protein, ActA protein, or PEST-like sequence-containing peptide to generate a recombinant peptide of methods of the present invention.
- the E6 protein that is utilized (either whole or as the source of the P-7771-PC3 fragments) has, in another embodiment, the sequence
- E6 protein is a homologue of SEQ ID NO: 32.
- E6 protein is a variant of SEQ ID NO: 32.
- E6 protein is an isoform of SEQ ID NO: 32.
- E6 protein is a fragment of SEQ ID NO: 32.
- the E6 protein is a fragment of a homologue of SEQ ID NO: 32. In another embodiment, the E6 protein is a fragment of a variant of SEQ ID NO: 32. In another embodiment, the E6 protein is a fragment of an isoform of SEQ ID NO: 32.
- sequence of the E6 protein is:
- the E6 protein is a homologue of SEQ ID NO: 33.
- the E6 protein is a variant of SEQ ID NO: 33.
- the E6 protein is an isoform of SEQ ID NO: 33.
- the E6 protein is a fragment of SEQ ID NO: 33.
- the E6 protein is a fragment of a homologue of SEQ ID NO: 33. In another embodiment, the E6 protein is a fragment of a variant of SEQ ID NO: 33. In another embodiment, the E6 protein is a fragment of an isoform of SEQ ID NO: 33.
- the E6 protein is encoded by a nucleic acid sequence set forth in one of the following GenBank entries: NC_004500, VOl 116, X62843, M14119 or other sequences known in the art.
- the E6 protein has the sequence set forth in NCBFs Genbank Accession No.: NP_775305.1, CAA24314.1 , CAA44647.1, AAA46927.1, ABI32364.1 , AAY69378.1, AAY69373.1, AAY69366.1, CAA63881.1, CAA75470.1, NP_932319.1, AAP 19632.1, or other sequences known in the art.
- the E6 protein is a homologue of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is a variant of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is an isoform of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is a fragment of a sequence from one of the above GenBank entries. In another embodiment, the E6 P-7771-PC3 protein is a fragment of a homologue of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is a fragment of a variant of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is a fragment of an isoform of a sequence from one of the above GenBank entries. Each possibility represents a separate embodiment of the present invention.
- variant refers to an amino acid or nucleic acid sequence (or in other embodiments, an organism or tissue) that is different from the majority of the population but is still sufficiently similar to the common mode to be considered to be one of them, for example splice variants.
- isoform refers to a version of a molecule, for example, a protein, with only slight differences compared to another isoform, or version, of the same protein.
- isoforms may be produced from different but related genes, or in another embodiment, may arise from the same gene by alternative splicing.
- isoforms are caused by single nucleotide polymorphisms.
- fragment refers to a protein or polypeptide that is shorter or comprises fewer amino acids than the full length protein or polypeptide.
- fragment refers to a nucleic acid that is shorter or comprises fewer nucleotides than the full length nucleic acid.
- the fragment is an N-terminal fragment.
- the fragment is a C-terminal fragment.
- the fragment is an intrasequential section of the protein, peptide, or nucleic acid.
- the fragment is a functional fragment.
- the fragment is an immunogenic fragment.
- a fragment has 10-20 nucleic or amino acids, while in another embodiment, a fragment has more than 5 nucleic or amino acids, while in another embodiment, a fragment has 100-200 nucleic or amino acids, while in another embodiment, a fragment has 100-500 nucleic or amino acids, while in another embodiment, a fragment has 50-200 nucleic or amino acids, while in another embodiment, a fragment has 10-250 nucleic or amino acids.
- immunogenicity or “immunogenic” is used herein to refer to the innate ability of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response in an animal when the protein, peptide, nucleic acid, antigen or organism is administered to the animal.
- enhancing the immunogenicity in one embodiment, refers to increasing the ability of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response in an animal when the protein, peptide, nucleic acid, antigen or organism is administered to an animal.
- the increased ability P-7771-PC3 of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response can be measured by, in one embodiment, a greater number of antibodies to a protein, peptide, nucleic acid, antigen or organism, a greater diversity of antibodies to an antigen or organism, a greater number of T-cells specific for a protein, peptide, nucleic acid, antigen or organism, a greater cytotoxic or helper T-cell response to a protein, peptide, nucleic acid, antigen or organism, and the like.
- treating refers to either therapeutic treatment or prophylactic or preventative measures, wherein the object is to prevent or lessen the targeted pathologic condition or disorder as described hereinabove.
- treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing the severity of, delaying the onset of, reducing symptoms associated with the disease, disorder or condition, or a combination thereof.
- "treating” refers inter alia to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof.
- preventing refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof.
- “suppressing” or “inhibiting” refers inter alia to reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.
- a "homologue” refers to a nucleic acid or amino acid sequence which shares a certain percentage of sequence identity with a particular nucleic acid or amino acid sequence.
- a sequence useful in the composition and methods of the present invention may be a homologue of a particular LLO sequence or N-terminal fragment thereof, ActA sequence or N- terminal fragment thereof, E7 sequence, E6 sequence, or PEST-like sequence described herein or known in the art.
- a sequence useful in the composition and methods of the present invention may be a homologue of any sequence described herein.
- a homologue shares at least 70% identity with a particular sequence.
- a homologue shares at least 72% identity with a particular sequence.
- a homologue shares at least 75% identity with a particular sequence. In another embodiment, a homologue shares at least 78% identity with a particular sequence. In another embodiment, a homologue shares at least 80% identity with a particular sequence. In another embodiment, a homologue shares at least 82% identity with a particular sequence. In another embodiment, a homologue shares at least 83% identity with a particular sequence. In another embodiment, a P-7771-PC3 homologue shares at least 85% identity with a particular sequence. In another embodiment, a homologue shares at least 87% identity with a particular sequence. In another embodiment, a homologue shares at least 88% identity with a particular sequence. In another embodiment, a homologue shares at least 90% identity with a particular sequence.
- a homologue shares at least 92% identity with a particular sequence. In another embodiment, a homologue shares at least 93% identity with a particular sequence. In another embodiment, a homologue shares at least 95% identity with a particular sequence. In another embodiment, a homologue shares at least 96% identity with a particular sequence. In another embodiment, a homologue shares at least 97% identity with a particular sequence. In another embodiment, a homologue shares at least 98% identity with a particular sequence. In another embodiment, a homologue shares at least 99% identity with a particular sequence. In another embodiment, a homologue shares 100% identity with a particular sequence. Each possibility represents a separate embodiment of the present invention.
- "functional" within the meaning of the invention is used herein to refer to the innate ability of a protein, peptide, nucleic acid, fragment or a variant thereof to exhibit a biological activity or function.
- a biological function is its binding property to an interaction partner, e.g., a membrane-associated receptor, and in another embodiment, its trimerization property.
- these biological functions may in fact be changed, e.g., with respect to their specificity or selectivity, but with retention of the basic biological function.
- Protein and/or peptide homology for any AA sequence listed herein is determined, in one embodiment, by methods well described in the art, including immunoblot analysis, or via computer algorithm analysis of AA sequences, utilizing any of a number of software packages available, via established methods. Some of these packages include the FASTA, BLAST, MPsrch or Scanps packages, and employ, in other embodiments, the use of the Smith and Waterman algorithms, and/or global/local or BLOCKS alignments for analysis, for example. Each method of determining homology represents a separate embodiment of the present invention.
- the LLO protein, ActA protein, or fragment thereof is attached to the E7 or E6 antigen by chemical conjugation.
- glutaraldehyde is used for the conjugation.
- the conjugation is performed using any suitable method known P-7771-PC3 in the art. Each possibility represents another embodiment of the present invention.
- fusion proteins of the present invention are prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods discussed below.
- subsequences are cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments are then ligated, in another embodiment, to produce the desired DNA sequence.
- DNA encoding the fusion protein is produced using DNA amplification methods, for example polymerase chain reaction (PCR). First, the segments of the native DNA on either side of the new terminus are amplified separately.
- the 5' end of the one amplified sequence encodes the peptide linker, while the 3' end of the other amplified sequence also encodes the peptide linker. Since the 5' end of the first fragment is complementary to the 3' end of the second fragment, the two fragments (after partial purification, e.g. on LMP agarose) can be used as an overlapping template in a third PCR reaction.
- the amplified sequence will contain codons, the segment on the carboxy side of the opening site (now forming the amino sequence), the linker, and the sequence on the amino side of the opening site (now forming the carboxyl sequence).
- the insert is then ligated into a plasmid.
- the term “comprising” refers to the inclusion of other recombinant polypeptides, amino acid sequences, or nucleic acid sequences, as well as inclusion of other polypeptides, amino acid sequences, or nucleic acid sequences, that may be known in the art, which in one embodiment may comprise antigens or Listeria polypeptides, amino acid sequences, or nucleic acid sequences.
- the term “consisting essentially of” refers to a composition for use in the methods of the present invention, which has the specific recombinant polypeptide, amino acid sequence, or nucleic acid sequence, or fragment thereof.
- compositions for use in the methods of the present invention having a particular recombinant polypeptide, amino acid sequence, or nucleic acid sequence, or fragment or combination of recombinant polypeptides, amino acid sequences, or nucleic acid sequences or fragments of the present invention, in any form or embodiment as described herein.
- the LLO protein, ActA protein, the E7, E6, or other antigen, or fragment thereof are conjugated by a means known to those of skill in the art.
- the E7, E6, or fragment thereof is conjugated, either directly or through a linker (spacer), to the ActA protein or LLO protein.
- the chimeric molecule is recombinantly expressed as P-7771-PC3 a single-chain fusion protein.
- a fusion peptide of the present invention is synthesized using standard chemical peptide synthesis techniques.
- the chimeric molecule is synthesized as a single contiguous polypeptide.
- the LLO protein, ActA protein, the E7, E6, or other antigen, or fragment thereof are synthesized separately, then fused by condensation of the amino terminus of one molecule with the carboxyl terminus of the other molecule, thereby forming a peptide bond.
- the ActA protein or LLO protein and antigen are each condensed with one end of a peptide spacer molecule, thereby forming a contiguous fusion protein.
- the peptides and proteins of the present invention are prepared by solid-phase peptide synthesis (SPPS) as described by Stewart et al. in Solid Phase Peptide Synthesis,
- a suitably protected AA residue is attached through its carboxyl group to a derivatized, insoluble polymeric support, such as cross-linked polystyrene or polyamide resin.
- "Suitably protected” refers to the presence of protecting groups on both the alpha-amino group of the amino acid, and on any side chain functional groups. Side chain protecting groups are generally stable to the solvents, reagents and reaction conditions used throughout the synthesis, and are removable under conditions which will not affect the final peptide product.
- Stepwise synthesis of the oligopeptide is carried out by the removal of the N-protecting group from the initial AA, and couple thereto of the carboxyl end of the next AA in the sequence of the desired peptide.
- This AA is also suitably protected.
- the carboxyl of the incoming AA can be activated to react with the N-terminus of the support-bound AA by formation into a reactive group such as formation into a carbodiimide, a symmetric acid anhydride or an "active ester" group such as hydroxybenzotriazole or pentafluorophenly esters.
- the present invention provides a kit to for conveniently practicing the methods of the present invention comprising one or more vaccines of the present invention, an applicator, and instructional material that describes how to use the kit components in practicing the methods of the present invention.
- compositions used in any methods of the present invention may be used in the preparation of a composition for treating, preventing, inhibiting, suppressing, or ameliorating symptoms associated with, the diseases and conditions described in the present invention.
- TC-I The C57BL/6 syngeneic TC-I tumor was immortalized with HPV- 16 E6 and E7 and transformed with the c-Ha-ras oncogene.
- TC-I provided by T. C. Wu (Johns Hopkins University School of Medicine, Baltimore, MD) is a highly tumorigenic lung epithelial cell expressing low levels of with HPV- 16 E6 and E7 and transformed with the c-Ha-ras oncogene.
- TC-I was grown in RPMI 1640, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 100 ⁇ M nonessential amino acids, 1 mM sodium pyruvate, 50 micromolar (mcM) 2-ME, 400 microgram (mcg)/ml G418, and 10% National Collection Type Culture-109 medium at 37° with 10% CO 2 .
- C3 is a mouse embryo cell from C57BL/6 mice immortalized with the complete genome of HPV 16 and transformed with pEJ-ras.
- EL-4/E7 is the thymoma EL-4 retrovirally transduced with E7.
- Listeria strains used were Lm-LLO-E7 (hly-E7 fusion gene in an episomal expression system; Figure IA), Lm-E7 (single-copy E7 gene cassette integrated into Listeria genome), Lm-LLO-NP ("DP-L2028”; hly-NP fusion gene in an episomal expression system), and Lm-Gag ("ZY-18"; single- copy HIV-I Gag gene cassette integrated into the chromosome).
- E7 was amplified by PCR using the primers 5'-GGCTCGAGCATGGAGATACACC-S' (SEQ ID NO: 8; Xhol site is underlined) and 5'- GGGGACTAGTTTATGGTTTCTGAGAACA-S' (SEQ ID NO: 9; Spel site is underlined) and ligated into pCR2.1 (Invitrogen, San Diego, CA). E7 was excised from pCR2.1 by Xhol/ Spel digestion and ligated into pGG-55.
- the hly-E7 fusion gene and the pluripotential transcription factor prfA were cloned into pAM401 , a multicopy shuttle plasmid (Wirth R et al, J Bacterid, 165: 831, 1986), generating pGG-55.
- the hly promoter drives the expression of the first 441 AA of the hly gene product, (lacking the hemolytic C-terminus, referred to below as " ⁇ LLO,” and having the sequence set forth in SEQ ID NO: 25), which is joined by the Xhol site to the E7 gene, yielding a hly-E7 fusion gene that is transcribed and secreted as LLO-E7.
- the prfA gene was PCR amplified using primers 5'- GACTACAAGGACGATGACCGACAAGTGATAACCCGGGATCTAAATAAATCCGTTT-S' (SEQ ID NO: 12; Xbal site is underlined) and 5'-CCCGTCGACCAGCTCTTCTTGGTGAAG-S' (SEQ ID NO: 13; Sail site is underlined).
- Lm-E7 was generated by introducing an expression cassette containing the hly promoter and signal sequence driving the expression and secretion of E7 into the orfZ domain of the LM genome.
- E7 was amplified by PCR using the primers 5'- GCGGATCCCATGGAGATACACCTAC-3' (SEQ ID NO: 28; BamHI site is underlined) and 5'- GCTCTAGATTATGGTTTCTGAG-S' (SEQ ID NO: 29; Xbal site is underlined). E7 was then ligated into the pZY-21 shuttle vector. LM strain 10403S was transformed with the resulting plasmid, pZY- 21-E7, which includes an expression cassette inserted in the middle of a 1.6-kb sequence that corresponds to the orfX, Y, Z domain of the LM genome.
- the homology domain allows for insertion of the E7 gene cassette into the orfZ domain by homologous recombination.
- Clones were screened for integration of the E7 gene cassette into the orfZ domain.
- Bacteria were grown in brain heart infusion medium with (Lm-LLO-E7 and Lm-LLO-NP) or without (Lm-E7 and ZY- 18) chloramphenicol (20 ⁇ g/ml). Bacteria were frozen in aliquots at -80 0 C. Expression was verified by Western blotting ( Figure 2).
- the gels were transferred to polyvinylidene difluoride and probed with an anti-E7 monoclonal antibody (mAb) (Zymed Laboratories, South San Francisco, CA), then incubated with HRP- conjugated anti-mouse secondary Ab (Amersham Pharmacia Biotech, Little Chalfont, U.K.), developed with Amersham ECL detection reagents, and exposed to Hyperfilm (Amersham Pharmacia Biotech).
- mAb monoclonal antibody
- Tumors were measured every other day with calipers spanning the shortest and longest surface diameters. The mean of these two measurements was plotted as the mean tumor diameter in millimeters against various time points. Mice were sacrificed when the tumor diameter reached 20 mm. Tumor measurements for each time point are shown only for surviving mice. P-7771-PC3 Effects of Listeria recombinants on established tumor growth
- spleens were harvested.
- Splenocytes were established in culture with irradiated TC-I cells (100:1, splenocytes:TC-l) as feeder cells; stimulated in vitro for 5 days, then used in a standard 51 Cr release assay, using the following targets: EL-4, EL- 4/E7, or EL-4 pulsed with E7 H-2b peptide (RAHYNTVTF).
- E:T cell ratios were 80:1, 40:1, 20:1, 10:1, 5:1, and 2.5:1. Following a 4-h incubation at 37°C, cells were pelleted, and 50 ⁇ l supernatant was removed from each well. Samples were assayed with a Wallac 1450 scintillation counter (Gaithersburg, MD). The percent specific lysis was determined as [(experimental counts per minute (cpm)- spontaneous cpm)/(total cpm - spontaneous cpm)] x 100.
- C57BL/6 mice were immunized with 0.1 LD50 and boosted by i.p. injection 20 days later with 1 LD 50 Lm-LLO-E7, Lm-E7, Lm-LLO-NP, or Lm-Gag.
- spleens were harvested from immunized and naive mice.
- Splenocytes were established in culture at 5 x 10 5 /well in flat-bottom 96- well plates with 2.5 x 10 4 , 1.25 x 10 4 , 6 x 10 3 , or 3 x 10 3 irradiated TC-I cells/well as a source of E7 Ag, or without TC-I cells or with 10 ⁇ g/ml Con A.
- C57BL/6 mice were immunized intravenously (i.v.) with 0.1 LD50 Lm-LLO-E7 or Lm-E7 and boosted 30 days later.
- Three-color flow cytometry for CD8 (53-6.7, PE conjugated), CD62 ligand (CD62L; MEL- 14, APC conjugated), and E7 H-2Db tetramer was performed using a FACSCalibur® flow cytometer with CellQuest® software (Becton Dickinson, Mountain View, CA).
- CD8 + , CD62L low cells were analyzed.
- mice 24 C57BL/6 mice were inoculated with 5 x 10 5 B16F0-Ova cells. On days 3, 10 and 17, groups of 8 mice were immunized with 0.1 LD 50 Lm-OVA (10 6 cfu), Lm-LLO-OVA (10 8 cfu) and eight animals were left untreated.
- Lm-E7 and Lm-LLO-E7 were compared for their abilities to impact on TC-I growth.
- Subcutaneous tumors were established on the left flank of C57BL/6 mice. Seven days later tumors had reached a palpable size (4-5 mm).
- Mice were vaccinated on days 7 and 14 with 0.1 LD 5 O Lm-E7, Lm- LLO-E7, or, as controls, Lm-Gag and Lm-LLO-NP.
- Lm-LLO-E7 induced complete regression of 75% of established TC-I tumors, while tumor growth was controlled in the other 2 mice in the group ( Figure 3). By contrast, immunization with Lm-E7 and Lm-Gag did not induce tumor regression.
- EXAMPLE 2 LM-LLO-E7 TREATMENT ELICITS TC l SPECIFIC SPLENOCYTE
- EXAMPLE 3 ActA-E7 and PEST-E7 FUSIONS CONFER ANTI-TUMOR IMMUNITY
- Lm-ActA-E7 is a recombinant strain of LM, comprising a plasmid that expresses the E7 protein fused to a truncated version of the actA protein.
- Lm-actA-E7 was generated by introducing a plasmid vector pDD-1, constructed by modifying pDP-2028, into Listeria.
- pDD-1 comprises an expression cassette expressing a copy of the 310 bp hly promoter and the hly signal sequence (ss), which drives the expression and secretion of ActA-E7; 1 170 bp of the actA gene that comprises four PEST sequences (SEQ ID NO: 37) (the truncated ActA polypeptide consists of the first 390 AA of the molecule, SEQ ID NO: 36); the 300 bp HPV E7 gene; the 1019 bp prfA gene (controls expression of the virulence genes); and the CAT gene (chloramphenicol resistance gene) for selection of transformed bacteria clones (Sewell et al. (2004), Arch. Otolaryngol. Head Neck Surg., 130: 92-97).
- the hly promoter (pHly) and gene fragment were PCR amplified from pGG55 (Example 1 ) using primer 5'-GGGGTCTAGACCTCCTTTGATTAGTATATTC-S' (Xba I site is underlined; SEQ ID NO: 14) and primer 5'-ATCTTCGCTATCTGTCGCCGCGGCGCGTGCTTCAGTTTGTTGCGC- '3 (Not I site is underlined.
- the first 18 nucleotides are the ActA gene overlap; SEQ ID NO: 15).
- actA gene was PCR amplified from the LM 10403s wildtype genome using primer 5'- GCGCAACAAACTGAAGCAGCGGCCGCGGCGACAGATAGCGAAGAT-S' (Notl site is underlined; SEQ ID NO: 16) and primer 5'-
- the E7 gene was PCR amplified from pGG55 (pLLO-E7) using primer 5'- GGAATTGATCGCCTAGCTCTCGAGCATGGAGATACACCTACA-S 1 (Xhol site is underlined; SEQ ID NO: 18) and primer 5'-
- a AACGGATTT ATTTAGATCCCGGGTTATGGTTTCTGAGAACA-3' (Xmal site is underlined; SEQ ID NO: 19).
- the prfA gene was PCR amplified from the LM 10403s wild-type genome using primer 5'-TGTTCTCAGAAACCATAACCCGGGATCTAAATAAATCCGTTT-S' (Xmal site is underlined; SEQ ID NO: 20) and primer 5'-GGGGGTCGACCAGCTCTTCTTGGTGAAG-S' (Sail site is underlined; SEQ ID NO: 21 ).
- the hly promoter- actA gene fusion was PCR P-7771-PC3 generated and amplified from purified pHly DNA and purified actA DNA using the upstream pHly primer (SEQ ID NO: 14) and downstream actA primer (SEQ ID NO: 17).
- E7 gene fused to the prfA gene was PCR generated and amplified from purified E7 DNA and purified prfA DNA using the upstream E7 primer (SEQ ID NO: 18) and downstream prfA gene primer (SEQ ID NO: 21).
- the pHly-actA fusion product fused to the E7-prfA fusion product was PCR generated and amplified from purified fused pHly-actA DNA product and purified fused E7-prfA DNA product using the upstream pHly primer (SEQ ID NO: 14) and downstream prfA gene primer (SEQ ID NO: 21) and ligated into pCRII (Invitrogen, La Jolla, Calif.). Competent E. coli (TOPIO'F, Invitrogen, La Jolla, Calif.) were transformed with pCRII-ActAE7.
- the plasmid was screened by restriction analysis using BamHI (expected fragment sizes 770 bp and 6400 bp (or when the insert was reversed into the vector: 2500 bp and 4100 bp)) and BstXI (expected fragment sizes 2800 bp and 3900 bp) and also screened with PCR analysis using the upstream pHly primer (SEQ ID NO: 14) and the downstream prfA gene primer (SEQ ID NO: 21).
- pHly-actA-E7- ⁇ rfA DNA insert was excised from pCRII by double digestion with Xba I and Sal I and ligated into pDP-2028 also digested with Xba I and Sal I. After transforming TOPIO'F competent E. coli (Invitrogen, La Jolla, Calif.) with expression system pActAE7, chloramphenicol resistant clones were screened by PCR analysis using the upstream pHly primer (SEQ ID NO: 14) and the downstream PrfA gene primer (SEQ ID NO: 21).
- a clone comprising pActAE7 was grown in brain heart infusion medium (with chloramphenicol (20 meg (microgram)/ml (milliliter), Difco, Detroit, Mich.) and pActAE7 was isolated from the bacteria cell using a midiprep DNA purification system kit (Promega, Madison, Wis.).
- a prfA-negative strain of penicillin-treated Listeria was transformed with expression system pActAE7, as described in Dconomidis et al. (1994, J. Exp. Med. 180: 2209-2218) and clones were selected for the retention of the plasmid in vivo.
- Clones were grown in brain heart infusion with chloramphenicol (20 mcg/ml) at 37 0 C. Bacteria were frozen in aliquots at -80 0 C.
- Tris-glycine sodium dodecyl sulfate-polyacrylamide gels (NOVEX, San Diego, Calif). Gels were transferred to P-7771-PC3 polyvinylidene difluoride membranes and probed with 1 :2500 anti-E7 monoclonal antibody (Zymed Laboratories, South San Francisco, Calif), then with 1 :5000 horseradish peroxidase-conjugated anti- mouse IgG (Amersham Pharmacia Biotech, Little Chalfont, England). Blots were developed with Amersham enhanced chemiluminescence detection reagents and exposed to autoradiography film (Amersham) ( Figure 5A).
- Lm-PEST-E7 is identical to Lm-LL0-E7, except that it contains only the promoter and PEST sequence of the hly gene, specifically the first 50 AA of LLO.
- the hly promoter and PEST regions were fused to the full-length E7 gene using the SOE (gene splicing by overlap extension) PCR technique.
- the E7 gene and the hly-PEST gene fragment were amplified from the plasmid pGG-55, which contains the first 441 AA of LLO, and spliced together by conventional PCR techniques.
- pVS16.5 To create a final plasmid, pVS16.5, the hly-PEST-E7 fragment and the prfA gene were subcloned into the plasmid pAM401, which includes a chloramphenicol resistance gene for selection in vitro, and the resultant plasmid was used to transform XFL-7.
- Lm- ⁇ PEST-E7 is a recombinant Listeria strain that is identical to Lm- LLO-E7 except that it lacks the PEST sequence. It was made essentially as described for Lm-PEST-E7, except that the episomal expression system was constructed using primers designed to remove the PEST-containing region (bp 333-387) from the hly-E7 fusion gene.
- Lm-E7epi is a recombinant strain that secretes E7 without the PEST region or LLO. The plasmid used to transform this strain contains a gene fragment of the hly promoter and signal sequence fused to the E7 gene.
- Lm-E7epi is completely isogenic to Lm- LLO-E7, Lm-PEST-E7, and Lm- ⁇ PEST-E7 except for the form of the E7 antigen expressed.
- Lm-LLO-E7, Lm-PEST-E7, Lm- ⁇ PEST-E7, and Lm-E7epi were compared for P-7771-PC3 their ability to cause regression of E7-expressing tumors.
- S.c. TC-I tumors were established on the left flank of 40 C57BL/6 mice. After tumors had reached 4-5 mm, mice were divided into 5 groups of 8 mice. Each groups was treated with 1 of 4 recombinant LM vaccines, and 1 group was left untreated.
- Lm-LLO-E7 and Lm-PEST-E7 induced regression of established tumors in 5/8 and 3/8 cases, respectively.
- EXAMPLE 4 FUSION OF E7 TO LLO. ActA. OR A PEST-LIKE SEQUENCE ENHANCES E7-SPECIFIC IMMUNITY AND GENERATES TUMOR-INFILTRATING E7-SPECIFIC
- [00359] 500 mcl (microliter) of MATRIGEL®, comprising 100 mcl of 2 x 10 5 TC-I tumor cells in phosphate buffered saline (PBS) plus 400 mcl of MATRIGEL® (BD Biosciences, Franklin Lakes, N.J.) were implanted subcutaneously on the left flank of 12 C57BL/6 mice (n 3). Mice were immunized intraperitoneally on day 7, 14 and 21, and spleens and tumors were harvested on day 28. Tumor MATRIGELs were removed from the mice and incubated at 4 0 C overnight in tubes containing 2 milliliters (ml) of RP 10 medium on ice.
- PBS phosphate buffered saline
- MATRIGEL® BD Biosciences, Franklin Lakes, N.J.
- Tumors were minced with forceps, cut into 2 mm blocks, and incubated at 37 °C for 1 hour with 3 ml of enzyme mixture (0.2 mg/ml collagenase-P, 1 mg/ml DNAse-1 in PBS). The tissue suspension was filtered through nylon mesh and washed with 5% fetal bovine serum + 0.05% of NaN 3 in PBS for tetramer and IFN-gamma staining.
- Splenocytes and tumor cells were incubated with 1 micromole (mem) E7 peptide for 5 hours in the presence of brefeldin A at 10 7 cells/ml.
- Cells were washed twice and incubated in 50 mcl of anti-mouse Fc receptor supernatant (2.4 G2) for 1 hour or overnight at 4 0 C.
- Cells were stained for surface molecules CD8 and CD62L, permeabilized, fixed using the permeabilization kit Golgi-stop® or Golgi-Plug® (Pharmingen, San Diego, Calif.), and stained for IFN-gamma.
- 500,000 events were acquired using two-laser flow cytometer FACSCalibur and analyzed using Cellquest Software (Becton P-7771-PC3
- H-2D b tetramer was loaded with phycoerythrin (PE)-conjugated E7 peptide (RAHYNIVTF, SEQ BD NO: 22), stained at rt for 1 hour, and stained with anti- allophycocyanin (APC) conjugated MEL- 14 (CD62L) and FITC-conjugated CD8D at 4 0 C for 30 min.
- PE phycoerythrin
- APC anti- allophycocyanin conjugated MEL- 14
- CD8D FITC-conjugated CD8D
- mice were implanted with TC-I tumor cells and immunized with either Lm-LLO-E7 (1 x 10 7 CFU), Lm-E7 (1 x 10 6 CFU), or Lm-ActA-E7 (2 x 10 8 CFU), or were untreated (naive). Tumors of mice from the Lm-
- LLO-E7 and Lm-ActA-E7 groups contained a higher percentage of IFN-gamma-secreting CD8 + T cells (Figure 7A) and tetramer-specific CD8 + cells ( Figure 7B) than in Lm-E7 or naive mice.
- mice were administered Lm-LLO-E7, Lm-PEST-E7, Lm- ⁇ PEST-E7, or Lm-E7epi, and levels of E7-specific lymphocytes within the tumor were measured.
- Mice were treated on days 7 and 14 with 0.1 LD 50 of the 4 vaccines. Tumors were harvested on day 21 and stained with antibodies to CD62L, CD8, and with the E7/Db tetramer. An increased percentage of tetramer-positive lymphocytes within the tumor were seen in mice vaccinated with Lm-LL0-E7 and Lm-PEST-E7 (Figure 8A). This result was reproducible over three experiments ( Figure 8B).
- Lm-LLO-E7, Lm-ActA-E7, and Lm-PEST-E7 are each efficacious at induction of tumor-infiltrating CD8 + T cells and tumor regression.
- EXAMPLE 5 E6/E7 TRANSGENIC MOUSE PHENOTYPE: A MODEL FOR SPONTANEOUS TUMOR GROWTH AND TOLERANCE TO A TUMOR ANTIGEN
- the zygosity of Fl breeding pair derived generations was P-7771-PC3 determined by Taqman real-time PCR and the ⁇ Ct method (Charles River, 2001). Homozygous E7 transgenic mice were selected for F2 x F2 breeding. The subsequent F3 generation was screened via Taqman real-time PCR and backcrossing to confirm fidelity of homozygosity. The levels of gene copy number and transgene expression of the E7 gene was assessed for every homozygous line using Taqman real-time PCR. After 6 back-crossings, these lines were used as the parents of the colony. Transgene expression was further confirmed by appearance of thyroid hyperplasia, as described in the Results section.
- E6/E7 transgenic mice were generated, and their phenotype assessed. The mice began to develop thyroid hyperplasia at 8 weeks and palpable goiters at 6 months. By 6 to 8 months, most mice exhibited thyroid cancer. Transgenic mice sacrificed at 3 months of age exhibited de-differentiation of the normal thyroid architecture, indicative of an early stage of cancer. The enlarged, de-differentiated cells were filled with colloid, where thyroid hormones accumulate (Figure 9).
- EXAMPLE 6 E7 IS EXPRESSED IN MEDULLARY THYMIC EPITHELIAL CELLS OF E6/E7 TRANSGENIC MICE
- AIRE is a transcription factor that maintains tolerance to self.
- E7 is expressed in the thymus of the transgenic mice, P-7771-PC3 showing that these mice exhibit tolerance to the E7 antigen.
- EXAMPLE 7 PEPTIDE-BASED VACCINES DO NOT PROTECT AGAINST TUMOR CHALLENGE IN E6/E7 TRANSGENIC MICE
- E6/E7 transgenic mice were tested in a tumor protection experiment using an E7 peptide (RAHYNIVTF)-based vaccine, along with the immunostimulatory CpG sequence 1826 (Krieg AM, Yi AK, Matson S, Waldschmidt
- EXAMPLE 8 LLO AND ActA FUSIONS OVERCOME IMMUNE TOLERANCE OF E6/E7 TRANSGENIC MICE TO E7-EXPRESSING TUMORS
- mice 10 5 TC-I cells were implanted subcutaneously (s.c.) and allowed to form solid tumors in 6-8 week old wild-type and transgenic mice 7 and 14 days later, mice were left unimmunized or were immunized i.p. with LM-NP (control), 1 x 10 cfu LM-LLO-E7 ( Figure 12A) or 2.5 x 10 8 cfu LM-ActA-E7 ( Figure 12B). The naive mice had a large tumor burden, as anticipated, and were sacrificed by day 28 or 35 due to tumors of over 2 cm.
- vaccines of the present invention were able to overcome immune tolerance of E6/E7 transgenic mice to E7 -expressing tumors.
- LLO-antigen and ActA-antigen fusions (a) induce tumor-specific immune response that include tumor-infiltrating antigen-specific T cells; and are capable of inducing tumor regression and controlling tumor growth of both normal and particularly aggressive tumors; (b) overcome tolerance to self antigens; and (c) prevent spontaneous tumor growth.
- These findings are generalizable to a large number of antigens, PEST-like sequences, and tumor types, as evidenced by their successful implementation with a variety of different antigens, PEST-like sequences, and tumor types.
- EXAMPLE 10 LM-LLO-E7 VACCINES ARE SAFE AND IMPROVE CLINICAL INDICATORS IN CERVICAL CANCER PATIENTS
- Study Design The study was an open label, non-randomized study. A total of 20 adult females with progressive, recurrent or advanced squamous cell carcinoma of the cervix were to be enrolled into the study, but only 15 patients were treated and analyzed. Lm-LL0-E7 was administered P-7771-PC3 intravenously once every 21 days for a total of two treatments. Patients were kept in-patient for 5 days following each administration and received IV and oral ampicillin following each infusion. Follow up visits were to be conducted for the purpose of assessing safety and efficacy, and for obtaining samples for immunologic analysis according to the study plan. All patients entered into this study were to be followed until their deaths.
- Protocol Patients were administered 2 vaccinations at a 3-week interval as a 30-minute intravenous (IV) infusion in 250 ml of normal saline to inpatients. After 5 days, patients received a single course of IV ampicillin and were released with an additional 10 days of oral ampicillin.
- Karnofsky Performance Index which is a measurement of overall vitality and quality of life such as appetite, ability to complete daily tasks, restful sleep, etc, was used to determine overall well-being.
- alkaline phosphatase alkaline phosphatase
- bilirubin both direct and total
- gamma glutamyl transpeptidase ggt
- cholesterol systole
- diastole diastole
- heart rate Eastern Collaborative Oncology Group's (ECOG)'s criteria for assessing disease progression- a Karnofsky like - quality of life indicator
- hematocrit hemoglobin
- platelet levels lymphocytes levels
- AST aspartate aminotransferase
- ALT alanine aminotransferase
- LDH lactate dehydrogenase
- Duration of Treatment Overall patient participation lasted for up to 11 1 days (excluding P-7771-PC3 screening) with two treatments of LM-LLO-E7, on Day 1 and Day 22.
- Safety of LM-LLO-E7 administration was assessed through changes from a pre-dose baseline with respect to: Observation of the injection site for swelling, irritation, immune reaction or other abnormalities, 10 minutes after injection, Physical examination findings, Vital signs, Changes in laboratory parameters (hematology and serum chemistry), Presence of Listeria monocytogenes in urine, blood and stool samples, ECOG performance status, Reported adverse events.
- Listeria strains The production of LM-LLO-E7 is described in Example 1. Bacteria were passaged twice through mice prior to preparation of the working cell bank, as described in Example 12. The cell bank exhibited viability upon thawing of greater than 90%.
- mice Prior to the clinical trial, a preclinical experiment was performed to determine the anti-tumor efficacy of intravenous (i.v.) vs. i.p. administration of LM-LLO-E7.
- a tumor containing 1 x 10 4 TC-I cells was established sub-cutaneously.
- mice On days 7 and 14, mice were immunized with either 10 LM- LLO-E7 i.p. or LM-LLO-E7 i.v. at doses of 10 8 , 10 7 , 10 6 , or 10 5 .
- i.v. administration of LM- LLO-E7 is more effective than i.p. administration.
- a phase I/II clinical trial was conducted to assess safety and efficacy of LM-LLO-E7 vaccines in patients with advanced, progressive, or recurrent cervical cancer.
- 5 patients each were assigned to cohorts 1-2, which received 1 x 10 9 or 3.3 x 10 9 CFU, respectively.
- An additional 5 patients each were assigned to cohorts 3-4, which received 1 x 10 10 or 3.31 x 10 10 CFU, respectively.
- the scheduled fourth cohort was not dosed as the dose limiting toxicity criteria was met and the study discontinued as a result following the third cohort.
- Patient 5 responded to initial vaccination with mild fever over the 48 hours subsequent to administration, and was treated with anti-inflammatory agents. On 1 occasion, the fever rose to P-7771-PC3 moderate severity (at no time above 38.4 0 C), after which she was given a course of ampicillin, which resolved the fever. During the antibiotic administration she experienced mild urticaria, which ended after antibiotic administration. Blood cultures were all sterile, cardiovascular data were within the range observed for other patients, and serum chemistry values were normal, showing that this patient had no listerial disease. Further, the anergy panel indicated a robust response to 1/3 memory antigens, indicating the presence of functional immunity (similar to the other patients). Patient 5 subsequently evidenced a response similar to all other patients upon receiving the boost.
- Patient 1 entered the trial with 2 tumors of 20 mm each, which shrunk to 18 and 14 mm over the course of the trial, indicating therapeutic efficacy of the vaccine.
- patient 1 entered the trial with a Karnofsky Performance Index of 70, which rose to 90 after dosing.
- Patient 4 entered the trial with 2 tumors of 20 mm each, which shrunk to 18 and 14 mm over the course of the trial, indicating therapeutic efficacy of the vaccine.
- Patient 4 exhibited a weight gain of 1.6 Kg and an increased hemoglobin count of approximately 10% between the first and second doses.
- Tumors loads for the 2 cohorts are depicted in Figure 13B.
- LM-LLO-E7 administered in a therapeutic regimen containing a priming injection and a single boost, achieved 3 objective responses out of 6 patients for whom data has been collected.
- LM-LLO-E7 results in a flu-like constellation of side effects including fever, chills, nausea and vomiting in a majority of patients; These side effects were mild to moderate well tolerated in the IxIO 9 and 3.3xlO 9 groups; Side effects associated with drug administration were comprised primarily of a flu-like syndrome that was short lived and amenable to intervention; The relationship between liver function and LM-LLO-E7 could not be determined in this trial, although it appears that LM-LLO-E7 alone as a proximate cause of elevated LFT is unlikely; Dose limiting hypotension was observed at a dose of IxIO 10 ' LM-LLO-E7 , at doses of IxIO 9 and 3.3xlO 9 , can be used safely in end-stage cervical cancer.
- LM-LLO-E7 is safe in human subjects and improves clinical indicators of cervical cancer patients, even when administered at relatively low doses. Additional positive results are likely to be observed when the number of booster vaccinations is increased; and/or when antibiotics are administered in smaller doses or at a later time point after infusion. Additional booster doses are very likely to further enhance the immune responses obtained. Moreover, the positive effects of the observed therapeutic immune response are likely to continue with the passage of additional time, as the immune system continues to attack the cancer.
- Patients must have either Stage II or Stage III Cervical Intraepithelial Neoplasia for which surgical intervention is indicated, and for whom the disease is sufficiently indolent to allow for a 6-month treatment and observation period to occur prior to surgery.
- Patients must respond positively to at least 1 of the test agents used in the anergy panel described for the previous Example.
- a positive reaction defined by the formation of a local tissue response of at least 5 mm in sum of the orthogonal measures in reaction to the administration of a delayed hypersensitivity stimulus is required.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Hepatitis, cirrhosis, or any other impaired hepatic function as determined by serum enzymes - Pregnant women and women actively trying to become pregnant. Known HIV-positive patients. Penicillin allergy.
- Rate of clearance of LM-LLO-E7 from the blood as determined by quantitative blood cultures during the inpatient portion of the study following the initial administration.
- TAA tumor-associated antigen
- IFN- ⁇ , TNF- ⁇ , EL- 2 & IL-12 are assessed in serum of patients, collected at the following times:
- cytokine release profiles are assessed HPV- 16 E7 stimulated T cells of patients: IFN- ⁇ , TNF- ⁇ , BL-2 & IL-4
- Assays are performed on cells sampled from patients at the following times: Screening, Day 1 pre-dosing, day 22 pre-dosing, day 43 pre-dosing, day 126, and day 180
- DTH testing is conducted on the following study days: Screening, Day 5, Day 26, Day 47, Day 126 and Day 180.
- Day 1 pre-dose Day 1, 3 h post-dose, Day 1, 12 h post-dose, Day 2, 24 h post-dose, and Day 5.
- LM-LLO-E7 is administered as a 30 min. i.v. infusion with each dose freshly thawed and diluted in 250 ml normal saline.
- Adverse Events are graded based on the National Cancer Institute (NCI) Common Toxicity Criteria. Dose limiting toxicity is defined as any of the following:
- ANC Absolute neutrophil count
- LM-LLO-E7 reduces the fraction of women that subsequently require surgery and/or the degree of disease among those that P-7771-PC3 require surgery.
- EXAMPLE 12 PASSAGING OF LISTERIA VACCINE VECTORS THROUGH MICE ELICITS INCREASED IMMUNE RESPONSES TO HETEROLOGOUS AND
- L. monocytogenes strain 10403S serotype 1 (ATCC, Manassas, Va.) was the wild type organism used in these studies and the parental strain of the constructs described below.
- Strain 10403S has an LD 50 of approximately 5 x 10 4 CFU when injected into BALB/c mice.
- "Lm- Gag” is a recombinant LM strain containing a copy of the HIV-I strain HXB (subtype B laboratory strain with a syncytia-forming phenotype) gag gene stably integrated into the listerial chromosome using a modified shuttle vector pKSV7. Gag protein was expressed and secreted by the strain, as determined by Western blot. All strains were grown in brain-heart infusion (BHI) broth or agar plates (Difco Labs, Detroit, Mich).
- Bacteria from a single clone expressing the passenger antigen and/or fusion protein were selected and cultured in BHI broth overnight. Aliquots of this culture were frozen at " 70°C with no additives. From this stock, cultures were grown to 0.1-0.2 O.D. at 600 nm, and aliquots were again frozen at -70 0 C with no additives. To prepare cloned bacterial pools, the above procedure was used, but after each passage a number of bacterial clones were selected and checked for expression of the target antigen, as described herein. Clones in which expression of the foreign antigen was confirmed were used for the next passage.
- mice 6-8 week old female BALB/c (H-2d) mice were purchased from Jackson Laboratories (Bar Harbor, Me) and were maintained in a pathogen-free microisolator environment. The titer of viable bacteria in an aliquot of stock culture, stored frozen at -70 0 C, was determined by plating on BHI agar plates on thawing and prior to use. In all, 5 x 10 5 bacteria were injected intravenously into BALB/c mice. After 3 days, spleens were harvested, homogenized, and serial dilutions of the spleen homogenate were incubated in BHI broth overnight and plated on BHI agar plates.
- Lymphocytes were cultured for 5 hours in complete RPMI-10 medium supplemented with 50 U/ml human recombinant IL-2 and 1 microliter/ml Brefeldin A (GolgistopTM; PharMingen, San Diego, CA) in the presence or absence of either the cytotoxic T-cell (CTL) epitope for HTV-GAG (AMQMLKETI; SEQ ID NO: 34), Listeria LLO (GYKDGNEYI; SEQ ID NO: 35) or the HPV virus gene E7 (RAHYNIVTF (SEQ ID NO: 22), at a concentration of 1 micromole.
- CTL cytotoxic T-cell epitope for HTV-GAG
- AQMLKETI cytotoxic T-cell
- SEQ ID NO: 34 Listeria LLO
- GYKDGNEYI Listeria LLO
- RAHYNIVTF SEQ ID NO: 22
- Sample data were acquired on either a FACScanTM flowcytometer or FACSCaliburTM instrument (Becton Dickinson, San Jose, CA).
- Three- color flow cytometry for CD8 (PERCP conjugated, rat anti-mouse, clone 53-6.7 Pharmingen, San Diego, Calif.), CD62L (APC conjugated, rat anti-mouse, clone MEL- 14), and intracellular IFN- gamma was performed using a FACSCaliburTM flow cytometer, and data were further analyzed with CELLQuest software (Becton Dickinson, Mountain View, CA). Cells were gated on CD8 high and CD62L low before they were analyzed for CD8 + and intracellular IFN-gamma staining.
- This plasmid was used to complement a prfA negative mutant so that in a live host, selection pressures would favor conservation of the plasmid, because without it the bacterium is avirulent. All 3 constructs had been propagated extensively in vitro for many bacterial generations.
- EXAMPLE 13 A PrfA-CONTAINING PLASMID IS STABLE IN AN LM STRAIN WITH A Prf A DELETION IN THE ABSENCE OF ANTIBIOTICS
- L. monocytogenes strain XFL7 contains a 300 base pair deletion in the prfA gene XFL7 carries pGG55 which partially restores virulence and confers CAP resistance, and is described in United States Patent Application Publication No. 2005001 18184.
- the plasmid DNA was resuspended in 30 ⁇ L rather than 50 ⁇ L to increase the concentration.
- the cells were incubated for 15min in Pl buffer + Lysozyme, then incubated with P2 (lysis buffer) and P3 (neutraliztion buffer) at room temperature.
- plasmid DNA was subjected to agarose gel electrophoresis, followed by ethidium bromide staining. While the amount of plasmid in the preps varied slightly between samples, the overall trend was a constant amount of plasmid with respect to the generational number of the bacteria ( Figures 16A-B). Thus, pGG55 exhibited stability in strain XFL7, even in the absence of antibiotic.
- Plasmid stability was also monitored during the stability study by replica plating on agar plates at each stage of the subculture. Consistent with the results from the agarose gel electrophoresis, there was no overall change in the number of plasmid-containing cells throughout the study in either LB or TB liquid culture ( Figures 17 and 18, respectively).
- EXAMPLE 14 OPTIMIZATION OF CRYOPRESERVATION CONDITIONS FOR
- RWCB LB Research Working Cell Bank
- 5 ODmL samples were taken from 20OmL cultures grown in LB or TB with 34 ⁇ g/mL CAP in 2L shake flasks at several different OD 60O .
- the 5 ODmL samples were cryopreserved using 20% v/v glycerol and frozen at less than -7O 0 C for one day, then were thawed and used to inoculate 50 mL of the same media used for the starter cultures.
- the initial growth kinetics of these cultures was measured by monitoring the OD ⁇ oo and comparing the growth curves for any sign of lag phase.
- an LB Research Working Cell Bank (RWCB) was produced by adding 20% v/v glycerol to an 0.8 OD 6 Oo culture and storing below -7O 0 C (see Materials and Experimental Methods section above). Viability of the RWCB was determined before freezing by replica plating as described for Example 13. Vials of the RWCB were thawed after defined intervals, and viability was determined. As depicted in Figure 20, the viability in the first LB cell bank appeared to decrease from 1 x 10 9 to 3 x l O 8 CFU/mL following storage at -7O 0 C.
- a second and a third LB RWCB were generated, this time at OD 600 of 0.72 and 0.74, P-7771-PC3 respectively. These two RWCB exhibited viabilities ranging between 8 and 12 x 10 8 CFU/mL, with no decrease in viability, throughout the course of the study. The difference between these RWCB and first are likely due to difference in the OD 60O at the time of cryopreservation. Thus, an optical density of 0.8 likely corresponds to the end of exponential growth and the beginning of stationary phase of Lm-LLO-E7 in. Consequently, an OD OOO of 0.7 was used subsequently.
- the second RWCB was assigned the number 2003#0933A and was utilized to inoculate the cultures used in subsequent experiments.
- EXAMPLE 15 OPTIMIZATION OF MEDIA FOR GROWTH OF LISTERIA VACCINE STRAINS IN SHAKE FLASK FERMENTATIONS MATERIALS AND EXPERIMENTAL METHODS
- Table 3A Original defined media composition.
- Bulk medium i.e. water plus the basic components in Table 3A), essential components, amino acids, vitamins and trace elements.
- the final OD 600 of each of the 4X supplements was 4.5, which corresponded to 1.1 x 10 10 CFU/mL, approximately the same as the final biomass obtained with TB.
- a defined media was developed that supported growth of a Listeria vaccine strain to the same extent as TB.
- media containing 4x the original concentration of the four groups of supplements from Table 3A (referred to henceforth as "4X media") supported optimal growth of Lm- LLO-E7 in 50 mL and 200 mL shake flask cultures. Iron was required for optimal growth. Increasing the glucose from 10 to 15 g/L increased the total biomass achieved.
- the resulting optimized defined media recipe is depicted in Table 3B.
- EXAMPLE 16 OPTIMIZATION OF MEDIA FOR GROWTH OF LISTERIA VACCINE STRAINS IN BATCH FERMENTATIONS
- FT Applikon 5/7L fermenter vessels containing 4500 mL of either TB or defined medium with 34 Dg/mL CAP were utilized in this Example.
- 20 ODmL of Lm-LL0-E7 was used to inoculate a 200 mL starter culture containing CAP, which was grown at 37°C in an orbital shaker at 200 rpm for 10 hours until it reached mid-log phase; 450 ODmL of this culture was used to inoculate the fermenter vessels.
- the temperature, pH and dissolved oxygen concentration were continuously monitored and controlled during the fermentation at levels of 37°C, 7.0, and 20% of saturation.
- Factors such as dissolved oxygen concentration or pH likely limited the growth of Lm-LLO- E7 in the previous Example, as they are not controlled in shake flasks. Consistent with this possibility, the pH of the cultures in the shake flasks had decreased to approximately 5.5 units. In a batch fermenter, by contrast, pH and dissolved oxygen levels are continuously monitored and controlled. Thus, separate experiments were performed in this Example to optimize the media used for batch fermentations.
- the iron and magnesium salts could be dissolved separately in water and heated to 60° C, then filter-sterilized and simultaneously added to the fermenter culture medium.
- a shake flask containing 200 mL of the 4X media from Table 3B was grown to an OD ⁇ oo of 1.6. Fifteen 10 mL samples were pelleted by centrifugation, the supernatants removed, and the cells resuspended in 10 mL of PBS containing 2% w/v of the appropriate cryoprotectant. One mL aliquots of each resuspended sample were transferred into vials and stored using the appropriate method. Viability was measured by replica plating (with and without CAP) before storage and after 3-28 days or storage, and the percentage of viable cells remaining was calculated.
- E7 reached a higher biomass concentration in 5L batch fermenters compared to shake flask cultivation, likely due to the ability to control the pH in fermenters.
- the optimum method for P-7771-PC3 cryopreservation of the cells was also investigated.
- Lm-LLO-E7 cryopreserved in PBS containing 2% w/v glycerol exhibited approximately 100% viability following storage at less than -70 0 C for 3 days.
- EXAMPLE 18 LM-LLO-E7 VACCINES AT A DOSE OF IxIO 9 AND 3.3xlO 9 ARE SAFE AND IMPROVE CLINICAL INDICATORS IN CERVICAL CANCER PATIENTS [00465]
- the regimen used was intentionally designed to be the minimal vaccine regimen; a single prime and boost dose.
- Stable disease was reported for 53.85% of patients in the Intent-to-Treat group, progressive disease reported in 38.5% of patients, and 1 patient (7.7%) had an objective partial response (PR).
- PR objective partial response
- Protocol Lm-LLO-E7-01 was an open label, non-randomized study. A total of 20 adult females with progressive, recurrent or advanced squamous cell carcinoma of the cervix were to be enrolled into the study. Lm-LL0-E7 was administered intravenously once every 21 days for a total of two treatments. Patients were kept in-patient for 5 days following each administration and received IV and oral ampicillin following each infusion. Follow up visits were to be conducted for the purpose of assessing safety and efficacy, and for obtaining samples for immunologic analysis according to the study plan.
- Diagnosis and Main Criteria for Inclusion Patients age 18 and older were eligible to participate in the study. Patients must have had histologically confirmed cervical cancer that was P-7771-PC3 progressive, recurrent or advanced and was refractory to existing therapies, and have a positive response to a delayed type hypersensitivity (DTH) screening panel. Patients must have had only one primary cancer. Patients must have had an Eastern Cooperative Oncology Group (ECOG) performance status ⁇ 2 (Karnofsky > 60%). Patients must have had a life expectancy greater than six months.
- EOG Eastern Cooperative Oncology Group
- Test Product, Dose and Mode of Administration, and Lot Number(s): Lm-LLO-E7 was administered via intravenous (i.v.) infusion at three dose levels using a dose escalation design across cohorts with each patient in a cohort receiving two administrations of the same dose. The infusion occurred over 30 minutes to each study participant once every 21 days for a total of two treatments.
- a scheduled fourth cohort was not dosed as the dose limiting toxicity criteria was met and the study discontinued following the third cohort as a result.
- Tumor response was determined by the RECIST criteria.
- AEs adverse events
- Drug-related AEs were comprised of a 'flu-like' syndrome including pyrexia, vomiting, chills, headache, tachycardia, and nausea.
- SAEs serious adverse events
- Lm-LL0-E7 results in a flu-like constellation of side effects including fever, chills, nausea and vomiting in a majority of patients; these side effects were mainly mild to moderate in intensity.
- Lm-LL0-E7 at doses of IxIO 9 and 3.3xlO 9 , can be used safely in end-stage cervical cancer patients.
- the safety population consists of all patients who received at least one dose of study vaccine.
- the intent-to-treat (ITT) population consists of all patients who received at least one dose of study vaccine and provided at least one efficacy assessment after the first dose.
- Nominal doses are assigned based upon the optical density of the formulation at the time of manufacture, and are determined by quantifying the amount of light in the 600 nm range that is transmitted through the formulation. This rapid procedure is used because batches need to be aliquoted into containers and require freezing in order that release tests can be performed. The number of freeze thaw cycles must be minimized as it has been shown to damage the efficacy of Lm-LLO-E7. Actual concentrations are performed by diluting, plating and counting, then extrapolating the dose based upon the counts. This occurs following the initial vialing and is provided with the CoA for each dose.
- Table 10 Number (%) of Patients With AEs by SOC (Safety Population)
- SOCs System Organ Classes
- Table 11 Number (%) of Patients With AEs by Preferred Term (Safety Population)
- Tachycardia 1 (20.0) 5 (100) 1 (20.0) 7 (46.7)
- the most commonly reported AEs of severe intensity were pyrexia in 3 (20.0%) patients, overall: 2 (40.0%) patients in the 3.3x 10 9 group and 1 (20.0%) patient in the I x IO 10 group; anemia in 3 (20.0%) patients: 1 (20.0%) patient in the 1 x10 9 group and 2 (40.0%) patients in the I xIO 10 group; gamma-glutamyl transferase increased in 2 (13.3%) patients (both patients in the 3.3x10 9 group); musculoskeletal pain in 2 (13.3%) patients (both patients in the 1 x10 9 group).
- AU other AE believed to be treatment-related were experienced by no more than one patient in any treatment group and included asthenia, fatigue, alanine amino transferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, blood lactate dehydrogenase increased, lipase increased, weight increase, anemia, somnolence, chest wall pain and rash.
- Table 12 Number (%) of Patients With Most Commonly Reported Treatment Related AEs by Preferred Term
- Tachycardia 1 (20.0) 5 (100) 1 (20.0) 7 (46.7)
- An AE of interest is defined as being one that might be predicated from the known pathophysiology of Listeria infection and thus can be assessed thoroughly.
- the most frequently reported events of interest were fever in 15 [100%] patients; nausea and vomiting symptoms in 11 (73.3%) patients: 3 (60.6%) in the IxIO 9 group and 4 (80.0%) patients each in the 3.3xlO 9 and IxIO 10 groups; chills in 8 (53.3%) patients: 4 (80.0%) patients each in the IxIO 9 and IxIO 10 groups.
- Patient 01-007 experienced a diastolic BP of 45 mm Hg 8 hours after receiving her second dose. This event was associated with a systolic BP of 75 mm Hg and a maximum elevated temperature at 3 hours post dosing of 41 0 C.
- Patient 02-006 experienced diastolic BP between 39-49 mm Hg between 2 and 12 hours following her second dose. These events were associated with systolic BP of between 76-92 mm Hg and temperatures between 37.3 to 38.7°C. Diastolic BP below 50 mm Hg was also observed in this patient on Days 23 & 24.
- Patient 04-006 experienced diastolic BP of 45 mm Hg 12 hours after receiving her initial dose; associated with a systolic BP of 87 mm Hg and a temperature of 40 0 C 3 hours post dosing. This patient also experienced diastolic BP of between 42-44 mm Hg from 3 to 10 hours after receiving her second dose, which was associated with systolic BP of between 72-86 mm Hg and temperatures between 39.2 and 37.1 0 C. This patient also manifest diastolic BP below 50 mm Hg on Days 2, 8 and 23.
- Grade 3 fevers were reported in 5 patients. Severe fevers occurred in all dosage groups, were treated immediately upon occurrence, and none persisted for over a 1 hour duration.
- Patient 04-001 in the I x I O 9 group experienced a fever of 40.1 0 C 2 hours after receiving her first dose.
- Patient 04-002 in the 3.3x 10 9 group experienced a fever of 40.5 0 C 3 hours after receiving her first dose, and a fever of 40.2 0 C 3 hours after receiving her second dose.
- Patient 04-003 experienced a fever of 40.1 0 C in the 3.3x lO 9 group 2 hours after receiving her second dose.
- Patient 01 -007 in the l xl O 10 group experienced P-7771-PC3 a temperature of 41 0 C 3 hours after receiving her second dose.
- Time from first dose to any AEs of interest was a median of 1 day after the first dose of treatment was reported for the majority of AEs of interest.
- TLS Tumor Lysis Syndrome
- Patie Age (years) (Investigator top Intens Action Outco Study nt No. Race Term) Date ity Taken me Drug
- GGT Gamma-glutamyl transferase
- LDH Lactate dehydrogenase P-7771-PC3
- Patie Age (yrs) (Investigator Onset/St Intensi Action Outco Study nt No. Race Term) op Date ty Taken me Drug
- Concomitant medication used to treat the event iv fluids with Sodium bicarbonate and Nalbuphine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a recombinant Listeria strain, comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide for uses related to treating and protecting against cervical cancer. The present invention also provides use of the recombinant Listeria strain in methods for inducing an anti-E7 CTL response in a human subject and for treating HPV-mediated diseases, disorders, and symptoms.
Description
P-7771-PC3
COMPOSITIONS AND METHODS FOR TREATMENT QF CERVICAL CANCER
FIELD OF INVENTION
[001] The present invention provides a recombinant Listeria strain, comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N- terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a
PEST-like sequence-containing peptide for uses related to treating and protecting against cervical cancer. The present invention also provides use of the recombinant Listeria strain in methods for inducing an anti-E7 CTL response in a human subject and for treating HPV-mediated diseases, disorders, and symptoms.
BACKGROUND OF THE INVENTION
[002] Worldwide, approximately 500,000 cases of cervical cancer are diagnosed each year. Cancer of the cervix (cervical cancer) begins in the lining of the cervix. Normal cervical cells gradually develop pre-cancerous changes that turn into cancer. Several terms are used to describe these pre- cancerous changes, including cervical intraepithelial neoplasia (CIN), squamous intraepithelial lesion (SIL), and neoplasia in situ, dysplasia.
[003] There are 2 major types of cervical cancers: squamous cell carcinoma and adenocarcinoma. Cervical cancers and cervical precancers are classified by microscopic appearance. About 80%-90% of cervical cancers are squamous cell carcinomas, which are composed of cells that resemble the flat, thin cells called squamous cells that cover the surface of the endocervix. Squamous cell carcinomas most often begin where the ectocervix joins the endocervix.
[004] The remaining 10%-20% of cervical cancers are adenocarcinomas. Adenocarcinomas are becoming more common in women born in the last 20 to 30 years. Cervical adenocarcinoma develops from the mucus-producing gland cells of the endocervix. Less commonly, cervical cancers have features of both squamous cell carcinomas and adenocarcinomas. These are called "adenosquamous carcinomas" or "mixed carcinomas."
[005] Improved therapies for cervical cancers are urgently needed in the art.
SUMMARY OF THE INVENTION
[006] The present invention provides a recombinant Listeria strain, comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-
P-7771-PC3 terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide for uses related to treating and protecting against cervical cancer. The present invention also provides use of the recombinant Listeria strain in methods for inducing an anti-E7 CTL response in a human subject and for treating HPV-mediated diseases, disorders, and symptoms.
[007] In one embodiment, provided herein is a use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for treating a cervical cancer in a human subject, whereby said recombinant Listeria strain induces an immune response against said E7 antigen and wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 109 organisms.
[008] In one embodiment, provided herein is a use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for protecting a human subject against a cervical cancer, whereby said recombinant Listeria strain induces an immune response against said E7 antigen, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 -
3.31 x 109 organisms.
[009] In another embodiment, provided herein is a use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and a PEST-like sequence-containing peptide for the preparation of a composition for inducing an immune response against a cervical cancer in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a
. dose of 1 x 109 - 3.31 x 1010 organisms.
[001O] In another embodiment, provided herein is a use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide,
P-7771-PC3 for the preparation of a composition for inducing an anti-E7 cytotoxic T cell response in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 1010 organisms.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1. Lm-E7 and Lm-LLO-E7 use different expression systems to express and secrete E7. Lm-E7 was generated by introducing a gene cassette into the orfZ domain of the L. monocytogenes genome (A) The hly promoter drives expression of the hly signal sequence and the first five amino acids (AA) of LLO followed by HPV- 16 E7. (B), Lm-LL0-E7 was generated by transforming the prfA- strain XFL-7 with the plasmid pGG-55. pGG-55 has the hly promoter driving expression of a nonhemolytic fusion of LLO-E7. pGG-55 also contains the prfA gene to select for retention of the plasmid by XFL-7 in vivo.
[0012] Figure 2. Lm-E7 and Lm-LL0-E7 secrete E7. Lm-Gag (lane 1), Lm-E7 (lane 2), Lm-LLO-NP (lane 3), Lm-LL0-E7 (lane 4), XFL-7 (lane 5), and 10403S (lane 6) were grown overnight at 37°C in Luria-Bertoni broth. Equivalent numbers of bacteria, as determined by OD at 600 nm absorbance, were pelleted and 18 ml of each supernatant was TCA precipitated. E7 expression was analyzed by Western blot. The blot was probed with an anti-E7 mAb, followed by HRP-conjugated anti-mouse (Amersham), then developed using ECL detection reagents.
[0013] Figure 3. Tumor immunotherapeutic efficacy of LLO-E7 fusions. Tumor size in millimeters in mice is shown at 7, 14, 21, 28 and 56 days post tumor-inoculation. Naive mice: open-circles; Lm- LLO-E7: filled circles; Lm-E7: squares; Lm-Gag: open diamonds; and Lm-LLO-NP: filled triangles.
[0014] Figure 4. Splenocytes from Lm-LL0-E7-immunized mice proliferate when exposed to TC-I cells. C57BL/6 mice were immunized and boosted with Lm-LLO-E7, Lm-E7, or control rLm strains. Splenocytes were harvested 6 days after the boost and plated with irradiated TC-I cells at the ratios shown. The cells were pulsed with 3H thymidine and harvested. Cpm is defined as (experimental cpm) - (no-TC-1 control).
[0015] Figure 5. (A) Western blot demonstrating that Lm-ActA-E7 secretes E7. Lane 1 : Lm-LLO-E7; lane 2: Lm-ActA-E7.001 ; lane 3; Lm-ActA-E7-2.5.3; lane 4: Lm-ActA-E7-2.5.4. (B) Tumor size in mice administered Lm-ActA-E7 (rectangles), Lm-E7 (ovals), Lm-LLO-E7 (X), and naive mice (non- vaccinated; solid triangles).
[0016] Figure 6. (A) schematic representation of the plasmid inserts used to create 4 LM vaccines. Lm-LL0-E7 insert contains all of the Listeria genes used. It contains the hly promoter, the first
P-7771-PC3
1.3 kb of the hly gene (which encodes the protein LLO), and the HPV-16 E7 gene. The first 1.3 kb of hly includes the signal sequence (ss) and the PEST region. Lm-PEST-E7 includes the hly promoter, the signal sequence, and PEST and E7 sequences but excludes the remainder of the truncated LLO gene. Lm-ΔPEST-E7 excludes the PEST region, but contains the hly promoter, the signal sequence, E7, and the remainder of the truncated LLO. Lm-E7epi has only the hly promoter, the signal sequence, and E7. (B) Top panel: Listeria constructs containing PEST regions induce tumor regression. Bottom panel: Average tumor sizes at day 28 post-tumor challenge in 2 separate experiments. (C) Listeria constructs containing PEST regions induce a higher percentage of E7-specific lymphocytes in the spleen. Average and SE of data from 3 experiments are depicted.
[0017] Figure 7. (A) Induction of E7-specific IFN-gamma-secreting CD8+ T cells in the spleens and the numbers penetrating the tumors, in mice administered TC-I tumor cells and subsequently administered Lm-E7, Lm-LLO-E7, Lm-ActA-E7, or no vaccine (naive). (B) Induction and penetration of E7 specific CD8+ cells in the spleens and tumors of the mice described for (A).
[0018] Figure 8. Listeria constructs containing PEST regions induce a higher percentage of E7- specific lymphocytes within the tumor. A. representative data from 1 experiment. B. average and SE of data from all 3 experiments.
[0019] Figure 9. E6/E7 transgenic mice develop tumors in their thyroid, where the E7 gene is expressed. Mice were sacrificed at 3 months and had their thyroids removed, sectioned, and stained by hematoxylin and eosin. A. Left panel: normal thyroid at 20 x magnification. Follicles are of normal size and lined with cuboidal cells with abundant pink cytoplasm (arrow). Right panel: E6/E7 transgenic mouse thyroid. Note the greatly enlarged follicles because of the increased production of colloid. The cuboidal cells lining the follicles are smaller with very little cytoplasm.
[0020] Figure 10. E7 message is expressed in the thyroid and medullary thymic epithelial cells of the E6/E7 transgenic mouse. (A) Tissue-specific expression of the E7 transgene is detected in the thyroid only but not the liver, spleen, or whole thymus. Lane 1 : Liver; Lane 2: Spleen; Lane 3: Thyroid; Lane 4: Whole Thymus. (B) Medullary thymic epithelial cells (mTECs) express E7. RT-PCR results are as shown for equivalent amounts of cDNA loaded for 40 cycles. Lane 5: Cathepsin S; Lane 6: E7; Lane 7: Actin; Lane 8: Negative Control.
[0021] Figure 11. RAHYNIVTF peptide plus CpG adjuvant does not protect against TC-I challenge in E6/E7 transgenic mice. Two groups of transgenic mice received either E7 peptide plus adjuvant or
PBS. A third group of wild type C57B1/6 control mice received E7 peptide plus adjuvant. The mice were vaccinated twice intraperitoneally (i.p.), 7 days apart and challenged with 5 x 104 TC -1 cells 7
P-7771-PC3 days later. Tumors were measured every 5 days until unimmunized mice needed to be sacrificed. Error bars: standard deviations from the mean value.
[0022] Figure 12. Vaccines of the present invention induce regression of solid tumors in the E6/E7 transgenic mice in wild-type mice and transgenic mice immunized with LM-LLO-E7 (A), or LM- ActA-E7 (B), left naive, or treated with LM-NP (control).
[0023] Figure 13. (A) IV immunization of LM-LLO-E7 is effective at inducing the regression of established tumors at doses as low as 1 x 106 CFU per mouse. (B) Tumor loads for the 2 cohorts in the LM-LLO-E7 clinical trial.
[0024] Figure 14. (A) Effect of passaging on bacterial load (virulence) of recombinant Listeria vaccine vectors. Top panel. Lm-Gag. Bottom panel. Lm-LL0-E7. (B) Effect of passaging on bacterial load of recombinant Lm-E7 in the spleen. Average CFU of live bacteria per milliliter of spleen homogenate from four mice is depicted.
[0025] Figure 15. Induction of antigen-specific CD8+ T-cells for HIV-Gag and LLO after administration of passaged Lm-Gag versus unpassaged Lm-Gag. Mice were immunized with 10 (A, B, E, F) or 105 (C, D, G, H) CFU passaged Listeria vaccine vectors, and antigen-specific T-cells were analyzed. B, D, F, H: unpassaged Listeria vaccine vectors. A-D immune response to MHC class I HIV-Gag peptide. E-H: immune response to an LLO peptide. I: splenocytes from mice immunized with 105 CFU passaged Lm-Gag stimulated with a control peptide from HPV E7.
[0026] Figure 16. (A) Plasmid isolation throughout LB stability study. (B) Plasmid isolation throughout TB stability study. (C) Quantitation of TB stability study.
[0027] Figure 17. Numbers of viable bacteria chloramphenicol (CAP)-resistant and CAP-sensitive colony-forming units (CFU) from bacteria grown in LB. Dark bars: CAP+; white bars: CAP". The two dark bars and two white bars for each time point represent duplicate samples.
[0028] Figure 18. Numbers of viable bacteria CAP-resistant and CAP-sensitive CFU from bacteria grown in TB. Dark bars: CAP+; white bars: CAP. The two dark bars and two white bars for each time point represent duplicate samples.
[0029] Figure 19. Growth of L. monocytogenes following short-term cryopreservation.
[0030] Figure 20. Viability of LB RWCB following storage at -700C.
P-7771-PC3 [0031] Figure 21. Viability of TB RWCB following storage at -700C.
[0032] Figure 22. Growth curve of 200 mL LB and TB cultures of Lm-LL0-E7.
[0033] Figure 23. Growth of Lm-LL0-E7 in 4 defined media with and without AA, vitamins and trace elements, at the 50 mL stage. "AA + Vits + TE +" denotes bulk medium, essential components, AA, vitamins and trace elements; "AA + Vits + TE -" denotes bulk medium, essential components, AA, and vitamins; "AA + Vits - TE -" denotes bulk medium, essential components, and AA; "AA - Vits - TE -" denotes bulk medium and essential components.
[0034] Figure 24. Growth of Lm-LLO-E7 in 4 defined media with and without amino acids, vitamins and trace elements, at the 200 mL stage. Groups are labeled as for Figure 23.
[0035] Figure 25. Growth of Lm-LLO-E7 in 200 mL cultures of defined media with different concentrations of supplements, with and without inorganic nitrogen.
[0036] Figure 26. Growth of Lm-LLO-E7 in 200 mL cultures of defined media supplemented with different concentrations of supplements, with and without glutamine and iron.
[0037] Figure 27. (A) Growth curves of Lm-LLO-E7 in 5 L fermenters in TB and defined media. B. Viability of Lm-LLO-E7 grown in 5 L fermenters in TB to different densities. C. Viability of Lm- LLO-E7 grown in 5 L fermenters in defined media to different densities.
[0038] Figure 28. Percentage of viable cells remaining after storage at -20 0C for 3 days.
[0039] Figure 29. Percentage of viable cells remaining after storage at -70 0C for 3 days
[0040] Figure 30. (A) Percentage of viable cells remaining following snap freezing in liquid nitrogen and storage at -70 0C for 3 days. (B) Summary of viability studies for several conditions. C. Growth kinetics of cryopreserved samples after thawing.
[0041] Figure 31. Listeria vaccine vectors grown in defined media effectively protect mice against growth of established tumors. "BHI cultured"- vectors cultured in Brain-Heart Infusion media "Terrific Broth cultured" and "defined media cultured"- vectors cultured in indicated media.
DETAILED DESCRIPTION OF THE INVENTION
[0042] The present invention provides methods of treating, protecting against, and inducing an immune response against cervical cancer, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprising a listeriolysin O (LLO)
P-7771-PC3 fragment and an E7 antigen. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.
[0043] In one embodiment, the present invention provides a method of treating, inhibiting, suppressing, or preventing a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an Human Papilloma Virus (HPV) E7 antigen, whereby the recombinant Listeria strain induces an immune response against the E7 antigen, thereby treating a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. In another embodiment, the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen. Each possibility represents a separate embodiment of the present invention.
[0044] The N-terminal LLO protein fragment and HPV E7 antigen are, in another embodiment, fused directly to one another. In another embodiment, the genes encoding the N-terminal LLO protein fragment and HPV E7 antigen are fused directly to one another. In another embodiment, the N- terminal LLO protein fragment and HPV E7 antigen are attached via a linker peptide. In another embodiment, the N-terminal LLO protein fragment and HPV E7 antigen are attached via a heterologous peptide. In another embodiment, the N-terminal LLO protein fragment is N-terminal to the HPV E7 antigen. In another embodiment, the N-terminal LLO protein fragment is the N-terminal- most portion of the fusion protein. Each possibility represents a separate embodiment of the present invention.
[0045] In another embodiment, the present invention provides a method for inducing an immune response against a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing an immune response against a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. In another
P-7771-PC3 embodiment, the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen. Each possibility represents a separate embodiment of the present invention.
[0046] In another embodiment, provided herein is a method for inducing an anti-E7 cytotoxic T cell response in a human subject, comprising the step of administering to said subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing an anti-E7 cytotoxic T cell response in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. In another embodiment, the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen. Each possibility represents a separate embodiment of the present invention.
[0047] The N-terminal fragment of an LLO protein and HPV E7 antigen are, in another embodiment, fused directly to one another. In another embodiment, the genes encoding the N-terminal fragment of an LLO protein and HPV E7 antigen are fused directly to one another. In another embodiment, the N- terminal fragment of an LLO protein and HPV E7 antigen are attached via a linker peptide. In another embodiment, the N-terminal fragment of an LLO protein and HPV E7 antigen are attached via a heterologous peptide. In another embodiment, the N-terminal fragment of an LLO protein is N- terminal to the HPV E7 antigen. In another embodiment, the N-terminal fragment of an LLO protein is the N-terminal-most portion of the fusion protein. Each possibility represents a separate embodiment of the present invention. 48] As provided herein, recombinant Listeria strains expressing LLO-antigen fusions induce anti- tumor immunity (Example 1 ), elicit antigen-specific T cell proliferation (Example 2), generate antigen-specific, tumor-infiltrating T cells (Example 4), and abrogate central and peripheral tolerance to antigens such as E6 and E7 (Examples 5-9). Thus, vaccines of the present invention are efficacious at inducing immune responses against E7 and E6. Further, the recombinant Listeria strains are safe and
P-7771-PC3 improve disease indicators in human subjects (Example 10).
[0049] In another embodiment, the present invention provides a method of treating, inhibiting, suppressing, or preventing a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an ActA protein and an HPV E7 antigen, whereby the recombinant Listeria strain induces an immune response against the E7 antigen, thereby treating a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0050] In another embodiment, the present invention provides a method for inducing an immune response against a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an ActA protein and an HPV E7 antigen, thereby inducing an immune response against a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0051] In another embodiment, provided herein is a method for inducing an anti-E7 cytotoxic T cell response in a human subject, comprising the step of administering to the subject a recombinant
Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an
N-terminal fragment of an ActA protein and an HPV E7 antigen, thereby inducing an anti-E7 cytotoxic T cell response in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. In another embodiment, the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen. Each possibility represents a separate embodiment of the present invention.
10052] The N-terminal ActA protein fragment and HPV E7 antigen are, in another embodiment, fused
P-7771-PC3 directly to one another. In another embodiment, the genes encoding the N-terminal ActA protein fragment and HPV E7 antigen are fused directly to one another. In another embodiment, the N- terminal ActA protein fragment and HPV E7 antigen are attached via a linker peptide. In another embodiment, the N-terminal ActA protein fragment and HPV E7 antigen are attached via a heterologous peptide. In another embodiment, the N-terminal ActA protein fragment is N-terminal to the HPV E7 antigen. In another embodiment, the N-terminal ActA protein fragment is the N-terminal- most portion of the fusion protein. Each possibility represents a separate embodiment of the present invention.
[0053] As provided herein, recombinant Listeria strains expressing ActA-antigen fusions induce anti- tumor immunity (Example 3), generate antigen-specific, tumor-infiltrating T cells (Example 4), and abrogate central and peripheral tolerance to antigens such as E6 and E7 (Examples 5-9). Further, recombinant Listeria strains of the present invention are safe and improve disease indicators in human subjects (Example 10).
[0054] In another embodiment, the present invention provides a method of treating, inhibiting, suppressing, or preventing a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising a PEST-like sequence-containing peptide and an HPV E7 antigen, whereby the recombinant Listeria strain induces an immune response against the E7 antigen, thereby treating a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. In another embodiment, the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen. Each possibility represents a separate embodiment of the present invention.
[0055] In another embodiment, the present invention provides a method for inducing an immune response against a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising a PEST-like sequence-containing peptide and an HPV E7 antigen, thereby inducing an immune response against a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the
P-7771-PC3 recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0056] In another embodiment, provided herein is a method for inducing an anti-E7 cytotoxic T cell response in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising a PEST-like sequence-containing peptide and an HPV E7 antigen, thereby inducing an anti-E7 cytotoxic T cell response in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. In another embodiment, the method further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the human subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen. Each possibility represents a separate embodiment of the present invention.
[0057] The PEST sequence and HPV E7 antigen are, in another embodiment, fused directly to one another. In another embodiment, the genes encoding the PEST sequence and HPV E7 antigen are fused directly to one another. In another embodiment, the PEST sequence and HPV E7 antigen are attached via a linker peptide. In another embodiment, the PEST sequence and HPV E7 antigen are attached via a heterologous peptide. In another embodiment, the PEST sequence is N-terminal to the HPV E7 antigen. In another embodiment, the PEST sequence is the N-terminal-most portion of the fusion protein. Each possibility represents a separate embodiment of the present invention.
[0058] As provided herein, recombinant Listeria strains expressing PEST-like sequence-antigen fusions induce anti-tumor immunity (Example 3) and generate antigen-specific, tumor-infiltrating T cells (Example 4). Further, recombinant Listeria strains of the present invention are safe and improve disease indicators in human subjects (Example 10). 59] In another embodiment, provided herein is a method for inducing an anti-E7 cytotoxic T cell response in a human subject, comprising the step of administering to said subject a recombinant Listeria strain. In another embodiment, said recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen. In another embodiment, said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide,
P-7771-PC3 thereby inducing an anti-E7 cytotoxic T cell response in a human subject. Each possibility represents a separate embodiment of the present invention.
[0060] The present invention provides a recombinant Listeria strain, comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N- terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide for uses related to treating and protecting against cervical cancer. The present invention also provides use of the recombinant Listeria strain in methods for inducing an anti-E7 CTL response in a human subject and for treating HPV-mediated diseases, disorders, and symptoms.
[006I] In one embodiment, provided herein is a use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for treating a cervical cancer in a human subject, whereby said recombinant Listeria strain induces an immune response against said E7 antigen and wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 10 - 3.31 x 10 organisms.
[0062] In one embodiment, provided herein is a use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for protecting a human subject against a cervical cancer, whereby said recombinant Listeria strain induces an immune response against said E7 antigen, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 109 organisms.
[0063] In another embodiment, provided herein is a use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and a PEST-like sequence-containing peptide for the preparation of a composition for inducing an immune response against a cervical cancer in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 1010 organisms.
P-7771-PC3
[0064] In another embodiment, provided herein is a use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for inducing an anti-E7 cytotoxic T cell response in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 1010 organisms.
[0065] In another embodiment, provided herein is a method of treating a cervical cancer in a human subject, comprising the step of administering to the subject an attenuated, auxotrophic Listeria strain. In another embodiment, provided herein is a method of protecting a human subject against a cervical cancer, comprising the step of administering to the subject an attenuated, auxotrophic Listeria strain. In another embodiment, provided herein is a method for inducing an immune response against a cervical cancer in a human subject, comprising the step of administering to the subject an attenuated, auxotrophic Listeria strain. In another embodiment, provided herein is a method of treating, inhibiting, preventing, or suppressing a cervical cancer in a human subject, or inducing an immune response against a cervical cancer in a human subject, comprising the step of administering to the subject an attenuated, auxotrophic Listeria monocytogenes strain. In another embodiment the attenuated, auxotrophic Listeria strain comprises a mutation in dal gene. In another embodiment the attenuated, auxotrophic Listeria strain comprises a mutation in the dat gene. In another embodiment the attenuated auxotrophic Listeria strain comprises a mutation in the dal and the dat genes. In another embodiment the attenuated, auxotrophic Listeria comprises a mutation in prephenate dehydratase. In another embodiment, the enzyme prephenate dehydratase is an enzyme acting late in the pathway of biosynthesis of phenylalanine. In another embodiment, the recombinant Listeria requires exogenous phenylalanine for growth. In another embodiment, the attenuated, auxotrophic Listeria strain requires exogenous alanine for growth. In another embodiment, the attenuated, auxotrophic Listeria strain requires exogenous D-alanine for growth. In another embodiment, the attenuated, auxotrophic Listeria strain requires exogenous threonine for growth. In another embodiment, the recombinant Listeria strain expresses a recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. In another embodiment, the attenuated, auxotrophic Listeria strain Listeria strain comprises a recombinant polypeptide. In another embodiment, the attenuated, auxotrophic Listeria strain comprises an antigen. In another embodiment the recombinant Listeria strain comprises a PEST-like sequence-containing peptide and an HPV E7 antigen. In another embodiment, the recombinant Listeria strain induces an immune response against the E7 antigen. In another embodiment, an induced immune response against the E7 antigen treats a
P-7771-PC3 cervical cancer in a human subject.
[0066] In another embodiment, the present invention provides a method for vaccinating a human subject against an HPV, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N- terminal fragment of an LLO protein and an HPV E7 antigen, thereby vaccinating a human subject against an HPV. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0067] In another embodiment, the present invention provides a method for vaccinating a human subject against an HPV, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N- terminal fragment of an ActA protein and an HPV E7 antigen, thereby vaccinating a human subject against an HPV. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0068] In another embodiment, the present invention provides a method for vaccinating a human subject against an HPV, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising a PEST-like sequence-containing peptide and an HPV E7 antigen, thereby vaccinating a human subject against an HPV. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0069] As provided herein, recombinant Listeria strains expressing fusions of an antigen to LLO, ActA, or a PEST-like sequence-containing peptide induce anti-E6 and E7 immunity (Example 3), and abrogate central and peripheral tolerance to antigens such as E6 and E7 (Examples 5-9). Further, recombinant Listeria strains of the present invention are safe and improve disease indicators in human subjects (Example 10). Thus, Listeria strains of the present invention can be used to vaccinate a subject against an HPV, thereby preventing or inhibiting HPV-mediated carcinogenesis.
[0070] In another embodiment, the subject is at risk for developing an HPV-mediated carcinogenesis, which in one embodiment is cervical cancer. In one embodiment, human papillomavirus DNA can be
P-7771-PC3 detected in over 90% of cervical cances lesions. In another embodiment, the subject is at risk for developing an HPV-mediated carcinogenesis, which in one embodiment, is a non-cervical anogenital tract cancer, which in one embodiment is an anal, vulvar, or vaginal tumour. In one embodiment, the HPV-mediated carcinogenesis is penile intraepithelial neoplasia, which in one embodiment, is found in high prevalence in the sexual partners of women with cervical intraepithelial neoplasia. In one embodiment, the HPV-mediated carcinogenesis is a cancer of the non-cervical anogenital epithelium. In another embodiment, the subject is HPV-positive. In another embodiment, the subject's sexual partner is HPV-positive. In another embodiment, the subject exhibits cervical intraepithelial neoplasia. In another embodiment, the subject exhibits a squamous intraepithelial lesion. In another embodiment, the subject exhibits a dysplasia in the cervix. Each possibility represents a separate embodiment of the present invention.
[0071] The HPV that is the target of methods of the present invention is, in another embodiment, an HPV 16. In another embodiment, the HPV is an HPV-18. In another embodiment, the HPV is selected from HPV-16 and HPV-18. In another embodiment, the HPV is an HPV-31. In another embodiment, the HPV is an HPV-35. In another embodiment, the HPV is an HPV-39. In another embodiment, the HPV is an HPV-45. In another embodiment, the HPV is an HPV-51. In another embodiment, the HPV is an HPV-52. In another embodiment, the HPV is an HPV-58. In another embodiment, the HPV is a high-risk HPV type. In another embodiment, the HPV is a mucosal HPV type. Each possibility represents a separate embodiment of the present invention.
[0072] In another embodiment, the present invention provides a method for inducing a regression of a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing a regression of a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0073] In another embodiment, the present invention provides a method for reducing an incidence of relapse of a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby reducing an incidence of relapse of a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant
P-7771-PC3
Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0074] In another embodiment, the present invention provides a method for suppressing a formation of a cervical tumor in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby suppressing a formation of a cervical tumor in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0075] In another embodiment, the present invention provides a method for inducing a remission of a cervical cancer in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing a remission of a cervical cancer in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0076] In another embodiment, the present invention provides a method for impeding a growth of a cervical tumor in a human subject, comprising the step of administering to the subject a recombinant
Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an
N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby impeding a growth of a cervical tumor in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0077] In another embodiment, the present invention provides a method for reducing a size of a cervical tumor in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby reducing a size of a cervical tumor in a human subject. In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide. In another embodiment, the recombinant Listeria strain comprises a plasmid
P-7771-PC3 that encodes the recombinant polypeptide. Each possibility represents a separate embodiment of the present invention.
[0078] The cervical tumor targeted by methods of the present invention is, in another embodiment, a squamous cell carcinoma.
[0079] In another embodiment, methods of the present invention may be used to prevent, treat, inhibit or suppress a progressive squamous cell cancer of the cervix. In another embodiment, methods of the present invention may be used to prevent, treat, inhibit or suppress a recurrent squamous cell cancer of the cervix. In another embodiment, methods of the present invention may be used to prevent, treat, inhibit or suppress an advanced squamous cell cancer of the cervix. In another embodiment, methods of the present invention may be used to prevent, treat, inhibit or suppress any other form or type of cervical cancer known in the art.
[0080] In another embodiment, the cervical tumor is an adenocarcinoma. In another embodiment, the cervical tumor is an adenosquamous carcinoma. In another embodiment, the cervical tumor is a small cell carcinoma. In another embodiment, the cervical tumor is any other type of cervical tumor known in the art. Each possibility represents a separate embodiment of the present invention.
[0081] In another embodiment, an HPV E6 antigen is utilized instead of or in addition to an E7 antigen in a method of the present invention for treating, protecting against, or inducing an immune response against a cervical cancer.
[0082] In another embodiment, an ActA protein fragment is utilized instead of or in addition to an LLO fragment in a method of the present invention for treating, protecting against, or inducing an immune response against a cervical cancer.
[0083] In another embodiment, a PEST-like sequence-containing protein fragment is utilized instead of or in addition to an LLO fragment in a method of the present invention for treating, protecting against, or inducing an immune response against a cervical cancer.
[0084] In another embodiment, the present invention provides a method for inducing an anti-E7 cytotoxic T cell (CTL) response in a human subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, thereby inducing an anti-E7 CTL response in a human subject. In another embodiment, the recombinant Listeria strain comprises a plasmid that encodes the recombinant polypeptide. In another embodiment, the method further comprises the step of boosting the subject with a recombinant Listeria strain of
P-7771-PC3 the present invention. In another embodiment, the method further comprises the step of boosting the subject with an immunogenic composition comprising an E7 antigen. In another embodiment, the method further comprises the step of boosting the subject with an immunogenic composition that directs a cell of the subject to express an E7 antigen. In another embodiment, the CTL response is capable of therapeutic efficacy against an HPV-mediated disease, disorder, or symptom. In another embodiment, the CTL response is capable of prophylactic efficacy against an HPV-mediated disease, disorder, or symptom. Each possibility represents a separate embodiment of the present invention.
[0085] In another embodiment, the present invention provides a method of treating or ameliorating an HPV-mediated disease, disorder, or symptom in a subject, comprising the step of administering to the subject a recombinant Listeria strain, the recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein and an HPV E7 antigen, whereby the recombinant Listeria strain induces an immune response against the E7 antigen, thereby treating or ameliorating an HPV-mediated disease, disorder, or symptom in a subject. In another embodiment, the subject is a human subject. In another embodiment, the subject is any other type of subject known in the art. Each possibility represents a separate embodiment of the present invention.
[0086] The HPV causing the disease, disorder, or symptom is, in another embodiment, an HPV 16. In another embodiment, the HPV is an HPV- 18. In another embodiment, the HPV is an HPV-31. In another embodiment, the HPV is an HPV-35. In another embodiment, the HPV is an HPV-39. In another embodiment, the HPV is an HPV-45. In another embodiment, the HPV is an HPV-51. In another embodiment, the HPV is an HPV-52. In another embodiment, the HPV is an HPV-58. In another embodiment, the HPV is a high-risk HPV type. In another embodiment, the HPV is a mucosal HPV type. Each possibility represents a separate embodiment of the present invention.
[0087] In another embodiment, the HPV-mediated disease, disorder, or symptom is genital warts. In another embodiment, the HPV-mediated disease, disorder, or symptom is non-genital warts. In another embodiment, the HPV-mediated disease, disorder, or symptom is a respiratory papilloma. In another embodiment, the HPV-mediated disease, disorder, or symptom is any other HPV-mediated disease, disorder, or symptom known in the art. Each possibility represents a separate embodiment of the present invention.
[0088] In another embodiment, an HPV E6 antigen is utilized instead of or in addition to an E7 antigen in a method of the present invention for treating or ameliorating an HPV-mediated disease, disorder, or symptom.
[0089] In another embodiment, an ActA protein fragment is utilized instead of or in addition to an
P-7771-PC3
LLO fragment in a method of the present invention for treating or ameliorating an HPV-mediated disease, disorder, or symptom.
[0090] In another embodiment, a PEST-like sequence-containing protein fragment is utilized instead of or in addition to an LLO fragment in a method of the present invention for treating or ameliorating an HPV-mediated disease, disorder, or symptom.
[0091] In another embodiment, an HPV E6 antigen is utilized instead of or in addition to an E7 antigen in a method of the present invention for treating or ameliorating an HPV-mediated disease, disorder, or symptom.
[0092] The antigen of methods and compositions of the present invention is, in another embodiment, an HPV E7 protein. In another embodiment, the antigen is an HPV E6 protein. In another embodiment, the antigen is any other HPV protein known in the art. Each possibility represents a separate embodiment of the present invention.
[0093] "E7 antigen" refers, in another embodiment, to an E7 protein. In another embodiment, the term refers to an E7 fragment. In another embodiment, the term refers to an E7 peptide. In another embodiment, the term refers to any other type of E7 antigen known in the art. Each possibility represents a separate embodiment of the present invention.
[0094] The E7 protein of methods and compositions of the present invention is, in another embodiment, an HPV 16 E7 protein. In another embodiment, the E7 protein is an HPV- 18 E7 protein. In another embodiment, the E7 protein is an HPV-31 E7 protein. In another embodiment, the E7 protein is an HPV-35 E7 protein. In another embodiment, the E7 protein is an HPV-39 E7 protein. In another embodiment, the E7 protein is an HPV-45 E7 protein. In another embodiment, the E7 protein is an HPV-51 E7 protein. In another embodiment, the E7 protein is an HPV-52 E7 protein. In another embodiment, the E7 protein is an HPV-58 E7 protein. In another embodiment, the E7 protein is an E7 protein of a high-risk HPV type. In another embodiment, the E7 protein is an E7 protein of a mucosal HPV type. Each possibility represents a separate embodiment of the present invention.
[0095] "E6 antigen" refers, in another embodiment, to an E6 protein. In another embodiment, the term refers to an E6 fragment. In another embodiment, the term refers to an E6 peptide. In another embodiment, the term refers to any other type of E6 antigen known in the art. Each possibility represents a separate embodiment of the present invention.
[0096] The E6 protein of methods and compositions of the present invention is, in another embodiment, an HPV 16 E6 protein. In another embodiment, the E6 protein is an HPV- 18 E6
P-7771-PC3 protein. In another embodiment, the E6 protein is an HPV-31 E6 protein. In another embodiment, the E6 protein is an HPV-35 E6 protein. In another embodiment, the E6 protein is an HPV-39 E6 protein. In another embodiment, the E6 protein is an HPV-45 E6 protein. In another embodiment, the E6 protein is an HPV-51 E6 protein. In another embodiment, the E6 protein is an HPV-52 E6 protein. In another embodiment, the E6 protein is an HPV-58 E6 protein. In another embodiment, the E6 protein is an E6 protein of a high-risk HPV type. In another embodiment, the E6 protein is an E6 protein of a mucosal HPV type. Each possibility represents a separate embodiment of the present invention.
[0097] In another embodiment, the present invention provides a method of vaccinating a human subject against an antigen of interest, the method comprising the step of administering intravenously to the human subject a recombinant Listeria strain comprising or expressing the antigen of interest, wherein the first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, thereby vaccinating a human subject against an antigen of interest.
[0098] In another embodiment, the present invention provides a method of vaccinating a human subject against an antigen of interest, the method comprising the step of administering intravenously to the human subject an immunogenic composition, comprising a fusion of a first peptide to the antigen of interest, wherein the first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, thereby vaccinating a human subject against an antigen of interest.
[0099] In another embodiment, the present invention provides a method of vaccinating a human subject against an antigen of interest, the method comprising the step of administering intravenously to the human subject a recombinant Listeria strain comprising a recombinant polypeptide, the recombinant polypeptide comprising a first peptide fused to the antigen of interest, wherein the first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N- terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, thereby vaccinating a human subject against an antigen of interest.
[0010O] In one embodiment, the compositions for use in the methods of the present invention are administered intravenously. In another embodiment, the vaccine is administered orally, whereas in another embodiment, the vaccine is administered parenterally (e.g., subcutaneously, intramuscularly, and the like).
[00101 J Further, in another embodiment, the compositions or vaccines are administered as a suppository, for example a rectal suppository or a urethral suppository. Further, in another
P-7771-PC3 embodiment, the pharmaceutical compositions are administered by subcutaneous implantation of a pellet. In a further embodiment, the pellet provides for controlled release of an agent over a period of time. In yet another embodiment, the pharmaceutical compositions are administered in the form of a capsule.
[00102] In one embodiment, the route of administration may be parenteral. In another embodiment, the route may be intra-ocular, conjunctival, topical, transdermal, intradermal, subcutaneous, intraperitoneal, intravenous, intra-arterial, vaginal, rectal, intratumoral, parcanceral, transmucosal, intramuscular, intravascular, intraventricular, intracranial, inhalation (aerosol), nasal aspiration (spray), intranasal (drops), sublingual, oral, aerosol or suppository or a combination thereof. For intranasal administration or application by inhalation, solutions or suspensions of the compounds mixed and aerosolized or nebulized in the presence of the appropriate carrier suitable. Such an aerosol may comprise any agent described herein. In one embodiment, the compositions as set forth herein may be in a form suitable for intracranial administration, which in one embodiment, is intrathecal and intracerebroventricular administration. In one embodiment, the regimen of administration will be determined by skilled clinicians, based on factors such as exact nature of the condition being treated, the severity of the condition, the age and general physical condition of the patient, body weight, and response of the individual patient, etc.
[00103] For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories and enemas. Ampoules are convenient unit dosages. Such a suppository may comprise any agent described herein.
[00104] Sustained or directed release compositions can be formulated, e.g., liposomes or those wherein the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. Such compositions may be formulated for immediate or slow release. It is also possible to freeze-dry the new compounds and use the lyophilisates obtained, for example, for the preparation of products for injection.
[00105] For liquid formulations, pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, emulsions or oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Examples of oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.
P-7771-PC3
[00106] In one embodiment, compositions of this invention are pharmaceutically acceptable. In one embodiment, the term "pharmaceutically acceptable" refers to any formulation which is safe, and provides the appropriate delivery for the desired route of administration of an effective amount of at least one compound for use in the present invention. This term refers to the use of buffered formulations as well, wherein the pH is maintained at a particular desired value, ranging from pH 4.0 to pH 9.0, in accordance with the stability of the compounds and route of administration.
[00107] In one embodiment, a composition of or used in the methods of this invention may be administered alone or within a composition. In another embodiment, compositions of this invention admixture with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, enteral (e.g., oral) or topical application which do not deleteriously react with the active compounds may be used. In one embodiment, suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatine, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, white paraffin, glycerol, alginates, hyaluronic acid, collagen, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc. In another embodiment, the pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds. In another embodiment, they can also be combined where desired with other active agents, e.g., vitamins.
[00108] In one embodiment, the compositions for use in the methods of the present invention may be administered with a carrier/diluent. Solid carriers/diluents include, but are not limited to, a gum, a starch (e.g., corn starch, pregeletanized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g., microcrystalline cellulose), an acrylate (e.g., polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
In one embodiment, the compositions of the present invention may comprise the composition of this invention and one or more additional compounds effective in preventing or treating cervical cancer. In some embodiments, the additional compound may comprise a compound useful in chemotherapy, which in one embodiment, is Cisplatin. In another embodiment, Ifosfamide, Fluorouracilor5-FU, Irinotecan, Paclitaxel (Taxol), Docetaxel, Gemcitabine, Topotecan or a combination thereof, may be administered with a composition of the present invention for use in the methods of the present invention. In another embodiment, Amsacrine, Bleomycin, Busulfan, Capecitabine, Carboplatin,
P-7771-PC3
Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crisantaspase, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Docetaxel, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Gliadelimplants, Hydroxycarbamide, Idarubicin, Ifosfamide, Irinotecan, Leucovorin, Liposomaldoxorubicin, Liposomaldaunorubicin, Lomustine, Melphalan, Mercaptopurine, Mesna, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Pentostatin, Procarbazine, Raltitrexed, Satraplatin, Streptozocin, Tegafur-uracil, Temozolomide, Teniposide, Thiotepa, Tioguanine, Topotecan, Treosulfan, Vinblastine, Vincristine, Vindesine, Vinorelbine, or a combination thereof, may be administered with a composition of the present invention for use in the methods of the present invention.
[00109] In another embodiment, the present invention provides a method of inducing a CTL response in a human subject against an antigen of interest, the method comprising the step of administering to the human subject a recombinant Listeria strain comprising or expressing the antigen of interest, thereby inducing a CTL response in a human subject against an antigen of interest. In another embodiment, the step of administering is intravenous administration. Each possibility represents a separate embodiment of the present invention.
[00110] As provided herein, recombinant Listeria strains expressing LLO-antigen fusions induce antitumor immunity (Example 1), elicit antigen-specific T cell proliferation (Example 2), generate antigen-specific, tumor-infiltrating T cells (Example 4), and abrogate peripheral tolerance to antigens such as E6 and E7 (Examples 5-9). Thus, vaccines of the present invention are efficacious at inducing immune responses against E7 and E6. Further, the recombinant Listeria strains are safe and improve disease indicators in human subjects (Example 10).
[00111] In another embodiment, the antigen of interest is HPV-E7. In another embodiment, the antigen is HPV-E6. In another embodiment, the antigen is Her-2. In another embodiment, the antigen is NY- ESO-I . In another embodiment, the antigen is telomerase. In another embodiment, the antigen is SCCE. In another embodiment, the antigen is HMW-MAA. In another embodiment, the antigen is WT-I . In another embodiment, the antigen is HIV-I Gag. In another embodiment, the antigen is Proteinase 3. In another embodiment, the antigen is Tyrosinase related protein 2. In another embodiment, the antigen is PSA (prostate-specific antigen). In another embodiment, the antigen is selected from E7, E6, Her-2, NY-ESO-I , telomerase, SCCE, HMW-MAA, WT-I , HIV-I Gag, Proteinase 3, Tyrosinase related protein 2, Mucl, PSA (prostate-specific antigen), or a combination thereof.
[001 12] In another embodiment, the antigen is a tumor-associated antigen, which in one embodiment,
P-7771-PC3 is one of the following tumor antigens: a MAGE (Melanoma-Associated Antigen E) protein, e.g. MAGE 1, MAGE 2, MAGE 3, MAGE 4, a tyrosinase; a mutant ras protein; a mutant p53 protein; p97 melanoma antigen, a ras peptide or p53 peptide associated with advanced cancers; the HPV 16/18 antigens associated with cervical cancers, KLH antigen associated with breast carcinoma, CEA (carcinoembryonic antigen) associated with colorectal cancer, gplOO, a MARTl antigen associated with melanoma, or the PSA antigen associated with prostate cancer. In another embodiment, the antigen for the compositions and methods of the present invention are melanoma-associated antigens, which in one embodiment are TRP-2, MAGE-I, MAGE-3, gp-100, tyrosinase, HSP-70, beta-HCG, or a combination thereof.
[00113] In another embodiment, the antigen is an infectious disease antigen.
[00114] In other embodiments, the antigen is derived from a fungal pathogen, bacteria, parasite, helminth, or viruses. In other embodiments, the antigen is selected from tetanus toxoid, hemagglutinin molecules from influenza virus, diphtheria toxoid, HIV gpl20, HIV gag protein, IgA protease, insulin peptide B, Spongospora subterranea antigen, vibriose antigens, Salmonella antigens, pneumococcus antigens, respiratory syncytial virus antigens, Haemophilus influenza outer membrane proteins, Helicobacter pylori urease, Neisseria meningitidis pilins, N. gonorrhoeae pilins, human papilloma virus antigens El and E2 from type HPV-16, -18, -31, -33, -35 or -45 human papilloma viruses, or a combination thereof.
[00115] In other embodiments, the antigen is associated with one of the following diseases; cholera, diphtheria, Haemophilus, hepatitis A, hepatitis B, influenza, measles, meningitis, mumps, pertussis, small pox, pneumococcal pneumonia, polio, rabies, rubella, tetanus, tuberculosis, typhoid, Varicella- zoster, whooping cough3 yellow fever, the immunogens and antigens from Addison's disease, allergies, anaphylaxis, Bruton's syndrome, cancer, including solid and blood borne tumors, eczema, Hashimoto's thyroiditis, polymyositis, dermatomyositis, type 1 diabetes mellitus, acquired immune deficiency syndrome, transplant rejection, such as kidney, heart, pancreas, lung, bone, and liver transplants, Graves' disease, polyendocrine autoimmune disease, hepatitis, microscopic polyarteritis, polyarteritis nodosa, pemphigus, primary biliary cirrhosis, pernicious anemia, coeliac disease, antibody-mediated nephritis, glomerulonephritis, rheumatic diseases, systemic lupus erthematosus, rheumatoid arthritis, seronegative spondylarthritides, rhinitis, Sjogren's syndrome, systemic sclerosis, sclerosing cholangitis, Wegener's granulomatosis, dermatitis herpetiformis, psoriasis, vitiligo, multiple sclerosis, encephalomyelitis, Guillain-Barre syndrome, myasthenia gravis, Lambert-Eaton syndrome, sclera, episclera, uveitis, chronic mucocutaneous candidiasis, urticaria, transient hypogammaglobulinemia of infancy, myeloma, X-linked hyper IgM syndrome, Wiskott-Aldrich
P-7771-PC3 syndrome, ataxia telangiectasia, autoimmune hemolytic anemia, autoimmune thrombocytopenia, autoimmune neutropenia, Waldenstrom's macroglobulinemia, amyloidosis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, malarial circumsporozite protein, microbial antigens, viral antigens, autoantigens, and lesteriosis.
[00116] Each antigen represents a separate embodiment of the present invention.
[00117] The immune response induced by methods and compositions of the present invention is, in another embodiment, a T cell response. In another embodiment, the immune response comprises a T cell response. In another embodiment, the response is a CD8+ T cell response. In another embodiment, the response comprises a CD8+ T cell response. Each possibility represents a separate embodiment of the present invention.
[00118] The N-terminal LLO protein fragment of methods and compositions of the present invention comprises, in another embodiment, SEQ ID NO: 1. In another embodiment, the fragment comprises an LLO signal peptide. In another embodiment, the fragment comprises SEQ ID NO: 25. In another embodiment, the fragment consists approximately of SEQ ID NO: 25. In another embodiment, the fragment consists essentially of SEQ ID NO: 25. In another embodiment, the fragment corresponds to SEQ ID NO: 25. In another embodiment, the fragment is homologous to SEQ ID NO: 25. In another embodiment, the fragment is homologous to a fragment of SEQ ID NO: 25. The ΔLLO used in some of the Examples was 416 AA long (exclusive of the signal sequence), as 88 residues from the amino terminus which is inclusive of the activation domain containing cysteine 484 were truncated. It will be clear to those skilled in the art that any ΔLLO without the activation domain, and in particular without cysteine 484, are suitable for methods and compositions of the present invention. In another embodiment, fusion of an E7 or E6 antigen to any ΔLLO, including the PEST-like AA sequence, SEQ ID NO: 1, enhances cell mediated and anti-tumor immunity of the antigen. Each possibility represents a separate embodiment of the present invention.
[001 19] The LLO protein utilized to construct vaccines of the present invention has, in another embodiment, the sequence:
MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSMAPPASPPASPKTPIEKKHADEIDKYIQ GLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQNNADIQVVNAISSLTYP GALVKANSELVENQPDVLPVKRDSLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVER WNEKY AQAYPNVSAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVIS FKQIYYNVNVNEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGRQVYLKLSTNSHST KVKAAFD AA VSGKSVSGDVELTNJIKNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATF
P-7771-PC3
NRETPGVPIAYTTNFLKDNELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVN YDPEGNEIVQHKNWSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEWWRTVIDDRN LPLVKNRNISIWGTTLYPKYSNKVDNPIE (GenBank Accession No. P13128; SEQ ID NO: 27; nucleic acid sequence is set forth in GenBank Accession No. Xl 5127). The first 25 AA of the proprotein corresponding to this sequence are the signal sequence and are cleaved from LLO when it is secreted by the bacterium. Thus, in this embodiment, the full length active LLO protein is 504 residues long. In another embodiment, the above LLO fragment is used as the source of the LLO fragment incorporated in a vaccine of the present invention. Each possibility represents a separate embodiment of the present invention.
[00120] In another embodiment, the N-terminal fragment of an LLO protein utilized in compositions and methods of the present invention has the sequence:
MKKIMLVFΓΓLILVSLPIAQQTEAKDASAFNKENSISSVAPPASPPASPKTPIEKKHADEΓDKYIQ
GLD YNKNNVLVYHGDA VTNVPPRKGYKDGNEYΓVVEKKKKSINQNN ADIQVVNAISSLTYP GALVKANSELVENQPDVLPVKRDSLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVER WNEKYAQAYSNVSAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVIS FKQIYYNVNVNEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGRQVYLKLSTNSHST KVKAAFD AAVSGKSVSGDVELTNIIKNSSFKA VIYGGSAKDEVQIIDGNLGDLRDILKKGATF NRETPGVPIAYTTNFLKDNELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVN YD (SEQ ID NO: 25).
[00121] In another embodiment, the LLO fragment corresponds to about AA 20-442 of an LLO protein utilized herein.
[00122] In another embodiment, the LLO fragment has the sequence:
MKKIMLVHTLILVSLPIAQQTEAKDASAFNKENSISSVAPPASPPASPKTPIEKKHADEIDKYIQ GLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQNNADIQVVNAISSLTYP GALVKANSELVENQPDVLPVKRDSLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVER WNEKYAQAYSNVSAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVIS FKQIYYNVNVNEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGRQVYLKLSTNSHS TKVKAAFDAAVSGKSVSGDVELTNIIKNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGAT FNRETPGVPIAYTTNFLKDNELAVIKNNSEYIETTSKAYTD (SEQ ID NO: 26).
[00123] In another embodiment, "truncated LLO" or "ΔLLO" refers to a fragment of LLO that comprises the PEST-like domain. In another embodiment, the terms refer to an LLO fragment that
P-7771-PC3 comprises a PEST sequence.
[00124] In another embodiment, the terms refer to an LLO fragment that does not contain the activation domain at the amino terminus and does not include cysteine 484. In another embodiment, the terms refer to an LLO fragment that is not hemolytic. In another embodiment, the LLO fragment is rendered non-hemolytic by deletion or mutation of the activation domain. In another embodiment, the LLO fragment is rendered non-hemolytic by deletion or mutation of cysteine 484. In another embodiment, the LLO fragment is rendered non-hemolytic by deletion or mutation at another location. Each possibility represents a separate embodiment of the present invention.
[00125] In another embodiment, the LLO fragment consists of about the first 441 AA of the LLO protein. In another embodiment, the LLO fragment consists of about the first 420 AA of LLO. In another embodiment, the LLO fragment is a non-hemolytic form of the LLO protein.
[00126] In another embodiment, the LLO fragment contains residues of a homologous LLO protein that correspond to one of the above AA ranges. The residue numbers need not, in another embodiment, correspond exactly with the residue numbers enumerated above; e.g. if the homologous LLO protein has an insertion or deletion, relative to an LLO protein utilized herein, then the residue numbers can be adjusted accordingly.
[00127] In another embodiment, the LLO fragment is any other LLO fragment known in the art. Each possibility represents a separate embodiment of the present invention.
[00128] In another embodiment, the present invention provides a method of treating, suppressing, inhibiting, or reducing an incidence of an HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention. In one embodiment, the HSV infection is an HSV-I infection. In one embodiment, the HSV infection is an HSV-2 infection. In one embodiment, the HSV infection is a primary HSV infection. In one embodiment, the HSV infection is a flare, recurrence, or HSV labialis following a primary HSV infection. In one embodiment, the HSV infection is HSV encephalitis. In one embodiment, the HSV infection is an HSV neonatal infection. In one embodiment, the subject is HIV-infected.
[00129] In another embodiment, the present invention provides a method of inhibiting an HSV labialis following a primary HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention.
[00130] In another embodiment, the present invention provides a method of preventing a recurrence of an HSV infection, the method comprising the step of administering to said subject a vaccine of the
P-7771-PC3 present invention. In another embodiment, the present invention provides a method of diminishing the severity of a recurrence of an HSV infection, the method comprising the step of administering to said subject a vaccine of the present invention. In another embodiment, the present invention provides a method of reducing the frequency of a recurrence of an HSV infection, the method comprising the step of administering to said subject a vaccine of the present invention. In one embodiment, the present invention provides any of the described methods in an HIV-infected subject.
[00131] "HSV-2" refers, in another embodiment, to a Herpes Simplex Virus-2. In another embodiment, the term refers to an HSV-2 333 strain. In another embodiment, the term refers to a 2.12 strain. In another embodiment, the term refers to an HG52 strain. In another embodiment, the term refers to an MS strain. In another embodiment, the term refers to a G strain. In another embodiment, the term refers to an 186 strain. In another embodiment, the term refers to any other HSV-2 strain known in the art.
[00132] In another embodiment, the present invention provides a method of vaccinating a subject against an HSV infection, the method comprising the step of administering to said subject a vaccine of the present invention. In another embodiment, the present invention provides a method of suppressing an HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention. In another embodiment, the present invention provides a method of impeding an HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention. In another embodiment, the present invention provides a method of impeding a primary HSV infection in a subject, the method comprising the step of administering to said subject a vaccine of the present invention. In another embodiment, the present invention provides a method of impeding neuronal HSV spread in a subject, the method comprising the step of administering to said subject a vaccine of the present invention.
[00133] In one embodiment, the terms impeding an infection (for example, in one embodiment, "impeding a HSV infection" or "impeding a primary HSV infection") refer to decreasing the titer of infectious virus by 90%. In another embodiment, the titer is decreased by 50%. In another embodiment, the titer is decreased by 55%. In another embodiment, the titer is decreased by 60%. In another embodiment, the titer is decreased by 65%. In another embodiment, the titer is decreased by
70%. In another embodiment, the titer is decreased by 75%. In another embodiment, the titer is decreased by 80%. In another embodiment, the titer is decreased by 85%. In another embodiment, the titer is decreased by 92%. In another embodiment, the titer is decreased by 95%. In another embodiment, the titer is decreased by 96%. In another embodiment, the titer is decreased by 97%. In another embodiment, the titer is decreased by 98%. In another embodiment, the titer is decreased by
P-7771-PC3
99%. In another embodiment, the titer is decreased by over 99%.
[00134] In another embodiment, the terms refer to decreasing the extent of viral replication by 90%. In another embodiment, replication is reduced by 50%. In another embodiment, replication is reduced by
55%. In another embodiment, replication is reduced by 60%. In another embodiment, replication is reduced by 65%. In another embodiment, replication is reduced by 70%. In another embodiment, replication is reduced by 75%. In another embodiment, replication is reduced by 80%. In another embodiment, replication is reduced by 85%. In another embodiment, replication is reduced by 92%. In another embodiment, replication is reduced by 95%. In another embodiment, replication is reduced by
96%. In another embodiment, replication is reduced by 97%. In another embodiment, replication is reduced by 98%. In another embodiment, replication is reduced by 99%. In another embodiment, replication is reduced by over 99%.
[00135] Methods of determining the extent of HSV replication and HSV infection are well known in the art, and are described, for example, in Lambiase A et al. (Topical treatment with nerve growth factor in an animal model of herpetic keratitis. Graefes Arch Clin Exp Ophthalmol. 2007 May 4), Ramaswamy M et al. (Interactions and management issues in HSV and HTV coinfection. Expert Rev Anti Infect Ther. 2007 Apr;5(2):231-43), and Jiang C et al. (Mutations that decrease DNA binding of the processivity factor of the herpes simplex virus DNA polymerase reduce viral yield, alter the kinetics of viral DNA replication, and decrease the fidelity of DNA replication. J Virol. 2007 Apr;81(7):3495-502). Each method represents a separate embodiment of the present invention.
[00136] In another embodiment, the present invention provides a method of treating, reducing the pathogenesis of, ameliorating the symptoms of, ameliorating the secondary symptoms of, reducing the incidence of, prolonging the latency to a relapse of a Herpes Simplex Virus (HSV) infection in a subject, comprising the step of administering to the subject a vaccine of the present invention. The HSV infection that is treated or ameliorated by methods and compositions of the present invention is, in another embodiment, a genital HSV infection.
[00137] It is to be understood that the methods of the present invention may be used to treat, inhibit, suppress, etc an HSV infection or primary or secondary symptoms related to such an infection following exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in treating, inhibiting, suppressing, etc an HSV infection or primary or secondary symptoms related to such an infection.
P-7771-PC3
[00138] In one embodiment, symptoms are primary, while in another embodiment, symptoms are secondary. In one embodiment, "primary" refers to a symptom that is a direct result of the subject viral infection, while in one embodiment, "secondary" refers to a symptom that is derived from or consequent to a primary cause. In one embodiment, the compositions and strains for use in the present invention treat primary or secondary symptoms or secondary complications related to HSV infection.
[00139] In another embodiment, the recombinant Listeria strain is administered to the human subject at a dose of 1 x 109 - 3.31 x 1010 CFU. In another embodiment, the dose is 5-500 x 108 CFU. In another embodiment, the dose is 7-500 x 108 CFU. In another embodiment, the dose is 10-500 x 108 CFU. In another embodiment, the dose is 20-500 x 108 CFU. In another embodiment, the dose is 30-500 x 108 CFU. In another embodiment, the dose is 50-500 x 108 CFU. In another embodiment, the dose is 70- 500 x 108 CFU. In another embodiment, the dose is 100-500 x 108 CFU. In another embodiment, the dose is 150-500 x 108 CFU. In another embodiment, the dose is 5-300 x 108 CFU. In another embodiment, the dose is 5-200 x 108 CFU. In another embodiment, the dose is 5-150 x 108 CFU. In another embodiment, the dose is 5-100 x 108 CFU. In another embodiment, the dose is 5-70 x 108 CFU. In another embodiment, the dose is 5-50 x 108 CFU. In another embodiment, the dose is 5-30 x 108 CFU. In another embodiment, the dose is 5-20 x 108 CFU. In another embodiment, the dose is 1- 30 x 109 CFU. In another embodiment, the dose is 1-20 x 109 CFU. In another embodiment, the dose is 2-30 x 109 CFU. In another embodiment, the dose is 1-10 x 109 CFU. In another embodiment, the dose is 2-10 x 109 CFU. In another embodiment, the dose is 3-10 x 109 CFU. In another embodiment, the dose is 2-7 x 109 CFU. In another embodiment, the dose is 2-5 x 109 CFU. In another embodiment, the dose is 3-5 x 109 CFU.
[00140] In another embodiment, the dose is 1 x 109-3.31 x 109 organisms, which is an unexpectedly low dose of recombinant Listeria in view of pre-clinical data.
[00141 ] In another embodiment, the dose is 1.5 x 109 organisms. In another embodiment, the dose is 2 x 109 organisms. In another embodiment, the dose is 3 x 109 organisms. In another embodiment, the dose is 4 x 109 organisms. In another embodiment, the dose is 5 x 109 organisms. In another embodiment, the dose is 6 x 109 organisms. In another embodiment, the dose is 7 x 109 organisms. In another embodiment, the dose is 8 x 109 organisms. In another embodiment, the dose is 10 x 109 organisms. In another embodiment, the dose is 1.5 x 1010 organisms. In another embodiment, the dose is 2 x l θ'° organisms. In another embodiment, the dose is 2.5 x 1010 organisms. In another embodiment, the dose is 3 x 1010 organisms. In another embodiment, the dose is 3.3 x l θ'° organisms.
In another embodiment, the dose is 4 x l θ'° organisms. In another embodiment, the dose is 5 x 1010
P-7771-PC3 organisms.
[00142] Each dose and range of doses represents a separate embodiment of the present invention.
[00143] In another embodiment, the recombinant polypeptide of methods of the present invention is expressed by the recombinant Listeria strain. In another embodiment, the expression is mediated by a nucleotide molecule carried by the recombinant Listeria strain. Each possibility represents a separate embodiment of the present invention.
[00144] In another embodiment, the recombinant Listeria strain expresses the recombinant polypeptide by means of a plasmid that encodes the recombinant polypeptide. In another embodiment, the plasmid comprises a gene encoding a bacterial transcription factor. In another embodiment, the plasmid encodes a Listeria transcription factor. In another embodiment, the transcription factor is prfA. In another embodiment, the transcription factor is any other transcription factor known in the art. Each possibility represents a separate embodiment of the present invention.
[00145] In another embodiment, the plasmid comprises a gene encoding a metabolic enzyme. In another embodiment, the metabolic enzyme is a bacterial metabolic enzyme. In another embodiment, the metabolic enzyme is a Listerial metabolic enzyme. In another embodiment, the metabolic enzyme is an amino acid metabolism enzyme. In another embodiment, the amino acid metabolism gene is involved in a cell wall synthesis pathway. In another embodiment, the metabolic enzyme is the product of a D-amino acid aminotransferase gene (dat). In another embodiment, the metabolic enzyme is the product of an alanine racemase gene (dal). In another embodiment, the metabolic enzyme is any other metabolic enzyme known in the art. Each possibility represents a separate embodiment of the present invention.
[00146] In another embodiment, a method of present invention further comprises the step of boosting the human subject with a recombinant Listeria strain of the present invention. In another embodiment, the recombinant Listeria strain used in the booster inoculation is the same as the strain used in the initial "priming" inoculation. In another embodiment, the booster strain is different from the priming strain. In another embodiment, the same doses are used in the priming and boosting inoculations. In another embodiment, a larger dose is used in the booster. In another embodiment, a smaller dose is used in the booster. Each possibility represents a separate embodiment of the present invention.
[00147] In another embodiment, a method of present invention further comprises the step of inoculating the human subject with an immunogenic composition comprising the E7 antigen. In another embodiment, the immunogenic composition comprises a recombinant E7 protein or fragment
P-7771-PC3 thereof. In another embodiment, the immunogenic composition comprises a nucleotide molecule expressing a recombinant E7 protein or fragment thereof. In another embodiment, the non-Listerial inoculation is administered after the Listerial inoculation. In another embodiment, the non-Listerial inoculation is administered before the Listerial inoculation. Each possibility represents a separate embodiment of the present invention.
[00148] "Boosting" refers, in another embodiment, to administration of an additional vaccine dose to a subject. In another embodiment of methods of the present invention, 2 boosts (or a total of 3 inoculations) are administered. In another embodiment, 3 boosts are administered. In another embodiment, 4 boosts are administered. In another embodiment, 5 boosts are administered. In another embodiment, 6 boosts are administered. In another embodiment, more than 6 boosts are administered. Each possibility represents a separate embodiment of the present invention.
[00149] In one embodiment, a vaccine boost is provided 21 days after the initial vaccination. In another embodiment, a boost is provided 7 days after the initial vaccination. In another embodiment, a boost is provided 14 days after the initial vaccination. In another embodiment, a boost is provided 28 days after the initial vaccination. In another embodiment, a boost is provided 10 days after the initial vaccination. In another embodiment, a boost is provided 25 days after the initial vaccination. In another embodiment, a boost is provided 1 month after the initial vaccination. In another embodiment, a boost is provided 6 weeks after the initial vaccination. In another embodiment, a boost is provided 2 months after the initial vaccination. In another embodiment, a boost is provided 3 months after the initial vaccination. In another embodiment, a boost is provided 4 months after the initial vaccination. In another embodiment, a boost is provided 5 months after the initial vaccination. In another embodiment, a boost is provided 6 months after the initial vaccination. In one embodiment, a boost is provided in any combination of the time periods described hereinabove.
[00150] The recombinant Listeria strain of methods and compositions of the present invention is, in another embodiment, a recombinant Listeria monocytogenes strain. In another embodiment, the
Listeria strain is a recombinant Listeria seeligeri strain. In another embodiment, the Listeria strain is a recombinant Listeria grayi strain. In another embodiment, the Listeria strain is a recombinant Listeria ivanovii strain. In another embodiment, the Listeria strain is a recombinant Listeria murrayi strain. In another embodiment, the Listeria strain is a recombinant Listeria welshimeri strain. In another embodiment, the Listeria strain is a recombinant strain of any other Listeria species known in the art.
Each possibility represents a separate embodiment of the present invention.
[0015I ] In another embodiment, a recombinant Listeria strain of the present invention has been
P-7771-PC3 passaged through an animal host. In one embodiment, said passaging occurs prior to the step of administering the recombinant Listeria strain. In another embodiment, the passaging maximizes efficacy of the strain as a vaccine vector. In another embodiment, the passaging stabilizes the immunogenicity of the Listeria strain. In another embodiment, the passaging stabilizes the virulence of the Listeria strain. In another embodiment, the passaging increases the immunogenicity of the Listeria strain. In another embodiment, the passaging increases the virulence of the Listeria strain. In another embodiment, the passaging removes unstable sub-strains of the Listeria strain. In another embodiment, the passaging reduces the prevalence of unstable sub-strains of the Listeria strain. In another embodiment, the Listeria strain contains a genomic insertion of the gene encoding the antigen- containing recombinant peptide. In another embodiment, the Listeria strain carries a plasmid comprising the gene encoding the antigen-containing recombinant peptide. In another embodiment, the passaging is performed as described herein (e.g. in Example 12) or as described in WO 04/062597, which is incorporated herein by reference. In another embodiment, the passaging is performed by any other method known in the art. Each possibility represents a separate embodiment of the present invention.
[00152] In another embodiment, the recombinant Listeria strain utilized in methods of the present invention has been stored in a frozen cell bank. In another embodiment, the recombinant Listeria strain has been stored in a lyophilized cell bank. Each possibility represents a separate embodiment of the present invention. In one embodiment, the cell bank is as described in WO 2007/061848, which is incorporated herein by reference.
[00153] In one embodiment, methods for cryopreservation and lyophilization of a Listeria strain, methods for producing a cell bank or a batch of vaccine doses of same, methods of characterizing same, and defined microbiological media useful in the methods of the present invention are as described in WO 2007/061848, which is incorporated herein by reference in its entrirety.
[00154] In another embodiment, the cell bank of methods and compositions of the present invention is a master cell bank. In another embodiment, the cell bank is a working cell bank. In another embodiment, the cell bank is Good Manufacturing Practice (GMP) cell bank. In another embodiment, the cell bank is intended for production of clinical-grade material. In another embodiment, the cell bank conforms to regulatory practices for human use. In another embodiment, the cell bank is any other type of cell bank known in the art. Each possibility represents a separate embodiment of the present invention.
[00155] "Good Manufacturing Practices" are defined, in another embodiment, by (21 CFR 210-21 1 ) of
P-7771-PC3 the United States Code of Federal Regulations. In another embodiment, "Good Manufacturing Practices" are defined by other standards for production of clinical-grade material or for human consumption; e.g. standards of a country other than the United States. Each possibility represents a separate embodiment of the present invention.
[00156] In another embodiment, a recombinant Listeria strain utilized in methods of the present invention is from a batch of vaccine doses.
[00157] In another embodiment, a recombinant Listeria strain utilized in methods of the present invention is from a frozen stock produced by a method disclosed herein.
[00158] In another embodiment, a recombinant Listeria strain utilized in methods of the present invention is from a lyophilized stock produced by a method disclosed herein.
[00159] In another embodiment, a cell bank, frozen stock, or batch of vaccine doses of the present invention exhibits viability upon thawing of greater than 90%. In another embodiment, the thawing follows storage for cryopreservation or frozen storage for 24 hours. In another embodiment, the storage is for 2 days. In another embodiment, the storage is for 3 days. In another embodiment, the storage is for 4 days. In another embodiment, the storage is for 1 week. In another embodiment, the storage is for 2 weeks. In another embodiment, the storage is for 3 weeks. In another embodiment, the storage is for 1 month. In another embodiment, the storage is for 2 months. In another embodiment, the storage is for 3 months. In another embodiment, the storage is for 5 months. In another embodiment, the storage is for 6 months. In another embodiment, the storage is for 9 months. In another embodiment, the storage is for 1 year. Each possibility represents a separate embodiment of the present invention.
[00160] In another embodiment, a cell bank, frozen stock, or batch of vaccine doses of the present invention is cryopreserved by a method that comprises growing a culture of the Listeria strain in a nutrient media, freezing the culture in a solution comprising glycerol, and storing the Listeria strain at below -20 degrees Celsius. In another embodiment, the temperature is about -70 degrees Celsius. In another embodiment, the temperature is about "70 - "80 degrees Celsius.
[00161] In another embodiment, a cell bank, frozen stock, or batch of vaccine doses of the present invention is cryopreserved by a method that comprises growing a culture of the Listeria strain in a defined media of the present invention (as described below), freezing the culture in a solution comprising glycerol, and storing the Listeria strain at below -20 degrees Celsius. In another embodiment, the temperature is about -70 degrees Celsius. In another embodiment, the temperature is
P-7771-PC3 about "70 - "80 degrees Celsius. In another embodiment, any defined microbiological media of the present invention may be used in this method. Each defined microbiological media represents a separate embodiment of the present invention.
[00162] In another embodiment of methods and compositions of the present invention, the culture (e.g. the culture of a Listeria vaccine strain that is used to produce a batch of Listeria vaccine doses) is inoculated from a cell bank. In another embodiment, the culture is inoculated from a frozen stock. In another embodiment, the culture is inoculated from a starter culture. In another embodiment, the culture is inoculated from a colony. In another embodiment, the culture is inoculated at mid-log growth phase. In another embodiment, the culture is inoculated at approximately mid-log growth phase. In another embodiment, the culture is inoculated at another growth phase. Each possibility represents a separate embodiment of the present invention.
[00163] In another embodiment of methods and compositions of the present invention, the solution used for freezing contains glycerol in an amount of 2-20%. In another embodiment, the amount is 2%. In another embodiment, the amount is 20%. In another embodiment, the amount is 1%. In another embodiment, the amount is 1.5%. In another embodiment, the amount is 3%. In another embodiment, the amount is 4%. In another embodiment, the amount is 5%. In another embodiment, the amount is 2%. In another embodiment, the amount is 2%. In another embodiment, the amount is 7%. In another embodiment, the amount is 9%. In another embodiment, the amount is 10%. In another embodiment, the amount is 12%. In another embodiment, the amount is 14%. In another embodiment, the amount is 16%. In another embodiment, the amount is 18%. In another embodiment, the amount is 222%. In another embodiment, the amount is 25%. In another embodiment, the amount is 30%. In another embodiment, the amount is 35%. In another embodiment, the amount is 40%. Each possibility represents a separate embodiment of the present invention.
[00164] In another embodiment, the solution used for freezing contains another colligative additive or additive with anti-freeze properties, in place of glycerol. In another embodiment, the solution used for freezing contains another colligative additive or additive with anti-freeze properties, in addition to glycerol. In another embodiment, the additive is mannitol. In another embodiment, the additive is
DMSO. In another embodiment, the additive is sucrose. In another embodiment, the additive is any other colligative additive or additive with anti-freeze properties that is known in the art. Each possibility represents a separate embodiment of the present invention.
[00165] In another embodiment, the nutrient media utilized for growing a culture of a Listeria strain is LB. In another embodiment, the nutrient media is TB. In another embodiment, the nutrient media is a
P-7771-PC3 defined media. In another embodiment, the nutrient media is a defined media of the present invention. In another embodiment, the nutrient media is any other type of nutrient media known in the art. Each possibility represents a separate embodiment of the present invention.
[00166] In another embodiment of methods and compositions of the present invention, the step of growing is performed with a shake flask. In another embodiment, the flask is a baffled shake flask. In another embodiment, the growing is performed with a batch fermenter. In another embodiment, the growing is performed with a stirred tank or flask. In another embodiment, the growing is performed with an airflit fermenter. In another embodiment, the growing is performed with a fed batch. In another embodiment, the growing is performed with a continuous cell reactor. In another embodiment, the growing is performed with an immobilized cell reactor. In another embodiment, the growing is performed with any other means of growing bacteria that is known in the art. Each possibility represents a separate embodiment of the present invention.
[00167] In another embodiment, a constant pH is maintained during growth of the culture (e.g. in a batch fermenter). In another embodiment, the pH is maintained at about 7.0. In another embodiment, the pH is about 6. In another embodiment, the pH is about 6.5. In another embodiment, the pH is about 7.5. In another embodiment, the pH is about 8. In another embodiment, the pH is 6.5-7.5. In another embodiment, the pH is 6-8. In another embodiment, the pH is 6-7. In another embodiment, the pH is 7- 8. Each possibility represents a separate embodiment of the present invention.
[00168] In another embodiment, a constant temperature is maintained during growth of the culture. In another embodiment, the temperature is maintained at about 37 0C. In another embodiment, the temperature is 37 0C. In another embodiment, the temperature is 25 0C. In another embodiment, the temperature is 27 °C. In another embodiment, the temperature is 28 0C. In another embodiment, the temperature is 30 0C. In another embodiment, the temperature is 32 0C. In another embodiment, the temperature is 34 °C. In another embodiment, the temperature is 35 °C. In another embodiment, the temperature is 36 0C. In another embodiment, the temperature is 38 0C. In another embodiment, the temperature is 39 0C. Each possibility represents a separate embodiment of the present invention.
[00169] In another embodiment, a constant dissolved oxygen concentration is maintained during growth of the culture. In another embodiment, the dissolved oxygen concentration is maintained at 20% of saturation. In another embodiment, the concentration is 15% of saturation. In another embodiment, the concentration is 16% of saturation. In another embodiment, the concentration is 18% of saturation. In another embodiment, the concentration is 22% of saturation. In another embodiment, the concentration is 25% of saturation. In another embodiment, the concentration is 30% of saturation. In another
P-7771-PC3 embodiment, the concentration is 35% of saturation. In another embodiment, the concentration is 40% of saturation. In another embodiment, the concentration is 45% of saturation. In another embodiment, the concentration is 50% of saturation. In another embodiment, the concentration is 55% of saturation. In another embodiment, the concentration is 60% of saturation. In another embodiment, the concentration is 65% of saturation. In another embodiment, the concentration is 70% of saturation. In another embodiment, the concentration is 75% of saturation. In another embodiment, the concentration is 80% of saturation. In another embodiment, the concentration is 85% of saturation. In another embodiment, the concentration is 90% of saturation. In another embodiment, the concentration is 95% of saturation. In another embodiment, the concentration is 100% of saturation. In another embodiment, the concentration is near 100% of saturation. Each possibility represents a separate embodiment of the present invention.
[00170] In another embodiment of methods and compositions of the present invention, the culture is grown in media having a maximum volume of 2 liters (L) per vessel. In another embodiment, the media has a maximum volume of 200 ml per vessel. In another embodiment, the media has a maximum volume of 300 ml per vessel. In another embodiment, the media has a maximum volume of 500 ml per vessel. In another embodiment, the media has a maximum volume of 750 ml per vessel. In another embodiment, the media has a maximum volume of 1 L per vessel. In another embodiment, the media has a maximum volume of 1.5 L per vessel. In another embodiment, the media has a maximum volume of 2.5 L per vessel. In another embodiment, the media has a maximum volume of 3 L per vessel.
[0017I] In another embodiment, the media has a minimum volume of 2 L per vessel. In another embodiment, the media has a minimum volume of 500 ml per vessel. In another embodiment, the media has a minimum volume of 750 ml per vessel. In another embodiment, the media has a minimum volume of 1 L per vessel. In another embodiment, the media has a minimum volume of 1.5 L per vessel. In another embodiment, the media has a minimum volume of 2.5 L per vessel. In another embodiment, the media has a minimum volume of 3 L per vessel. In another embodiment, the media has a minimum volume of 4 L per vessel. In another embodiment, the media has a minimum volume of 5 L per vessel. In another embodiment, the media has a minimum volume of 6 L per vessel. In another embodiment, the media has a minimum volume of 8 L per vessel. In another embodiment, the media has a minimum volume of 10 L per vessel.
[00172] Each volume represents a separate embodiment of the present invention.
[00173] In another embodiment of methods and compositions of the present invention, the step of
P-7771-PC3 freezing or lyophilization is performed when the culture has an OD600 of 0.7 units. In another embodiment, the culture has an OD600 of 0.8 units. In another embodiment, the OD600 is about 0.7 units. In another embodiment, the OD600 is about 0.8 units. In another embodiment, the OD600 is 0.6 units. In another embodiment, the OD600 is 0.65 units. In another embodiment, the OD6O0 is 0.75 units. In another embodiment, the OD600 is 0.85 units. In another embodiment, the OD60O is 0.9 units. In another embodiment, the OD60O is 1 unit. In another embodiment, the OD60O is 0.6-0.9 units. In another embodiment, the OD600 is 0.65-0.9 units. In another embodiment, the OD600 is 0.7-0.9 units. In another embodiment, the OD600 is 0.75-0.9 units. In another embodiment, the OD600 is 0.8-0.9 units. In another embodiment, the OD600 is 0.75-1 units. In another embodiment, the OD600 is 0.9-1 units. In another embodiment, the OD600 is greater than 1 unit.
[00174] In another embodiment, the OD60O is significantly greater than 1 unit (e.g. when the culture is produced in a batch fermenter). In another embodiment, the OD600 is 7.5-8.5 units. In another embodiment, the OD600 is 1.2 units. In another embodiment, the OD600 is 1.5 units. In another embodiment, the OD600 is 2 units. In another embodiment, the OD600 is 2.5 units. In another embodiment, the OD600 is 3 units. In another embodiment, the OD600 is 3.5 units. In another embodiment, the OD600 is 4 units. In another embodiment, the OD600 is 4.5 units. In another embodiment, the OD600 is 5 units. In another embodiment, the OD600 is 5.5 units. In another embodiment, the OD600 is 6 units. In another embodiment, the OD600 is 6.5 units. In another embodiment, the OD600 is 7 units. In another embodiment, the OD600 is 7.5 units. In another embodiment, the OD600 is 8 units. In another embodiment, the OD600 is 8.5 units. In another embodiment, the OD600 is 9 units. In another embodiment, the OD600 is 9.5 units. In another embodiment, the OD600 is 10 units. In another embodiment, the OD600 is more than 10 units.
[00175] In another embodiment, the OD600 is 1 -2 units. In another embodiment, the OD600 is 1.5-2.5 units. In another embodiment, the OD600 is 2-3 units. In another embodiment, the OD600 is 2.5-3.5 units. In another embodiment, the OD600 is 3-4 units. In another embodiment, the OD600 is 3.5-4.5 units. In another embodiment, the OD60O is 4-5 units. In another embodiment, the OD600 is 4.5-5.5 units. In another embodiment, the OD600 is 5-6 units. In another embodiment, the OD600 is 5.5-6.5 units. In another embodiment, the OD600 is 1 -3 units. In another embodiment, the OD600 is 1.5-3.5 units. In another embodiment, the OD600 is 2-4 units. In another embodiment, the OD600 is 2.5-4.5 units. In another embodiment, the OD600 is 3-5 units. In another embodiment, the OD600 is 4-6 units. In another embodiment, the OD600 is 5-7 units. In another embodiment, the OD6O0 is 2-5 units. In another embodiment, the OD6oo is 3-6 units. In another embodiment, the OD600 is 4-7 units. In another embodiment, the OD60O is 5-8 units. In another embodiment, the OD600 is 1.2-7.5 units. In another embodiment, the OD6Oo >s 1.5-7.5 units. In another embodiment, the OD600 is 2-7.5 units. In another
P-7771-PC3 embodiment, the OD600 is 2.5-7.5 units. In another embodiment, the OD600 is 3-7.5 units. In another embodiment, the OD600 is 3.5-7.5 units. In another embodiment, the OD600 is 4-7.5 units. In another embodiment, the OD600 is 4.5-7.5 units. In another embodiment, the OD600 is 5-7.5 units. In another embodiment, the OD600 is 5.5-7.5 units. In another embodiment, the OD600 is 6-7.5 units. In another embodiment, the OD600 is 6.5-7.5 units. In another embodiment, the OD600 is 7-7.5 units. In another embodiment, the OD600 is more than 10 units. In another embodiment, the OD600 is 1.2-8.5 units. In another embodiment, the OD6O0 is 1.5-8.5 units. In another embodiment, the OD600 is 2-8.5 units. In another embodiment, the OD600 is 2.5-8.5 units. In another embodiment, the OD600 is 3-8.5 units. In another embodiment, the OD600 is 3.5-8.5 units. In another embodiment, the OD600 is 4-8.5 units. In another embodiment, the OD60O is 4.5-8.5 units. In another embodiment, the OD600 is 5-8.5 units. In another embodiment, the OD6oo is 5.5-8.5 units. In another embodiment, the OD600 is 6-8.5 units. In another embodiment, the OD6O0 is 6.5-8.5 units. In another embodiment, the OD6O0 is 7-8.5 units. In another embodiment, the OD600 is 7.5-8.5 units. In another embodiment, the OD6O0 is 8-8.5 units. In another embodiment, the OD6O0 is 9.5-8.5 units. In another embodiment, the OD600 is 10 units.
[00176] In another embodiment, the step of freezing or lyophilization is performed when the culture has a biomass of 1 x 109 colony-forming units (CFU)/ml. In another embodiment, the biomass is 1.5 x 109 CFR/ml. In another embodiment, the biomass is 1.5 x 109 CFR/ml. In another embodiment, the biomass is 2 x 109 CFR/ml. In another embodiment, the biomass is 3 x 109 CFR/ml. In another embodiment, the biomass is 4 x 109 CFR/ml. In another embodiment, the biomass is 5 x 109 CFR/ml. In another embodiment, the biomass is 7 x 109 CFR/ml. In another embodiment, the biomass is 9 x 109 CFR/ml. In another embodiment, the biomass is 10 x 109 CFR/ml. In another embodiment, the biomass is 12 x 109 CFR/ml. In another embodiment, the biomass is 15 x 109 CFR/ml. In another embodiment, the biomass is 20 x 10 CFR/ml. In another embodiment, the biomass is 25 x 10 CFR/ml. In another embodiment, the biomass is 30 x 109 CFR/ml. In another embodiment, the biomass is 33 x 109 CFR/ml. In another embodiment, the biomass is 4O x 109 CFR/ml. In another embodiment, the biomass is 50 x 109 CFR/ml. In another embodiment, the biomass is more than 50 x 109 CFR/ml.
[00177] Each number and range of OD600 readings and culture biomass measurements represents a separate embodiment of the present invention.
[00178] In another embodiment of methods and compositions of the present invention, the Listeria culture is flash-frozen in liquid nitrogen, followed by storage at the final freezing temperature. In another embodiment, the culture is frozen in a more gradual manner; e.g. by placing in a vial of the culture in the final storage temperature. In another embodiment, the culture is frozen by any other method known in the art for freezing a bacterial culture. Each possibility represents a separate
P-7771-PC3 embodiment of the present invention.
[00179] In another embodiment of methods and compositions of the present invention, the storage temperature of the culture is between "20 and "80 degrees Celsius (0C). In another embodiment, the temperature is significantly below "20 0C. In another embodiment, the temperature is not warmer than "70 0C. In another embodiment, the temperature is "70 0C. In another embodiment, the temperature is about "70 0C. In another embodiment, the temperature is "20 0C. In another embodiment, the temperature is about "20 0C. In another embodiment, the temperature is "30 0C. In another embodiment, the temperature is "40 0C. In another embodiment, the temperature is "50 0C. In another embodiment, the temperature is "60 0C. In another embodiment, the temperature is "80 °C. In another embodiment, the temperature is "30 - "70 0C. In another embodiment, the temperature is "40 - "70 0C. In another embodiment, the temperature is "50 - "70 0C. In another embodiment, the temperature is "60 - "70 0C. In another embodiment, the temperature is "30 - "80 0C. In another embodiment, the temperature is "40 - "80 0C. In another embodiment, the temperature is "50 - "80 0C. In another embodiment, the temperature is "60 - "80 0C. In another embodiment, the temperature is "70 - "80 0C. In another embodiment, the temperature is colder than "70 0C. In another embodiment, the temperature is colder than "80 °C. Each possibility represents a separate embodiment of the present invention.
[0018O] In another embodiment of methods and compositions of the present invention, the cryopreservation, frozen storage, or lyophilization is for a maximum of 24 hours. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 2 days. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 3 days. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 4 days. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 1 week. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 2 weeks. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 3 weeks. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 1 month. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 2 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 3 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 5 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 6 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 9 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for maximum of 1 year.
P-7771-PC3
[0018I] In another embodiment, the cryopreservation, frozen storage, or lyophilization is for a minimum of 1 week. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 2 weeks. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 3 weeks. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 1 month. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 2 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 3 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 5 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 6 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 9 months. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 1 year. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 1.5 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 2 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 3 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 5 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 7 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for minimum of 10 years. In another embodiment, the cryopreservation, frozen storage, or lyophilization is for longer than 10 years.
[00182] Each length of cryopreservation, frozen storage, or lyophilization represents a separate embodiment of the present invention.
[00183] In another embodiment of methods and compositions of the present invention, the Listeria bacteria exhibit exponential growth essentially immediately after thawing following an extended period of cryopreservation or frozen storage (Example 14). In another embodiment, the Listeria bacteria exhibit exponential growth essentially immediately after reconstitution following an extended period of lyophilization. In another embodiment, "essentially immediately" refers to within about 1 hour after inoculating fresh media with cells from the cell bank or starter culture. In another embodiment, the bacteria exhibit exponential growth shortly after (e.g. in various embodiments, after 10 minutes (min), 20 min, 30 min, 40 min, 50 min, 1 hour, 75 min, 90 min, 105 min, or 2 hours) thawing following the period of cryopreservation or storage. Each possibility represents a separate embodiment of the present invention.
[00184] The "extended period" of cryopreservation, frozen storage, or lyophilization is, in another
P-7771-PC3 embodiment, 1 month. In another embodiment, the period is 2 months. In another embodiment, the period is 3 months. In another embodiment, the period is 5 months. In another embodiment, the period is 6 months. In another embodiment, the period is 9 months. In another embodiment, the period is 1 year. In another embodiment, the period is 1.5 years. In another embodiment, the period is 2 years. Each possibility represents a separate embodiment of the present invention.
[00185] In another embodiment, "exponential growth" refers to a doubling time that is close to the maximum observed for the conditions (e.g. media type, temperature, etc.) in which the culture is growing. In another embodiment, "exponential growth" refers to a doubling time that is reasonable constant several hours (e.g. 1 hour, 1.5 hours, 2 hours, or 2.5 hours) after dilution of the culture; optionally following a brief recovery period. Each possibility represents a separate embodiment of the present invention.
[00186] In another embodiment, a Listeria vaccine strain of methods and compositions of the present invention retains a viability of over 90% after thawing following 14 days of cryopreservation (Example 14). In another embodiment, the viability upon thawing is close to 100% following the period of cryopreservation. In another embodiment, the viability upon thawing is about 90%. In another embodiment, the viability upon thawing is close to 90%. In another embodiment, the viability upon thawing is at least 90%. In another embodiment, the viability upon thawing is over 80%. Each possibility represents a separate embodiment of the present invention.
[00187] In another embodiment, a Listeria vaccine strain of methods and compositions of the present invention retains a viability of over 90% after reconstitution following lyophilization. In another embodiment, the viability upon thawing is close to 100% following the period of lyophilization. In another embodiment, the viability upon thawing is about 90%. In another embodiment, the viability upon thawing is close to 90%. In another embodiment, the viability upon thawing is at least 90%. In another embodiment, the viability upon thawing is over 80%. Each possibility represents a separate embodiment of the present invention.
[00188] In another embodiment, a cell bank, frozen stock, or batch of vaccine doses of the present invention is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L of methionine; and (2) effective amounts of: (a) cysteine; (b) a pH buffer; (c) a carbohydrate; (d) a divalent cation; (e) ferric or ferrous ions; (f) glutamine or another nitrogen source; (g) riboflavin; (h) thioctic acid (also known as lipoic acid); (i) another or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and
P-7771-PC3 nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00189] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L of cysteine; and (2) effective amounts of: (a) methionine; (b) a pH buffer; (c) a carbohydrate; (d) a divalent cation; (e) ferric or ferrous ions; (f) glutamine or another nitrogen source; (g) riboflavin; (h) thioctic acid; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00190] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.00123 - 0.00246 moles of ferric or ferrous ions per liter; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) glutamine or another nitrogen source; (g) riboflavin; (h) thioctic acid; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00191] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 1.8 - 3.6 g/L of glutamine or another nitrogen source; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate: (c) a divalent cation; (d) methionine (e) cysteine; (f) ferric or ferrous ions (g) riboflavin (h); thioctic acid; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00192] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 15 and about 30 mg/L of riboflavin; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) thioctic acid; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-
P-7771-PC3 aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00193] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1) between about 0.3 and about 0.6 g/L of thioctic acid; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate (c) a divalent cation; (d) methionine
(e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00194] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; and (6) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (e) one or more components selected from adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide; and (f) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00195] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; and (6) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) leucine; (e) isoleucine; (f) valine; (g) arginine; (h) histidine; (i) tryptophan; (j) phenylalanine; (k) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (1) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00196] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1) between about 0.3 and about 0.6 g/L each of one or
P-7771-PC3 more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00197] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1) between about 0.3 and about 0.6 g/L each of leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00198] hi another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1) between about 0.2 and about 0.75 of one or more components selected from biotin and adenine; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (k) one or more components selected from thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (1) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00199] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising (1 ) between about 3 and about 6 mg/L each of one or more components selected from thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation;
(d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (k) biotin; (1) adenine; and (1) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00200] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a
P-7771-PC3 defined microbiological media, comprising: (1) between about 0.2 and about 0.75 mg/L each of one or more components selected from biotin and adenine; (2) between about 3 and about 6 mg/L each of one or more components selected from thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; and (3) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; and (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and citrate.
[00201] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.005 and about 0.02 g/L each of one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, and calcium; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine;
(e) cysteine; (f) ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; and (k) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide.
[00202] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.4 and about 1 g/L of citrate; and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine; (0 ferric or ferrous ions; (g) glutamine or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j) one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (k) one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, and calcium; and (1) one or more components selected from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide.
[00203] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1 ) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and about 0.6 g/L each of one or more components selected from leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (7) between about 0.2 and about 0.75 mg/L each of one or more components selected from biotin and adenine; (8) between about 3 and about 6 mg/L each of one or more components selected from thiamine, pyridoxal, para-aminobenzoic
P-7771-PC3 acid, pantothenate, and nicotinamide; (9) between about 0.005 and about 0.02 g/L each of one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, and calcium; (10) between about 0.4 and about 1 g/L of citrate; and (11) and effective amounts of: (a) a pH buffer; (b) a carbohydrate; and (c) a divalent cation.
[00204] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and about 0.6 g/L each of leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (7) between about 0.2 and about 0.75 mg/L each of one or more components selected from biotin and adenine; (8) between about 3 and about 6 mg/L each of one or more components selected from thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; (9) between about 0.005 and about 0.02 g/L each of one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, and calcium; (10) between about 0.4 and about 1 g/L of citrate; and (11) and effective amounts of: (a) a pH buffer; (b) a carbohydrate; and (c) a divalent cation.
[00205] In another embodiment, the cell bank, frozen stock, or batch of vaccine doses is grown in a defined microbiological media, comprising: (1) between about 0.3 and about 0.6 g/L each of methionine and cysteine; (2) between about 0.00123 and 0.00246 moles of ferric or ferrous ions per liter; (3) between about 1.8 and about 3.6 g/L of glutamine or another nitrogen source; (4) between about 0.3 and about 0.6 g/L of thioctic acid; (5) between about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and about 0.6 g/L each of leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine; (7) between about 0.2 and about 0.75 mg/L each of biotin and adenine; (8) between about 3 and about 6 mg/L each of thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide; (9) between about 0.005 and about 0.02 g/L each of one or more components selected from cobalt, copper, boron, manganese, molybdenum, zinc, and calcium; (10) between about 0.4 and about 1 g/L of citrate; and (1 1) and effective amounts of: (a) a pH buffer; (b) a carbohydrate; and (c) a divalent cation.
[00206] In another embodiment, a defined microbiological media of the present invention further comprises an aqueous solvent. In another embodiment, the aqueous solvent is water. In another embodiment, the aqueous solvent is any other aqueous solvent known in the art. Each possibility
P-7771-PC3 represents a separate embodiment of the present invention.
[00207] The carbohydrate utilized in methods and compositions of the present invention is, in another embodiment, glucose. In another embodiment, the carbohydrate is lactose. In another embodiment, the carbohydrate is fructose. In another embodiment, the carbohydrate is mannose. In another embodiment, the carbohydrate is cellobiose. In another embodiment, the carbohydrate is trehalose. In another embodiment, the carbohydrate is maltose. In another embodiment, the carbohydrate is glycerol. In another embodiment, the carbohydrate is glucosamine. In another embodiment, the carbohydrate is N-acetylglucosamine. In another embodiment, the carbohydrate is N-acetylmuramic acid. In another embodiment, the carbohydrate is any other carbohydrate that can be utilized by Listeria. Each possibility represents a separate embodiment of the present invention.
[00208] In another embodiment, the amount of a carbohydrate present in a defined microbiological media of methods and compositions of the present invention is between about 12-18 grams/liter (g/L). In another embodiment, the amount is 15 g/L. In another embodiment, the amount is 10 g/L. In another embodiment, the amount is 9 g/L. In another embodiment, the amount is 1 1 g/L. In another embodiment, the amount is 12 g/L. In another embodiment, the amount is 13 g/L. In another embodiment, the amount is 14 g/L. In another embodiment, the amount is 16 g/L. In another embodiment, the amount is 17 g/L. In another embodiment, the amount is 18 g/L. In another embodiment, the amount is 19 g/L. In another embodiment, the amount is 20 g/L. In another embodiment, the amount is more than 20 g/L.
[00209] In another embodiment, the amount is 9-15 g/L. In another embodiment, the amount is 10-15 g/L. In another embodiment, the amount is 11-15 g/L. In another embodiment, the amount is 12-16 g/L. In another embodiment, the amount is 13-17 g/L. In another embodiment, the amount is 14-18 g/L. In another embodiment, the amount is 16-19 g/L. In another embodiment, the amount is 17-20 g/L. In another embodiment, the amount is 10-20 g/L. In another embodiment, the amount is 12-20 g/L. In another embodiment, the amount is 15-20 g/L.
[00210] In another embodiment, the total amount of carbohydrate in the media is one of the above amounts. In another embodiment, the amount of one of the carbohydrates in the media is one of the above amounts. In another embodiment, the amount of each of the carbohydrates in the media is one of the above amounts.
[0021 1] Each of the above amounts of carbohydrates represents a separate embodiment of the present invention.
P-7771-PC3
[00212] The cobalt present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a cobalt ion. In another embodiment, the cobalt is present as a cobalt salt. In another embodiment, the salt is cobalt chloride. In another embodiment, the salt is any other cobalt salt known in the art. In another embodiment, the cobalt is present as any other form of cobalt known in the art.
[00213] In another embodiment, the cobalt salt is a hydrate (e.g. cobalt chloride hexahydrate). In another embodiment, the cobalt salt is anhydrous. In another embodiment, the cobalt salt is any other form of a cobalt salt known in the art. Each of the above forms of cobalt represents a separate embodiment of the present invention.
[00214] A hydrate of a component of a defined media of methods and compositions of the present invention is, in another embodiment, a monohydrate. In another embodiment, the hydrate is a dihydrate. In another embodiment, the hydrate is a trihydrate. In another embodiment, the hydrate is a tetrahydrate. In another embodiment, the hydrate is a pentahydrate. In another embodiment, the hydrate is a hexahydrate. In another embodiment, the hydrate is a heptahydrate. In another embodiment, the hydrate is any other hydrate known in the art. Each possibility represents a separate embodiment of the present invention.
[00215] The copper present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a copper ion. In another embodiment, the copper ion is a copper (I) ion. In another embodiment, the copper ion is a copper (II) ion. In another embodiment, the copper ion is a copper (III) ion.
[00216] In another embodiment, the copper is present as a copper salt. In another embodiment, the salt is copper chloride. In another embodiment, the salt is any other copper salt known in the art. In another embodiment, the copper is present as any other form of copper known. in the art.
[00217] In another embodiment, the copper salt is a hydrate (e.g. copper chloride dihydrate). In another embodiment, the copper salt is anhydrous. In another embodiment, the copper salt is any other form of a copper salt known in the art. Each of the above forms of copper represents a separate embodiment of the present invention.
[00218] The boron present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a borate ion. In another embodiment, the boron is present as a borate acid (e.g. boric acid, H3BO3). In another embodiment, the boron is present as any other form of boron known in the art.
P-7771-PC3
[00219] In another embodiment, the borate salt or borate acid is a hydrate. In another embodiment, the borate salt or borate acid is anhydrous. In another embodiment, the borate salt or borate acid is any other form of a borate salt or borate acid known in the art. Each of the above forms of boron represents a separate embodiment of the present invention.
[00220] The manganese present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a manganese ion. In another embodiment, the manganese is present as a manganese salt. In another embodiment, the salt is manganese sulfate. In another embodiment, the salt is any other manganese salt known in the art. In another embodiment, the manganese is present as any other form of manganese known in the art.
[00221] In another embodiment, the manganese salt is a hydrate (e.g. manganese sulfate monohydrate). In another embodiment, the manganese salt is anhydrous. In another embodiment, the manganese salt is any other form of a manganese salt known in the art. Each of the above forms of manganese represents a separate embodiment of the present invention.
[00222] The molybdenum present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a molybdate ion. In another embodiment, the molybdenum is present as a molybdate salt. In another embodiment, the salt is sodium molybdate.
In another embodiment, the salt is any other molybdate salt known in the art. In another embodiment, the molybdenum is present as any other form of molybdenum known in the art.
[00223] In another embodiment, the molybdate salt is a hydrate (e.g. sodium molybdate dihydrate). In another embodiment, the molybdate salt is anhydrous. In another embodiment, the molybdate salt is any other form of a molybdate salt known in the art. Each of the above forms of molybdenum represents a separate embodiment of the present invention.
[00224] The zinc present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a zinc ion. In another embodiment, the zinc is present as a zinc salt. In another embodiment, the salt is zinc chloride. In another embodiment, the salt is any other zinc salt known in the art. In another embodiment, the zinc is present as any other form of zinc known in the art.
[00225] In another embodiment, the zinc salt is a hydrate (e.g. zinc chloride heptahydrate). In another embodiment, the zinc salt is anhydrous. In another embodiment, the zinc salt is any other form of a zinc salt known in the art. Each of the above forms of zinc represents a separate embodiment of the present invention.
P-7771-PC3
[00226] The iron present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a ferric ion. In another embodiment, the iron is present as a ferrous ion. In another embodiment, the iron is present as a ferric salt. In another embodiment, the iron is present as a ferrous salt. In another embodiment, the salt is ferric sulfate. In another embodiment, the salt is ferric citrate. In another embodiment, the salt is any other ferric salt known in the art. In another embodiment, the salt is any other ferrous salt known in the art. In another embodiment, the iron is present as any other form of iron known in the art.
[00227] In another embodiment, the ferric or ferrous salt is a hydrate (e.g. ferric sulfate monohydrate). In another embodiment, the ferric or ferrous salt is anhydrous. In another embodiment, the ferric or ferrous salt is any other form of a ferric or ferrous salt known in the art. Each of the above forms of iron represents a separate embodiment of the present invention.
[00228] The calcium present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a calcium ion. In another embodiment, the calcium is present as a calcium salt. In another embodiment, the salt is calcium chloride. In another embodiment, the salt is any other calcium salt known in the art. In another embodiment, the calcium is present as any other form of calcium known in the art.
[00229] In another embodiment, the calcium salt is a hydrate (e.g. calcium chloride dihydrate). In another embodiment, the calcium salt is anhydrous. In another embodiment, the calcium salt is any other form of a calcium salt known in the art. Each of the above forms of calcium represents a separate embodiment of the present invention.
[00230] The citrate present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present as a citrate ion. In another embodiment, the citrate is present as a citrate salt. In another embodiment, the citrate is present as a citrate acid (e.g. citric acid). In another embodiment, the citrate is present as both ferric citrate and citric acid (Examples 15-16). In another embodiment, the citrate is present as any other form of citrate known in the art.
[00231] In another embodiment, the citrate salt or citrate acid is a hydrate. In another embodiment, the citrate salt or citrate acid is anhydrous. In another embodiment, the citrate salt or citrate acid is any other form of a citrate salt or citrate acid known in the art. Each of the above forms of citrate represents a separate embodiment of the present invention.
[00232] The cobalt present in defined microbiological media of methods and compositions of the
P-7771-PC3 present invention is, in another embodiment, present in an amount of 0.02 g/L (Examples 15-16). In another embodiment, the amount is about 0.02 g/L. In another embodiment, the amount is 0.003 g/L. In another embodiment, the amount is 0.005 g/L. In another embodiment, the amount is 0.007 g/L. In another embodiment, the amount is 0.01 g/L. In another embodiment, the amount is 0.015 g/L. In another embodiment, the amount is 0.025 g/L. In another embodiment, the amount is 0.03 g/L. In another embodiment, the amount is 0.003-0.006 g/L. In another embodiment, the amount is 0.005-0.01 g/L. In another embodiment, the amount is 0.01-0.02 g/L. In another embodiment, the amount is 0.02- 0.04 g/L. In another embodiment, the amount is 0.03-0.06 g/L.
[00233] In another embodiment, the cobalt is present in an amount that is the molar equivalent of 0.02 g/L of cobalt chloride hexahydrate. In another embodiment, the amount of cobalt present is the molar equivalent of about 0.02 g/L of cobalt chloride hexahydrate. In another embodiment, the amount of cobalt present is the molar equivalent of another of the above amounts or ranges of cobalt chloride hexahydrate. Each of the above amounts or ranges of cobalt represents a separate embodiment of the present invention.
[00234] The copper present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.019 g/L (Examples 15-16). In another embodiment, the amount is about 0.019 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
[00235] In another embodiment, the copper is present in an amount that is the molar equivalent of 0.019 g/L of copper chloride dihydrate. In another embodiment, the amount of copper present is the molar equivalent of about 0.019 g/L of copper chloride dihydrate. In another embodiment, the amount of copper present is the molar equivalent of copper chloride dihydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of copper represents a separate embodiment of the present invention.
[00236] The borate present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.016 g/L (Examples 15-16). In another embodiment, the amount is about 0.016 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
[00237] In another embodiment, the borate is present in an amount that is the molar equivalent of 0.016 g/L of boric acid. In another embodiment, the amount of borate present is the molar equivalent of about 0.016 g/L of boric acid. In another embodiment, the amount of borate present is the molar equivalent of boric acid in any of the amounts or ranges listed above for cobalt. Each of the above
P-7771-PC3 amounts or ranges of borate represents a separate embodiment of the present invention.
[00238] The manganese present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.016 g/L (Examples 15-16). In another embodiment, the amount is about 0.016 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
[00239] In another embodiment, the manganese is present in an amount that is the molar equivalent of 0.016 g/L of manganese sulfate monohydrate. In another embodiment, the amount of manganese present is the molar equivalent of about 0.016 g/L of manganese sulfate monohydrate. In another embodiment, the amount of manganese present is the molar equivalent of manganese sulfate monohydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of manganese represents a separate embodiment of the present invention.
[00240] The molybdenum present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.02 g/L (Examples 15-16). In another embodiment, the amount is about 0.02 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
[00241] In another embodiment, the molybdenum is present in an amount that is the molar equivalent of 0.2 g/L of sodium molybdate dihydrate. In another embodiment, the amount of molybdenum present is the molar equivalent of about 0.02 g/L of sodium molybdate dihydrate. In another embodiment, the amount of molybdenum present is the molar equivalent of sodium molybdate dihydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of molybdenum represents a separate embodiment of the present invention.
[00242] The zinc present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.02 g/L (Examples 15-16). In another embodiment, the amount is about 0.02 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
[00243] In another embodiment, the zinc is present in an amount that is the molar equivalent of 0.02 g/L of zinc chloride heptahydrate. In another embodiment, the amount of zinc present is the molar equivalent of about 0.02 g/L of zinc chloride heptahydrate. In another embodiment, the amount of zinc present is the molar equivalent of zinc chloride heptahydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of zinc represents a separate embodiment of the present invention.
P-7771-PC3
[00244] In another embodiment, ferric sulfate or a related compound is present in defined microbiological media of methods and compositions of the present invention. In another embodiment, the ferric sulfate or related compound is present in an amount of 0.01 g/L (Examples 15-16). In another embodiment, the amount is about 0.01 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
[00245] In another embodiment, the iron is present in an amount that is the molar equivalent of 0.01 g/L of ferric sulfate. In another embodiment, the amount of iron present is the molar equivalent of about
0.01 g/L of ferric sulfate. In another embodiment, the amount of iron present is the molar equivalent of ferric sulfate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of iron represents a separate embodiment of the present invention.
[00246] The calcium present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.01 g/L (Examples 15-16). In another embodiment, the amount is about 0.01 g/L. In other embodiments, the amount is any of the amounts or ranges listed above for cobalt.
[00247] In another embodiment, the calcium is present in an amount that is the molar equivalent of 0.01 g/L of calcium chloride dihydrate. In another embodiment, the amount of calcium present is the molar equivalent of about 0.01 g/L of calcium chloride dihydrate. In another embodiment, the amount of calcium present is the molar equivalent of calcium chloride dihydrate in any of the amounts or ranges listed above for cobalt. Each of the above amounts or ranges of calcium represents a separate embodiment of the present invention.
[00248] The citrate present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in an amount of 0.9 g/L (Examples 15-16). In another embodiment, the amount is 0.6 g/L in the form of citric acid (Examples 15-16). In another embodiment, the amount is 0.4 g/L in the form of ferric citrate (Examples 15-16). In another embodiment, the amount is 0.6 g/L in the form of citric acid and 0.4 g/L in the form of ferric citrate (Examples 15-16). In another embodiment, the amount is about 0.6 g/L. In another embodiment, the amount is 0.1 g/L. In another embodiment, the amount is 0.2 g/L. In another embodiment, the amount is 0.3 g/L. In another embodiment, the amount is 0.4 g/L. In. another embodiment, the amount is 0.5 g/L. In another embodiment, the amount is 0.7 g/L. In another embodiment, the amount is 0.8 g/L. In another embodiment, the amount is 1 g/L. In another embodiment, the amount is more than 1 g/L.
[00249] In another embodiment, the citrate is . present in an amount that is the molar equivalent of 0.6 g/L of citric acid. In another embodiment, the amount of citrate present is the molar equivalent of
P-7771-PC3 about 0.6 g/L of citric acid. In another embodiment, the amount of citrate present is the molar equivalent of about 0.4 g/L of ferric citrate. In another embodiment, the amount of citrate present is the molar equivalent of 0.4 g/L of ferric citrate. In another embodiment, the amount of citrate present is the molar equivalent of 0.6 g/L of citric acid and 0.4 g/L of ferric citrate. In another embodiment, the amount of citrate present is the about molar equivalent of 0.6 g/L of citric acid and 0.4 g/L of ferric citrate. In another embodiment, the amount of citrate present is the molar equivalent of citric acid in any of the amounts or ranges listed above for citrate. Each of the above amounts or ranges of citrate represents a separate embodiment of the present invention.
[00250] One or more of the adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide present in defined microbiological media of methods and compositions of the present invention are, in another embodiment, present as the free compound. In another embodiment, one of the above compounds is present as a salt thereof. In another embodiment, one of the above compounds is present as a derivative thereof. In another embodiment, one of the above compounds is present as a hydrate thereof. In other embodiments, the salt, derivative, or hydrate can be any salt, derivative, or hydrate known in the art. Each of the above forms of adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide represents a separate embodiment of the present invention.
[00251] The thiamine (vitamin Bl) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of thiamine HCl. In another embodiment, the thiamine is present as any other salt, derivative, or hydrate of thiamine known in the art. In another embodiment, another form of vitamin Bl is substituted for thiamine. Each possibility represents a separate embodiment of the present invention.
[00252] In another embodiment, the thiamine is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is about 0.5 mg/L. In another embodiment, the amount is 0.7 mg/L. In another embodiment, the amount is 1 mg/L. In another embodiment, the amount is 1.5 mg/L. In another embodiment, the amount is 2 mg/L. In another embodiment, the amount is 3 mg/L. In another embodiment, the amount is 5 mg/L. In another embodiment, the amount is 6 mg/L. In another embodiment, the amount is 8 mg/L. In another embodiment, the amount is more than 8 mg/L. In another embodiment, the thiamine is present in an amount that is the molar equivalent of 4 mg/L of thiamine HCl. In another embodiment, the thiamine is present in an amount that is the molar equivalent of thiamine HCl in one of the above amounts. Each possibility represents a separate embodiment of the present invention.
P-7771-PC3
[00253] The pyridoxal (vitamin B6) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of pyridoxal HCl.
In another embodiment, the pyridoxal is present as any other salt, derivative, or hydrate of pyridoxal known in the art. In another embodiment, another form of vitamin B6 is substituted for pyridoxal. Each possibility represents a separate embodiment of the present invention.
[00254] In another embodiment, the pyridoxal is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of pyridoxal present is the molar equivalent of about 4 mg/L of pyridoxal HCl. In another embodiment, the amount of pyridoxal present is the molar equivalent of pyridoxal HCl in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the present invention.
[00255] The adenine (vitamin B4) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of free adenine.
In another embodiment, the adenine is present as any other salt, derivative, or hydrate of adenine known in the art. In another embodiment, another form of vitamin B4 is substituted for adenine. Each possibility represents a separate embodiment of the present invention.
[00256] In another embodiment, the adenine is present in an amount of 0.25 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for cobalt. In another embodiment, the amount of adenine present is the molar equivalent of about 0.25 mg/L of free adenine. In another embodiment, the amount of adenine present is the molar equivalent of free adenine in any of the amounts or ranges listed above for cobalt. Each possibility represents a separate embodiment of the present invention.
[00257] The biotin (vitamin B7) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of free biotin. In another embodiment, the biotin is present as any other salt, derivative, or hydrate of biotin known in the art. In another embodiment, another form of vitamin B7 is substituted for biotin. Each possibility represents a separate embodiment of the present invention.
[00258] In another embodiment, the biotin is present in an amount of 2 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of biotin present is the molar equivalent of about 2 mg/L of free biotin. In another embodiment, the amount of biotin present is the molar equivalent of free biotin in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the
P-7771-PC3 present invention.
[00259] The para-aminobenzoic acid (vitamin B-x) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of free para-aminobenzoic acid. In another embodiment, the para-aminobenzoic acid is present as any other salt, derivative, or hydrate of para-aminobenzoic acid known in the art. In another embodiment, another form of vitamin B-x is substituted for para-aminobenzoic acid. Each possibility represents a separate embodiment of the present invention.
[00260] In another embodiment, the para-aminobenzoic acid is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of para-aminobenzoic acid present is the molar equivalent of about 4 mg/L of free para-aminobenzoic acid. In another embodiment, the amount of para-aminobenzoic acid present is the molar equivalent of free para-aminobenzoic acid in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the present invention.
[00261] The pantothenate (vitamin B5) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of calcium pantothenate. In another embodiment, the pantothenate is present as any other salt, derivative, or hydrate of pantothenate known in the art. In another embodiment, another form of vitamin B5 is substituted for pantothenate. Each possibility represents a separate embodiment of the present invention.
[00262] In another embodiment, the pantothenate is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of pantothenate present is the molar equivalent of about 4 mg/L of calcium pantothenate. In another embodiment, the amount of pantothenate present is the molar equivalent of calcium pantothenate in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the present invention.
[00263] The nicotinamide (vitamin B3) present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, present in the form of free nicotinamide. In another embodiment, the nicotinamide is present as any other salt, derivative, or hydrate of nicotinamide known in the art. In another embodiment, another form of vitamin B3 is substituted for nicotinamide. Each possibility represents a separate embodiment of the present
P-7771-PC3 invention.
[00264] In another embodiment, the nicotinamide is present in an amount of 4 mg/L (Examples 15-16). In another embodiment, the amount is any of the amounts or ranges listed above for thiamine. In another embodiment, the amount of nicotinamide present is the molar equivalent of about 4 mg/L of free nicotinamide. In another embodiment, the amount of nicotinamide present is the molar equivalent of free nicotinamide in any of the amounts or ranges listed above for thiamine. Each possibility represents a separate embodiment of the present invention.
[00265] One or more of the leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine present in defined microbiological media of methods and compositions of the present invention are, in another embodiment, present as free amino acids. In another embodiment, one of the above compounds is present as a salt thereof. In another embodiment, one of the above compounds is present as a derivative thereof. In another embodiment, one of the above compounds is present as a hydrate thereof. In other embodiments, the salt, derivative, or hydrate can be any salt, derivative, or hydrate known in the art. Each of the above forms of adenine, biotin, thiamine, pyridoxal, para- aminobenzoic acid, pantothenate, and nicotinamide represents a separate embodiment of the present invention.
[00266] In another embodiment, one or more of the leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine is present in an amount of 0.4 g/L (Examples 15-16). In another embodiment, the amount is about 0.05 g/L. In another embodiment, the amount is 0.07 g/L. In another embodiment, the amount is 0.1 g/L. In another embodiment, the amount is 0.15 g/L. In another embodiment, the amount is 0.2 g/L. In another embodiment, the amount is 0.3 g/L. In another embodiment, the amount is 0.5 g/L. In another embodiment, the amount is 0.6 g/L. In another embodiment, the amount is 0.8 g/L. In another embodiment, the amount is more than 0.8 g/L. In another embodiment, one or more of these AA is present in an amount that is the molar equivalent of 0.4 g/L of the free AA. In another embodiment, the amount is the molar equivalent of thiamine the free AA in one of the above amounts. Each possibility represents a separate embodiment of the present invention.
[00267] In another embodiment, a defined media of methods and compositions of the present invention contains two of the amino acids (AA) listed in the second section of Table 3B, e.g. leucine, isoleucine, valine, arginine, histidine, tryptophan, and phenylalanine. In another embodiment, the defined media contains 3 of these AA. In another embodiment, the media contains 4 of these AA. In another embodiment, the media contains 3 of these AA. In another embodiment, the media contains 5 of these
P-7771-PC3
AA. In another embodiment, the media contains 6 of these AA. In another embodiment, the media contains all of these AA. In another embodiment, the media contains at least 2 of these AA. In another embodiment, the media contains at least 3 of these AA. In another embodiment, the media contains at least 4 of these AA. In another embodiment, the media contains at least 5 of these AA. In another embodiment, the media contains at least 6 of these AA. Each possibility represents a separate embodiment of the present invention.
[00268] In another embodiment, a defined media of methods and compositions of the present invention contains 2 of the vitamins listed in the third section of Table 3B, e.g. adenine, biotin, thiamine, pyridoxal, para-ami nobenzoic acid, pantothenate, and nicotinamide. In another embodiment, the defined media contains 3 of these vitamins. In another embodiment, the media contains 4 of these vitamins. In another embodiment, the media contains 3 of these vitamins. In another embodiment, the media contains 5 of these vitamins. In another embodiment, the media contains 6 of these vitamins. In another embodiment, the media contains all of these vitamins. In another embodiment, the media contains at least 2 of these vitamins. In another embodiment, the media contains at least 3 of these vitamins. In another embodiment, the media contains at least 4 of these vitamins. In another embodiment, the media contains at least 5 of these vitamins. In another embodiment, the media contains at least 6 of these vitamins. Each possibility represents a separate embodiment of the present invention.
[00269] In another embodiment, a defined media of methods and compositions of the present invention contains 2 of the trace elements listed in the fourth section of Table 3B, e.g. cobalt, copper, boron, manganese, molybdenum, zinc, iron, calcium, and citrate. In another embodiment, the defined media contains 3 of these trace elements. In another embodiment, the media contains 4 of these trace elements. In another embodiment, the media contains 3 of these trace elements. In another embodiment, the media contains 5 of these trace elements. In another embodiment, the media contains 6 of these trace elements. In another embodiment, the media contains 7 of these trace elements. In another embodiment, the media contains 7 of these trace elements. In another embodiment, the media contains all of these trace elements. In another embodiment, the media contains at least 2 of these trace elements. In another embodiment, the media contains at least 3 of these trace elements. In another embodiment, the media contains at least 4 of these trace elements. In another embodiment, the media contains at least 5 of these trace elements. In another embodiment, the media contains at least 6 of these trace elements. In another embodiment, the media contains at least 7 of these trace elements. In another embodiment, the media contains at least 8 of these trace elements. Each possibility represents a separate embodiment of the present invention.
P-7771-PC3
[00270] In another embodiment, a defined media of methods and compositions of the present invention contains more than 1 component from 2 of the above classes of components; e.g more than one of the AA listed in the second section of Table 3B, and more than one of the vitamins listed in the third section. In another embodiment, the media contains more than 2 components from 2 of the above classes of components; e.g more than 2 of the AA listed in the second section of Table 3B, and more than 2 of the trace elements listed in the fourth section. In another embodiment, the media contains more than 3 components from 2 of the above classes. In another embodiment, the media contains more than 4 components from 2 of the above classes. In another embodiment, the media contains more than 5 components from 2 of the above classes. In another embodiment, the media contains more than 6 components from 2 of the above classes. In another embodiment, the media contains all of the components from 2 of the above classes.
[00271] In another embodiment, a defined media of methods and compositions of the present invention contains more than 1 component from all of the above classes of components (e.g. more than 1 component each from AA, vitamins and trace elements). In another embodiment, the media contains more than 2 components from all of the above classes of components. In another embodiment, the media contains more than 3 components from all of the above classes. In another embodiment, the media contains more than 4 components from all of the above classes. In another embodiment, the media contains more than all components from 2 of the above classes. In another embodiment, the media contains more than 6 components from all of the above classes. In another embodiment, the media contains all of the components from all of the above classes.
[00272] In another embodiment, the media contains any other combination of numbers of components from each of the above classes; e.g. 2 AA, 2 vitamins, and 3 trace elements; 3 AA, 3 vitamins, and 2 trace elements; 2 AA, 3 vitamins, and all of the trace elements, etc.
[00273] Each of the above combinations of numbers of components from each of the above classes represents a separate embodiment of the present invention.
[00274] In another embodiment, a defined media of methods and compositions of the present invention consists of one of the above recipes, mixtures of components, lists of components in specified amounts, or combinations of numbers of components from each of the above classes. Each possibility represents a separate embodiment of the present invention.
[00275] The divalent cation present in defined microbiological media of methods and compositions of the present invention is, in another embodiment, Mg. In another embodiment, the divalent cation is Ca. In another embodiment, the divalent cation is any other divalent cation known in the art. Mg can, in
P-7771-PC3 other embodiments, be present in any form of Mg known in the art, e.g. MgSO4 (Examples 15-16). In another embodiment, the divalent cation is present in an amount that is the molar equivalent of about 0.41 g/mL. In other embodiments, the divalent cation is present in another effective amount, as known to those skilled in the art.
[00276] In another embodiment, a nitrogen source other than glutamine is utilized in defined media of the present invention. In another embodiment, the nitrogen source is another AA. In another embodiment, the nitrogen source is another source of peptides or proteins (e.g. casitone or casamino acids). In another embodiment, the nitrogen source is ammonium chloride. In another embodiment, the nitrogen source is ammonium nitrate. In another embodiment, the nitrogen source is ammonium sulfate. In another embodiment, the nitrogen source is another ammonium salt. In another embodiment, the nitrogen source is any other nitrogen source known in the art. Each possibility represents a separate embodiment of the present invention.
[00277] In another embodiment, a defined microbiological media of methods and compositions of the present invention does not contain a component derived from an animal source. In another embodiment, the defined microbiological media does not contain an animal-derived component of incompletely defined composition (e.g. yeast extract, bacto-tryptone, etc.). Each possibility represents a separate embodiment of the present invention.
[00278] In another embodiment, "defined microbiological media" refers to a media whose components are known. In another embodiment, the term refers to a media that does not contain a component derived from an animal source. In another embodiment, the term refers to a media whose components have been chemically characterized. Each possibility represents a separate embodiment of the present invention.
[00279] In another embodiment, a defined media of methods and compositions of the present invention supports growth of the Listeria strain to about 1.1 x 1010 CFU/mL (e.g. when grown in flasks; Examples 13-16). In another embodiment, the defined media supports growth to about 1.1 x 1010 CFU/mL (e.g. when grown in fermenters; Examples 13-16). In another embodiment, the defined media supports growth to about 5 x 109 CFU/mL (e.g. when grown in fermenters; Examples 13-16). In another embodiment, the defined media supports growth of viable bacteria (e.g. bacteria that can be cryopreserved without significant loss of viability) to about 3 x 1010 CFU/mL (e.g. when grown in fermenters; Examples 13-16). In another embodiment, the defined media supports growth to an ODδoo of about 4.5 (Examples 13-16). In other embodiments, the defined media supports growth to another ODόoo value enumerated herein. In other embodiments, the defined media supports growth to another
P-7771-PC3
CFU/mL value enumerated herein. In another embodiment, the defined media supports growth to a density approximately equivalent to that obtained with TB. In another embodiment, the defined media supports growth to a density approximately equivalent to that obtained with LB. Each possibility represents a separate embodiment of the present invention.
[00280] In another embodiment, a defined media of methods and compositions of the present invention supports a growth rate of the Listeria strain of about 0.25 h"1 (Examples). In another embodiment, the growth rate is about 0.15 h"1. In another embodiment, the growth rate is about 0.2 h"1. In another embodiment, the growth rate is about 0.3 h'1. In another embodiment, the growth rate is about 0.4 h"1. In another embodiment, the growth rate is about 0.5 h"1. In another embodiment, the growth rate is about 0.6 h"1. In another embodiment, the defined media supports a growth rate approximately equivalent to that obtained with TB. In another embodiment, the defined media supports a growth rate approximately equivalent to that obtained with LB. Each possibility represents a separate embodiment of the present invention.
[0028I] In another embodiment, a peptide of the present invention is a fusion peptide. In another embodiment, "fusion peptide" refers to a peptide or polypeptide comprising 2 or more proteins linked together by peptide bonds or other chemical bonds. In another embodiment, the proteins are linked together directly by a peptide or other chemical bond. In another embodiment, the proteins are linked together with 1 or more AA (e.g. a "spacer") between the 2 or more proteins. Each possibility represents a separate embodiment of the present invention.
[00282] In another embodiment, a vaccine of the present invention further comprises an adjuvant. The adjuvant utilized in methods and compositions of the present invention is, in another embodiment, a granulocyte/macrophage colony-stimulating factor (GM-CSF) protein. In another embodiment, the adjuvant comprises a GM-CSF protein. In another embodiment, the adjuvant is a nucleotide molecule encoding GM-CSF. In another embodiment, the adjuvant comprises a nucleotide molecule encoding GM-CSF. In another embodiment, the adjuvant is saponin QS21. In another embodiment, the adjuvant comprises saponin QS21. In another embodiment, the adjuvant is monophosphoryl lipid A. In another embodiment, the adjuvant comprises monophosphoryl lipid A. In another embodiment, the adjuvant is SBAS2. In another embodiment, the adjuvant comprises SBAS2. In another embodiment, the adjuvant is an unmethylated CpG-containing oligonucleotide. In another embodiment, the adjuvant comprises an unmethylated CpG-containing oligonucleotide. In another embodiment, the adjuvant is an immune- stimulating cytokine. In another embodiment, the adjuvant comprises an immune-stimulating cytokine. In another embodiment, the adjuvant is a nucleotide molecule encoding an immune- stimulating cytokine. In another embodiment, the adjuvant comprises a nucleotide molecule encoding
P-7771-PC3 an immune-stimulating cytokine. In another embodiment, the adjuvant is or comprises a quill glycoside. In another embodiment, the adjuvant is or comprises a bacterial mitogen. In another embodiment, the adjuvant is or comprises a bacterial toxin. In another embodiment, the adjuvant is or comprises any other adjuvant known in the art. Each possibility represents a separate embodiment of the present invention.
[00283] In another embodiment, a nucleotide of the present invention is operably linked to a promoter, regulatory sequence, or combination thereof that drives expression of the encoded peptide in the Listeria strain. Promoter, regulatory sequences, and combinations thereof useful for driving constitutive expression of a gene are well known in the art and include, but are not limited to, for example, the PhiyA, PA«A, hly, ActA, and p60 promoters of Listeria, the Streptococcus bac promoter, the Streptomyces griseus sgiA promoter, and the B. thuringiensis phaZ promoter. In another embodiment, inducible and tissue specific expression of the nucleic acid encoding a peptide of the present invention is accomplished by placing the nucleic acid encoding the peptide under the control of an inducible or tissue specific promoter/regulatory sequence. Examples of tissue specific or inducible regulatory sequences, promoters, and combinations thereof which are useful for his purpose include, but are not limited to the MMTV LTR inducible promoter, and the SV40 late enhancer/promoter. In another embodiment, a promoter that is induced in response to inducing agents such as metals, glucocorticoids, and the like, is utilized. Thus, it will be appreciated that the invention includes the use of any promoter or regulatory sequence, which is either known or unknown, and which is capable of driving expression of the desired protein operably linked thereto. In one embodiment, a regulatory sequence is a promoter, while in another embodiment, a regulatory sequence is an enhancer, while in another embodiment, a regulatory sequence is a suppressor, while in another embodiment, a regulatory sequence is a repressor, while in another embodiment, a regulatory sequence is a silencer.
[00284] In one embodiment, the ActA sequence for use in the compositions and methods of the present invention is from Listeria monocytogenes, which in one embodiment, is the EGD strain, the 10403S strain (Genbank accession number: DQ054585) the NICPBP 54002 strain (Genbank accession number: EU394959, the S3 strain (Genbank accession number: EU394960), the NCTC 5348 strain (Genbank accession number: EU394961), the NICPBP 54006 strain (Genbank accession number: EU394962), the M7 strain (Genbank accession number: EU394963), the S 19 strain (Genbank accession number: EU394964), or any other strain of Listeria monocytogenes which is known in the art.
[00285] In one embodiment, an N-terminal fragment of an ActA protein utilized in methods and
P-7771-PC3 compositions of the present invention comprises or consists of the first 390 AA of ActA, in another embodiment, the first 418 AA of ActA, in another embodiment, the first 50 AA of ActA, in another embodiment, the first 100 AA of ActA, which in one embodiment, comprise a PEST-like sequence such as that provided in SEQ ID NO: 2. In another embodiment, an N-terminal fragment of an ActA protein utilized in methods and compositions of the present invention comprises or consists of the first 150 AA of ActA, in another embodiment, the first approximately 200 AA of ActA, which in one embodiment comprises 2 PEST-like sequences as described herein. In another embodiment, an N- terminal fragment of an ActA protein utilized in methods and compositions of the present invention comprises or consists of the first 250 AA of ActA, in another embodiment, the first 300 AA of ActA. In another embodiment, the ActA fragment contains residues of a homologous ActA protein that correspond to one of the above AA ranges. The residue numbers need not, in another embodiment, correspond exactly with the residue numbers enumerated above; e.g. if the homologous ActA protein has an insertion or deletion, relative to an ActA protein utilized herein, then the residue numbers can be adjusted accordingly, as would be routine to a skilled artisan using sequence alignment tools such as NCBI BLAST that are well-known in the art.
[00286] In another embodiment, the N-terminal portion of the ActA protein comprises 1, 2, 3, or 4 PEST-like sequences, which in one embodiment are SEQ ID NOs: 2-5, 38-40, or their homologs, as described herein or other PEST-like sequences as can be determined using the methods and algorithms described herein or by using alternative methods known in the art.
[00287] An N-terminal fragment of an ActA protein utilized in methods and compositions of the present invention has, in another embodiment, the sequence set forth in SEQ ID NO: 23:
MRAMMVVFITANCITINPDΠFAATDSEDSSLNTDEWEEEKTEEQPSEVNTGPRYETAREVSSR DIKELEKSNKVRNTNKADLIAMLKEKAEKGPNINNNNSEQTENAAINEEASGADRPAIQVERR HPGLPSDSAAEIKKRRKAIASSDSELESLTYPDKPTKVNKKKVAKESVADASESDLDSSMQSA DESSPQPLKANQQPFFPKVFKKIKDAGKWVRDKIDENPEVKKAIVDKSAGLIDQLLTKKKSEE VNASDFPPPPTDEELRLALPETPMLLGFNAPATSEPSSFEFPPPPTDEELRLALPETPMLLGFNA PATSEPSSFEFPPPPTEDELEΠRETASSLDSSFTRGDLASLRNAINRHSQNFSDFPPIPTEEELNG
RGGRP (SEQ ID NO: 23). In another embodiment, the ActA fragment comprises the sequence set forth in SEQ ID NO: 23. In another embodiment, the ActA fragment is any other ActA fragment known in the art. In another embodiment, the ActA protein is a homologue of SEQ ID NO: 23. In another embodiment, the ActA protein is a variant of SEQ ID NO: 23. In another embodiment, the ActA protein is an isoform of SEQ ID NO: 23. In another embodiment, the ActA protein is a fragment of SEQ ID NO: 23. In another embodiment, the ActA protein is a fragment of a homologue of SEQ ID
P-7771-PC3
NO: 23. In another embodiment, the ActA protein is a fragment of a variant of SEQ ID NO: 23. In another embodiment, the ActA protein is a fragment of an isoform of SEQ ID NO: 23. Each possibility represents a separate embodiment of the present invention. Each possibility represents a separate embodiment of the present invention.
[00288] In another embodiment, the recombinant nucleotide encoding a fragment of an ActA protein comprises the sequence set forth in SEQ ID NO: 24: atgcgtgcgatgatggtggttttcattactgccaattgcattacgattaaccccgacataatatttgcagcgacagatagcgaagattctagtctaaaca cagatgaatgggaagaagaaaaaacagaagagcaaccaagcgaggtaaatacgggaccaagatacgaaactgcacgtgaagtaagttcacgtg atattaaagaactagaaaaatcgaataaagtgagaaatacgaacaaagcagacctaatagcaatgttgaaagaaaaagcagaaaaaggtccaaata tcaataataacaacagtgaacaaactgagaatgcggctataaatgaagaggcttcaggagccgaccgaccagctatacaagtggagcgtcgtcatc caggattgccatcggatagcgcagcggaaattaaaaaaagaaggaaagccatagcatcatcggatagtgagcttgaaagccttacttatccggata aaccaacaaaagtaaataagaaaaaagtggcgaaagagtcagttgcggatgcttctgaaagtgacttagattctagcatgcagtcagcagatgagtc ttcaccacaacctttaaaagcaaaccaacaaccatttttccctaaagtatttaaaaaaataaaagatgcggggaaatgggtacgtgataaaatcgacga aaatcctgaagtaaagaaagcgattgttgataaaagtgcagggttaattgaccaattattaaccaaaaagaaaagtgaagaggtaaatgcttcggact tcccgccaccacctacggatgaagagttaagacttgctttgccagagacaccaatgcttcttggttttaatgctcctgctacatcagaaccgagctcatt cgaatttccaccaccacctacggatgaagagttaagacttgctttgccagagacgccaatgcttcttggttttaatgctcctgctacatcggaaccgag ctcgttcgaatttccaccgcctccaacagaagatgaactagaaatcatccgggaaacagcatcctcgctagattctagttttacaagaggggatttagc tagtttgagaaatgctattaatcgccatagtcaaaatttctctgatttcccaccaatcccaacagaagaagagttgaacgggagaggcggtagacca (SEQ ID NO: 24). In another embodiment, the recombinant nucleotide has the sequence set forth in SEQ ED NO: 24. In another embodiment, the recombinant nucleotide comprises any other sequence that encodes a fragment of an ActA protein. Each possibility represents a separate embodiment of the present invention.
[00289] An N-terminal fragment of an ActA protein utilized in methods and compositions of the present invention has, in another embodiment, the sequence set forth in SEQ ID NO: 36: MRAMMVVFITANCITINPDIIFAATDSEDSSLNTDEWEEEKTEEQPSEVNTGPRYETAREVSSR DIEELEKSNKVKNTNKADLIAMLKAKAEKGPNNNNNNGEQTGNVAINEEASGVDRPTLQVE RRHPGLSSDSAAEIKKRRKAIASSDSELESLTYPDKPTKANKRKVAKESVVDASESDLDSSMQ SADESTPQPLKANQKPFFPKVFKKIKDAGKWVRDKIDENPEVKKAIVDKSAGLIDQLLTKKKS EEVNASDFPPPPTDEELRLALPETPMLLGFNAPTPSEPSSFEFPPPPTDEELRLALPETPMLLGFN APATSEPSSFEFPPPPTEDELEIMRETAPSLDSSFTSGDLASLRSAINRHSENFSDFPLIPTEEELN
GRGGRP (SEQ ID NO: 36), which in one embodiment is the first 390 AA for ActA from Listeria monocytogenes, strain 10403S. In another embodiment, the ActA fragment comprises the sequence set forth in SEQ ID NO: 36. In another embodiment, the ActA fragment is any other ActA fragment known in the art. In another embodiment, the ActA protein is a homologue of SEQ ID NO: 36.
P-7771-PC3
In another embodiment, the ActA protein is a variant of SEQ ID NO: 36. In another embodiment, the ActA protein is an isoform of SEQ DD NO: 36. In another embodiment, the ActA protein is a fragment of SEQ ID NO: 36. In another embodiment, the ActA protein is a fragment of a homologue of SEQ ID NO: 36. In another embodiment, the ActA protein is a fragment of a variant of SEQ ID NO: 36. In another embodiment, the ActA protein is a fragment of an isoform of SEQ ID NO: 36. Each possibility represents a separate embodiment of the present invention. Each possibility represents a separate embodiment of the present invention.
[00290] In another embodiment, the recombinant nucleotide encoding a fragment of an ActA protein comprises the sequence set forth in SEQ ID NO: 37: atgcgtgcgatgatggtagttttcattactgccaactgcattacgattaaccccgacataatatttgcagcgacagatagcgaagattccagtctaaaca cagatgaatgggaagaagaaaaaacagaagagcagccaagcgaggtaaatacgggaccaagatacgaaactgcacgtgaagtaagttcacgtg atattgaggaactagaaaaatcgaataaagtgaaaaatacgaacaaagcagacctaatagcaatgttgaaagcaaaagcagagaaaggtccgaat aacaataataacaacggtgagcaaacaggaaatgtggctataaatgaagaggcttcaggagtcgaccgaccaactctgcaagtggagcgtcgtca tccaggtctgtcatcggatagcgcagcggaaattaaaaaaagaagaaaagccatagcgtcgtcggatagtgagcttgaaagccttacttatccagat aaaccaacaaaagcaaataagagaaaagtggcgaaagagtcagttgtggatgcttctgaaagtgacttagattctagcatgcagtcagcagacgag tctacaccacaacctttaaaagcaaatcaaaaaccatttttccctaaagtatttaaaaaaataaaagatgcggggaaatgggtacgtgataaaatcgac gaaaatcctgaagtaaagaaagcgattgttgataaaagtgcagggttaattgaccaattattaaccaaaaagaaaagtgaagaggtaaatgcttcgga cttcccgccaccacctacggatgaagagttaagacttgctttgccagagacaccgatgcttctcggttttaatgctcctactccatcggaaccgagctc attcgaatttccgccgccacctacggatgaagagttaagacttgctttgccagagacgccaatgcttcttggttttaatgctcctgctacatcggaaccg agctcattcgaatttccaccgcctccaacagaagatgaactagaaattatgcgggaaacagcaccttcgctagattctagttttacaagcggggattta gctagtttgagaagtgctattaatcgccatagcgaaaatttctctgatttcccactaatcccaacagaagaagagttgaacgggagaggcggtagacc a (SEQ ID NO: 37), which in one embodiment, is the first 1170 nucleotides encoding ActA in Listeria monocytogenes 10403S strain. In another embodiment, the recombinant nucleotide has the sequence set forth in SEQ ID NO: 37. In another embodiment, the recombinant nucleotide comprises any other sequence that encodes a fragment of an ActA protein. Each possibility represents a separate embodiment of the present invention.
[00291] In another embodiment of the methods and compositions of the present invention, a PEST-like AA sequence is fused to the antigen, which in one embodiment is the E7 or E6 antigen. In another embodiment, a PEST sequence is fused to the antigen. In another embodiment, a PEST-containing sequence is fused to the antigen. As provided herein, recombinant Listeria strains expressing PEST- like sequence-antigen fusions induce anti-tumor immunity (Example 3) and generate antigen-specific, tumor-infiltrating T cells (Example 4). Further, enhanced cell mediated immunity was demonstrated for fusion proteins comprising an antigen and LLO containing the PEST-like AA sequence
P-7771-PC3
KENSISSMAPPASPPASPKTPIEKKHADEIDK (SEQ ID NO: 1).
[00292] In another embodiment, fusion of an antigen to other LM PEST-like sequences and PEST-like sequences derived from other prokaryotic organisms will also enhance immunogenicity of the antigen. The PEST-like AA sequence has, in another embodiment, a sequence selected from SEQ ID NO: 2-7. In another embodiment, the PEST-like sequence is a PEST-like sequence from an LM ActA protein. In another embodiment, an ActA protein comprises PEST-like sequences as set forth in SEQ ID NO: 2, 3, and 4. In another embodiment, an ActA protein comprises PEST-like sequences as set forth in SEQ ID NO: 2, 3, 4, and 5. In another embodiment, the PEST-like sequences that the ActA protein comprises is set forth in SEQ ID NO: 2, 3, 4 or their combination. In another embodiment, the PEST- like sequences that the ActA protein comprises is set forth in SEQ ID NO: 2, 3, 4, 5, or their combination. In another embodiment, an ActA protein comprises a PEST-like sequence as set forth in SEQ ID NO: 2. In another embodiment, an ActA protein comprises a PEST-like sequence as set forth in SEQ ID NO: 3. In another embodiment, an ActA protein comprises a PEST-like sequence that is 82% homologous to the sequence as set forth in SEQ ID NO: 3. In another embodiment, an ActA protein comprises a PEST-like sequence as set forth in SEQ ID NO: 4. In another embodiment, an ActA protein comprises a PEST-like sequence that is 95% homologous to the sequence as set forth in SEQ ID NO: 4. In another embodiment, an ActA protein comprises a PEST-like sequence as set forth in SEQ ID NO: 5. In another embodiment, an ActA fragment comprises a PEST-like sequence as set forth in SEQ ID NO: 2. In another embodiment, an ActA fragment comprises a PEST-like sequence as set forth in SEQ ID NO: 3. In another embodiment, an ActA fragment comprises a PEST-like sequence as set forth in SEQ ED NO: 4. In another embodiment, an ActA fragment comprises a PEST- like sequence as set forth in SEQ ID NO: 5. In another embodiment, the the ActA fragment comprises PEST-like sequences as set forth in SEQ ID NO: 2, 3, 4 or their combination. In another embodiment, the the ActA fragment comprises PEST-like sequences as set forth in SEQ ID NO: 2, 3, 4, 5 or their combination. In another embodiment, the PEST-like sequence is KTEEQPSEVNTGPR (SEQ ID NO: 2), KASVTDTSEGDLDSSMQSADESTPQPLK (SEQ ED NO: 3),
KESVADASESDLDSSMQSADESSPQPLK (SEQ ID NO: 38), KNEEVNASDFPPPPTDEELR (SEQ ID NO: 4), KSEEVNASDFPPPPTDEELR (SEQ ID NO: 39), or RGGIPTSEEFSSLNSGDFTDDENSETTEEEIDR (SEQ ID NO: 5), RGGRPTSEEFSSLNSGDFTDDENSETTEEEIDR (SEQ ID NO: 40). In another embodiment, the PEST-like sequence is from Streptolysin O protein of Streptococcus sp. In another embodiment, the PEST-like sequence is from Streptococcus pyogenes Streptolysin O, e.g. KQNTASTETTTTNEQPK (SEQ ID NO: 6), which in one embodiment is at AA 35-51 of Streptolysin O. In another embodiment, the PEST-like sequence is from Streptococcus equisimilis Streptolysin O, e.g.
P-7771-PC3
KQNTANTETTTTNEQPK (SEQ ID NO: 7), which in one embodiment, is at AA 38-54 of Streptolysin O. In another embodiment, the PEST-like sequence is another PEST-like AA sequence derived from a prokaryotic organism. In another embodiment, the PEST-like sequence is any other PEST-Hke sequence known in the art. Each possibility represents a separate embodiment of the present invention.
[00293] PEST-like sequences of other prokaryotic organism can be identified in accordance with methods such as described by, for example Rechsteiner and Rogers (1996, Trends Biochem. Sci. 21:267-271) for LM. Alternatively, PEST-like AA sequences from other prokaryotic organisms can also be identified based on this method. Other prokaryotic organisms wherein PEST-like AA sequences would be expected to include, but are not limited to, other Listeria species. In another embodiment, the PEST-like sequence is embedded within the antigenic protein. Thus, in another embodiment, "fusion" refers to an antigenic protein comprising both the antigen and the PEST-like amino acid sequence either linked at one end of the antigen or embedded within the antigen.
[00294] In another embodiment, the PEST-like sequence is identified using any other method or algorithm known in the art, e.g the CaSPredictor (Garay-Malpartida HM, Occhiucci JM, Alves J,
Belizario JE. Bioinformatics. 2005 Jun;21 Suppl l:il69-76). In another embodiment, the PEST-like sequence is identified using the PESTfind Program, which in one embodiment, is publicly available at:http://bio.dfci.harvard.edu/cgi-bin/EMBOSS/emboss.pl? action=manual& app=pestfind, which in one embodiment, is an application written by Michael K. Schuster and Martin Grabner, from the Austrian National EMBnet node. In one embodiment, the original PESTfind Program written by Scott
Rogers and Martin Rechsteiner (C) 1986, may be used.
[00295] A PEST index is calculated for each 30-35 AA stretch by assigning a value of 1 to the amino acids Ser, Thr, Pro, GIu, Asp, Asn, or GIn. The coefficient value (CV) for each of the PEST residue is 1 and for each of the other AA (non-PEST) is 0.
[00296] In another embodiment, a PEST-like sequence has a CV of 1. In another embodiment, a PEST- like sequence has a CV of 2. In another embodiment, a PEST-like sequence has a CV of 3. In another embodiment, a PEST-like sequence has a CV of 4. In another embodiment, a PEST-like sequence has a CV of 5. In another embodiment, a PEST-like sequence has a CV of 6. In another embodiment, a PEST-like sequence has a CV of 2. In another embodiment, a PEST-like sequence has a CV of 7. In another embodiment, a PEST-like sequence has a CV of 8. In another embodiment, a PEST-like sequence has a CV of 9. In another embodiment, a PEST-like sequence has a CV of 10. In another embodiment, a PEST-like sequence has a CV of 1 1. In another embodiment, a PEST-like sequence
P-7771-PC3 has a CV of 12. In another embodiment, a PEST-like sequence has a CV of 13. In another embodiment, a PEST-like sequence has a CV of 14. In another embodiment, a PEST-like sequence has a CV of 15. In another embodiment, a PEST-like sequence has a CV of 16. In another embodiment, a PEST-like sequence has a CV of 17. In another embodiment, a PEST-like sequence has a CV of 18. In another embodiment, a PEST-like sequence has a CV of 19. In another embodiment, a PEST-like sequence has a CV of 20. In another embodiment, a PEST-like sequence has a CV of 20. In another embodiment, a PEST-like sequence has a CV of 21. In another embodiment, a PEST-like sequence has a CV of 22. In another embodiment, a PEST-like sequence has a CV of 23. In another embodiment, a PEST-like sequence has a CV of 24. In another embodiment, a PEST-like sequence has a CV of 25. In another embodiment, a PEST-like sequence has a CV of 26. In another embodiment, a PEST-like sequence has a CV of 27. In another embodiment, a PEST-like sequence has a CV of 28. In another embodiment, a PEST-like sequence has a CV of 29. In another embodiment, a PEST-like sequence has a CV of 30. In another embodiment, a PEST-like sequence has a CV of 31. In another embodiment, a PEST-like sequence has a CV of 32. In another embodiment, a PEST-like sequence has a CV of 33. In another embodiment, a PEST-like sequence has a CV of 34. In another embodiment, a PEST-like sequence has a CV of 35.
[00297] In one embodiment, a PEST-like sequence is a PEST sequence identified using one of the algorithms described herein or known in the art. In another embodiment, a PEST-like sequence is a sequence that is similar to a known PEST sequence in structure, while in another embodiment, a PEST-like sequence has a similar function to known PEST sequences, or in another embodiment, a PEST-like sequence is similar both structurally and functionally to known PEST sequences. In one embodiment, a similar structure to a known PEST sequence is one that would receive a higher than threshold score, which in one embodiment, is 5 using one of the algorithms described hereinabove, which in one embodiment, is PESTfϊnd. In one embodiment, a PEST-like sequence is a sequence comprising a PEST motif. Each method for identifying a PEST-like sequence represents a separate embodiment of the present invention.
[00298] In another embodiment, the LLO protein, ActA protein, or fragment thereof of the present invention need not be that which is set forth exactly in the sequences set forth herein, but rather other alterations, modifications, or changes can be made that retain the functional characteristics of an LLO or ActA protein fused to an antigen as set forth elsewhere herein. In another embodiment, the present invention utilizes an analog of an LLO protein, ActA protein, or fragment thereof. Analogs differ, in another embodiment, from naturally occurring proteins or peptides by conservative AA sequence differences or by modifications which do not affect sequence, or by both. For example,
P-7771-PC3 conservative amino acid changes may be made, which although they alter the primary sequence of the protein or peptide, do not normally alter its function. In one embodiment, conservative amino acid substitutions include substitutions within the following groups: (a) glycine, alanine; (b) valine, isoleucine, leucine; (c) aspartic acid, glutamic acid; (d) asparagine, glutamine; (e) serine, threonine; (f) lysine, arginine; (g) phenylalanine, tyrosine. In one embodiment, conservative AA substitution comprise substitutions of polar AAs with other polar AAs, non-polar AAs with other non-polar AAs, charged AAs with other charged AAs, non-charged AAs with other non-charged AAs, hydrophobic AAs with other hydrophobic AAs, basic AAs with other basic AAs, acidic AAs with other acidic AAs, or a combination thereof, as is well known in the art.
[00299] In one embodiment, modifications (which do not normally alter primary sequence) include in vivo, or in vitro chemical derealization of polypeptides, e.g., acetylation, or carboxylation. Also included are modifications of glycosylation, e.g., those made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing or in further processing steps; e.g., by exposing the polypeptide to enzymes which affect glycosylation, e.g., mammalian glycosylating or deglycosylating enzymes. Also included are sequences which have phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.
[00300] Also included are polypeptides which have been modified using ordinary molecular biological techniques so as to improve their resistance to proteolytic degradation or to optimize solubility properties or to render them more suitable as a therapeutic agent. Analogs of such polypeptides include those containing residues other than naturally occurring L-amino acids, e.g., D-amino acids or non- naturally occurring synthetic amino acids. The peptides of the invention are not limited to products of any of the specific exemplary processes listed herein.
[0030I] In one embodiment, the vaccines of the present invention comprise an adjuvant, while in another embodiment, the vaccines do not comprise an adjuvant. "Adjuvant" refers, in another embodiment, to compounds that, when administered to an individual or tested in vitro, increase the immune response to an antigen in the individual or test system to which the antigen is administered. In another embodiment, an immune adjuvant enhances an immune response to an antigen that is weakly immunogenic when administered alone, i.e., inducing no or weak antibody titers or cell-mediated immune response. In another embodiment, the adjuvant increases antibody titers to the antigen. In another embodiment, the adjuvant lowers the dose of the antigen effective to achieve an immune response in the individual.
[00302J The adjuvant utilized in methods and compositions of the present invention is, in another
P-7771-PC3 embodiment, a CpG-containing nucleotide sequence. In another embodiment, the adjuvant is a CpG- containing oligonucleotide. In another embodiment, the adjuvant is a CpG-containing oligodeoxynucleotide (CpG ODN). In another embodiment, the adjuvant is ODN 1826, which in one embodiment, is acquired from Coley Pharmaceutical Group. In another embodiment, the adjuvant is an aluminum salt adjuvant. In another embodiment, the adjuvant is a Montanide ISA adjuvant. In another embodiment, the adjuvant is a trimer of complement component C3d. In another embodiment, the trimer is covalently linked to the protein immunogen. In another embodiment, the adjuvant is MF59. In another embodiment, the adjuvant is a granulocyte/macrophage colony-stimulating factor (GM-CSF) protein. In another embodiment, the adjuvant is a mixture comprising a GM-CSF protein. In another embodiment, the adjuvant is a nucleotide molecule encoding GM-CSF. In another embodiment, the adjuvant is a mixture comprising a nucleotide molecule encoding GM-CSF. In another embodiment, the adjuvant is saponin QS21. In another embodiment, the adjuvant is a mixture comprising saponin QS21. In another embodiment, the adjuvant is monophosphoryl lipid A (MPL). In another embodiment, the adjuvant is a mixture comprising MPL. In another embodiment, the adjuvant is SBAS2. In another embodiment, the adjuvant is a mixture comprising SBAS2. In another embodiment, the adjuvant is an unmethylated CpG-containing oligonucleotide. In another embodiment, the adjuvant is a mixture comprising an unmethylated CpG-containing oligonucleotide. In another embodiment, the adjuvant is an immune-stimulating cytokine. In another embodiment, the adjuvant is a mixture comprising an immune-stimulating cytokine. In another embodiment, the adjuvant is a nucleotide molecule encoding an immune-stimulating cytokine. In another embodiment, the adjuvant is a mixture comprising a nucleotide molecule encoding an immune-stimulating cytokine. In another embodiment, the adjuvant is a mixture comprising a quill glycoside. In another embodiment, the adjuvant is a mixture comprising a bacterial mitogen. In another embodiment, the adjuvant is a mixture comprising a bacterial toxin. In another embodiment, the adjuvant is a mixture comprising any other adjuvant known in the art. In another embodiment, the adjuvant is a mixture of one or more of the above adjuvants.
[00303] "CpG-containing nucleotide," "CpG-containing oligonucleotide," "CpG oligonucleotide," and similar terms refer, in another embodiment, to a nucleotide molecule of 8-50 nucleotides in length that contains an unmethylated CpG moiety.
[00304] In another embodiment, "nucleic acids" or "nucleotide" refers to a string of at least 2 base- sugar-phosphate combinations. The term includes, in another embodiment, DNA and RNA. "Nucleotides" refers, in one embodiment, to the monomelic units of nucleic acid polymers. RNA is, in one embodiment, in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA
(ribosomal RNA), mRNA (messenger RNA), and- sense RNA, small inhibitory RNA (siRNA),
P-7771-PC3 micro RNA (miRNA) and ribozymes. The use of siRNA and miRNA has been described (Caudy AA et al., Genes & Devel 16: 2491-96 and references cited therein). DNA can be, in other embodiments, in form of plasmid DNA, viral DNA, linear DNA, or chromosomal DNA or derivatives of these groups. In addition, these forms of DNA and RNA can be single, double, triple, or quadruple stranded. The term also includes, in another embodiment, artificial nucleic acids that contain other types of backbones but the same bases. In one embodiment, the artificial nucleic acid is a PNA (peptide nucleic acid). PNA contain peptide backbones and nucleotide bases and are able to bind, in one embodiment, to both DNA and RNA molecules. In another embodiment, the nucleotide is oxetane modified. In another embodiment, the nucleotide is modified by replacement of one or more phosphodiester bonds with a phosphorothioate bond. In another embodiment, the artificial nucleic acid contains any other variant of the phosphate backbone of native nucleic acids known in the art. The use of phosphothiorate nucleic acids and PNA are known to those skilled in the art, and are described in, for example, Neilsen PE, Curr Opin Struct Biol 9:353-57; and Raz NK et al. Biochem Biophys Res Commun. 297:1075-84. The production and use of nucleic acids is known to those skilled in art and is described, for example, in Molecular Cloning, (2001), Sambrook and Russell, eds. and Methods in Enzymology: Methods for molecular cloning in eukaryotic cells (2003) Purchio and G. C. Fareed. Each nucleic acid derivative represents a separate embodiment of the present invention.
[00305] Each type of modified oligonucleotide represents a separate embodiment of the present invention.
[00306] Methods for production of nucleic acids having modified backbones are well known in the art, and are described, for example in U.S. Pat. Nos. 5,723,335 and 5,663,153 issued to Hutcherson et al. and related PCT publication WO95/26204. Each method represents a separate embodiment of the present invention.
[00307] In another embodiment, either a whole E7 protein or a fragment thereof is fused to a LLO protein, ActA protein, or PEST-like sequence-containing peptide to generate a recombinant peptide of methods of the present invention. The E7 protein that is utilized (either whole or as the source of the fragments) has, in another embodiment, the sequence:
[OOSOSI MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFC
CKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP (SEQ ID NO: 30). In another embodiment, the E7 protein is a homologue of SEQ ID NO: 30. In another embodiment, the E7 protein is a variant of SEQ ID NO: 30. In another embodiment, the E7 protein is an isoform of SEQ
ID NO: 30. In another embodiment, the E7 protein is a fragment of SEQ ID NO: 30. In another
P-7771-PC3 embodiment, the E7 protein is a fragment of a homologue of SEQ ID NO: 30. In another embodiment, the E7 protein is a fragment of a variant of SEQ ID NO: 30. In another embodiment, the E7 protein is a fragment of an isoform of SEQ ID NO: 30. Each possibility represents a separate embodiment of the present invention.
[00309] In another embodiment, the sequence of the E7 protein is:
[00310] MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQR HTMLCMCCKCEARIELVVESSADDLRAFQQLFLNTLSFVCPWCASQQ (SEQ ID NO: 31). In another embodiment, the E7 protein is a homologue of SEQ ID NO: 31. In another embodiment, the E7 protein is a variant of SEQ ID NO: 31. In another embodiment, the E7 protein is an isoform of SEQ ID NO: 31. In another embodiment, the E7 protein is a fragment of SEQ ID NO: 31. In another embodiment, the E7 protein is a fragment of a homologue of SEQ ID NO: 31. In another embodiment, the E7 protein is a fragment of a variant of SEQ ID NO: 31. In another embodiment, the E7 protein is a fragment of an isoform of SEQ ID NO: 31. Each possibility represents a separate embodiment of the present invention.
[00311] In another embodiment, the E7 protein is encoded by a nucleic acid sequence set forth in one of the following GenBank entries: M24215, NC_004500, VOl 116, X62843, M14119 or other sequences known in the art. In another embodiment, the E7 protein has the sequence set forth in NCBFs Genbank Accession No.: NPJ775306.1, CAA24316.1, CAA44648.1, AAA46928.1, CAA75471, CAA63874, CAA63883.1, NP_932320.1, NP_043417.1, AAR13015.1 or other sequences known in the art. In another embodiment, the E7 protein is a homologue of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a variant of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is an isoform of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a fragment of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a fragment of a homologue of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a fragment of a variant of a sequence from one of the above GenBank entries. In another embodiment, the E7 protein is a fragment of an isoform of a sequence from one of the above GenBank entries. Each possibility represents a separate embodiment of the present invention..
[00312] In another embodiment, either a whole E6 protein or a fragment thereof is fused to a LLO protein, ActA protein, or PEST-like sequence-containing peptide to generate a recombinant peptide of methods of the present invention. The E6 protein that is utilized (either whole or as the source of the
P-7771-PC3 fragments) has, in another embodiment, the sequence
[00313] MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLC IVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEE KQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL (SEQ ID NO: 32). In another embodiment, the E6 protein is a homologue of SEQ ID NO: 32. In another embodiment, the E6 protein is a variant of SEQ ID NO: 32. In another embodiment, the E6 protein is an isoform of SEQ ID NO: 32. In another embodiment, the E6 protein is a fragment of SEQ ID NO: 32. In another embodiment, the E6 protein is a fragment of a homologue of SEQ ID NO: 32. In another embodiment, the E6 protein is a fragment of a variant of SEQ ID NO: 32. In another embodiment, the E6 protein is a fragment of an isoform of SEQ ID NO: 32. Each possibility represents a separate embodiment of the present invention.
[00314] In another embodiment, the sequence of the E6 protein is:
[00315] MARFEDPTRRPYKLPDLCTELNTSLQDffilTCVYCKTVLELTEVFEFAFKDLFVVYRDS IPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRCQKPLNPAEKLRHLNE KRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV (SEQ ID NO: 33). In another embodiment, the E6 protein is a homologue of SEQ ID NO: 33. In another embodiment, the E6 protein is a variant of SEQ ID NO: 33. In another embodiment, the E6 protein is an isoform of SEQ ID NO: 33. In another embodiment, the E6 protein is a fragment of SEQ ID NO: 33. In another embodiment, the E6 protein is a fragment of a homologue of SEQ ID NO: 33. In another embodiment, the E6 protein is a fragment of a variant of SEQ ID NO: 33. In another embodiment, the E6 protein is a fragment of an isoform of SEQ ID NO: 33. Each possibility represents a separate embodiment of the present invention.
[00316] In another embodiment, the E6 protein is encoded by a nucleic acid sequence set forth in one of the following GenBank entries: NC_004500, VOl 116, X62843, M14119 or other sequences known in the art. In another embodiment, the E6 protein has the sequence set forth in NCBFs Genbank Accession No.: NP_775305.1, CAA24314.1 , CAA44647.1, AAA46927.1, ABI32364.1 , AAY69378.1, AAY69373.1, AAY69366.1, CAA63881.1, CAA75470.1, NP_932319.1, AAP 19632.1, or other sequences known in the art. In another embodiment, the E6 protein is a homologue of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is a variant of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is an isoform of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is a fragment of a sequence from one of the above GenBank entries. In another embodiment, the E6
P-7771-PC3 protein is a fragment of a homologue of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is a fragment of a variant of a sequence from one of the above GenBank entries. In another embodiment, the E6 protein is a fragment of an isoform of a sequence from one of the above GenBank entries. Each possibility represents a separate embodiment of the present invention.
[00317] In one embodiment, "variant" refers to an amino acid or nucleic acid sequence (or in other embodiments, an organism or tissue) that is different from the majority of the population but is still sufficiently similar to the common mode to be considered to be one of them, for example splice variants.
[00318] In one embodiment, "isoform" refers to a version of a molecule, for example, a protein, with only slight differences compared to another isoform, or version, of the same protein. In one embodiment, isoforms may be produced from different but related genes, or in another embodiment, may arise from the same gene by alternative splicing. In another embodiment, isoforms are caused by single nucleotide polymorphisms.
[00319] In one embodiment, "fragment" refers to a protein or polypeptide that is shorter or comprises fewer amino acids than the full length protein or polypeptide. In another embodiment, fragment refers to a nucleic acid that is shorter or comprises fewer nucleotides than the full length nucleic acid. In another embodiment, the fragment is an N-terminal fragment. In another embodiment, the fragment is a C-terminal fragment. In one embodiment, the fragment is an intrasequential section of the protein, peptide, or nucleic acid. In one embodiment, the fragment is a functional fragment. In another embodiment, the fragment is an immunogenic fragment. In one embodiment, a fragment has 10-20 nucleic or amino acids, while in another embodiment, a fragment has more than 5 nucleic or amino acids, while in another embodiment, a fragment has 100-200 nucleic or amino acids, while in another embodiment, a fragment has 100-500 nucleic or amino acids, while in another embodiment, a fragment has 50-200 nucleic or amino acids, while in another embodiment, a fragment has 10-250 nucleic or amino acids.
[00320] In one embodiment, "immunogenicity" or "immunogenic" is used herein to refer to the innate ability of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response in an animal when the protein, peptide, nucleic acid, antigen or organism is administered to the animal. Thus, "enhancing the immunogenicity" in one embodiment, refers to increasing the ability of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response in an animal when the protein, peptide, nucleic acid, antigen or organism is administered to an animal. The increased ability
P-7771-PC3 of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response can be measured by, in one embodiment, a greater number of antibodies to a protein, peptide, nucleic acid, antigen or organism, a greater diversity of antibodies to an antigen or organism, a greater number of T-cells specific for a protein, peptide, nucleic acid, antigen or organism, a greater cytotoxic or helper T-cell response to a protein, peptide, nucleic acid, antigen or organism, and the like.
[00321] In one embodiment, "treating" refers to either therapeutic treatment or prophylactic or preventative measures, wherein the object is to prevent or lessen the targeted pathologic condition or disorder as described hereinabove. Thus, in one embodiment, treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing the severity of, delaying the onset of, reducing symptoms associated with the disease, disorder or condition, or a combination thereof. Thus, in one embodiment, "treating" refers inter alia to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof. In one embodiment, "preventing" refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof. In one embodiment, "suppressing" or "inhibiting", refers inter alia to reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.
[00322] In one embodiment, a "homologue" refers to a nucleic acid or amino acid sequence which shares a certain percentage of sequence identity with a particular nucleic acid or amino acid sequence. In one embodiment, a sequence useful in the composition and methods of the present invention may be a homologue of a particular LLO sequence or N-terminal fragment thereof, ActA sequence or N- terminal fragment thereof, E7 sequence, E6 sequence, or PEST-like sequence described herein or known in the art. In another embodiment, a sequence useful in the composition and methods of the present invention may be a homologue of any sequence described herein. In one embodiment, a homologue shares at least 70% identity with a particular sequence. In another embodiment, a homologue shares at least 72% identity with a particular sequence. In another embodiment, a homologue shares at least 75% identity with a particular sequence. In another embodiment, a homologue shares at least 78% identity with a particular sequence. In another embodiment, a homologue shares at least 80% identity with a particular sequence. In another embodiment, a homologue shares at least 82% identity with a particular sequence. In another embodiment, a homologue shares at least 83% identity with a particular sequence. In another embodiment, a
P-7771-PC3 homologue shares at least 85% identity with a particular sequence. In another embodiment, a homologue shares at least 87% identity with a particular sequence. In another embodiment, a homologue shares at least 88% identity with a particular sequence. In another embodiment, a homologue shares at least 90% identity with a particular sequence. In another embodiment, a homologue shares at least 92% identity with a particular sequence. In another embodiment, a homologue shares at least 93% identity with a particular sequence. In another embodiment, a homologue shares at least 95% identity with a particular sequence. In another embodiment, a homologue shares at least 96% identity with a particular sequence. In another embodiment, a homologue shares at least 97% identity with a particular sequence. In another embodiment, a homologue shares at least 98% identity with a particular sequence. In another embodiment, a homologue shares at least 99% identity with a particular sequence. In another embodiment, a homologue shares 100% identity with a particular sequence. Each possibility represents a separate embodiment of the present invention.
[00323] In one embodiment, it is to be understood that a homolog of any of the sequences of the present invention and/or as described herein is considered to be a part of the invention.
[00324] In one embodiment, "functional" within the meaning of the invention, is used herein to refer to the innate ability of a protein, peptide, nucleic acid, fragment or a variant thereof to exhibit a biological activity or function. In one embodiment, such a biological function is its binding property to an interaction partner, e.g., a membrane-associated receptor, and in another embodiment, its trimerization property. In the case of functional fragments and the functional variants of the invention, these biological functions may in fact be changed, e.g., with respect to their specificity or selectivity, but with retention of the basic biological function.
[00325] Protein and/or peptide homology for any AA sequence listed herein is determined, in one embodiment, by methods well described in the art, including immunoblot analysis, or via computer algorithm analysis of AA sequences, utilizing any of a number of software packages available, via established methods. Some of these packages include the FASTA, BLAST, MPsrch or Scanps packages, and employ, in other embodiments, the use of the Smith and Waterman algorithms, and/or global/local or BLOCKS alignments for analysis, for example. Each method of determining homology represents a separate embodiment of the present invention.
[00326] In another embodiment, the LLO protein, ActA protein, or fragment thereof is attached to the E7 or E6 antigen by chemical conjugation. In another embodiment, glutaraldehyde is used for the conjugation. In another embodiment, the conjugation is performed using any suitable method known
P-7771-PC3 in the art. Each possibility represents another embodiment of the present invention.
[00327] In another embodiment, fusion proteins of the present invention are prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods discussed below. In another embodiment, subsequences are cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments are then ligated, in another embodiment, to produce the desired DNA sequence. In another embodiment, DNA encoding the fusion protein is produced using DNA amplification methods, for example polymerase chain reaction (PCR). First, the segments of the native DNA on either side of the new terminus are amplified separately. The 5' end of the one amplified sequence encodes the peptide linker, while the 3' end of the other amplified sequence also encodes the peptide linker. Since the 5' end of the first fragment is complementary to the 3' end of the second fragment, the two fragments (after partial purification, e.g. on LMP agarose) can be used as an overlapping template in a third PCR reaction. The amplified sequence will contain codons, the segment on the carboxy side of the opening site (now forming the amino sequence), the linker, and the sequence on the amino side of the opening site (now forming the carboxyl sequence). The insert is then ligated into a plasmid.
[00328] In some embodiments, the term "comprising" refers to the inclusion of other recombinant polypeptides, amino acid sequences, or nucleic acid sequences, as well as inclusion of other polypeptides, amino acid sequences, or nucleic acid sequences, that may be known in the art, which in one embodiment may comprise antigens or Listeria polypeptides, amino acid sequences, or nucleic acid sequences. In some embodiments, the term "consisting essentially of refers to a composition for use in the methods of the present invention, which has the specific recombinant polypeptide, amino acid sequence, or nucleic acid sequence, or fragment thereof. However, other polypeptides, amino acid sequences, or nucleic acid sequences may be included that are not involved directly in the utility of the recombinant polypeptide(s). In some embodiments, the term "consisting" refers to a composition for use in the methods of the present invention having a particular recombinant polypeptide, amino acid sequence, or nucleic acid sequence, or fragment or combination of recombinant polypeptides, amino acid sequences, or nucleic acid sequences or fragments of the present invention, in any form or embodiment as described herein.
[00329] In another embodiment, the LLO protein, ActA protein, the E7, E6, or other antigen, or fragment thereof are conjugated by a means known to those of skill in the art. In another embodiment, the E7, E6, or fragment thereof is conjugated, either directly or through a linker (spacer), to the ActA protein or LLO protein. In another embodiment, the chimeric molecule is recombinantly expressed as
P-7771-PC3 a single-chain fusion protein.
[00330] In another embodiment, a fusion peptide of the present invention is synthesized using standard chemical peptide synthesis techniques. In another embodiment, the chimeric molecule is synthesized as a single contiguous polypeptide. In another embodiment, the LLO protein, ActA protein, the E7, E6, or other antigen, or fragment thereof are synthesized separately, then fused by condensation of the amino terminus of one molecule with the carboxyl terminus of the other molecule, thereby forming a peptide bond. In another embodiment, the ActA protein or LLO protein and antigen are each condensed with one end of a peptide spacer molecule, thereby forming a contiguous fusion protein.
[0033I] In another embodiment, the peptides and proteins of the present invention are prepared by solid-phase peptide synthesis (SPPS) as described by Stewart et al. in Solid Phase Peptide Synthesis,
2nd Edition, 1984, Pierce Chemical Company, Rockford, 111.; or as described by Bodanszky and
Bodanszky (The Practice of Peptide Synthesis, 1984, Springer- Verlag, New York). In another embodiment, a suitably protected AA residue is attached through its carboxyl group to a derivatized, insoluble polymeric support, such as cross-linked polystyrene or polyamide resin. "Suitably protected" refers to the presence of protecting groups on both the alpha-amino group of the amino acid, and on any side chain functional groups. Side chain protecting groups are generally stable to the solvents, reagents and reaction conditions used throughout the synthesis, and are removable under conditions which will not affect the final peptide product. Stepwise synthesis of the oligopeptide is carried out by the removal of the N-protecting group from the initial AA, and couple thereto of the carboxyl end of the next AA in the sequence of the desired peptide. This AA is also suitably protected. The carboxyl of the incoming AA can be activated to react with the N-terminus of the support-bound AA by formation into a reactive group such as formation into a carbodiimide, a symmetric acid anhydride or an "active ester" group such as hydroxybenzotriazole or pentafluorophenly esters.
[00332] In another embodiment, the present invention provides a kit to for conveniently practicing the methods of the present invention comprising one or more vaccines of the present invention, an applicator, and instructional material that describes how to use the kit components in practicing the methods of the present invention.
[00333] It is to be understood that any compositions used in any methods of the present invention may be used in the preparation of a composition for treating, preventing, inhibiting, suppressing, or ameliorating symptoms associated with, the diseases and conditions described in the present invention.
[00334] Although model methods are described below, other useful methods will be apparent to the
P-7771-PC3 skilled artisan in light of the present disclosure. Each of these methods represents a separate embodiment of the present invention.
EXPERIMENTAL DETAILS SECTION
EXAMPLE 1: LLO-ANTIGEN FUSIONS INDUCE ANTI-TUMOR IMMUNITY
MATERIALS AND EXPERIMENTAL METHODS (EXAMPLES 1-2)
Cell lines
[00335] The C57BL/6 syngeneic TC-I tumor was immortalized with HPV- 16 E6 and E7 and transformed with the c-Ha-ras oncogene. TC-I, provided by T. C. Wu (Johns Hopkins University School of Medicine, Baltimore, MD) is a highly tumorigenic lung epithelial cell expressing low levels of with HPV- 16 E6 and E7 and transformed with the c-Ha-ras oncogene. TC-I was grown in RPMI 1640, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μM nonessential amino acids, 1 mM sodium pyruvate, 50 micromolar (mcM) 2-ME, 400 microgram (mcg)/ml G418, and 10% National Collection Type Culture-109 medium at 37° with 10% CO2. C3 is a mouse embryo cell from C57BL/6 mice immortalized with the complete genome of HPV 16 and transformed with pEJ-ras. EL-4/E7 is the thymoma EL-4 retrovirally transduced with E7.
L. monocytogenes strains and propagation
[00336] Listeria strains used were Lm-LLO-E7 (hly-E7 fusion gene in an episomal expression system; Figure IA), Lm-E7 (single-copy E7 gene cassette integrated into Listeria genome), Lm-LLO-NP ("DP-L2028"; hly-NP fusion gene in an episomal expression system), and Lm-Gag ("ZY-18"; single- copy HIV-I Gag gene cassette integrated into the chromosome). E7 was amplified by PCR using the primers 5'-GGCTCGAGCATGGAGATACACC-S' (SEQ ID NO: 8; Xhol site is underlined) and 5'- GGGGACTAGTTTATGGTTTCTGAGAACA-S' (SEQ ID NO: 9; Spel site is underlined) and ligated into pCR2.1 (Invitrogen, San Diego, CA). E7 was excised from pCR2.1 by Xhol/ Spel digestion and ligated into pGG-55. The hly-E7 fusion gene and the pluripotential transcription factor prfA were cloned into pAM401 , a multicopy shuttle plasmid (Wirth R et al, J Bacterid, 165: 831, 1986), generating pGG-55. The hly promoter drives the expression of the first 441 AA of the hly gene product, (lacking the hemolytic C-terminus, referred to below as "ΔLLO," and having the sequence set forth in SEQ ID NO: 25), which is joined by the Xhol site to the E7 gene, yielding a hly-E7 fusion gene that is transcribed and secreted as LLO-E7. Transformation of a prfA negative strain of Listeria, XFL-7 (provided by Dr. Hao Shen, University of Pennsylvania), with pGG-55 selected for the retention of the plasmid in vivo (Figures 1 A-B). The hly promoter and gene fragment were generated
P-7771-PC3 using primers 5'-GGGGGCTAGCCCTCCTTTGATTAGTATATTC-S' (SEQ ID NO: 10; Nhel site is underlined) and 5'-CTCCCTCGAGATCATAATTTACTTCATC-S' (SEQ ID NO: 11 ; Xhol site is underlined). The prfA gene was PCR amplified using primers 5'- GACTACAAGGACGATGACCGACAAGTGATAACCCGGGATCTAAATAAATCCGTTT-S' (SEQ ID NO: 12; Xbal site is underlined) and 5'-CCCGTCGACCAGCTCTTCTTGGTGAAG-S' (SEQ ID NO: 13; Sail site is underlined). Lm-E7 was generated by introducing an expression cassette containing the hly promoter and signal sequence driving the expression and secretion of E7 into the orfZ domain of the LM genome. E7 was amplified by PCR using the primers 5'- GCGGATCCCATGGAGATACACCTAC-3' (SEQ ID NO: 28; BamHI site is underlined) and 5'- GCTCTAGATTATGGTTTCTGAG-S' (SEQ ID NO: 29; Xbal site is underlined). E7 was then ligated into the pZY-21 shuttle vector. LM strain 10403S was transformed with the resulting plasmid, pZY- 21-E7, which includes an expression cassette inserted in the middle of a 1.6-kb sequence that corresponds to the orfX, Y, Z domain of the LM genome. The homology domain allows for insertion of the E7 gene cassette into the orfZ domain by homologous recombination. Clones were screened for integration of the E7 gene cassette into the orfZ domain. Bacteria were grown in brain heart infusion medium with (Lm-LLO-E7 and Lm-LLO-NP) or without (Lm-E7 and ZY- 18) chloramphenicol (20 μg/ml). Bacteria were frozen in aliquots at -800C. Expression was verified by Western blotting (Figure 2).
Western blotting [00337] Listeria strains were grown in Luria-Bertoni medium at 37°C and were harvested at the same optical density measured at 600 nm. The supernatants were TCA precipitated and resuspended in Ix sample buffer supplemented with 0.1 N NaOH. Identical amounts of each cell pellet or each TCA- precipitated supernatant were loaded on 4-20% Tris-glycine SDS-PAGE gels (NOVEX, San Diego, CA). The gels were transferred to polyvinylidene difluoride and probed with an anti-E7 monoclonal antibody (mAb) (Zymed Laboratories, South San Francisco, CA), then incubated with HRP- conjugated anti-mouse secondary Ab (Amersham Pharmacia Biotech, Little Chalfont, U.K.), developed with Amersham ECL detection reagents, and exposed to Hyperfilm (Amersham Pharmacia Biotech).
Measurement of tumor growth [00338] Tumors were measured every other day with calipers spanning the shortest and longest surface diameters. The mean of these two measurements was plotted as the mean tumor diameter in millimeters against various time points. Mice were sacrificed when the tumor diameter reached 20 mm. Tumor measurements for each time point are shown only for surviving mice.
P-7771-PC3 Effects of Listeria recombinants on established tumor growth
[00339] Six- to 8-wk-old C57BL/6 mice (Charles River) received 2 x 105 TC-I cells s.c. on the left flank. One week following tumor inoculation, the tumors had reached a palpable size of 4-5 mm in diameter. Groups of eight mice were then treated with 0.1 LD5O i.p. Lm-LLO-E7 (107 CFU), Lm- E7 (106 CFU), Lm-LLO-NP (107 CFU), or Lm-Gag (5 x 105 CFU) on days 7 and 14.
51Cr release assay
[00340] C57BL/6 mice, 6-8 wk old, were immunized i.p. with 0.1LD50 Lm-LLO-E7, Lm-E7, Lm- LLO-NP, or Lm-Gag. Ten days post-immunization, spleens were harvested. Splenocytes were established in culture with irradiated TC-I cells (100:1, splenocytes:TC-l) as feeder cells; stimulated in vitro for 5 days, then used in a standard 51Cr release assay, using the following targets: EL-4, EL- 4/E7, or EL-4 pulsed with E7 H-2b peptide (RAHYNTVTF). E:T cell ratios, performed in triplicate, were 80:1, 40:1, 20:1, 10:1, 5:1, and 2.5:1. Following a 4-h incubation at 37°C, cells were pelleted, and 50 μl supernatant was removed from each well. Samples were assayed with a Wallac 1450 scintillation counter (Gaithersburg, MD). The percent specific lysis was determined as [(experimental counts per minute (cpm)- spontaneous cpm)/(total cpm - spontaneous cpm)] x 100.
TC-1-specific proliferation
[00341] C57BL/6 mice were immunized with 0.1 LD50 and boosted by i.p. injection 20 days later with 1 LD50 Lm-LLO-E7, Lm-E7, Lm-LLO-NP, or Lm-Gag. Six days after boosting, spleens were harvested from immunized and naive mice. Splenocytes were established in culture at 5 x 105/well in flat-bottom 96- well plates with 2.5 x 104, 1.25 x 104, 6 x 103, or 3 x 103 irradiated TC-I cells/well as a source of E7 Ag, or without TC-I cells or with 10 μg/ml Con A. Cells were pulsed 45 h later with 0.5 μCi [3H]thymidine/well. Plates were harvested 18 h later using a Tomtec harvester 96 (Orange, CT), and proliferation was assessed with a Wallac 1450 scintillation counter. The change in cpm was calculated as experimental cpm - no Ag cpm.
Flow cytometric analysis
[00342] C57BL/6 mice were immunized intravenously (i.v.) with 0.1 LD50 Lm-LLO-E7 or Lm-E7 and boosted 30 days later. Three-color flow cytometry for CD8 (53-6.7, PE conjugated), CD62 ligand (CD62L; MEL- 14, APC conjugated), and E7 H-2Db tetramer was performed using a FACSCalibur® flow cytometer with CellQuest® software (Becton Dickinson, Mountain View, CA). Splenocytes harvested 5 days after the boost were stained at room temperature (it) with H-2Db tetramers loaded with the E7 peptide (RAHYNIVTF) or a control (HIV-Gag) peptide. Tetramers were used at a 1/200 dilution and were provided by Dr. Larry R. Pease (Mayo Clinic, Rochester, MN) and by the NIAID Tetramer Core Facility and the NIH AIDS Research and Reference Reagent Program. Tetramer+,
P-7771-PC3
CD8+, CD62Llow cells were analyzed.
B16F0-Ova experiment
[00343] 24 C57BL/6 mice were inoculated with 5 x 105 B16F0-Ova cells. On days 3, 10 and 17, groups of 8 mice were immunized with 0.1 LD50 Lm-OVA (106 cfu), Lm-LLO-OVA (108 cfu) and eight animals were left untreated.
Statistics
[00344] For comparisons of tumor diameters, mean and SD of tumor size for each group were determined, and statistical significance was determined by Student's t test, p < 0.05 was considered significant.
RESULTS
[00345] Lm-E7 and Lm-LLO-E7 were compared for their abilities to impact on TC-I growth. Subcutaneous tumors were established on the left flank of C57BL/6 mice. Seven days later tumors had reached a palpable size (4-5 mm). Mice were vaccinated on days 7 and 14 with 0.1 LD5O Lm-E7, Lm- LLO-E7, or, as controls, Lm-Gag and Lm-LLO-NP. Lm-LLO-E7 induced complete regression of 75% of established TC-I tumors, while tumor growth was controlled in the other 2 mice in the group (Figure 3). By contrast, immunization with Lm-E7 and Lm-Gag did not induce tumor regression. This experiment was repeated multiple times, always with very similar results. In addition, similar results were achieved for Lm-LLO-E7 under different immunization protocols. In another experiment, a single immunization was able to cure mice of established 5 mm TC-I tumors.
[00346] In other experiments, similar results were obtained with 2 other E7 -expressing tumor cell lines: C3 and EL-4/E7. To confirm the efficacy of vaccination with Lm-LLO-E7, animals that had eliminated their tumors were re-challenged with TC-I or EL-4/E7 tumor cells on day 60 or day 40, respectively. Animals immunized with Lm-LLO-E7 remained tumor free until termination of the experiment (day 124 in the case of TC-I and day 54 for EL-4/E7).
[00347] Thus, expression of an antigen as a fusion protein with ΔLLO enhances the immunogenicity of the antigen.
EXAMPLE 2: LM-LLO-E7 TREATMENT ELICITS TC l SPECIFIC SPLENOCYTE
PROLIFERATION
[00348] To measure induction of T cells by Lm-E7 with Lm-LLO-E7, TC-1-specific proliferative responses, a measure of antigen-specific immunocompetence, were measured in immunized mice.
P-7771-PC3
Splenocytes from Lm-LLO-E7-immunized mice proliferated when exposed to irradiated TC-I cells as a source of E7, at splenocyte: TC-I ratios of 20: 1, 40: 1, 80: 1, and 160:1 (Figure 4). Conversely, splenocytes from Lm-E7 and rLm control-immunized mice exhibited only background levels of proliferation.
EXAMPLE 3: ActA-E7 and PEST-E7 FUSIONS CONFER ANTI-TUMOR IMMUNITY
MATERIALS AND EXPERIMENTAL METHODS
Construction of Lm-ActA-E7
[00349] Lm-ActA-E7 is a recombinant strain of LM, comprising a plasmid that expresses the E7 protein fused to a truncated version of the actA protein. Lm-actA-E7 was generated by introducing a plasmid vector pDD-1, constructed by modifying pDP-2028, into Listeria. pDD-1 comprises an expression cassette expressing a copy of the 310 bp hly promoter and the hly signal sequence (ss), which drives the expression and secretion of ActA-E7; 1 170 bp of the actA gene that comprises four PEST sequences (SEQ ID NO: 37) (the truncated ActA polypeptide consists of the first 390 AA of the molecule, SEQ ID NO: 36); the 300 bp HPV E7 gene; the 1019 bp prfA gene (controls expression of the virulence genes); and the CAT gene (chloramphenicol resistance gene) for selection of transformed bacteria clones (Sewell et al. (2004), Arch. Otolaryngol. Head Neck Surg., 130: 92-97).
[00350] The hly promoter (pHly) and gene fragment were PCR amplified from pGG55 (Example 1 ) using primer 5'-GGGGTCTAGACCTCCTTTGATTAGTATATTC-S' (Xba I site is underlined; SEQ ID NO: 14) and primer 5'-ATCTTCGCTATCTGTCGCCGCGGCGCGTGCTTCAGTTTGTTGCGC- '3 (Not I site is underlined. The first 18 nucleotides are the ActA gene overlap; SEQ ID NO: 15). The actA gene was PCR amplified from the LM 10403s wildtype genome using primer 5'- GCGCAACAAACTGAAGCAGCGGCCGCGGCGACAGATAGCGAAGAT-S' (Notl site is underlined; SEQ ID NO: 16) and primer 5'-
TGTAGGTGTATCTCCATGCTCGAGAGCTAGGCGATCAATTTC-S' (Xhol site is underlined; SEQ ID NO: 17). The E7 gene was PCR amplified from pGG55 (pLLO-E7) using primer 5'- GGAATTGATCGCCTAGCTCTCGAGCATGGAGATACACCTACA-S1 (Xhol site is underlined; SEQ ID NO: 18) and primer 5'-
A AACGGATTT ATTTAGATCCCGGGTTATGGTTTCTGAGAACA-3' (Xmal site is underlined; SEQ ID NO: 19). The prfA gene was PCR amplified from the LM 10403s wild-type genome using primer 5'-TGTTCTCAGAAACCATAACCCGGGATCTAAATAAATCCGTTT-S' (Xmal site is underlined; SEQ ID NO: 20) and primer 5'-GGGGGTCGACCAGCTCTTCTTGGTGAAG-S' (Sail site is underlined; SEQ ID NO: 21 ). The hly promoter- actA gene fusion (pHly-actA) was PCR
P-7771-PC3 generated and amplified from purified pHly DNA and purified actA DNA using the upstream pHly primer (SEQ ID NO: 14) and downstream actA primer (SEQ ID NO: 17).
[00351] The E7 gene fused to the prfA gene (E7-prfA) was PCR generated and amplified from purified E7 DNA and purified prfA DNA using the upstream E7 primer (SEQ ID NO: 18) and downstream prfA gene primer (SEQ ID NO: 21).
[00352] The pHly-actA fusion product fused to the E7-prfA fusion product was PCR generated and amplified from purified fused pHly-actA DNA product and purified fused E7-prfA DNA product using the upstream pHly primer (SEQ ID NO: 14) and downstream prfA gene primer (SEQ ID NO: 21) and ligated into pCRII (Invitrogen, La Jolla, Calif.). Competent E. coli (TOPIO'F, Invitrogen, La Jolla, Calif.) were transformed with pCRII-ActAE7. After lysis and isolation, the plasmid was screened by restriction analysis using BamHI (expected fragment sizes 770 bp and 6400 bp (or when the insert was reversed into the vector: 2500 bp and 4100 bp)) and BstXI (expected fragment sizes 2800 bp and 3900 bp) and also screened with PCR analysis using the upstream pHly primer (SEQ ID NO: 14) and the downstream prfA gene primer (SEQ ID NO: 21).
[00353] The pHly-actA-E7-ρrfA DNA insert was excised from pCRII by double digestion with Xba I and Sal I and ligated into pDP-2028 also digested with Xba I and Sal I. After transforming TOPIO'F competent E. coli (Invitrogen, La Jolla, Calif.) with expression system pActAE7, chloramphenicol resistant clones were screened by PCR analysis using the upstream pHly primer (SEQ ID NO: 14) and the downstream PrfA gene primer (SEQ ID NO: 21). A clone comprising pActAE7 was grown in brain heart infusion medium (with chloramphenicol (20 meg (microgram)/ml (milliliter), Difco, Detroit, Mich.) and pActAE7 was isolated from the bacteria cell using a midiprep DNA purification system kit (Promega, Madison, Wis.). A prfA-negative strain of penicillin-treated Listeria (strain XFL-7) was transformed with expression system pActAE7, as described in Dconomidis et al. (1994, J. Exp. Med. 180: 2209-2218) and clones were selected for the retention of the plasmid in vivo. Clones were grown in brain heart infusion with chloramphenicol (20 mcg/ml) at 37 0C. Bacteria were frozen in aliquots at -80 0C.
Immunoblot Verification of Antigen Expression
[00354] To verify that Lm-ActA-E7 secretes ActA-E7, (about 64 kD), Listeria strains were grown in
Luria-Bertoni (LB) medium at 37°C. Protein was precipitated from the culture supernatant with trichloroacetic acid (TCA) and resuspended in Ix sample buffer with 0.1 N sodium hydroxide.
Identical amounts of each TCA precipitated supernatant were loaded on 4% to 20% Tris-glycine sodium dodecyl sulfate-polyacrylamide gels (NOVEX, San Diego, Calif). Gels were transferred to
P-7771-PC3 polyvinylidene difluoride membranes and probed with 1 :2500 anti-E7 monoclonal antibody (Zymed Laboratories, South San Francisco, Calif), then with 1 :5000 horseradish peroxidase-conjugated anti- mouse IgG (Amersham Pharmacia Biotech, Little Chalfont, England). Blots were developed with Amersham enhanced chemiluminescence detection reagents and exposed to autoradiography film (Amersham) (Figure 5A).
Construction of Lm-PEST-E7, Lm-JPEST-E7, and Lm-E7epi (Figure 6A)
[00355] Lm-PEST-E7 is identical to Lm-LL0-E7, except that it contains only the promoter and PEST sequence of the hly gene, specifically the first 50 AA of LLO. To construct Lm-PEST-E7, the hly promoter and PEST regions were fused to the full-length E7 gene using the SOE (gene splicing by overlap extension) PCR technique. The E7 gene and the hly-PEST gene fragment were amplified from the plasmid pGG-55, which contains the first 441 AA of LLO, and spliced together by conventional PCR techniques. To create a final plasmid, pVS16.5, the hly-PEST-E7 fragment and the prfA gene were subcloned into the plasmid pAM401, which includes a chloramphenicol resistance gene for selection in vitro, and the resultant plasmid was used to transform XFL-7.
[00356] Lm-ΔPEST-E7 is a recombinant Listeria strain that is identical to Lm- LLO-E7 except that it lacks the PEST sequence. It was made essentially as described for Lm-PEST-E7, except that the episomal expression system was constructed using primers designed to remove the PEST-containing region (bp 333-387) from the hly-E7 fusion gene. Lm-E7epi is a recombinant strain that secretes E7 without the PEST region or LLO. The plasmid used to transform this strain contains a gene fragment of the hly promoter and signal sequence fused to the E7 gene. This construct differs from the original Lm-E7, which expressed a single copy of the E7 gene integrated into the chromosome. Lm-E7epi is completely isogenic to Lm- LLO-E7, Lm-PEST-E7, and Lm-ΔPEST-E7 except for the form of the E7 antigen expressed.
RESULTS
[00357] To compare the anti-tumor immunity induced by Lm-ActA-E7 versus Lm-LLO-E7, 2 x 105 TC-I tumor cells were implanted subcutaneously in mice and allowed to grow to a palpable size (approximately 5 millimeters [mm]). Mice were immunized i.p. with one LD50 of either Lm-ActA-E7 (5 xlO8 CFU), (crosses) Lm-LLO-E7 (108 CFU) (squares) or Lm-E7 (106 CFU) (circles) on days 7 and 14. By day 26, all of the animals in the Lm-LLO-E7 and Lm-ActA-E7 were tumor free and remained so, whereas all of the naive animals (triangles) and the animals immunized with Lm-E7 grew large tumors (Figure 5B). Thus, vaccination with ActA-E7 fusions causes tumor regression.
[00358] In addition, Lm-LLO-E7, Lm-PEST-E7, Lm-ΔPEST-E7, and Lm-E7epi were compared for
P-7771-PC3 their ability to cause regression of E7-expressing tumors. S.c. TC-I tumors were established on the left flank of 40 C57BL/6 mice. After tumors had reached 4-5 mm, mice were divided into 5 groups of 8 mice. Each groups was treated with 1 of 4 recombinant LM vaccines, and 1 group was left untreated. Lm-LLO-E7 and Lm-PEST-E7 induced regression of established tumors in 5/8 and 3/8 cases, respectively. There was no statistical difference between the average tumor size of mice treated with Lm-PEST-E7 or Lm-LLO-E7 at any time point. However, the vaccines that expressed E7 without the PEST sequences, Lm-ΔPEST-E7 and Lm-E7epi, failed to cause tumor regression in all mice except one (Figure 6B, top panel). This was representative of 2 experiments, wherein a statistically significant difference in mean tumor sizes at day 28 was observed between tumors treated with Lm- LLO-E7 or Lm-PEST-E7 and those treated with Lm-E7epi or Lm-ΔPEST-E7; P < 0.001, Student's t test; Figure 6B, bottom panel). In addition, increased percentages of tetramer-positive splenocytes were seen reproducibly over 3 experiments in the spleens of mice vaccinated with PEST-containing vaccines (Figure 6C). Thus, vaccination with PEST-E7 fusions causes tumor regression.
EXAMPLE 4: FUSION OF E7 TO LLO. ActA. OR A PEST-LIKE SEQUENCE ENHANCES E7-SPECIFIC IMMUNITY AND GENERATES TUMOR-INFILTRATING E7-SPECIFIC
CD8+ CELLS
MATERIALS AND EXPERIMENTAL METHODS
[00359] 500 mcl (microliter) of MATRIGEL®, comprising 100 mcl of 2 x 105 TC-I tumor cells in phosphate buffered saline (PBS) plus 400 mcl of MATRIGEL® (BD Biosciences, Franklin Lakes, N.J.) were implanted subcutaneously on the left flank of 12 C57BL/6 mice (n=3). Mice were immunized intraperitoneally on day 7, 14 and 21, and spleens and tumors were harvested on day 28. Tumor MATRIGELs were removed from the mice and incubated at 4 0C overnight in tubes containing 2 milliliters (ml) of RP 10 medium on ice. Tumors were minced with forceps, cut into 2 mm blocks, and incubated at 37 °C for 1 hour with 3 ml of enzyme mixture (0.2 mg/ml collagenase-P, 1 mg/ml DNAse-1 in PBS). The tissue suspension was filtered through nylon mesh and washed with 5% fetal bovine serum + 0.05% of NaN3 in PBS for tetramer and IFN-gamma staining.
[00360] Splenocytes and tumor cells were incubated with 1 micromole (mem) E7 peptide for 5 hours in the presence of brefeldin A at 107 cells/ml. Cells were washed twice and incubated in 50 mcl of anti-mouse Fc receptor supernatant (2.4 G2) for 1 hour or overnight at 4 0C. Cells were stained for surface molecules CD8 and CD62L, permeabilized, fixed using the permeabilization kit Golgi-stop® or Golgi-Plug® (Pharmingen, San Diego, Calif.), and stained for IFN-gamma. 500,000 events were acquired using two-laser flow cytometer FACSCalibur and analyzed using Cellquest Software (Becton
P-7771-PC3
Dickinson, Franklin Lakes, NJ). Percentages of IFN-gamma secreting cells within the activated (CD62L|OW) CD8+ T cells were calculated.
[00361] For tetramer staining, H-2Db tetramer was loaded with phycoerythrin (PE)-conjugated E7 peptide (RAHYNIVTF, SEQ BD NO: 22), stained at rt for 1 hour, and stained with anti- allophycocyanin (APC) conjugated MEL- 14 (CD62L) and FITC-conjugated CD8D at 4 0C for 30 min. Cells were analyzed comparing tetramer+CD8+ CD62Llow cells in the spleen and in the tumor.
RESULTS
[00362] To analyze the ability of Lm-ActA-E7 to enhance antigen specific immunity, mice were implanted with TC-I tumor cells and immunized with either Lm-LLO-E7 (1 x 107 CFU), Lm-E7 (1 x 106 CFU), or Lm-ActA-E7 (2 x 108 CFU), or were untreated (naive). Tumors of mice from the Lm-
LLO-E7 and Lm-ActA-E7 groups contained a higher percentage of IFN-gamma-secreting CD8+ T cells (Figure 7A) and tetramer-specific CD8+ cells (Figure 7B) than in Lm-E7 or naive mice.
[00363] In another experiment, tumor-bearing mice were administered Lm-LLO-E7, Lm-PEST-E7, Lm-ΔPEST-E7, or Lm-E7epi, and levels of E7-specific lymphocytes within the tumor were measured. Mice were treated on days 7 and 14 with 0.1 LD50 of the 4 vaccines. Tumors were harvested on day 21 and stained with antibodies to CD62L, CD8, and with the E7/Db tetramer. An increased percentage of tetramer-positive lymphocytes within the tumor were seen in mice vaccinated with Lm-LL0-E7 and Lm-PEST-E7 (Figure 8A). This result was reproducible over three experiments (Figure 8B).
[00364] Thus, Lm-LLO-E7, Lm-ActA-E7, and Lm-PEST-E7 are each efficacious at induction of tumor-infiltrating CD8+ T cells and tumor regression.
EXAMPLE 5: E6/E7 TRANSGENIC MOUSE PHENOTYPE: A MODEL FOR SPONTANEOUS TUMOR GROWTH AND TOLERANCE TO A TUMOR ANTIGEN
MATERIALS AND EXPERIMENTAL METHODS [00365] Several C57BL/6 mouse zygotes were injected with plasmids containing the HPV- 16 E6/E7 gene under the control of the thyroglobulin promoter (provided by M Parmentier, Brussels). Tail clippings of several litters were screened via PCR for the E6/E7 gene. The E7 gene and the thyroglobulin promoter were integrated into the majority of the progeny. Positive mosaic E7 transgenic mice were then selected for FO x wild type breeding. Subsequent Fl generations were screened, via PCR, for the presence of the E7 gene. E7 positive pups generated from FO x wt breeding pairs were selected for Fl x Fl breeding. The zygosity of Fl breeding pair derived generations was
P-7771-PC3 determined by Taqman real-time PCR and the ΔΔCt method (Charles River, 2001). Homozygous E7 transgenic mice were selected for F2 x F2 breeding. The subsequent F3 generation was screened via Taqman real-time PCR and backcrossing to confirm fidelity of homozygosity. The levels of gene copy number and transgene expression of the E7 gene was assessed for every homozygous line using Taqman real-time PCR. After 6 back-crossings, these lines were used as the parents of the colony. Transgene expression was further confirmed by appearance of thyroid hyperplasia, as described in the Results section.
RESULTS
[00366] E6/E7 transgenic mice were generated, and their phenotype assessed. The mice began to develop thyroid hyperplasia at 8 weeks and palpable goiters at 6 months. By 6 to 8 months, most mice exhibited thyroid cancer. Transgenic mice sacrificed at 3 months of age exhibited de-differentiation of the normal thyroid architecture, indicative of an early stage of cancer. The enlarged, de-differentiated cells were filled with colloid, where thyroid hormones accumulate (Figure 9).
EXAMPLE 6: E7 IS EXPRESSED IN MEDULLARY THYMIC EPITHELIAL CELLS OF E6/E7 TRANSGENIC MICE
[00367] To determine whether or not E7 was expressed in the thymus, liver, spleen, thymus and thyroid were examined for the expression of the transgene in 6 to 8 week old mice. Abundant E7 message was found in the thyroid but not in other tissues (Figure 10A). The absence of E7 message in whole thymus preparations was not indicative of lack of expression in the thymus, since the level of message of a peripherally expressed, organ-specific antigen, including thyroglobulin, has been shown to be too low to detect in whole thymocyte preparations (Derbinski, J., A. Schulte, B. Kyewski, and L. Klein. 2001. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2:1032).
[00368] Tolerance to peripheral antigens in the thymus, including thyroglobulin, is mediated by the transient expression of these genes by the autoimmune regulator (AIRE) in thymic medullary epithelial cells (mTECs), with peak expression occurring prior to birth. AIRE is a transcription factor that maintains tolerance to self. To determine whether E7 expression in the transgenic mice followed the same pattern, mTECs from E6/E7 thymi of young mice (3-5 weeks) were examined for E7 expression.
[00369] The mTECs expressed E7 message, and also expressed Cathepsin S, which is known to be expressed in mTECs (Figure 10B). Thus, E7 is expressed in the thymus of the transgenic mice,
P-7771-PC3 showing that these mice exhibit tolerance to the E7 antigen.
EXAMPLE 7: PEPTIDE-BASED VACCINES DO NOT PROTECT AGAINST TUMOR CHALLENGE IN E6/E7 TRANSGENIC MICE
[00370] As a measure of the impact of the self-expression of E7 on vaccine efficacy, E6/E7 transgenic mice were tested in a tumor protection experiment using an E7 peptide (RAHYNIVTF)-based vaccine, along with the immunostimulatory CpG sequence 1826 (Krieg AM, Yi AK, Matson S, Waldschmidt
TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. Nature 374:546). While the peptide-based vaccine protected all the wild type mice from tumor challenge, it had no impact on tumor challenge in the transgenic mouse (Figure 11). Thus, the E6/E7 mice exhibit reduced ability to reject tumor challenge, providing further evidence that they are tolerant to E7.
EXAMPLE 8; LLO AND ActA FUSIONS OVERCOME IMMUNE TOLERANCE OF E6/E7 TRANSGENIC MICE TO E7-EXPRESSING TUMORS
[00371] To test the ability of vaccines of the present invention to overcome the immune tolerance of E6/E7 transgenic mice to E7-expressing tumors, 105 TC-I cells were implanted subcutaneously (s.c.) and allowed to form solid tumors in 6-8 week old wild-type and transgenic mice 7 and 14 days later, mice were left unimmunized or were immunized i.p. with LM-NP (control), 1 x 10 cfu LM-LLO-E7 (Figure 12A) or 2.5 x 108 cfu LM-ActA-E7 (Figure 12B). The naive mice had a large tumor burden, as anticipated, and were sacrificed by day 28 or 35 due to tumors of over 2 cm. By contrast, by day 35, administration of either LM-LLO-E7 or LM-ActA-E7 resulted in complete tumor regression in 7/8 or 6/8, respectively, of the wild-type mice and 3/8 of the transgenic mice. In the transgenic mice that did not exhibit complete tumor regression, a marked slowing of tumor growth was observed in the LM- LLO-E7-vaccinated and LM-ActA-E7-vaccinated mice.
[00372] The effectiveness of vaccines of the present invention in inducing complete tumor regression and/or slowing of tumor growth in transgenic mice was in marked contrast to the inefficacy of the peptide-based vaccine. Thus, vaccines of the present invention were able to overcome immune tolerance of E6/E7 transgenic mice to E7 -expressing tumors.
EXAMPLE 9: LLO AND ActA FUSIONS REDUCE AUTOCHTHONOUS (SPONTANEOUS) TUMORS IN E6/E7 TRANSGENIC MICE
[00373] To determine the impact of the Lm-LLO-E7 and Lm-ActA-E7 vaccines on autochthonous tumors in the E6/E7 transgenic mouse, 6 to 8 week old mice were immunized with 1 x 108 Lm-LLO-
E7 or 2.5 x 108 Lm-ActA-E7 once per month for 8 months. Mice were sacrificed 20 days after the
P-7771-PC3 last immunization and their thyroids removed and weighed. This experiment was performed twice (Table 1).
[00374] Table 1. Thyroid weight (mg) in unvaccinated and vaccinated transgenic mice at 8 months of age (mg)*.
* Statistical analyses performed using Student's t test showed that the difference in thyroid weight between Lm-LLO-NP treated mice and untreated mice was not significant but that the difference between Lm-LLO-E7 and Lm-ActA-E7 treated mice was highly significant (p<0.001)
[00375] The difference in thyroid weight between Lm-LLO-E7 treated mice and untreated mice and between Lm-LLO-ActA treated mice and untreated mice was significant (p<0.001 and p<0.05, respectively) for both experiments, while the difference between Lm-LLO-NP treated mice (irrelevant antigen control) and untreated mice was not significant (Student's t test), showing that Lm-LLO-E7 and Lm-ActA-E7 controlled spontaneous tumor growth. Thus, vaccines of the present invention prevent formation of new E7-expressing tumors.
[00376] To summarize the findings in the above Examples, LLO-antigen and ActA-antigen fusions (a) induce tumor-specific immune response that include tumor-infiltrating antigen-specific T cells; and are capable of inducing tumor regression and controlling tumor growth of both normal and particularly aggressive tumors; (b) overcome tolerance to self antigens; and (c) prevent spontaneous tumor growth. These findings are generalizable to a large number of antigens, PEST-like sequences, and tumor types, as evidenced by their successful implementation with a variety of different antigens, PEST-like sequences, and tumor types.
EXAMPLE 10: LM-LLO-E7 VACCINES ARE SAFE AND IMPROVE CLINICAL INDICATORS IN CERVICAL CANCER PATIENTS
MATERIALS AND EXPERIMENTAL METHODS
[00377] Study Design: The study was an open label, non-randomized study. A total of 20 adult females with progressive, recurrent or advanced squamous cell carcinoma of the cervix were to be enrolled into the study, but only 15 patients were treated and analyzed. Lm-LL0-E7 was administered
P-7771-PC3 intravenously once every 21 days for a total of two treatments. Patients were kept in-patient for 5 days following each administration and received IV and oral ampicillin following each infusion. Follow up visits were to be conducted for the purpose of assessing safety and efficacy, and for obtaining samples for immunologic analysis according to the study plan. All patients entered into this study were to be followed until their deaths.
[00378] Inclusion criteria. All patients in the trial were diagnosed with "advanced, progressive or recurrent cervical cancer," and an assessment at the time of entry indicated that all were staged as having Stage IVB disease. All patients manifested a positive immune response to an anergy panel containing 3 memory antigens selected from candidin, mumps, tetanus, or Tuberculin Purified Protein Derivative (PPD); were not pregnant or HIV positive, had taken no investigational drugs within 4 weeks, and were not receiving steroids. Patients age 18 and older were eligible to participate in the study. Patients had histologically confirmed cervical cancer that was progressive, recurrent or advanced and was refractory to existing therapies, and a positive response to a delayed type hypersensitivity (DTH) screening panel. Patients had only one primary cancer. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky > 60%). Patients had a life expectancy greater than six months.
[00379] Protocol: Patients were administered 2 vaccinations at a 3-week interval as a 30-minute intravenous (IV) infusion in 250 ml of normal saline to inpatients. After 5 days, patients received a single course of IV ampicillin and were released with an additional 10 days of oral ampicillin. Karnofsky Performance Index, which is a measurement of overall vitality and quality of life such as appetite, ability to complete daily tasks, restful sleep, etc, was used to determine overall well-being. In addition, the following indicators of safety and general well being were determined: alkaline phosphatase; bilirubin, both direct and total; gamma glutamyl transpeptidase (ggt); cholesterol; systole, diastole, and heart rate; Eastern Collaborative Oncology Group's (ECOG)'s criteria for assessing disease progression- a Karnofsky like - quality of life indicator; hematocrit; hemoglobin; platelet levels; lymphocytes levels; AST (aspartate aminotransferase); ALT (alanine aminotransferase); and LDH (lactate dehydrogenase). Patients were followed at 3 weeks and 3 months subsequent to the second dosing, at which time Response Evaluation Criteria in Solid Tumors (RECIST) scores of the patients were determined, scans were performed to determine tumor size, and blood samples were collected for immunological analysis at the end of the trial, which includes the evaluation of IFN-γ, IL-4, CD4+ and CD8+ cell populations.
[00380] Duration of Treatment: Overall patient participation lasted for up to 11 1 days (excluding
P-7771-PC3 screening) with two treatments of LM-LLO-E7, on Day 1 and Day 22.
[00381] Criteria for Evaluation:
Safety:
[00382] Safety of LM-LLO-E7 administration was assessed through changes from a pre-dose baseline with respect to: Observation of the injection site for swelling, irritation, immune reaction or other abnormalities, 10 minutes after injection, Physical examination findings, Vital signs, Changes in laboratory parameters (hematology and serum chemistry), Presence of Listeria monocytogenes in urine, blood and stool samples, ECOG performance status, Reported adverse events.
Immunogenicity:
[00383] The immunogenicity of two doses of LM-LLO-E7 administration was to be assessed through changes from a pre-dose baseline in parameters for anti-tumoral response as assessed by flow cytometry cytokine analysis for IFN-γ and IL-4, as well as by CD4+ and CD8+ activated cells determination. Blood samples for these analyses were collected prior to the initial dosing and at weeks 3, 6, 12 and 16. However, blood samples collected during the study were tested for viability. None of the samples collected were found to yield evaluable data due to poor viability. In addition samples were missing for some patients.
[00384] Efficacy:
[00385] Tumor response, as determined by the RECIST criteria.
[00386] All patients were monitored for survival for the duration of the study.
[00387] Statistical Methods: No inferential analysis was planned for this study. Analysis was done using descriptive statistics. All analyses were conducted with SAS® version 8.2 or higher using procedures appropriate for the particular analyses.
[00388] Listeria strains: The production of LM-LLO-E7 is described in Example 1. Bacteria were passaged twice through mice prior to preparation of the working cell bank, as described in Example 12. The cell bank exhibited viability upon thawing of greater than 90%.
RESULTS
Pre-Clinical
P-7771-PC3
[00389] Prior to the clinical trial, a preclinical experiment was performed to determine the anti-tumor efficacy of intravenous (i.v.) vs. i.p. administration of LM-LLO-E7. A tumor containing 1 x 104 TC-I cells was established sub-cutaneously. On days 7 and 14, mice were immunized with either 10 LM- LLO-E7 i.p. or LM-LLO-E7 i.v. at doses of 108, 107, 106, or 105. At day 35, 5/8 of the mice that received 108 LM-LLO-E7 by either route or 107 LM-LLO-E7 i.v, and 4/8 of the mice that received 106 LM-LLO-E7 i.v, were cured. By contrast, doses of less than 107 or in some cases even 108 LM-LLO- E7 administered i.p. were ineffective at controlling tumor growth. Thus, i.v. administration of LM- LLO-E7 is more effective than i.p. administration.
Clinical trial
[00390] A phase I/II clinical trial was conducted to assess safety and efficacy of LM-LLO-E7 vaccines in patients with advanced, progressive, or recurrent cervical cancer. 5 patients each were assigned to cohorts 1-2, which received 1 x 109 or 3.3 x 109 CFU, respectively. An additional 5 patients each were assigned to cohorts 3-4, which received 1 x 1010 or 3.31 x 1010 CFU, respectively. The scheduled fourth cohort was not dosed as the dose limiting toxicity criteria was met and the study discontinued as a result following the third cohort.
Safety data
First cohort
[00391] All patients in the first cohort reported onset of mild-to- moderate fever and chills within 1-2 hours after onset of the infusion. Some patients exhibited vomiting, with or without nausea. With one exception (described below), a single dose of a non-steroidal agent such as paracetamol was sufficient to resolve these symptoms. Modest, transient cardiovascular effects were observed, consistent with, and sharing the time course of, the fever. No other adverse effects were reported.
[00392] At this late stage of cervical cancer, 1 year survival is typically 10-15% of patients and no tumor therapy has ever been effective. Indeed, Patient 2 was a young patient with very aggressive disease who passed away shortly after completing the trial.
[00393] Quantitative blood cultures were assessed on days 2, 3, and 5 post-administration. Of the 5 evaluable patients in this cohort, 4 exhibited no serum Listeria at any time and 1 had a very small amount (35 cfu) of circulating Listeria on day 2, with no detectable Listeria on day 3 or 5.
[00394] Patient 5 responded to initial vaccination with mild fever over the 48 hours subsequent to administration, and was treated with anti-inflammatory agents. On 1 occasion, the fever rose to
P-7771-PC3 moderate severity (at no time above 38.4 0C), after which she was given a course of ampicillin, which resolved the fever. During the antibiotic administration she experienced mild urticaria, which ended after antibiotic administration. Blood cultures were all sterile, cardiovascular data were within the range observed for other patients, and serum chemistry values were normal, showing that this patient had no listerial disease. Further, the anergy panel indicated a robust response to 1/3 memory antigens, indicating the presence of functional immunity (similar to the other patients). Patient 5 subsequently evidenced a response similar to all other patients upon receiving the boost.
Second cohort and overall safety observations
[00395] In both cohorts, minor and transient changes in liver function tests were observed following infusion. These changes were determined by the attending physician monitoring the trial to have no clinical significance, and were expected for a short-lived infection of bacteria that are rapidly removed from the systemic circulation to the liver and spleen. In general, all the safety indicators described in the Methods section above displayed little or no net change, indicative of an excellent safety profile.
The side effect profile in this cohort was virtually identical to that seen in the in the initial cohort and appeared to be a dose independent series of symptoms related to the consequences of cytokines and similar agents that occur consequent to the induction of an iatrogenic infection. No serum Listeria was observed at any time and no dose limiting toxicity was observed in either cohort.
Efficacy- first cohort
[00396] The following indications of efficacy were observed in the 3 patients in the first cohort that finished the trial: (Table 2).
[00397] Patient 1 entered the trial with 2 tumors of 20 mm each, which shrunk to 18 and 14 mm over the course of the trial, indicating therapeutic efficacy of the vaccine. In addition, patient 1 entered the trial with a Karnofsky Performance Index of 70, which rose to 90 after dosing. In the Safety Review Panel meeting, Sinisa Radulovic, the chairman of the Department of Oncology, Institute for Oncology and Radiology, Belgrade, Serbia presented the results to a representative of the entity conducting the trials; Michael Kurman, an independent oncologist who works as a consultant for the entity; Kevin AuIt, an academic gynecologic oncologist at Emory University who conducted the phase III Gardasil trials for Merck and the Cervarix trials for Glaxo SmithKline; and Tate Thigpen, a founder of the Gynecologic Oncology Group at NCI and professor of gynecologic oncology at the University of Mississippi. In the opinion of Dr. Radulovic, patient 1 exhibited a clinical benefit from treatment with the vaccine.
P-7771-PC3
[00398] Before passing away, Patient 2 exhibited a mixed response, with 1/2 tumors shrinking.
[00399] Patient 3 enrolled with paraneoplastic disease, (an epiphenomenon of cancer wherein the overall debilitated state of the patient has other sequelae that are secondary to the cancer), including an elevation of platelet count to 936 x 109/ml. The count decreased to 465 x 109/ml, approximately a normal level, following the first dose.
[00400] Patient 4 entered the trial with 2 tumors of 20 mm each, which shrunk to 18 and 14 mm over the course of the trial, indicating therapeutic efficacy of the vaccine. Patient 4 exhibited a weight gain of 1.6 Kg and an increased hemoglobin count of approximately 10% between the first and second doses.
Efficacy- second cohort and general observations
[00401] In the lowest dose cohort, 2 patients demonstrated the shrinkage of tumors. The timing of this effect was consistent with that observed in immunological responses, in that it followed chronologically development of the immune response. One of the 2 patients in the second cohort evaluated so far for tumor burden exhibited a dramatic tumor load reduction at a post-vaccination time point. At the start of the trial, this patient had 3 tumors of 13, 13, and 14 mm. After the 2 doses of the vaccine, 2 of the tumor had shrunk to 9.4 and 12 mm, and the third was no longer detectable.
[00402] Tumors loads for the 2 cohorts are depicted in Figure 13B. In summary, even relatively low doses of LM-LLO-E7, administered in a therapeutic regimen containing a priming injection and a single boost, achieved 3 objective responses out of 6 patients for whom data has been collected.
Third cohort - safety
[00403] Dose Limiting Toxicity: In accordance with the DLT criteria detailed in the protocol, this study was discontinued due to events of hypotension experienced by three (3) patients (Patients 01- 007, 02-006, 04-006) in the 1x1010 dosage group.
[00404] The event of hypotension, which occurred either on Day 1 or Day 22 was considered moderate in severity and was considered by the investigator to be probably related to study vaccine. All patients received concomitant medication and the event resolved the same day for (Patients 01-007 and 04-006) however Patient 02-006 exhibited hypotension for an additional 2 days.
Discussion
[00405] At this late stage of cervical cancer, 1 year survival is typically 10-15% of patients and no
P-7771-PC3 tumor therapy has ever been effective. No treatment has shown to be effective in reversing stage IVB cervical cancer. Despite the difficulty of treating cervical cancer at this stage, an anti-tumor effect was observed in 2/6 patients in Cohorts I and II. In addition, other indications of efficacy were observed in patients that finished the trial, as described hereinabove.
[00406] In conclusion, LM-LLO-E7 results in a flu-like constellation of side effects including fever, chills, nausea and vomiting in a majority of patients; These side effects were mild to moderate well tolerated in the IxIO9 and 3.3xlO9 groups; Side effects associated with drug administration were comprised primarily of a flu-like syndrome that was short lived and amenable to intervention; The relationship between liver function and LM-LLO-E7 could not be determined in this trial, although it appears that LM-LLO-E7 alone as a proximate cause of elevated LFT is unlikely; Dose limiting hypotension was observed at a dose of IxIO10' LM-LLO-E7 , at doses of IxIO9 and 3.3xlO9, can be used safely in end-stage cervical cancer.
[00407] Thus, LM-LLO-E7 is safe in human subjects and improves clinical indicators of cervical cancer patients, even when administered at relatively low doses. Additional positive results are likely to be observed when the number of booster vaccinations is increased; and/or when antibiotics are administered in smaller doses or at a later time point after infusion. Additional booster doses are very likely to further enhance the immune responses obtained. Moreover, the positive effects of the observed therapeutic immune response are likely to continue with the passage of additional time, as the immune system continues to attack the cancer.
EXAMPLE 11; SAFETY AND EFFICACY OF LM-LLO-E7 FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA STAGES II AND III
MATERIALS AND EXPERIMENTAL METHODS
Inclusion criteria
Age 18 or older and capable of providing informed consent according to federal, state and institutional guidelines.
Patients must have either Stage II or Stage III Cervical Intraepithelial Neoplasia for which surgical intervention is indicated, and for whom the disease is sufficiently indolent to allow for a 6-month treatment and observation period to occur prior to surgery.
HPV- 16 E7 positive. - Cytological evidence consistent with a diagnosis of CIN II/III.
P-7771-PC3
All patients eligible for this study must be discussed with the principal investigators and be approved by the principal investigators before study entry.
Patients must respond positively to at least 1 of the test agents used in the anergy panel described for the previous Example. A positive reaction defined by the formation of a local tissue response of at least 5 mm in sum of the orthogonal measures in reaction to the administration of a delayed hypersensitivity stimulus is required.
Exclusion Criteria
Patients who have had chemotherapy, radiotherapy, or steroids within 4 weeks prior to the initial study dose or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
Patients who have received any other investigational agents for 28 days prior to dosing.
A history of Listeriosis.
A history of prior cancer or concomitant cancer.
Patients who are immunocompromised as demonstrated by a negative result from an anergy panel screening.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Hepatitis, cirrhosis, or any other impaired hepatic function as determined by serum enzymes. - Pregnant women and women actively trying to become pregnant. Known HIV-positive patients. Penicillin allergy.
Primary safety endpoints:
Incidence and severity of observations of the administration site including swelling, irritation, immune reaction or other abnormalities.
Incidence and severity of adverse events assessed throughout the duration of the study.
Changes in clinical hematology and serum chemistry test results at each time point from dosing through week 16.
P-7771-PC3
Rate of clearance of LM-LLO-E7 from the blood, as determined by quantitative blood cultures during the inpatient portion of the study following the initial administration.
Primary efficacy endpoints:
Regression of CIN to normal upon colposcopic examination
- Regression of CIN toward normal sufficient to cancel or delay surgery
Improved cytology subsequent to surgery
Primary Immunogenicity Endpoints:
HLA typing of patients for Class I and II,
Quantification of a serum cytokine profile subsequent to dosing that corresponds with observed side effects,
Quantification of macrophage activation parameters that assess macrophage activation subsequent to dosing,
Identification of tumor-associated antigen (TAA)-specific activated T cells and quantification of T cell responses subsequent to dosing,
- Quantification of T cell subsets migrating to TAA DTH.
Immunogenicity criteria:
Serum Cytokines
IFN-γ, TNF-α, EL- 2 & IL-12 are assessed in serum of patients, collected at the following times:
Screening, Day 1. - Day 1 , pre-dose, Day 1 , 3 h post-dose, Day 1 , 12 h post-dose, Day 2, 24 h post-dose, and
Day 5.
Day 22 pre-dose, Day 22, 3 h post-dose, Day 22, 12 h post-dose, Day 23, 24 h post-dose, and Day 26
Day 43 pre-dose, Day 43, 3 h post-dose, Day 43, 12 h post-dose, Day 44, 24 h post-dose, and Day 47
P-7771-PC3
T cell responses
The following cytokine release profiles are assessed HPV- 16 E7 stimulated T cells of patients: IFN-γ, TNF-α, BL-2 & IL-4
Assays are performed on cells sampled from patients at the following times: Screening, Day 1 pre-dosing, day 22 pre-dosing, day 43 pre-dosing, day 126, and day 180
Delayed Type Hypersensitivity testing
DTH testing is conducted on the following study days: Screening, Day 5, Day 26, Day 47, Day 126 and Day 180.
Macrophage Activation
Samples for the assessment of macrophage activation are collected on the following study days and times:
Day 1 pre-dose, Day 1, 3 h post-dose, Day 1, 12 h post-dose, Day 2, 24 h post-dose, and Day 5.
- Day 22 pre-dose, Day 22, 3 h post-dose, Day 22, 12 h post-dose, Day 23, 24 h post-dose, and Day 26.
- Day 43 pre-dose, Day 43, 3 h post-dose, Day 43, 12 h post-dose, Day 44, 24 h post-dose, and
Day 47.
Vaccine Administration
[00408] LM-LLO-E7 is administered as a 30 min. i.v. infusion with each dose freshly thawed and diluted in 250 ml normal saline.
Safety review
[00409] Adverse Events are graded based on the National Cancer Institute (NCI) Common Toxicity Criteria. Dose limiting toxicity is defined as any of the following:
Non-hematologic toxicity:
1. Presumptive bacterial meningitis as determined by symptoms. 2. Persistent listeremia at day 5 and 15 after a 10-day course of antibiotics.
P-7771-PC3
3. Clinical sepsis requiring ICU admission.
4. A drop in blood pressure sufficient to warrant therapeutic intervention,
5. Hepatitis as evidenced by grade 3-4 elevation in transaminases for a minimum of 7 days..
6. Gastrointestinal toxicity of grade 3-4 despite adequate medical intervention. 7. Any Grade 3 injection site reaction.
8. Any Grade 3 or higher adverse event that cannot be attributed to cervical cancer or other concurrent illnesses.
Hematologic toxicity:
1. Absolute neutrophil count (ANC) grade 4 for a minimum of 7 days or neutropenic fever defined as Grade 4 neutropenia with temperature of > 38.50C.
2. Platelet count grade 4 or bleeding with Grade 3 platelet count.
[00410] Dose escalation to the next cohort proceeds in each case, provided that there are no Grade 3 or higher adverse events related to the therapeutic vaccine.
RESULTS
[00411] Women are enrolled that have stage II or stage III Cervical Intraepithelial Neoplasia (CIN IUIlY) who have disease that is sufficiently indolent to allow for a 6 month period of treatment and evaluation to occur prior to surgery. Patients receive 3 doses of LM-LLO-E7 at 3 week intervals as inpatients and return for follow up visits to assess their response to the vaccine, collect samples for analysis, and assess their disease. Samples for immunologic analysis are collected throughout the trial and assayed upon the completion of the study.
[00412] Safety is assessed through standard physical, hematologic and serum chemistry measures, and by blood cultures to assess serum Listeria. Immunologic activity is assessed in the areas of serum cytokine release, activated T cell responses to tumor antigen, macrophage activation, and delayed hypersensitivity responses (DTH) to tumor antigen.
[00413] Clinically, patients are grouped by primary endpoints. Namely, whether patients exhibit sufficient remission of their disease to make surgery unnecessary. Patients that do require surgery, are grouped regarding whether they exhibit lesser disease than the control group. LM-LLO-E7 reduces the fraction of women that subsequently require surgery and/or the degree of disease among those that
P-7771-PC3 require surgery.
EXAMPLE 12: PASSAGING OF LISTERIA VACCINE VECTORS THROUGH MICE ELICITS INCREASED IMMUNE RESPONSES TO HETEROLOGOUS AND
ENDOGENOUS ANTIGENS
MATERIALS AND EXPERIMENTAL METHODS
Bacterial Strains
[00414] L. monocytogenes strain 10403S, serotype 1 (ATCC, Manassas, Va.) was the wild type organism used in these studies and the parental strain of the constructs described below. Strain 10403S has an LD50 of approximately 5 x 104 CFU when injected
into BALB/c mice. "Lm- Gag" is a recombinant LM strain containing a copy of the HIV-I strain HXB (subtype B laboratory strain with a syncytia-forming phenotype) gag gene stably integrated into the listerial chromosome using a modified shuttle vector pKSV7. Gag protein was expressed and secreted by the strain, as determined by Western blot. All strains were grown in brain-heart infusion (BHI) broth or agar plates (Difco Labs, Detroit, Mich).
Bacterial Culture
[00415] Bacteria from a single clone expressing the passenger antigen and/or fusion protein were selected and cultured in BHI broth overnight. Aliquots of this culture were frozen at "70°C with no additives. From this stock, cultures were grown to 0.1-0.2 O.D. at 600 nm, and aliquots were again frozen at -700C with no additives. To prepare cloned bacterial pools, the above procedure was used, but after each passage a number of bacterial clones were selected and checked for expression of the target antigen, as described herein. Clones in which expression of the foreign antigen was confirmed were used for the next passage.
Passage of Bacteria in Mice
[00416] 6-8 week old female BALB/c (H-2d) mice were purchased from Jackson Laboratories (Bar Harbor, Me) and were maintained in a pathogen-free microisolator environment. The titer of viable bacteria in an aliquot of stock culture, stored frozen at -70 0C, was determined by plating on BHI agar plates on thawing and prior to use. In all, 5 x 105 bacteria were injected intravenously into BALB/c mice. After 3 days, spleens were harvested, homogenized, and serial dilutions of the spleen homogenate were incubated in BHI broth overnight and plated on BHI agar plates. For further passage, aliquots were again grown to 0.1-0.2 O.D., frozen at -70 0C, and bacterial titer was again determined by serial dilution. After the initial passage (passage 0), this sequence was repeated for a
P-7771-PC3 total of 4 times.
Intracellular Cytokine Stain for IFN-Gamma
[00417] Lymphocytes were cultured for 5 hours in complete RPMI-10 medium supplemented with 50 U/ml human recombinant IL-2 and 1 microliter/ml Brefeldin A (Golgistop™; PharMingen, San Diego, CA) in the presence or absence of either the cytotoxic T-cell (CTL) epitope for HTV-GAG (AMQMLKETI; SEQ ID NO: 34), Listeria LLO (GYKDGNEYI; SEQ ID NO: 35) or the HPV virus gene E7 (RAHYNIVTF (SEQ ID NO: 22), at a concentration of 1 micromole. Cells were first surface- stained, then washed and subjected to intracellular cytokine stain using the Cytofix/Cytoperm kit in accordance with the manufacturer's recommendations (PharMingen, San Diego, CA). For intracellular IFN-gamma stain, FITC-conjugated rat anti-mouse IFN-gamma monoclonal antibody (clone XMG 1.2) and its isotype control Ab (rat IgGl; both from PharMingen) was used. In all, 106 cells were stained in PBS containing 1% Bovine Serum Albumin and 0.02% sodium azide (FACS Buffer) for 30 minutes at 4 0C. followed by 3 washes in FACS buffer. Sample data were acquired on either a FACScan™ flowcytometer or FACSCalibur™ instrument (Becton Dickinson, San Jose, CA). Three- color flow cytometry for CD8 (PERCP conjugated, rat anti-mouse, clone 53-6.7 Pharmingen, San Diego, Calif.), CD62L (APC conjugated, rat anti-mouse, clone MEL- 14), and intracellular IFN- gamma was performed using a FACSCalibur™ flow cytometer, and data were further analyzed with CELLQuest software (Becton Dickinson, Mountain View, CA). Cells were gated on CD8 high and CD62Llow before they were analyzed for CD8+ and intracellular IFN-gamma staining.
RESULTS
Passaging in Mice Increases the Virulence of Recombinant Listeria Monocytogenes
[00418] Three different constructs were used to determine the impact of passaging on recombinant Listeria vaccine vectors. Two of these constructs carry a genomic insertion of the passenger antigen: the first comprises the HIV gag gene (Lm-Gag), and the second comprises the HPV E7 gene (Lm-E7). The third (Lm-LLO-E7) comprises a plasmid with the fusion gene for the passenger antigen (HPV E7) fused with a truncated version of LLO and a gene encoding prfA, the positive regulatory factor that controls Listeria virulence factors. This plasmid was used to complement a prfA negative mutant so that in a live host, selection pressures would favor conservation of the plasmid, because without it the bacterium is avirulent. All 3 constructs had been propagated extensively in vitro for many bacterial generations.
[00419] Passaging the bacteria resulted in an increase in bacterial virulence, as measured by numbers of surviving bacteria in the spleen, with each of the first 2 passages. For Lm-Gag and Lm-LL0-E7,
P-7771-PC3 virulence increased with each passage up to passage 2 (Figure 14A). The plasmid-containing construct, Lm-LL0-E7, demonstrated the most dramatic increase in virulence. Prior to passage, the initial immunizing dose of Lm-LLO-E7 had to be increased to 107 bacteria and the spleen had to be harvested on day 2 in order to recover bacteria (whereas an initial dose of 105 bacteria for Lm-Gag was harvested on day 3). After the initial passage, the standard dosage of Lm-LLO-E7 was sufficient to allow harvesting on day 3. For Lm-E7, virulence increased by 1.5 orders of magnitude over unpassaged bacteria (Figure 14B).
[00420] Thus, passage through mice increases the virulence of Listeria vaccine strains.
Passaging Increases the Ability of L. monocytogenes to Induce CD8+ T Cells
[00421] Next, the effect of passaging on induction of antigen-specific CD8+ T cells was determined by intracellular cytokine staining with immunodominant peptides specific for MHC-class I using HIV- Gag peptide AMQMLKETI (SEQ ID NO: 34) and LLO 91-99 (GYKDGNEYI; SEQ ID NO: 35). Injection of 10 CFU passaged bacteria (Lm-Gag) into mice elicited significant numbers of HIV-Gag- specific CD8+ T cells, while the same dose of non-passaged Lm-Gag induced no detectable Gag- specific CD8+ T cells. Even increasing the dose of unpassaged bacteria 100-fold did not compensate for their relative avirulence; in fact, no detectable Gag-specific CD8+ T cells were elicited even at the higher dose. The same dose increase with passaged bacteria increased Gag-specific T cell induction by 50% (Figure 15). The same pattern of induction of antigen-specific CD8+ T cells was observed with LLO-specific CD8+ T cells, showing that these results were not caused by the properties of the passenger antigen, since they were observed with LLO, an endogenous Listeria antigen.
[00422] Thus, passage through mice increases the immunogenicity of Listeria vaccine strains.
EXAMPLE 13: A PrfA-CONTAINING PLASMID IS STABLE IN AN LM STRAIN WITH A Prf A DELETION IN THE ABSENCE OF ANTIBIOTICS
MATERIALS AND EXPERIMENTAL METHODS Bacteria
[00423] L. monocytogenes strain XFL7 contains a 300 base pair deletion in the prfA gene XFL7 carries pGG55 which partially restores virulence and confers CAP resistance, and is described in United States Patent Application Publication No. 2005001 18184.
Development of protocol for plasmid extraction from Listeria
P-7771-PC3
[00424] 1 rtiL of Listeria monocytogenes Lm-LLO-E7 research working cell bank vial was inoculated into 27 mL BHl medium containing 34 Gg/mL CAP and grown for 24 hours at 37°C and 200 rpm.
[00425] Seven 2.5 mL samples of the culture were pelleted (15000 rpm for 5 minutes), and pellets were incubated at 37°C with 50 Dl lysozyme solution for varying amounts of time, from 0-60 minutes.
[00426] Lysozyme solution:
- 29 μl 1 M dibasic Potassium Phosphate
- 21 μl 1 M monobasic Potassium Phosphate
- 500 μl 40% Sucrose (filter sterilized through 0.45 /Dm filter)
- 450 μl water - 60 μl lysozyme (50 mg/mL)
[00427] After incubation with the lysozyme, the suspensions were centrifuged as before and the supernatants discarded. Each pellet was then subjected to plasmid extraction by a modified version of the QIAprep Spin Miniprep Kit® (Qiagen, Germantown, Maryland) protocol. The changes to the protocol were as follows:
1. The volumes of buffers PI, P2 and N3 were all increased threefold to allow complete lysis of the increased biomass.
2. 2 mg/mL of lysozyme was added to the resuspended cells before the addition of P2. The lysis solution was then incubated at 37°C for 15 minutes before neutralization.
3. The plasmid DNA was resuspended in 30 μL rather than 50 μL to increase the concentration.
[00428] In other experiments, the cells were incubated for 15min in Pl buffer + Lysozyme, then incubated with P2 (lysis buffer) and P3 (neutraliztion buffer) at room temperature.
[00429] Equal volumes of the isolated plasmid DNA from each subculture were run on an 0.8% agarose gel stained with ethidium bromide and visualized for any signs of structural or segregation instability.
[00430] The results showed that plasmid extraction from L. monocytogenes Lm-LLO-E7 increases in efficiency with increasing incubation time with lysozyme, up to an optimum level at approximately 50 minutes incubation.
[00431 ] These results provide an effective method for plasmid extraction from Listeria vaccine
P-7771-PC3 strains.
Replica plating
[00432] Dilutions of the original culture were plated onto plates containing LB or TB agar in the absence or presence of 34 μg/mL CAP. The differences between the counts on selective and non- selective agar were used to determine whether there was any gross segregational instability of the plasmid.
RESULTS
[00433] The genetic stability (i.e. the extent to which the plasmid is retained by or remains stably associated with the bacteria in the absence of selection pressure; e.g. antibiotic selection pressure) of the pGG55 plasmid in L. monocytogenes strain XFL7 in the absence of antibiotic was assessed by serial sub-culture in both Luria-Bertani media (LB: 5 g/L NaCl, 10 g/ml soy peptone, 5 g/L yeast extract) and Terrific Broth media (TB: 10 g/L glucose, 11.8 g/L soy peptone, 23.6 g/L yeast extract, 2.2 g/L KH2PO4, 9.4 g/L K2HPO4), in duplicate cultures. 50 mL of fresh media in a 250 mL baffled shake flask was inoculated with a fixed number of cells (1 ODmL), which was then subcultured at 24 hour intervals. Cultures were incubated in an orbital shaker at 37°C and 200 rpm. At each subculture the OD600 was measured and used to calculate the cell doubling time (or generation) elapsed, until 30 generations were reached in LB and 42 in TB. A known number of cells (15 ODmL) at each subculture stage (approximately every 4 generations) were pelleted by centrifugation, and the plasmid DNA was extracted using the Qiagen QIAprep Spin Miniprep® protocol described above. After purification, plasmid DNA was subjected to agarose gel electrophoresis, followed by ethidium bromide staining. While the amount of plasmid in the preps varied slightly between samples, the overall trend was a constant amount of plasmid with respect to the generational number of the bacteria (Figures 16A-B). Thus, pGG55 exhibited stability in strain XFL7, even in the absence of antibiotic.
[00434] Plasmid stability was also monitored during the stability study by replica plating on agar plates at each stage of the subculture. Consistent with the results from the agarose gel electrophoresis, there was no overall change in the number of plasmid-containing cells throughout the study in either LB or TB liquid culture (Figures 17 and 18, respectively).
[00435] These findings demonstrate that prfA-encoding plasmids exhibit stability in the absence of antibiotic in Listeria strains containing mutations in prfA.
EXAMPLE 14: OPTIMIZATION OF CRYOPRESERVATION CONDITIONS FOR
LISTERIA VACCINE STRAINS
P-7771-PC3
MATERIALS AND EXPERIMENTAL METHODS
[00436] An LB Research Working Cell Bank (RWCB) was produced by the following protocol: 5 ODmL samples were taken from 20OmL cultures grown in LB or TB with 34 μg/mL CAP in 2L shake flasks at several different OD60O. The 5 ODmL samples were cryopreserved using 20% v/v glycerol and frozen at less than -7O0C for one day, then were thawed and used to inoculate 50 mL of the same media used for the starter cultures. The initial growth kinetics of these cultures was measured by monitoring the ODβoo and comparing the growth curves for any sign of lag phase.
[00437] An RWCB containing 50 vials of Lm-LLO-E7, cryopreserved in mid-log phase, was produced. Cells from the original glycerol stocks, CTL 2003#0810N, were streaked out onto an LB-agar plate with 34 μg/mL CAP. After a 24-hour incubation, single colonies were selected and grown in 5mL of LB-CAP for 24 hours at 37°C, which was then used to inoculate 50 mL of LB-CAP. At an OD6Oo of 0.7, cells were cryopreserved after adding glycerol to 20% v/v. The culture was 1-mL aliquots were placed into fifty sterile cryovials and stored below -700C.
RESULTS [00438] In order to determine the optimum culture density at which to cryopreserve the L. monocytogenes strain XFL7 carrying the pGG55 plasmid (which will be referred to as Lm-LLO-E7), bacteria were grown in 200 mL (milliliter) baffled shake flasks in either LB or TB. At various 600 A optical densities (OD6Oo), 5 ODmL (i.e. the product of the OD600 reading and the volume of culture in ml) aliquots were removed, glycerol was added to 20% v/v, and the cells were frozen at -700C. After 24 h (hours) storage at -7O0C, the 5 ODmL samples were thawed and used to inoculate 50 mL of fresh media of the same type (LB or TB), and initial growth kinetics of the cultures were monitored. All the cultures immediately entered exponential growth without showing any signs of a lag phase (Figure 19). Thus, among the OD60O utilized, the highest OD60O (0.8 for LB and 1.1 for TB) were determined to be optimum for short-term cryopreservation.
[00439] Next, an LB Research Working Cell Bank (RWCB) was produced by adding 20% v/v glycerol to an 0.8 OD6Oo culture and storing below -7O0C (see Materials and Experimental Methods section above). Viability of the RWCB was determined before freezing by replica plating as described for Example 13. Vials of the RWCB were thawed after defined intervals, and viability was determined. As depicted in Figure 20, the viability in the first LB cell bank appeared to decrease from 1 x 109 to 3 x l O8 CFU/mL following storage at -7O0C.
[00440] A second and a third LB RWCB were generated, this time at OD600 of 0.72 and 0.74,
P-7771-PC3 respectively. These two RWCB exhibited viabilities ranging between 8 and 12 x 108 CFU/mL, with no decrease in viability, throughout the course of the study. The difference between these RWCB and first are likely due to difference in the OD60O at the time of cryopreservation. Thus, an optical density of 0.8 likely corresponds to the end of exponential growth and the beginning of stationary phase of Lm-LLO-E7 in. Consequently, an ODOOO of 0.7 was used subsequently. The second RWCB was assigned the number 2003#0933A and was utilized to inoculate the cultures used in subsequent experiments.
[00441] In addition, a TB RWCB was generated from cultures at an OD600 of 1.1. The number of viable cells remained stable at 1 x 109 CFU/mL (Figure 21).
[00442] These findings demonstrate that methods of the present invention (e.g. conditions of 20% glycerol and OD600 of 0.7) have utility in generating cryopreserved Listeria vaccine strains and stocks with stable long-term viability.
EXAMPLE 15: OPTIMIZATION OF MEDIA FOR GROWTH OF LISTERIA VACCINE STRAINS IN SHAKE FLASK FERMENTATIONS MATERIALS AND EXPERIMENTAL METHODS
Cultures
[00443] 50 mL volumes of each of the four different defined media were inoculated with 250 μL aliquots of the LB RWCB and incubated in 250 mL shake flasks at 37°C overnight. 20 ODmL of the 50 mL culture were then used to inoculate 200 mL of the same media in 2 L shake flasks. This type of cell propagation procedure encourages viability and exponential growth of the bacteria.
RESULTS
[00444] The growth curves of the Listeria vaccine strain in LB and TB were investigated in more detail in order to assess its growth potential. The maximum OD6O0 reached in TB and LB were 4 and 0.8 units, which correspond to about 1 x 1010 and 9 x 108 CFU/mL, respectively (Figure 22).
[00445] Experiments were then performed to develop a defined synthetic medium that could support a similar growth to that of TB. A MOPS pH buffer was used instead of a phosphate buffer because its superior buffering capacity would be appropriate for the demands of shake flask growth. The formula outlined in Table 3A below was used as the starting point. In addition to the pH buffer and standard components ("basic components"), the medium contained supplements expected to improve growth of the vaccine strain. These supplements were divided into four groups: essential compounds,
P-7771-PC3 amino acids, vitamins and trace elements.
[00446] Table 3A. Original defined media composition.
[00447] In order to determine whether supplementation with the three latter groups (amino acids, vitamins, trace elements) improved the growth of Lm-LL0-E7, bacteria were grown in 50 mL starter cultures, then in 250 mL cultures, of the following media in shake flasks:
1. Bulk medium (i.e. water plus the basic components in Table 3A), essential components, amino acids, vitamins and trace elements.
2. Bulk medium, essential components, amino acids and vitamins.
3. Bulk medium, essential components and amino acids.
4. Bulk medium and essential components. [00448] Presence of both AA and vitamins was necessary to support significant growth in the 50 mL cultures, and the presence of trace elements enhanced the growth rate (Figure 23). However, at the 200 mL stage the presence of trace elements did not influence the growth rate (Figure 24). It is possible that the trace elements supported the adaptation of Lm-LLO-E7 from the LB cell bank into the defined medium at the 50 mL stage. Based on these results, all four of the groups in Table 3A were included in the defined medium in subsequent experiments.
[00449] The next experiment investigated the effect of increasing the concentrations of the 4 groups of supplements of Table 3. The concentrations of all the components of these four groups were increased by a factor of 2 or 4 to produce "2X" and "4X" defined media, respectively. In addition, 4X defined media containing 1 , 2 or 3 g/L of inorganic nitrogen in the form of NH4SO4 were tested. The growth of these five cultures was compared to the media of Table 3A ("control") in the 50 mL- 200 mL protocol described above.
[00450] All media tested exhibited similar growth for the first four hours. At this point, the growth
P-7771-PC3 in the control media began to decelerate, stopping completely at 13 hours, while the 2X and 4X media continued to support exponential growth (Figure 25). The flasks containing the 2X and 4X media reached final ODβoo of 2.5 units and 3.5, respectively. Inclusion of NH4SO4 slightly increased final biomass concentrations, but considerably decreased the growth rate.
[00451] Thus, increasing the nutrient level, but not inclusion of NH4SO4, significantly improved the growth of the vaccine strain in defined media. Based on these results, NH4SO4 was not included in subsequent experiments.
[00452] Next, the effect in 50 mL and 200 mL cultures of the following additional modifications to the media was examined: 1) further increasing the concentration of the 4 groups of supplements from Table 3A (to 6 and 8 times the original concentration); 2) increasing the concentration of glutamine (a source of organic nitrogen) to 8 times the original concentration; and 3) removing iron from the media. As depicted in Figure 26 (results from 200 mL cultures), further increasing the concentration of either glutamine or the 4 groups of supplements did not enhance the final biomass concentration of Lm-LLO-E7. Removal of iron, by contrast, reduced the maximum biomass concentration.
[00453] The effect of increasing the glucose concentration of the 4X media was examined. Increasing glucose concentration from 10 to 15 g/L significantly improved growth rate and biomass.
[00454] The final OD600 of each of the 4X supplements was 4.5, which corresponded to 1.1 x 1010 CFU/mL, approximately the same as the final biomass obtained with TB. Thus, a defined media was developed that supported growth of a Listeria vaccine strain to the same extent as TB.
[00455] In conclusion, media containing 4x the original concentration of the four groups of supplements from Table 3A (referred to henceforth as "4X media") supported optimal growth of Lm- LLO-E7 in 50 mL and 200 mL shake flask cultures. Iron was required for optimal growth. Increasing the glucose from 10 to 15 g/L increased the total biomass achieved. The resulting optimized defined media recipe is depicted in Table 3B.
[00456] Table 3B. Optimized defined media composition.
EXAMPLE 16: OPTIMIZATION OF MEDIA FOR GROWTH OF LISTERIA VACCINE STRAINS IN BATCH FERMENTATIONS
MATERIALS AND EXPERIMENTAL METHODS [00457] FT Applikon 5/7L fermenter vessels containing 4500 mL of either TB or defined medium with 34 Dg/mL CAP were utilized in this Example. 20 ODmL of Lm-LL0-E7 was used to inoculate a 200 mL starter culture containing CAP, which was grown at 37°C in an orbital shaker at 200 rpm for 10 hours until it reached mid-log phase; 450 ODmL of this culture was used to inoculate the fermenter vessels. The temperature, pH and dissolved oxygen concentration were continuously monitored and controlled during the fermentation at levels of 37°C, 7.0, and 20% of saturation.
RESULTS
[00458] Factors such as dissolved oxygen concentration or pH likely limited the growth of Lm-LLO- E7 in the previous Example, as they are not controlled in shake flasks. Consistent with this possibility, the pH of the cultures in the shake flasks had decreased to approximately 5.5 units. In a batch fermenter, by contrast, pH and dissolved oxygen levels are continuously monitored and controlled. Thus, separate experiments were performed in this Example to optimize the media used for batch fermentations.
[00459] 200 mL cultures of Lm-LL0-E7 were grown overnight in either TB or the defined medium from Table 3B until they reached mid-log phase (OD600 of 1 - T). 450 ODmLs of the starter culture was then used to inoculate 5L batch fermenters containing the same media. The bacteria grown in the TB culture began to grow exponentially immediately upon innoculation, with a specific growth rate of 0.5 h"', then entered into a deceleration phase about 7 hours after inoculation, reaching stationary phase at a viable cell density of 2.1 x 1010 CFU/mL (Figure 27A). The bacteria grown in the defined media also exhibited exponential growth; however, the growth rate was 0.25 h"1, and the final viable cell density was 1.4 x 1010 CFU/mL. A total yield of 8.9 x 1013 CFR was obtained from the batch fermentation. Both batch fermentations entered into stationary phase as a result of carbon limitation, as evidenced by the finding that the glucose concentration had reached zero at stationary phase. Since LM cannot utilize AA as a carbon source, the cells were unable to grow in the absence of carbohydrate.
P-7771-PC3
[00460] At all densities tested, the bacteria grown in TB retained their viability throughout subsequent steps in the process (Figure 27B). Bacteria grown in defined media maintained their viability up to an OD of 3-4 (Figure 27C).
[00461] It was further found that, to prevent iron precipitation, the iron and magnesium salts could be dissolved separately in water and heated to 60° C, then filter-sterilized and simultaneously added to the fermenter culture medium.
EXAMPLE 17: FURTHER OPTIMIZATION OF CRYOPRESERVATION CONDITIONS
FOR LISTERIA VACCINE STRAINS
[00462] The next experiment examined the viability of cryopreserved Lm-LL0-E7 in the presence of each of 4 different additives: namely, glycerol, mannitol, DMSO and sucrose. PBS was used as a control. In addition, three different storage methods were compared: -200C, -7O0C, and snap freezing in liquid nitrogen followed by storage at -700C.
[00463] A shake flask containing 200 mL of the 4X media from Table 3B was grown to an ODβoo of 1.6. Fifteen 10 mL samples were pelleted by centrifugation, the supernatants removed, and the cells resuspended in 10 mL of PBS containing 2% w/v of the appropriate cryoprotectant. One mL aliquots of each resuspended sample were transferred into vials and stored using the appropriate method. Viability was measured by replica plating (with and without CAP) before storage and after 3-28 days or storage, and the percentage of viable cells remaining was calculated. 2% w/v glycerol at -70° C was found to be the best short-term cryopreservation method; with the bacteria exhibiting approximately 100% viability. The cell viability remained high over the 3-28 days under several of the conditions utilized (Figures 28-30). Listeria vaccine vectors grown in defined media effectively protect mice against growth of established tumors (Figure 31).
Conclusion- Examples 13-17
[00464] The genetic stability of the pGG55 plasmid in Lm-LLO-E7 showed no signs of structural or segregational instability after 35 or 42 cell generations. A RWCB was produced, and the viability of the cells preserved in the RWCB remained constant at approximately 1 x 109 CFU/mL after freezing and thawing. The ability of two complex media to support the growth of Lm-LLO-E7 was assessed.
LB and TB supported growth to maximum cell densities of approximately 9 x 108 and 1 x 1010
CFU/mL, corresponding to ODOOO of 0.8 and 4.0 units, respectively. A defined media that supported growth to an extent similar to TB was developed and optimized for shake flask cultivations. Lm-LLO-
E7 reached a higher biomass concentration in 5L batch fermenters compared to shake flask cultivation, likely due to the ability to control the pH in fermenters. The optimum method for
P-7771-PC3 cryopreservation of the cells was also investigated. Lm-LLO-E7 cryopreserved in PBS containing 2% w/v glycerol exhibited approximately 100% viability following storage at less than -700C for 3 days.
EXAMPLE 18: LM-LLO-E7 VACCINES AT A DOSE OF IxIO9 AND 3.3xlO9 ARE SAFE AND IMPROVE CLINICAL INDICATORS IN CERVICAL CANCER PATIENTS [00465] The regimen used was intentionally designed to be the minimal vaccine regimen; a single prime and boost dose. Stable disease was reported for 53.85% of patients in the Intent-to-Treat group, progressive disease reported in 38.5% of patients, and 1 patient (7.7%) had an objective partial response (PR). Overall, reductions in tumor mass were seen in 4 of the 13 (30.08) assessable patients, with 3 patients experiencing approximately 20% of their tumor burden and one patients experiencing a 32% reduction. This trial established a dosage ceiling of less than IxIO10 organisms/vaccination.
Objectives:
[00466] Primary objective: To establish the safety and feasibility of vaccination with live Listeria monocytogenes vaccine vector expressing Human Papilloma Virus (HPV) type 16 E7 in progressive, recurrent or advanced, squamous cell carcinoma of the cervix.
[00467] Secondary objectives: To determine the type of immunity induced delivered by the vector and its relationship to the number of organisms delivered in the vaccine and to monitor survival for the duration of the study, and to describe any responses that occurred.
[00468] Study Design: Protocol Lm-LLO-E7-01 was an open label, non-randomized study. A total of 20 adult females with progressive, recurrent or advanced squamous cell carcinoma of the cervix were to be enrolled into the study. Lm-LL0-E7 was administered intravenously once every 21 days for a total of two treatments. Patients were kept in-patient for 5 days following each administration and received IV and oral ampicillin following each infusion. Follow up visits were to be conducted for the purpose of assessing safety and efficacy, and for obtaining samples for immunologic analysis according to the study plan.
[00469] All patients entered into this study were to be followed until their deaths.
[00470] Number and type of Patients (planned and analyzed): 20 planned, 15 treated and analyzed. Patients had metastatic cervical cancer and had failed prior chemotherapy, radiotherapy, and/or surgery.
[00471] Diagnosis and Main Criteria for Inclusion: Patients age 18 and older were eligible to participate in the study. Patients must have had histologically confirmed cervical cancer that was
P-7771-PC3 progressive, recurrent or advanced and was refractory to existing therapies, and have a positive response to a delayed type hypersensitivity (DTH) screening panel. Patients must have had only one primary cancer. Patients must have had an Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky > 60%). Patients must have had a life expectancy greater than six months.
[00472] Test Product, Dose and Mode of Administration, and Lot Number(s): Lm-LLO-E7 was administered via intravenous (i.v.) infusion at three dose levels using a dose escalation design across cohorts with each patient in a cohort receiving two administrations of the same dose. The infusion occurred over 30 minutes to each study participant once every 21 days for a total of two treatments.
[00473] A scheduled fourth cohort was not dosed as the dose limiting toxicity criteria was met and the study discontinued following the third cohort as a result.
[00474] Reference Therapy, Dose and Mode of Administration, and Lot Number(s): No reference therapy was used in this study.
[00475] Duration of Treatment: Overall patient participation lasted for up to 111 days (excluding screening) with two treatments of Lm-LL0-E7, which occurred at Day 1 and Day 22.
Criteria for Evaluation:
[00476] Safety:
[00477] Safety of Lm-LLO-E7 administration was assessed through changes from a pre-dose baseline with respect to:
• Observation of the injection site for swelling, irritation, immune reaction or other abnormalities, 10 minutes after injection
• Physical examination findings,
• Vital signs,
• Changes in laboratory parameters (hematology and serum chemistry),
• Presence of Listeria monocytogenes in urine, blood and stool samples,
• ECOG performance status,
P-7771-PC3
• Reported adverse events.
Immunogenicity
[00478] The immunogenicity of two doses of Lm-LLO-E7 administration was to be assessed through changes from a pre-dose baseline in parameters for anti-tumoral response as assessed by flow cytometry cytokine analysis for IFN-γ and IL-4, as well as by CD4+ and CD8+ activated cells determination. Blood samples for these analyses were collected prior to the initial dosing and at weeks
3, 6, 12 and 16.
[00479] Blood samples collected during the study were tested for viability. None of the samples collected were found to yield evaluable data due to poor viability. In addition samples were missing for some patients.
Efficacy:
[00480] Tumor response was determined by the RECIST criteria.
[00481] All patients were monitored for survival for the duration of the study.
Statistical Methods:
[00482] No inferential analysis was planned for this study. Analysis was done using descriptive statistics. All analyses were conducted with SAS® version 8.2 or higher using procedures appropriate for the particular analyses.
Safety Results:
[00483] Overall, 15 (100%) patients experienced adverse events (AEs). The most commonly reported AEs were pyrexia, chills, anemia, headache, vomiting, nausea, tachycardia and musculoskeletal pain. Drug-related AEs were comprised of a 'flu-like' syndrome including pyrexia, vomiting, chills, headache, tachycardia, and nausea.
[00484] A total of 2 patients reported 6 serious adverse events (SAEs): 1 patient each in the 3.3x109 and I x I O10 groups, respectively. SAEs included blood amylase increased, anemia, cardiorespiratory arrest, metabolic acidosis and renal failure in the 3.3x 109 group and blood creatinine increased in the l x lO10 group. The events were considered by the investigator not to be related to study vaccine. The
P-7771-PC3 patient in the 3.3xlO9 group died due to serious AEs.
[00485] A total of 2 (40.0%), 4 (80.0%), and 3 (60.0%) patients in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively, reported severe AEs. Treatment-related AEs of interest considered severe in five (33.3%) patients were febrile disorders (pyrexia) and liver function analyses (GGT increased and lactate dehydrogenase increased).
[00486] A majority of patients had abnormal clinical chemistry and hematology values during the study. A small number of these patients were reported with clinically significant values and for some of these patients abnormalities observed can be attributed to the underlying disease. Clinically significant chemistry parameters were mainly GGT, urea and creatinine in six patients. Clinically significant hematology parameters were mainly hematocrit, Hb and RBCs in eight patients; for most of these patients, anemia was reported as an AE which was considered by the investigator to be severe in intensity but unlikely related to study vaccine.
[00487] Overall, the changes in physical examination were considered not clinically significant. A majority of abnormal physical findings were associated with the disease, cancer of the cervix. Median changes in blood pressure (decreased), heart rate (increased) and temperature (increased) over time were reported for the majority of patients seemingly consistent with their febrile responses. However, at 12 hours post dose, median values were within normal limits with no differences across treatment groups. Given the well known relationship between fever and cardiovascular physiology such that elevated temperature results in diminished blood pressure and elevated heart rate, the observations of cardiovascular AE only in the presence of pyrexia indicates that these events are likely related and that hypotension and tachycardia are likely to be epiphenomenal to the fevers reported for most of the patients.
[00488] Listeria was rapidly cleared from the blood (only one patient showed a low Listeria, count on Day 2 after dosing, what was cleared on the next day) and no shedding in the urine of feces was observed.
[00489] In accordance with the DLT criteria, this study was discontinued due to events of hypotension experienced by three (3) patients (Patients 01-007, 02-006, 04-006) in the IxIO10 group.
Efficacy Results:
[00490] A total of 38.5% of patients were reported with progressive disease while stable disease was reported in 53.85% of patients, and a partial response by RECIST criteria was observed in 1 patient
(7.69%). Partial response of target lesion was reported for Patient 04-003 (32.5% reduction in
P-7771-PC3 total lesion size) and complete response of non-target lesion was reported for Patient 01-004.
[00491] Overall, there was no reduction in mean tumor size. Interestingly, when patients were reviewed on a case-by-case basis, a reduction in total tumor size was observed in four patients. It should be noted that not all lesions were counted for Patient 03-001 on Day 79. Owing to the small sample size, statistical power could not be applied. Further evaluations on a larger sample size are needed to determine the effect of Lm-LLO-E7 on target lesions and to evaluate overall response to treatment.
[00492] There were two deaths during the protocol period of the study, although one of these patients was withdrawn from the study prior to her death. Both deaths were characterized as unrelated to administration of study drug. Three additional patients have died during survival follow up period of the study.
[00493] Overall, there were no improvements in ECOG performance status and Karnofsky Index over time.
Conclusions:
[00494] Lm-LL0-E7 results in a flu-like constellation of side effects including fever, chills, nausea and vomiting in a majority of patients; these side effects were mainly mild to moderate in intensity.
[00495] Dose limiting hypotension in this population was observed at a dose of IxIO10.
[00496] Lm-LL0-E7, at doses of IxIO9 and 3.3xlO9, can be used safely in end-stage cervical cancer patients.
[00497] Disposition of Patients
[00498] An overview of patient disposition is presented in Table 4. A total of 15 patients were enrolled into the study. Five (5) patients each received two doses of Lm-LLO-E7 IxIO9, Lm-LLO-E7 3.3xl09or Lm-LLO-E7 IxIO10 (CFU). Seven patients completed all treatment and follow-up visits; no patients in the 3.3x109 cohort completed all follow up visits. A total of eight patients were discontinued from the study due to disease progression (6 patients), investigator decision and death (1 patient each).
[00499] Two patients were granted eligibility exceptions to be enrolled into the study. One patient was enrolled in the study with creatinine value higher than allowed in inclusion/exclusion criteria (01- 001 ) and patient 02-006 had no measurable lesions at the time of study entry. Justifications for
P-7771-PC3 eligibility exceptions was provided by study investigators and approved by study sponsor.
Table 4: Patient Disposition (All Enrolled Patients)
The safety population consists of all patients who received at least one dose of study vaccine.
2 The intent-to-treat (ITT) population consists of all patients who received at least one dose of study vaccine and provided at least one efficacy assessment after the first dose.
[00500] There were two deaths reported to have occurred during protocol period (1 1 1 days): patient 04-005 and 04-004, however, this latter patient has been prematurely withdrawn from the study and information on her death was captured during the survival follow up phase. Patients 01-001 , 01-002 and 01-003 have died during the survival follow up period.
[00501] Overall, the mean age of patients participating in this study was 56 years with a range of 35 to 72 years. Caucasian women made up 53.3% of the study population; the other racial groups included in the study were Latino/Hispanic. Sixty percent (60%) of patients, overall, were postmenopausal and 40% of patients were sterile. There were no differences between the treatment sequences with reference to age, height and weight.
Medical/Surgical History
[00502] Overall, the most commonly reported significant non-cancer medical/surgical history and concurrent illness was gastrointestinal: 4 (26.7%) patients; endocrine metabolic, musculoskeletal and genitourinary: 2 ( 13.3%) patients each.
[00503] Overall, the most commonly reported significant cancer-related medical/surgical history and concurrent illness reported was genitourinary: 9 (60%) patients; gastrointestinal, renal, and
P-7771-PC3 musculoskeletal: 6 (40.0%) patients each.
[00504] Median disease duration overall was 2.0 years. A total of 13 (86.7%) patients previously received chemotherapy and all of these patients received a platinum containing compound (Listing 16.4.5.6). No prior chemotherapy given to one patient (01-003), and one patient received estrogen only (02-006). With the exception of patients 04-001 and 01-005, all patients received prior radiation (86.7%) (Listing 16.4.5.6) Six patients (40%), two from each dosage group (01-002, 01-004, 04-002, 04-004, 01-005 and 02-006) had received prior surgery for their disease.
Prior and Concomitant Medications at Screening
[00505] Overall, concomitant medications frequently used by patients at Screening were analgesics, anti-inflammatory and antirheumatic products: 5 (33%) patients; diuretics: 4 (26%) patients; drugs for acid related disorders, and psycholepetics: 3 (20.0%) patients each.
[00506] Concomitant medications most commonly used, by preferred term, were tramadol (20.0%), declofenac and omeprazole (13.3%).
[00507] With the exception of 2 subjects (Subjects 01-003 (IxIO9 group) and 02-006 (IxIO10 group), all subjects previously received platinum therapy which was stopped at least four weeks before the administration of the first study dose.
Tissue Biopsy for HPV-16E7 at Screening
[00508] With the exception of patients 04-004 and 04-005 in the 3.3x109 group who had HPV-31 positive biopsies, all other patients had HPV- 16E7 positive biopsies at Screening. The biopsy sample from Patient 02-006 in the 1x10 group was not available for this patient, since she was enrolled with no measurable lesions at study start and there was no archive sample available.
Anergy Panel and Penicillin Allergy
[00509] All patients showed a positive reaction to one to three of the following antigens: candidin, tuberculin and/or tetanus/diphtheria. No patient demonstrated an allergic reaction to penicillin.
Disease Severity
[00510] In the table below, it can clearly be seen what the national origins are of each patient in each group, when they were diagnosed, their age, disease stage at diagnosis and at the time of dosing, and their prior therapy modalities. Note that the Stage at Diagnosis was not originally called for in the
P-7771-PC3 protocol but was collected by the CRO, verified and is to be entered into the database with the next protocol amendment that
Table 5: Disease Severity
[00512] Extent of disease severity was comparable across groups. All patients, save one, had failed chemotherapy, and most had also failed surgical and radiologic therapies as well. Safety evaluation
[00513] Extent of Exposure
[00514] All 15 patients enrolled in the study received study vaccine on Day 1 and 22 as a 30 minute IV infusion in a volume of 250 mL Normal Saline.
[00515] Actual Doses Administered
[00516] It was the intent of the sponsor to administer the nominal doses of IxIO9, 3.3xlO9, IxIO10 and 3.3x10 in this study. Study vials were labeled based on the nominal doses and the actual doses were provided with the Certificate of Analysis (CoA) for each dose. The concentrations were such that each 1 ml provided a complete dose, and 1.1 ml of fill was added to allow for some excess material in order to facilitate the precise withdrawal of 1 ml.
[00517] Nominal doses are assigned based upon the optical density of the formulation at the time of manufacture, and are determined by quantifying the amount of light in the 600 nm range that is transmitted through the formulation. This rapid procedure is used because batches need to be aliquoted into containers and require freezing in order that release tests can be performed. The number of freeze thaw cycles must be minimized as it has been shown to damage the efficacy of Lm-LLO-E7. Actual concentrations are performed by diluting, plating and counting, then extrapolating the dose based upon the counts. This occurs following the initial vialing and is provided with the CoA for each dose. Since an actual dose of the lowest dose in this study is defined as 1,000,000,000 microbes a true count is not possible, therefore a rapid estimate is made for operational purposes and a more quantitative figure is provided, with the recognition that there is variability to this figure, and that the actual dose of a drug lot with a nominal dose of 1 x 109 will vary, often more than 1A of a log unit.
P-7771-PC3
[00518] The actual doses administered in this trial are provided in Table 7 below.
Table 7: Actual doses administered to patient
[00519] Note that no actual dose given exceeded the nominal doses specified.
Exposure
[00520] All patients were exposed to Lm-LLO-E7 on two occasions, days 1 and 22, for a 30 minute 250 ml infusion. As presented below, the adverse events associated with Lm-LLO-E7 appear to be a flu-like syndrome of short duration.
Table 8:Time in Study per Patient
[00521] Six patients were patients were discontinued early do to disease progression. One patient died while on study, and one patient was discontinued early as the Investigator decided to reinitiate chemotherapy and surgery. That patient is discussed hereinbelow.
Adverse Events
[00522] Summary of Adverse Events
[00523] An overview of adverse events (AEs) is presented in Table 9. All nomenclature and definitions come from the Common Terminology Criteria for Adverse Events v.3.0 (CTCAE 3.0) and use a four point grading system that ranks AE as; 1 = mild, 2 = moderate, 3 = severe, and 4 = disabling or life threatening.
Table 9:Overview of Adverse Events (Safety Population)
P-7771-PC3
1 Denotes probably or possibly related to study vaccine.
Note: The same event occurring more than once in the same patient was counted only once, using the most severe event.
[00524] All 15 patients experienced at least one AE. The most commonly reported AEs were a 'flu- like' syndrome (pyrexia, chills headache, vomiting, nausea, musculoskeletal pain), anemia and tachycardia. Overall, 60.0% of patients experienced severe AEs, with slightly more patients reported in the 3.3xlO9 (80.0%) and IxIO10 (60.0%) groups compared to patients in the IxIO9 group (40.0%).
[00525] All 15 patients experienced treatment-related AEs (probably or possibly related). The AEs considered by the investigator to be related to study vaccine were pyrexia, vomiting, chills, headache, tachycardia, nausea, hypotension, gamma-glutamyl transferase (GGT) and blood alkaline phosphatase. Of the AEs of interest, the most frequently reported were febrile disorders, nausea and vomiting symptoms, and chills.
[00526] SAEs were experienced by patient 04-005 in the 3.3x10 group and patient 01-006 in the 1x10 group. 01-006 experienced an elevated creatinine. Patient 04-005 died during her participation in this trial. She experienced a variety of grade 4 and SAE related to renal failure, metabolic derangement, and cardiac death. A relationship between these events and treatment was considered "unlikely" in all events. Additionally, patient 01 -002 in the 1 x109 and 3.3x109 group experienced a grade 4 dyspnea which was treated and responded quickly.
[00527] No AEs lead to premature discontinuation of study vaccine. However, a total of eight patients
P-7771-PC3 were discontinued from the study (IxIO9 group: two patients; 3.3xlO9 group: five patients; 1x10 io group: 1 patient. Reasons for discontinuation were disease progression (6 patients), investigator decision (one patient), and death (one patient).
Analysis of Adverse Events
[00528] AEs by System Organ Class (SOC) are presented in Table 10.
Table 10: Number (%) of Patients With AEs by SOC (Safety Population)
Lm-LLO-E7 (CFU)
IxIO9 3.3xlO9 IxIO10 Total
N=5 N=5 N=5 N=15
AEs by SOC n (%) a (%) Il (%) n (%)
General disorders and 5 (100) 5 (100) 5 (100) 15 100 administrative site conditions
Gastrointestinal disorders 4 (80) 4 (80) 5 (100) 13 (86.7)
Blood and lymphatic system 1 (20) 5 (100) 3 (60) 9 (60.0) disorders
Nervous system disorders 3 (60) 1 (20) 4 (80) 8 (53.3)
Cardiac disorders 1 (20) 5 (100) 1 (20) 7 (46.7)
Investigations 0 4 (80) 3 (60) 7 (46.7)
Metabolic and nutrition 3 (60) 1 (20) 2 (40) 6 (40.0) disorders
Musculoskeletal and 2 (40) 1 (20) 1 (20) 4 (26.7) connective tissue disorders
Vascular disorders 0 0 4 (80) 4 (26.7)
[00529] Overall, the most commonly reported System Organ Classes (SOCs) were general disorders and administration site conditions (100%), gastrointestinal disorders (86.7%), blood lymphatic and system disorders (60.0%), nervous system disorders (53.3%), cardiac disorders (46.7%), investigations (46.7%), metabolism and nutrition disorders (40%), musculoskeletal and connective tissue disorders and vascular disorders (26.7%) respectively. All other events reported were experienced by no more than one patient.
[00530] Blood and lymphatic system disorders were reported by a higher proportion of patients in the 3.3xl O9 (5 [100%] patients) and the I xI O10 (3 [60.0%] patients) compared to the I x I O9 group (1
[20%] patient). Investigations were reported by patients in the 3.3x 109 (4 [80.0%] patients) and the l x l θ'° (3 [60.0%] patients), only. Only patients in the I x I O10 group reported vascular disorders (4
P-7771-PC3
[80.0%] patients).
[00531 ] AEs by preferred term are presented in Table 11.
Table 11: Number (%) of Patients With AEs by Preferred Term (Safety Population)
Headache 3 (60.0) 1 (20.0) 4 (80.0) 8 (53.3)
Nausea 3 (60.0) 1 (20.0) 3 (60.0) 7 (46.7)
Tachycardia 1 (20.0) 5 (100) 1 (20.0) 7 (46.7)
Musculoskeletal pain 2 (40.0) 1 (20.0) 1 (20.0) 4 (26.7)
Hypotension* 0 0 3 (60.0) 3 (20.0)
Blood alkaline phosphatase 0 2 (40.0) 1 (20.0) 3 (20.0) increased
Gamma-glutamyltransferase 0 2 (40.0) 1 (20.0) 3 (20.0) increased
Anorexia 3 (60.0) 0 0 3 (20.0)
Fatigue 2 (40.0) 0 0 2 (13.3)
Abdominal pain 0 1 (20.0) 1 (20.0) 2 (13.3)
Abdominal pain upper 1 (20.0) 0 1 (20.0) 2 (13.3)
Diarrhoea 2 (40.0) 0 0 2 (13.3)
Alanine aminotransferase 0 1 (20.0) 1 (20.0) 2 (13.3) increased
Dyspnea 1 (20.0) 0 1 (20.0) 2 (13.3)
Somnolence 0 0 2 (40.0) 2 (13.3)
*Event that meets dose limiting toxicity criteria
[00532] The most commonly reported AE, overall, were pyrexia (100%), chills, anemia and headache (53.3%), vomiting (60.0%), nausea and tachycardia (46.7%), musculoskeletal pain (26.6%), hypotension, blood alkaline phosphatase increased, gamma-glutamyl transferase increased, anorexia and fatigue (20.0%).
P-7771-PC3
[00533] Slightly more patients in the 3.3xlO9 (3 [60.0%] patients) and IxIO10 (4 [80.0%] patients) groups experienced vomiting compared to the lower dose group (2 [40.0%] patients). Anemia was experienced by a greater number of patients in the 3.3xlO9 (4 [80.0%] patients) and IxIO10 (3 [60.0%] patients) groups compared to the lower dose group (1 [20.0%] patients). Five (100%) patients in the 3.3x109 group experienced tachycardia compared to one patient (20.0%) in the other treatment groups. Hypotension was experienced by patients in the IxIO10 group only (3 [60.0%] patients); this event met the dose limiting toxicity criteria (refer to Section 7.2.3.3). Blood alkaline phosphatase increased and gamma-glutamyl transferase increased were reported by patients in the 3.3xlO9 (2 [40.0%] patients) and IxIO10 (1 [20.0%] patients) groups. Anorexia was experienced by 60.0% of patients in the IxIO9 group only. Abdominal pain and alanine aminotransferase increased were experienced by one patient each in the 3.3xlO9 and IxIO10 groups only. Two (40.0%) patients in the IxIO9 group only reported fatigue and 2 patients in the 1x1010 group only reported somnolence.
[00534] Severity of Adverse Events
[00535] A majority of the patients (9 [60.0%] patients) overall reported severe AEs. A total of 4 (26.6%) and 2 (13.3%) patients reported moderate and life threatening or disabling AEs, respectively. Severe AEs were reported by a greater number of patients in the 3.3xlO9 group (4 [80.0%] patients) and the IxIO10 group (3 [60.0%] patients) compared to the IxIO9 group (2 [40.0%] patients).
[00536] Overall, the most frequently reported SOCs were general disorders and administration site conditions in 5 (33.3%) patients, blood and lymphatic disorders in 3 (20.0%) patients, investigations in 4 (26.7%) patients, gastrointestinal disorders and musculoskeletal and connective tissue disorders in 2 (13.3%) patients. All other severe/life threatening events were experienced by no more that one patient in any treatment group. Life threatening or disabling events were associated with blood and lymphatic disorders, respiratory, thoracic and mediastinal disorders, cardiac disorders, metabolism and nutrition disorders, and renal and urinary disorders.
[00537] By preferred term, the most commonly reported AEs of severe intensity were pyrexia in 3 (20.0%) patients, overall: 2 (40.0%) patients in the 3.3x 109 group and 1 (20.0%) patient in the I x IO10 group; anemia in 3 (20.0%) patients: 1 (20.0%) patient in the 1 x109 group and 2 (40.0%) patients in the I xIO10 group; gamma-glutamyl transferase increased in 2 (13.3%) patients (both patients in the 3.3x109 group); musculoskeletal pain in 2 (13.3%) patients (both patients in the 1 x109 group). All other severe events were reported by no more than one patient in any treatment group and included fatigue, generalized edema, abdominal pain, diarrhea, convulsion, blood amylase increased, blood creatinine increased, blood lactate dehydrogenase increased, lymphedema, and chest wall pain. Patient
P-7771-PC3
04-005 in the 3.3x109 group experienced elevated amylase, anemia, acidosis, renal failure and cardiac arrest. This patient died while on study. Also, Patient 01-006 in the IxIO10 group experienced a severe creatinine elevation.
Relationship of Adverse Events to Study Drug
[00538] Number of patients with AE that were ascribed by the investigator as treatment-related (possible or probable) AEs by preferred term is summarized in Table 12. The most frequently reported vaccine related events overall, were pyrexia in 15 (100%) patients; vomiting in 9 (60%) patients; chills in 8 (53.3%) patients; tachycardia and headache in 7 (46.7%) patients; nausea in 5 (33.3%) patients; gamma-glutamyl transferase increased and hypotension in 3 (20.0%) patients and blood alkaline phosphatase increased in 2 (13.3%) patients. AU other AE believed to be treatment-related were experienced by no more than one patient in any treatment group and included asthenia, fatigue, alanine amino transferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, blood lactate dehydrogenase increased, lipase increased, weight increase, anemia, somnolence, chest wall pain and rash.
Table 12: Number (%) of Patients With Most Commonly Reported Treatment Related AEs by Preferred Term
Lm-LLO-E7 (CFU)
IxIO9 3.3xlO9 IxIO10 Total
N=5 N=5 I sr=5 N=15
Treatment-related AEs by n (%) r ι (%) n (%) n (%) preferred term
Pyrexia 5 (100) 5 (100) 5 (100) 15 (100)
Vomiting 2 (40.0) 3 (60.0) 4 (80.0) 9 (60.0)
Chills 4 (80.0) 0 4 (80.0) 8 (53.3)
Headache 3 (60.0) 1 (20.0) 3 (60.0) 7 (46.7)
Tachycardia 1 (20.0) 5 (100) 1 (20.0) 7 (46.7)
Nausea 3 (60.0) 1 (20.0) 1 (20.0) 5 (33.3)
Hypotension* 0 0 3 (60.0) 3 (20.0)
Gamma-glutamyl transferase 0 2 (40.0) 1 (20.0) 3 (20.0) increased
Blood alkaline phosphatase 0 1 (20.0) 1 (20.0) 2 (13.3) increased
*Event that meets dose limiting toxicity (DLT) criteria
[00539] Severe AEs considered possibly or probably related to study vaccine were reported in six (6)
P-7771-PC3 patients as follows:
Lm-LLO-E7 IxIO9
[00540] Patients 01-001 experienced fatigue on 04 April 2006 (Day 1); no action was taken and the event resolved the same day.
Lm-LLO-E7 3.3x109
[00541] Patients 03-001 was diagnosed with GGT increased on 21 December 2006 (Day 8); no action was taken and the event was ongoing at the time of the study.
[00542] Patient 04-002 and 04-003 experienced pyrexia on 16 and 27 November 2006 (Day 22 for both), respectively; concomitant medication was administered and the event resolved the same day.
[00543] Patient 04-004 had GGT increased and blood lactate dehydrogenase increased on 11 January 2007 (Day 29). Elevated GGT was deemed to be clinically significant on study days 29 and 36, but not on study day 43, the last day of this patients study participaton. LDH values were never deemed to be significant by the investigator and returned to normal by study day 43. No action was taken and both events were ongoing at the time of the study.
Lm-LLO-E7 IxIO10
[00544] Patients 01-007 experienced pyrexia on 06 March 2007 (Day 23); concomitant medication was administered and the event resolved the same day.
[00545] Life threatening AEs were considered by the investigator not to be related to study vaccine.
[00546] A total of three (3) patients in the IxIO10 group experienced hypotension which resulted in study discontinuation as per dose limiting toxicity criteria.
[00547] Adverse Events of Interest and Dose Limiting Toxicity
[00548] An AE of interest is defined as being one that might be predicated from the known pathophysiology of Listeria infection and thus can be assessed thoroughly.
[00549] Five events of interest were body temperature perception [chills], febrile disorders, liver function analyses, nausea and vomiting symptoms, and vascular hypotensive disorders. All patients across treatment groups experienced at least one event of interest with the exception of two events of interest not reported in the 3.3x lO9 group (chills and vascular hypotensive disorders) and not reported
P-7771-PC3 in the IxIO9 group (liver function analyses and vascular hypotensive disorders). All events were considered treatment related. The most frequently reported events of interest were fever in 15 [100%] patients; nausea and vomiting symptoms in 11 (73.3%) patients: 3 (60.6%) in the IxIO9 group and 4 (80.0%) patients each in the 3.3xlO9 and IxIO10 groups; chills in 8 (53.3%) patients: 4 (80.0%) patients each in the IxIO9 and IxIO10 groups.
[00550] Dose Limiting Toxicity: In accordance with the DLT criteria detailed in the protocol, this study was discontinued due to events of hypotension experienced by three (3) patients (Patients 01- 007, 02-006, 04-006) in the IxIO10 group.
[00551] Patient 01-007 experienced a diastolic BP of 45 mm Hg 8 hours after receiving her second dose. This event was associated with a systolic BP of 75 mm Hg and a maximum elevated temperature at 3 hours post dosing of 410C.
[00552] Patient 02-006 experienced diastolic BP between 39-49 mm Hg between 2 and 12 hours following her second dose. These events were associated with systolic BP of between 76-92 mm Hg and temperatures between 37.3 to 38.7°C. Diastolic BP below 50 mm Hg was also observed in this patient on Days 23 & 24.
[00553] Patient 04-006 experienced diastolic BP of 45 mm Hg 12 hours after receiving her initial dose; associated with a systolic BP of 87 mm Hg and a temperature of 400C 3 hours post dosing. This patient also experienced diastolic BP of between 42-44 mm Hg from 3 to 10 hours after receiving her second dose, which was associated with systolic BP of between 72-86 mm Hg and temperatures between 39.2 and 37.10C. This patient also manifest diastolic BP below 50 mm Hg on Days 2, 8 and 23.
[00554] The event of hypotension, which occurred either on Day 1 or Day 22 was considered moderate in severity and was considered by the investigator to be probably related to study vaccine. All patients received concomitant medication and the event resolved the same day for (Patients 01 -007 and 04-006) however Patient 02-006 exhibited hypotension for an additional 2 days.
[00555] Grade 3 fevers were reported in 5 patients. Severe fevers occurred in all dosage groups, were treated immediately upon occurrence, and none persisted for over a 1 hour duration. Patient 04-001 in the I x I O9 group experienced a fever of 40.10C 2 hours after receiving her first dose. Patient 04-002 in the 3.3x 109 group experienced a fever of 40.50C 3 hours after receiving her first dose, and a fever of 40.20C 3 hours after receiving her second dose. Patient 04-003 experienced a fever of 40.10C in the 3.3x lO9 group 2 hours after receiving her second dose. Patient 01 -007 in the l xl O10 group experienced
P-7771-PC3 a temperature of 410C 3 hours after receiving her second dose.
[00556] Two other patients in the 3.3xlO9 group exhibited severe AE of interest manifest as changes seen in the liver function analyses. Patient 03-001 experienced a severe elevation of GGT first observed on day 8 after receiving the first dose which had resolved by the time of the second dose, and reoccurred on Day 29 following the second dosing on Day 22. Patient 04-004 manifest significant elevations of ALT and GGT on Day 22, prior to receiving the second dose that was not present on Day 15. The severe elevation in GGT, but not ALT, was present on Day 29 and 36, but was no longer severe on Day 43, the last day of this patient's participation in the trial. All other events of interest were mild or moderate in severity.
[00557] Time from first dose to any AEs of interest was a median of 1 day after the first dose of treatment was reported for the majority of AEs of interest.
[00558] Time from second dose to any AEs of interest followed a simlar pattern to those seen following first dose.
[00559] With regard to time from first dose to any AEs of interest with maximum severity, a median of 22 days was reported for the IxIO9 and 3.3xlO9 groups and 1 day reported for the IxIO10 group.
Listing of Adverse Events by Patient
Deaths
[00560] One patient (Patient 04-005) died during the active study participation. This death was due to renal failure, metabolic acidosis and cardiac arrest. Results are summarized in Section 7.3.1.2 and a narrative presented is in Section 7.3.2. One patient has died during the protocol period of 111 days (04-004), but subsequent to being withdrawn from the study for disease progression. Up to the date of data base lock (August 31 , 2007) three patients (01-001 , 01-002, and 01-003 have died during the survival follow up period that is ongoing every three months.
[00561] The death on study of 04-005 was ascribed by the attending physician as resulting from Tumor Lysis Syndrome (TLS). Her final lab examination occurred on Day 29 following the administration of her second dose on Day 22. She had a elevated creatinine on Day 8 and Day 15 after her initial dose. On the day of her second dose she presented with clinically significant abnormal
CO2/Bicarbonate, Urea/Bun, Creatinine which continued through Day 29, at which time Amylase &
Lipase were also elevated. During this time, this patient lost much of her renal function, became very acidotic, and suffered a fatal coronary. TLS is often associated with elevated potassium and/or
P-7771-PC3 phosphates, which were not observed in this case.
Other Serious Adverse Events
[00562] All SAEs experienced by Patient 04-005 in the 3.3xlO9 group were considered life- threatening but unlikely related to study vaccine. These consisted of renal failure, acidosis, and subsequent fatal cardiac failure. The SAE experienced by Patient 01-006 in the IxIO10 group which were comprised of anemia and elevated serum creatinine, were considered severe but unlikely related to study medication.
Other Significant Adverse Events
[00563] Patients with severe AEs related to study vaccine and DLTs resulting in study discontinuation are listed in Table 13 and Table 14, respectively.
P-7771-PC3 Table 13: Patients With Severe Treatment-Related AEs
MedDRA Preferred Visit; Relations Term Onset/S hip to
Patie Age (years) (Investigator top Intens Action Outco Study nt No. Race Term) Date ity Taken me Drug
Lm-LLO-E7 1x10"
01- 63 Fatigue (fatigue) Day 1 ; Severe No action Resolve Possible 001 Caucasian 04Apr06 taken d
I
I
04Apr06
01- 70 Chest wall pain Day 6; Severe No action Resolve Possible 003 Caucasian (pain / chest lOMayO taken d wall) 6 / lOMayO 6
Lm-LLO-E7 3.3xlOy
03- 43 GGT increased Day 8; Severe No action Ongoin Possible 001 Latino/Hi spa (elevation of 21Dec0 taken g nic GGT) 6
04- 72 Pyrexia (fever) Day 22; Severe Concomit Resolve Probable 002 Latino/Hi spa 16NovO ant d nic 6 / Medicati 16NovO on 6
04- 56 Pyrexia (fever) Day 22; Severe Concomit Resolve Probable 003 Latino/Hi spa 27NovO ant d nic 6 / Medicati 27NovO on 6
04- 55 GGT increased Day 29; Severe No action Ongoin Possible 004 Latino/Hispa (elevation of l lJanO7 taken g nic GGT) Blood lactate Day 29; Severe No action Ongoin Possible dehydrogenase l lJanO7 taken g increased (LDH elevated)
Lm-LLO-E7 IxIO10
01- 36 Pyrexia (fever) Day 23; Severe Concomit Resolve Probable 007 Caucasian O6MarO ant d 1 1 medicatio 06Mar0 n 7
GGT = = Gamma-glutamyl transferase; LDH = Lactate dehydrogenase
P-7771-PC3 Table 14: Patients With Hypotension Leading to Study Discontinuation
MedDRA Preferred Relations Term Visit; hip to
Patie Age (yrs) (Investigator Onset/St Intensi Action Outco Study nt No. Race Term) op Date ty Taken me Drug
Lm-LLO-E7 lxlθiυ
01- 36 Hypotension* Day 23; Modera Concomit Resolve Probable 007 Caucasian (hypotension) O6MarO7 te ant d I medicatio 06Mar07 n
02- 38 Hypotension* Day 22; Modera Concomit Resolve Probable 006 Caucasian (hypotension) HApr07 te ant d / medicatio 15Apr07 n
04- 68 Hypotension* Day 22; Modera Concomit Resolve Probable 006 Latino/Hi spa (hypotension) 08Mar07 te ant d nic / medicatio O8MarO7 n
*DLT criteria met
[00564] Narratives of Deaths, Other Serious Adverse Events, and Certain Other Significant Adverse Events
[00565] Narratives for those patients reported with AEs considered by the investigator to be serious, are presented in this section.
[00566] Patient 04-005 - Renal Failure / Metabolic Acidosis 3.3xlO9 Group
[00567] This 62-year old Hispanic female patient with a history of gastritis (since November 2006), hydronephrosis bilateral (since April 2006), bilateral dilated ureters (since April 2006), Anemia (since April 2006), lymphedema right pelvic member (since April 2006), was diagnosed with progressive, recurrent and advanced squamous cell cancer of the cervix (unresectable; Stage lib) in December 2004. She received her last radiation therapy on 01 June 2005 and chemotherapy (Carboplatin) on 12 October 2006. She was enrolled in the study on 24 November 2006. On 14 December 2006, she received her first dose of study vaccine (3.3x10 cfu Lm-LLO-E7).
[00568] On 19 January 2007 (Day 38) the patient was admitted to hospital with signs and symptoms of renal failure with consequent metabolic acidosis. The patient was reported with blood amylase increased, anemia, and abdominal pain. The patient was administered sodium bicarbonate 5OmEq i.v. and nalfufin (Nalbuphine) 10 mg i.v. for metabolic acidosis and pain, respectively. The same day the patient experienced cardio-respiratory arrest and died. In the opinion of the Investigator, abdominal
P-7771-PC3 pain was due to tumor lysis syndrome, renal failure was likely a result of hydronephrosis, as expected, and death was bought on by renal failure, metabolic acidosis and cardiac arrest. She was WNL at screening, however on the day of the 1st dosing she presented with elevated Urea/BUN and creatinine. Her Creatinine remained elevated on Days 8 and 15, and on Day 22 she presented with clinically significant changes in creatine, BUN and bicarbonate, which persisted on day 29. On Day 29, her last study visit, amylase and lipase were also significantly elevated. On day 22 she also presented with clinically significant decreases in RBC, Hb and hematocrit which were gone by Day 29, however on this day she presented with clinically significant decreases in WBC and absolute neutrophils. She expired shortly thereafter.
[00569] The investigator considered the events to be serious due to death, severe (blood amylase increased) to life-threatening (metabolic acidosis, anemia, abdominal pain, renal failure and cardiorespiratory arrest) in intensity and not related to study vaccine.
[00570] Concomitant medication used to treat the event: iv fluids with Sodium bicarbonate and Nalbuphine.
Table 15
♦Normal range; *Clinically significant
V=Visit; H=High, above normal range; L= Low, below normal range.
P-7771-PC3
[00571] Patient 01-006 - Blood Creatinine Increased lxlθ Λiioυ Group
[00572] This 62-year old Caucasian female patient with a history of benign ovarian cyst (surgically removed in January 1977), herpes zoster of the right leg (April 2006), blood and mucus in the stool (since December 2006), was diagnosed with progressive, recurrent and advanced squamous cell cancer of the cervix (metastatic and unresectable; stage IIIB) on 27 December 2005. She received her last radiation therapy on 07 March 2006 and chemotherapy (Cisplatin) on 02 August, 2006. She was enrolled in the study on 09 January 2007. On 31 January 2007, she received her first dose of study vaccine (IxIO10 cfu Lm-LLO-E7).
[00573] On 07 March 2007(Day 36) the patient presented with increased blood creatinine and was hospitalized the next day. On 15 March a percutaneous nephrostomy (PCN) was placed in the patient resulting in a decrease in blood creatinine. In the investigator's opinion, this event of severe intensity was due to hospitalization, but unlikely related to study vaccine. On lOMarch 2007 (Day 39) the patient received a single transfusion of red blood cells to treat anemia which started on the 09 March
2007. The event, which lasted three days, was considered severe, but unlikely related to study vaccine. On 12 March 2007 (Day 41), the patient was treated with one dose of phenobarbital for convulsion
(seizures) which stopped the same day. An endocranial CT scan performed on the 20 March 2007 showed no signs of CNS metastases. An abdominal and pelvic scan and a supraclavicular ultrasound performed on 21 March 2007 (Day 50) showed disease progression. In the opinion of the investigator, the event was severe, unlikely related to study vaccine, but was associated with anemia (an underlying disease progression). The patient was discharged from the hospital on 28 March 2007 with PCN still in place and all events had resolved.
[00574] Concomitant medication and interventions used to treat the event: Phenobarbital, Blood transfusion and Percutaneous nephrostomy.
Table 16
*Normal range; •=*Clinically significant
V=Visit; H=High, above normal range; L= Low, below normal range.
[00575] Analysis and Discussion of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events
[00576] One death was reported during this study and 4 other deaths were reported in the post study CRF pages. A total of 2 patients reported 6 serious AEs: 1 patient each in the 3.3xlO9 and IxIO10 groups, respectively (Section 7.3.1.2). SAEs included blood amylase increased, anemia, cardiorespiratory arrest, metabolic acidosis and renal failure in the 3.3x109 group and blood creatinine increased in the IxIO10 group.
[00577] All SAEs were considered not related to study drug.
[00578] The only death that occurred to a patient enrolled n the trial was patient 04-005, who experienced sever or life threatening increase in blood amylase, anemia, metabolic acidosis and succumbed to cardiac arrest. . A narrative is presented in Section 7.3.2
[00579] Similarly, the narrative for patient 01-006 in the IxIO10 group, who experienced an SAE of elevated BUN and creatinine on Days 36 and 43, and an elevated creatinine through the end of the trial, is found in section 7.3.2.
[00580] Neither of these 2 SAE are believed to be related to Lm-LLO-E7.
[00581] A total of five (33.3%) patients reported severe AEs defined apriori to be of interest (febrile disorders, and liver function analyses): 4 (80.0%) patients in the 3.3x109 group and 1 (20.0%) patient in the 1x10 group. The events were considered related to study vaccine.
P-7771-PC3
[00582] DLT events of hypotension were reported by 3 patients in the IxIO10 group. The events resulted study discontinuation, as per protocol.
[00583] No patient experienced an AE that lead to permanent discontinuation of study drug.
Clinical Laboratory Evaluation
Laboratory Values Over Time
[00584] A majority of patients displayed abnormal clinical chemistry and/or hematology values during the study. Most of these laboratory abnormalities were not considered clinically significant by the investigators.
Individual Patient Changes
Clinical Chemistry
[00585] A clinically significant shift in clinical chemistry from baseline (Screening) was reported for CC^/bicarbonate, urea (BUN), creatinine, alkaline phosphatase, ALT, and GGT. No clinically significantly abnormal values were reported for urea (BUN), Cθ2/bicarbonate, alkaline phosphatase, ALT and GGT at baseline. Clinically significant values were reported in no more than three patients.
Hematology
[00586] A clinically significant shift in hematology from baseline was reported for RBCs, Hb, hematocrit, WBC, and absolute neutrophil count (ANC). There were no clinically significant baseline values.
Individual Clinically Significant Abnormalities
[00587] The majority of clinically significant laboratory values were GGT, creatinine and urea (BUN), hemoglobin, hematocrit, a number of which can be attributed either to the underlying disease or as a consequence of prior chemotherapy.
Clinical Chemistry
[00588] Clinically significantly abnormal chemistry values were reported in a total of six patients (Table 17): Patients 01-001 in the I xIO9 group, Patients 04-004, 04-005, 03-001 in the 3.3x lO9 group and Patients 01-005, 01-006 in the Ix 1010 group.
P-7771-PC3 Table 17: Patients With Clinically Significant Chemistry Values
03-001 Day 8 21 Dec GGT Severe GGT increased, reported as
2006 an AE
Day 15 27 Dec GGT Event ongoing
2006 Day 29 11 Jan GGT Event ongoing (non-significant on
2007 Day 43)
04-004 Day 22 04 Jan AP, ALT, GGT Enzymatic elevations without
2007 clinical correlation Day 29 1 1 Jan GGT Reactive hepatitis; GGT increased
2007 reported as an ongoing AE
Day 36 20 Jan GGT Reactive hepatitis
2007
04-005 Day 1 14 Dec Urea, Clinically significant values caused
2006 Creatinine by hydronephrosis and bilateral dilated ureters
P-7771-PC3
Day 15 28 Dec Urea, Hydronephrosis bilateral and
2006 Creatinine progressive renal failure
Day 22 04 Jan CO2/bicarbonat The cause was renal failure in
2007 e, urea, progress; severe metabolic acidosis creatinine reported as an AE.
Day 29 11 Jan CO2/bicarbonat Renal failure in progress with
2007 e, urea, metabolic acidosis and reactive creatinine, pancreatitis; severe blood amylase amylase, lipase reported as a SAE
Lm-LLO-E7 (CFU):
GGT = gamma-glutamyl transferase; ALT = Alanine-amino transferase; AP = alkaline phosphatase
Hematology
[00589] Clinically significantly abnormal hematology values were reported in a total of eight patients (Table 18): Patient 01-003 in the IxIO9 group, Patients 03-001, 04-002, 04-003, 04-004, 04-005 in the 3.3x109 group, and Patients 01-005 and 01-006 in the IxIO10 group.
[00590] Table 18: Patients With Clinically Significant Hematology Values
Patient Study Day Date Lab Clinically Comments ID done Significant Labs
Lm-LLO-E7 (CFU): IxIO9
01-003 Day 1 1 1 23 Aug Hb and AE of severe anemia reported 2006 hematocrit
P-7771-PC3
Lm-LLO-E7 (CFU): 3.3xlO9
01-005 Day 79 03 May RBC, Hb, AE reported 2007 hematocrit 01-006 Day 43 14 Mar RBC5 Hb AE reported 2007
Day 79 18 Apr Hb AE reported 2007
Day 111 16 May RBC, Hb, AE reported 2007 hematocrit
RBC = red blood cell; WBC = white blood cell Hb = ] lemoglobin; ANC = Absolute neutrophil count
[00591] Reported decreases in hemoglobin values could be attributed to underlying disease and other causes not related to administration of study drug (e.g. prior platinum therapy), so any relationship to investigational product should be investigated further in future studies.
[00592] Vital Signs, Physical Findings, and Other Observations Related to Safety
[00593] Vital Signs and Weight
100594] Vital signs and Weight were measured.
[00595] Day 1 Pre and Post Dosing
|00596] A consistent finding in all treated patients was increased body temperature,
P-7771-PC3 decreased blood pressure, increased heart rate, and increased respiration rate beginning shortly after dosing and continuing for some hours post dosing. These events were well tolerated in the lower 2 dosage groups and responded to non-prescription agents. In the IxIO10 group, the highest dose given, dose limiting hypotension was observed that required fluids, which resolved these matters quickly.
[00597] Overall, median systolic BP was 130.3 mm Hg, pre-dose, with group medians of 110.0, 140.0, 129.0 mm Hg in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively. Overall, there was a gradual decrease in median values over time i.e. from 1 hour post dose (129 mm Hg) to 8 hours post dose (93.0 mm Hg), followed by a slight increase at 10 and 12 hours post dose (95 and 100.0 mm Hg, respectively). At 12 hours post dose, median values were similar across treatment groups: 100.0, 91.0, and 99.0 mm Hg in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively. No severe changes in systolic BP were observed.
[00598] Overall, median diastolic BP was 77.0 mm Hg, pre-dose: 75.0, 90.0 and 72 mm Hg in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively. Overall, there was a gradual decrease in median diastolic BP over time. i.e. from 1 hour post dose (75 mm Hg) to 6 hours post dose (60.0 mm Hg). From 8 to 12 hours post dose, overall values remained consistent, at 60.0 mm Hg. At 12 hours post- dose median diastolic BP was 60.0 mm Hg in the IxIO9, 3.3xlO9 and IxIO10 groups. Clinically significant severe AE in diastolic BP were noted during this trial, and are presented in section 7.2.3.3.
[00599] Overall, median heart rate was 82.0 beats per minute (beats/min) pre dose: 72.0, 90.0, 78.0 beats/min in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively. Overall, there was a gradual increase in median heart rate from 1 hour post dosing (86.0 beats/min). A Median increase in heart rate, peaking at 3 hours post dose (110.0 beats/min) was followed by a gradual decrease to 96.0 beats/min, at 12 hours post-dose. Trends were similar across treatment groups. At 12 hours post dose, median values were similar across treatment groups: 96.0, 97.0, 93.0 in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively. No significant heart rate AE were observed during this trial.
[00600] Median respiratory rate was similar across treatment groups, pre-dose: 18.0, 20.0 and 18.0 in the I xIO9, 3.3x109 and IxIO10 groups, respectively. There were minimal changes at the different time points post dosing, with similar values observed across treatment groups. No significant respiratory rate AE were observed during this trial.
[00601] Overall, median temperature (0C) was 36.20C, pre-dose, with results similar across treatment groups. Median temperature increased from 37.8 (2 hours post dose) to 38.9 (4 hours post dose), followed by a gradual decrease from 37.7 (6 hours post dose) to 37.0 (12 hours post dose).
Temperature was >37.5 0C from 2 to 10 hours post dosing in the lxlO10 group, from 2 to 6 hours post
P-7771-PC3 dosing in the 3.3xlO9 group and from 3 to 6 hours post dosing in the IxIO9 group. At 12 hours post dose, median temperature was 37.0, 36.8 and 37.5 0C in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively. Clinically significant severe AE in body temperature were noted during this trial.
[00602] Pre-dose weight was similar across treatment groups, with an overall median of 64.0 Kg.
Day 22 Pre and Post Dosing
[00603] At Day 22, trends similar to vital signs and weight measured on Day 1 pre and post dosing were observed, except for the following:
[00604] Overall, there was an increase in median systolic BP, from 122.0 mm Hg (pre-dose) to 130 mm Hg (post-dose), 1 hour after dosing; median increase was due to large changes observed in the 1x109 dose group. Median values overall decreased from 1 hour onwards in a similar fashion to those described following dosing on Day 1. During this phase of treatment, three (3) patients in the IxIO10 group experienced hypotension.
Physical Findings
[00605] A small number of patients were reported with normal to abnormal physical examinations during the study. Abnormal physical findings reported were general appearance; head, eyes, ears, nose and throat; neck; lymph nodes; breasts, abdomen; neurological and musculoskeletal. Most of the normal to abnormal physical findings are likely attributed to the progression of the underlying disease, cancer of the cervix.
Injection Site Evaluation
[00606] No patient experienced swelling, irritation or an immune response at the injection site.
Blood, Urine and Stool Cultures
[00607] A blood sample from only one patient (Patient 01-001 in the IxIO9 group) on Study Day 2 was positive for Listeria (35 cfu/mL), which had cleared by Study Day 3.
[00608] Urine and stool testing was added to the protocol as part of amendment #5 and many patients had been enrolled prior to this amendment. No patient in the 1x109 cfu group was tested under this amendment. Two patients in the 3.3x109 cfu group (04-004 and 04-005) and 3 patients in the 1x109 cfu group (01 -005, 02-006, and 04-006) had fecal samples tested as described in Listing 16.4.4.6, and no samples were positive. The same patients provided samples for urine testing, and no Listeria was
P-7771-PC3 present in any sample (Listing 16.4.4.5). Thus, no Listeria was present in urine and stool cultures of any of the patients 5 patients in the two highest dose groups tested.
Concomitant Medication
Non-cancer related concomitant medications
[00609] Non-cancer related concomitant medications were used by 3 (60%) patients in the 3.3xlO9 cohort only; the medication by WHO ATC class level 2 were anti-inflammatory and antirheumatic products, antiviral agents for systemic use and drugs for functional gastrointestinal disorders.
[00610] There was no dose-related use of concomitant medications.
Cancer-related concomitant medications
[00611] Frequently reported cancer-related concomitant medications by WHO drug ATC category were analgesics: 15 (100%) patients; blood substitutes and perfusion solutions, drugs for functional gastrointestinal disorders: 7 (46.7%) patients each; antihistamines for systemic use, laxatives: 6 (40.0%) patients each; antianemic preparations: 5 (33.3%) patients, and antibacterials for systemic use: 4 (26.7%) patients. 100% of patients in the IxIO10 group received blood substitutes and perfusion solutions, and drugs for functional gastrointestinal disorders compared one to two patients in the lower dose groups. A greater percentage of patients in the 3.3xlO9 group (80.0%) received antianemics compared to patients in the Ix 1010 (20.0%) and 1x109 (0%) group. Results are summarized in Table 19.
[00612] Drugs for functional gastrointestinal disorders were taken mainly for vomiting and nausea which were, for the most part, treatment-related events. Patients with severe anemia (not related to study vaccine) were also administered drugs for functional gastrointestinal disorders.
Table 19 Commonly Reported Cancer Related Concomitant Medication by WHO Drug ATC Category
P-7771-PC3
Lm-LLO-E7 (CFU)
IxIO9 3.3xlO9 lxlO10 Total
N=5 N=5 1 Sf=S N=15
Cancer-related concomitant n (%) n (%) n (%) n (%) medications (WHO ATC class level 2)
Patients used cancer related 5 (100) 5 (100) 5 (100) 15 (100) conmeds
Analgesics 5 (100) 5 (100) 5 (100) 15 (100)
Blood substitutes and perfusion 1 (20.0) 1 (20.0) 5 (100) 7 (46.7) solutions
Drugs for functional 2 (40.0) 0 5 (100) 7 (46.7) gastrointestinal disorders
Antihistamines for systemic use 1 (20.0) 3 (60.0) 2 (40.0) 6 (40.0)
Laxatives 3 (60.0) 0 3 (60.0) 6 (40.0)
Antianemic preparations 0 4 (80.0) 1 (20.0) 5 (33.3)
Antibacterials for systemic use 1 (20.0) 0 3 (60.0) 4 (26.7)
Ampicillin administration
[00613] As specified in the protocol, all patients were to receive ampicillin IV on Day 6 and Day 27, allowing for 5 days to pass following each drug infusion prior to antibiotic administration. An additional 10 days of ampicillin PO was then given following each IV antibiotic administration. All enrolled patients were administered ampicillin as per study protocol, with the exception of patient 01-
004. Within forty-eight hours of infusion with Lm-LLO-E7, Patient 01-004 was administered ampicillin intravenously due to unremitting febrile state of moderate severity (maximum temperature
390C). The event lasted up to 48 hours, at which time the protocol mandated antibiotic therapy. The event resolved quickly thereafter. The patient was continued on ciprocinol instead of oral ampicillin due to local urticaria.
Early Termination of the Study
[00614] This trial was terminated subsequent to the complete enrollment and treatment of the IxIO10 group and before treating the IxIO10 group. This occurred per the protocol design with the occurrence of three patients experiencing dose limiting hypotension as described in section 7.2.3.3
Safety Conclusions
[00615] Conclusions regarding the safety of Lm-LLO-E7 in this study need to be assessed against the background of both severe, metastatic cervical cancer and the prior chemotherapy treatment
P-7771-PC3 that 13 of the 15 patients in this trial received. In all cases of prior chemotherapy, platinum based agents were used, and platinum is associated with many long term toxicities, including anemia and renal insufficiency.
[00616] All, 15 (100%) treated patients experienced AEs. The most commonly reported AEs were pyrexia, chills anemia, headache, vomiting, nausea, tachycardia and musculoskeletal pain. Drug- related AEs were comprised of a 'flu-like' syndrome including pyrexia, vomiting, chills, headache, tachycardia, and nausea. The reported "flu-like" syndrome was of mild to moderate intensity and responsive at doses of IxIO9 and 3.3xlO9 to standard non-prescription agents, so its tolerability could be considered acceptable. The dose of IxIO10 resulted in dose limiting toxicity described below.
[00617] A total of 2 patients reported 6 SAEs: 1 patient each in the 3.3xlO9 and IxIO10 groups, respectively. SAEs included blood amylase increased, anemia, cardiorespiratory arrest, metabolic acidosis and renal failure in the 3.3xlO9 group and blood creatinine increased in the IxIO10 group. The events were considered by the investigator not to be related to study vaccine. The patient in the 3.3x109 group died due to cardiac failure secondary to acidosis and renal failure.
[00618] A total of 2 (40.0%), 4 (80.0%), and 3 (60.0%) patients in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively, reported severe AEs. Treatment-related AEs of interest considered severe in five (33.3%) patients were febrile disorders (pyrexia) and liver function analyses (GGT increased and lactate dehydrogenase increased). Special attention was given to liver function tests due to known trophic effect of Listeria for liver and spleen, which was stressed in Investigators Brochure. However, LFT elevations in a terminally ill patient population is not uncommon and could also be attributed to underlying disease, previous treatments and antibiotic therapy. Moreover, it must be noted that all LFT elevations were noted after patients had received either sterilizing doses of ampicillin IV or both IV and PO, making it difficult to attribute elevated liver function abnormalities directly to Listeria injection. Future studies should be designed to determine whether any relationship between changes in LTFs and investigational drug could be established.
[00619] A majority of patients had abnormal clinical chemistry and hematology values during the study. Some of these patients were reported with clinically significant values, most of which can be attributed to the underlying disease or prior therapy. Clinically significant chemistry parameters were mainly GGT, urea and creatinine in six patients. Clinically significant hematology parameters were mainly hematocrit, Hb and RBCs in eight patients; for most of these patients, anemia was reported as an AE which was considered by the investigator to be severe in intensity but unlikely related to study vaccine.
P-7771-PC3
[00620] Overall, the changes in physical examination were considered not clinically significant. A majority of abnormal physical findings were associated with the disease, cancer of the cervix. Median changes in blood pressure (decreased), heart rate (increased) and temperature (increased) over time were reported for the majority of patients. However, at 12 hours post dose, median values were within normal limits with no differences across treatment groups. Given the known relationship between fever and cardiovascular physiology such that elevated temperature results in diminished blood pressure and elevated heart rate, the observations of cardiovascular AE only in the presence of pyrexia indicates that these events are likely related and that hypotension and tachycardia may be epiphenomenal to the fevers reported for most of the patients, and thus part of the flu-like syndrome.
[00621] Listeria was rapidly cleared from the blood, with only one patient showing any serum Listeria in very small concentrations (35 CFU) one day after drug administration, which was resolved on the next day. These results could provide reassurance that the probability of clinically significant Listeriosis caused by this investigational product is low. At the same time, as no shedding of Listeria in the urine or feces was observed in any of the patients tested, the conclusion can be made that shedding of Lm-LLO-E7 is not very likely to happen. However, having in mind relatively small number of patients involved in this study, these observations is to be confirmed with further investigations.
[00622] The side effect profile attributable to Lm-LLO-E7 appears to be consistent with the known pathophysiology of Listeria, as it appears to be comprised of a constellation of the flu-like symptoms nausea, vomiting, fever, and chills and these symptoms are commonly associated with Listerial disease. Listeria is a known stimulator of a strong innate immune response, and these symptoms are consistent with those associated with the release into the blood of cytokines that occurs during an innate immune response. To this extent, it appears that a valid assessment of the effects of Listeria in this patient population has been achieved, not withstanding a number of patients did not complete all follow up visits. With the exception of patient 04-005 who was an in-patient for her second drug administration on Days 22-26 but passed away prior to her Day 43 follow-up visit, follow up visits were obtained for all 14 of 15 on Day 43, for 10 of 15 patients on Day 79, and 7 of 15 patients on the final study day, 1 1 1. Since the AE associated with Lm-LLO-E7 all appeared to resolve prior to the Day 43 visit it does not appear that the absence of this information detracts from our understanding of the side effects of Lm-LLO-E7 in this trial.
[00623] In accordance with the DLT criteria detailed in the protocol (Amendment 5, 12 October 2006), this study was discontinued due to events of hypotension experienced by three (3) patients
P-7771-PC3
(Patients 01-007, 02-006, 04-006) in the IxIO10 group.
[00624] Thus, we draw the following conclusions regarding the safety of Lm-LLO-E7 as demonstrated in this study:
[00625] It appears as though in this study the side effects associated with Lm-LLO-E7 administration are limited to a flu-like syndrome. This is consistent with the known flu-like syndrome associated with infectious diseases and which results from the release of cytokines from immune cells into the general circulation. As Listeria is an infectious agent, and one that is known to stimulate a particularly strong innate immune response characterized by high levels of cytokine release, this pattern of side effects is consistent with Listeria's known actions
[00626] Even at doses which result in dose limiting toxicity in the form of hypotension Lm-LLO-E7 is rapidly cleared from the blood and not likely to result in symptoms associated with listeriosis.
[00627] In the patients tested, no urinary or fecal shedding of Listeria was observed. Although the numbers are small, these patients were in the highest two groups tested, indicating that Lm-LLO-E7 is not likely to result in Listeria shedding.
[00628] As high fever occurred in all dosage groups, and in the lowest dosage group tested one patient experienced a sustained mild-moderate fever that only resolved upon the administration of antibiotic, fever may be an idiosyncratic response to Lm-LLO-E7 and future work is necessary to characterize this important parameter.
[00629] Although Listeria is known to be trophic for liver and spleen, elevated liver function tests were seen only in some patients and only after sterilizing doses of antibiotic was administered. Since elevated LFT arise in many different situations and are associated with many circumstances (including the administration of ampicillin, as was done in this trial) no clear relationship can be drawn from this trial between Lm-LLO-E7 administration and elevated liver function tests.
[00630] At the two lower doses tested, 1x109 and 3.3x109 that Lm-LLO-E7 can be safely administered to women with severe metastatic cervical cancer, and that the observed side effect profile of Lm-LLO- E7 compares favorably with other therapeutic agents used in the treatment of this disease.
[00631] Efficacy Evaluation
[00632] Analysis of Efficacy
P-7771-PC3
[00633] Primary Efficacy Endpoint
[00634] The primary efficacy variable was tumor response as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
[00635] Best Overall Response
[00636] In the intent to treat group of 13 patients 7 (53.85%) had stable disease and 5 (38.5%) had progressive disease. Disease was stable for 2 (40%), 2 (50%) and 1 (25%) patients in the IxIO9, 3.3xlO9 and IxIO10 groups, respectively.
[00637] A partial response was reported for 1 patient (7.69%), Patient 04-003, with a change in target lesion size (-32.484%) from baseline to Day 79.
[00638] The PR of Patient 04-003
[00639] RECIST criteria stipulate that a repeat scan will be performed 4 weeks following the initial criterion response determination to confirm the response. In the case of patient 04-003 this was not possible. Nonetheless, the authors submit that this is a true PR, and is a clinically significant result in any event.
[00640] Patient 04-003 was diagnosed as an unresectable stage IIIB cervical cancer in 2004 at which time she received 2 cycles of cisplatin and pelvic irradiation simultaneously. She enrolled in this trial with 3 index lesions on spiral CT; a uterine lesion of 130 mm, a retrocrural lesion of 14 mm, and a right iliac node of 13 mm. At the day 79 evaluation this patient presented with a uterine mass of 90 mm, a retrocrural lesion of 12 mm, and no nodal in involvement. Rather than wait and follow the patient, her physician withdrew her from the trial, dosed her with 6 courses of paclitaxel and carboplatin, and performed a radical hysterectomy. Subsequent to the chemo therapy patient 04-003 had a 40 mm residual uterine mass and had lost the retrocrural disease. The mass was removed, and although it was believed to be benign, some malignancy was observed histopathologically at one margin of the specimen. Shortly after her surgery, her attending physician Dr. Gaona communicated with the sponsor to confirm that this patient was tumor free, manifest a normal performance score, and all of her laboratory values were within normal limits. This condition persists to the time of this writing, December 31 , 2007.
[00641] Correspondence with the CRO and the investigator is presented in Appendix A.
[00642] [The finding that immunotherapy can increase the rate of response to cytotoxic therapy is now being reported by others. In a recent trial of extensive non-small cell lung cancer that
P-7771-PC3 combined immuno therapy directed against p53 with platinum containing regimens that was associated with a 62% objective response rate when vaccinations were followed by cytotoxic therapy (4). Our experience would seem to be consistent with these authors.]
[00643] Thus, although events as they occurred did not include a follow up scan for patient 04-003 as the RECIST criteria require, the confirmation of the attending physician of the nature of this patient's response would indicate that Lm-LLO-E7 was of clinical benefit in this instance. Moreover, that this stage IVb patient is tumor free, with a normal performance score and all labs within normal limits today, 6 months after the close of the database and more than a year after she started this trial would indicate that a an unexpected and therapeutic benefit was derived from the use of Lm-LLO-E7 consistent with attributing this patients outcome as a response to drug.
[00644] Secondary Efficacy Endpoints
[00645] Change in sum of longest diameter and target lesions from baseline
[00646] Sum of longest diameter and target lesions were determined.
[00647] Tumor assessments were made on study days 43, 79 and 111 following the first dose. Study day 111 was the last day of the study.
[00648] In the aggregate, there was an increase in target lesion from baseline (69.2 mm) to Day 79
(79.6 mm), followed by a reduction by Day 111 (56.6 mm). At baseline, mean size of target lesion was larger in the 3.3xlO9 (87.0 mm) and the IxIO10 (72.8 mm) groups compared to the IxIO9 group
(52.2 mm). On Day 43, there was no change in tumor size in the 3.3xlO9 group compared to the IxIO9 (12.0 mm) and IxIO10 groups (10.8 mm).
[00649] On Day 79, a reduction by 37.0 mm was seen in the 3.3x109 group compared to the small increase in mean tumor size observed in the other treatment groups. The reduction observed in the 3.3x109 group, relative to the positive increase in mean values from baseline (103 mm on Day 79), was a consequence of calculations on a smaller sample size (2 patients) on Day 79 compared to baseline (4 patients) due to early discontinuation of some patients. Total lesion size for Patients 03-001 and 04-003 at baseline was 124 mm and 157 mm, respectively and on Day 79, total lesion size was 100 mm and 106 mm, respectively. It should be noted that not all lesions were counted for Patient 03-001 on Day 79.
[00650] As descriptive statistics were performed on this very small sample size of 13 patients in the Intent-to-Treat group in this study, it was important to analyze some of the patients on an individual
P-7771-PC3 basis. Tumor size data is presented in List 16.2.6.1. Overall, 4 patients in the intent to treat group (30.77%) experienced a reduction in their tumor burden in this trial. Three patients with stable disease experienced a reduction of their tumor burden. Patient 01-004 who received IxIO9 cfu experienced a diminution of her tumor burden of 20% (8mm). Patient 03-001 in the group that received 3O3xlO9 had an overall tumor burden reduction of 19.36% (24mm). And patient 01-007 in the IxIO10 group had a total tumor reduction of 20.83% (5mm). One patient in the 3.3xlO9 group, 04-003, was an objective PR by RECIST criteria, experiencing a reduction in tumor burden of 32.48% (51mm).
[00651] One target lesion for Patient 04-003 at baseline (13 mm) was not detected on Day 79 (0 mm). One non-target lesion present for Patient 01-004 at baseline was not detected by Day 43.
[00652] It is interesting to note that no dose response relationship was observed, and patient in all groups experienced progression, and patients in all groups experienced a reduction of their tumor burden. Of the 13 patients evaluable, 5 patients in the lower two dosage groups progressed, with increases in their tumor burden of between 30% and 142.5.
[00653] Individual Patient Tumor Measurements
Time to progression of disease and duration of stable disease
[00654] For patients who progressed, the length of time to progression of disease was within 43 days in the IxIO9, 3.3xlO9 and IxIO10 groups (3, 2 and 1 patient(s), respectively), with the exception of patient 01-001 (IxIO9) whose disease progressed at 80 days after the first dose of study vaccine.
[00655] Stable disease was reported no less than a mean of 43 days after the first dose of study vaccine for these patients prior to disease progression.
Duration of overall response
[00656] Summary results show no response to target lesion in the aggregate. However, based on individual patient analysis, one patient (Patient 04-003) had an objective partial response to Lm-LLO- E7 treatment including no detection of a target lesion (0 mm).
Survival
[00657] The table below was used in a presentation of this data at the World Vaccine Congress on October 9, 2007. The data therein is consistent with the closed database and was confirmed prior to presenting this information. It shows that as of that date 2 patients in the 1 x 109 group and three
P-7771-PC3 patients in the 3.3x10 ilO had died, but no patient in the high dose group had died.
Table 20; Survival as of October 9, 2007
Time to death
[00658] Of the 13 evaluable patients in the intent to treat group 5 received I xIO9, 4 received 3.3x109, and 4 received IxIO10. A total of 3/5 deaths were reported in the IxIO9 group: 1 19 days (Patient 01- 002), 348 days (Patient 01-003) and 368 days (Patient 01-001) post first dose. A total of 1/4 death was reported 88 days after first dose, in the 3.3x109 group (Patient 04-004). There were no deaths in the I xIO10 group (4/4 patients).
Change in ECOG performance status from baseline
100659] In the aggregate, there were no meaningful changes in mean ECOG performance status from baseline. In the I x IO9 group, 2 patients improved and 3 remained unchanged. In the 3.3x 109 group, 3 patients performance status worsened and 2 remained unchanged. In the 1 x 10 group, 2 patients
P-7771-PC3 worsened and 3 remained unchanged.
Change in Karnofsky Index from baseline
[00660] At baseline, mean Karnofsky Index was 78.0, 75.0 and 90.0% in the 1x109, 3.3x109 and
IxIO10 groups. In the aggregate, there was no meaningful change in mean Karnofsky Index from baseline, over time. However, a notable, but small decrease from baseline to Day 43 (-17.5%) was observed in IxIO10 group compared to patients in the IxIO9 group (6.0%) and the 3.3xlO9 group (-
2.5%). As can be seen in Listing 16.2.5.2 improvements in the Karnofsky status scores were seen in 2 patients in the IxIO9 group. Worsening of performance status was seen in 1, 3, and 2 patients respectively in the IxIO9, 3.3xlO9, IxIO10 dosage groups; while no change in performance status was seen in 2, 2,and 3 patients respectively in the IxIO9, 3.3xlO9, IxIO10 dosage groups
The Role of HPV species
[00661] Lm-LLO-E7 is directed against HPV-16 E7, and in the beginning of this trial only HPV-16 patients were enrolled. However, the protocol was amended to allow for all HPV species, since the literature indicated that HPV-16 directed antigenic attach may have efficacy against disease induced by other HPV species. Of the patients who experienced a diminution of tumor, 01-004 (IxIO9), 03-001
(3.3xlO9), 04-003 (3.3xlO9) and 01-007 (IxIO10) were all HPV-16 positive (Listing 16.4.5.4).
I mm unogenicity
[00662] Blood samples collected during the study were tested for viability. None of the samples collected were found to yield evaluable data due to poor viability. In addition, samples were missing for some patients.
Efficacy Conclusions
[00663] In an Intent-to-Treat sample of 13 patients, a total of 38.5% of patients were reported with progressive disease and four of these patients died, one during the trial, one during the trial interval but after discontinuation from the trial for progressive disease, and 3 more after the end of the trial, but in time to be reported in the post-study CRFs (3 patients in the 1x109 group and 1 patient in the 3.3x109 group). Stable disease was reported in 53.85% of patients of whom 3 patients experienced a reduction in their overall tumor mass. Partial response of target lesion was reported for 1 (7.69%) patient, 04-003 (32.5 % reduction in total lesion size), and the complete disappearance of one target (04-003) and one non-target (01 -004) lesion was reported.
P-7771-PC3
[00664] When all patients were viewed in the aggregate, there was no reduction in mean tumor size. Interestingly, when patients were reviewed on a case-by-case basis, a reduction in total tumor size was observed in four patients. It should be noted that not all lesions were counted for Patient 03-001 on Day 79. Owing to the small sample size, statistical power could not be applied. Further evaluations on a larger sample size are needed to determine the effect of Lm-LLO-E7 on target lesions and to evaluate overall response to treatment.
[00665] Overall, there were no improvements in ECOG performance status and Karnofsky Index over time.
[00666] No conclusions can be made regarding the efficacy of Lm-LLO-E7 in the treatment of advanced, recurrent or progressive cervical cancer based upon this data.
Discussion And Overall Conclusions
[00667] This phase I, open-label, dose escalation study was designed to primarily establish the safety and feasibility of vaccination with live Listeria monocytogenes expressing human papilloma virus type 16-E7 (Lm-LLO-E7). The study was to also evaluate immunogenicity following vaccination. Although the samples for immunogenicity analysis were assayed, missing samples for study Day 1 and the overall poor quality of the samples collected did not allow for any useful interpretation of the data. Immunogenicity samples were analyzed by the sponsor.
[00668] Any response was to be reported and survival was to be monitored for the duration of the study. A total of 15 patients with progressive, recurrent and advanced squamous cell cancer of the cervix were included in the study. These were terminally ill patients with no other treatment options left. AU of this set of patients had failed prior therapy and most of them had failed multiple courses of therapy. 13 out of 15 patients had received prior platinum based drugs which are known to have long term consequences on renal and hematologic function. When assessing the response of these patients to Lm-LLO-E7 it must be considered in the context of their disease and the effects of prior therapy.
[00669] All enrolled patients had a positive anergy panel, which is an indication of the patient's ability to mount an immune response against the development of listeriosis, and Lm-LLO-E7 appeared to be well tolerated in the lower two dosage groups, with drug related Adverse Events limited to either a flu like syndrome that for the most part responded to non-prescription remedies, or elevated liver function tests.
[00670] L monocytogenes is a gram positive bacterium which, at pathological levels, may cause mild gastrointestinal upset, nausea and diarrhea in healthy individuals, and may also cause serious
P-7771-PC3 infections in immunocompromised individuals and neonates. Drug-related AEs were predominantly comprised of a 'flu-like' syndrome (including pyrexia [fever], vomiting, chills, nausea, tachycardia, and headache) that is frequently associated with immune stimulating therapies such as Lm-LLO-E7. As such, these side effects tended to be acute and transient were clearly observed in all patients, and typically resolved within hours.
[00671] The significance of the observed flu-like syndrome remains to be seen. It is associated with serum cytokines that result from an innate immune response, and is often associated with a strong adaptive immune response. It should be noted that Listeria is associated with a strong innate immune response and Listeria related disease is accompanied by a flu-like syndrome.
[00672] Two patients in the 3.3xlO9 group (40%) and 1 patient in the IxIO10 groups (20%) but none in the IxIO9 group reported elevated LFTs . However, all elevations in LFTs occurred after FV and oral administration of ampicillin, at a dosage known to sterilize Listeria, ampicillin use is documented to have a moderate and transient effect on the elevation of LFTs, and patients were receiving the antibiotic beginning 5 days after each infusion and for 11 days there after. Patients were taking ampicillin during the day 8 and 29 day visits, when these events occurred. Also, elevated LFTs are common in severe disease, which characterizes the patient population in this study.
[00673] An increase in temperature, heart rate and low blood pressure were reported for a majority of patients for up to 12 hours after the administration of Lm-LLO-E7. A total of three patients in the IxIO10 group experienced events of hypotension resulting in study discontinuation due to DLT, as per the protocol. Only patient 01-007 reported severe pyrexia (fever) in association with hypotension. The other two patients reported moderate fever in association with hypotension. These events occurred during periods of in-patient evaluation and appropriate therapies were given immediacy such that all serous or severe events resolved quickly.
[00674] One question fundamental to the understanding of the use of Listeria as a therapeutic vaccine vector is the relationship between virulence and immune efficacy. It is believed that innate immunity "sets the stage" for an effective adaptive immune response. Thus, the release of serum cytokines as part of a strong innate immune reaction is presumed to presage an effective therapeutic response.
[00675] Most of the patients (1 1/15) received a combination of radio- and chemo-therapy, while the remaining four patients received just one of the two mentioned treatment options. Although all toxic effects of previous treatment had to be resolved prior to study inclusion, it can not be ruled out that previous aggressive treatments may have caused irreversible organ system(s) damage. Thus, all safety parameters in this study should be considered in light of this fact. For example, it is well documented
P-7771-PC3 that platinum based treatment may lead to anemias and renal impairment. It appears many of the side effects are associated with prior therapy of disease or disease progression.
[00676] We observed stable disease was reported for 53.85% of patients in the Intent-to-Treat group, progressive disease reported in 38.5% of patients, and 1 patient (7.7%) had an objective PR. Overall, reductions in tumor mass were seen in 4 of the 13 (30.08) assessable patients, with 3 patients experiencing approximately 20% of their tumor burden and one patients experiencing a 32% reduction. There was no reduction in mean tumor size in the aggregate. Owing to the small sample size, statistical power could not be applied. Further evaluations on a larger sample size are needed to determine the effectiveness of Lm-LLO-E7 on target lesions and to evaluate overall response to treatment.
[00677] It is now known that, unlike classic chemo- and radio-therapies, immuno-therapies are characterized by late responses. This is due to the need to reconstitute the immune system which then results in a therapeutic response at a later time than does the directly toxic therapies.
[00678] Early termination of patients results from the current models of cancer therapy based upon chemo- and radio-therapy in which toxic mechanisms of action result in fairly rapid responses, and physicians are used to a much quicker response (if one is to occur) than are seen with immunotherapy.
In a recent proposal for a new method of conducting immunotherapeutic trials put forward by the
Cancer Vaccine Consortium it is recognized that 4-6 months or longer might be required for immuno therapies to manifest efficacy, and this group proposes that patients remain untreated for a sufficient duration for efficacy to be determined experimentally, even in the presence of near term disease progression.
[00679] In conclusion,
• Lm-LLO-E7 results in a flu-like constellation of side effects including fever, chills, nausea and vomiting in a majority of patients
• These side effects were mild to moderate well tolerated in the I xIO9 and 3.3x109 groups
• Side effects associated with drug administration were comprised primarily of a flu-like syndrome that was short lived and amenable to intervention.
• The relationship between liver function and Lm-LLO-E7 could not be determined in this trial, although it appears that Lm-LLO-E7 alone as a proximate cause of elevated LFT is
1-PC3 unlikely.
• Dose limiting hypotension was observed at a dose of IxIO10
• Lm-LLO-E7, at doses of IxIO9 and 3.3xlO9, can be used safely in end-stage cervical cancer.
Claims
1. Use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to a Human Papilloma virus (HPV) E7 antigen, wherein said first peptide is selected from (a) a N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for treating a cervical cancer in a human subject, whereby said recombinant Listeria strain induces an immune response against said E7 antigen and wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 109 organisms.
2. Use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, in the preparation of a composition for protecting a human subject against a cervical cancer, whereby said recombinant Listeria strain induces an immune response against said E7 antigen and wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 1010 organisms.
3. Use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and a PEST-like sequence-containing peptide for the preparation of a composition for inducing an immune response against a cervical cancer in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 1010 organisms.
4. Use of a recombinant Listeria strain comprising a recombinant polypeptide comprising a first peptide fused to an Human Papilloma Virus (HPV) E7 antigen, wherein said first peptide is P-7771-PC3
selected from (a) an N-terminal fragment of an LLO protein; (b) an ActA protein or N-terminal fragment thereof; and (c) a PEST-like sequence-containing peptide, for the preparation of a composition for inducing an anti-E7 cytotoxic T cell response in a human subject, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 - 3.31 x 101 organisms.
5. The use of any of claims 1-4, wherein said N-terminal fragment of an LLO protein comprises SEQ E) NO: 1.
6. The use of any of claims 1-4, wherein said ActA protein comprises SEQ K) NOs: 2-5.
7. The use of any of claims 1-4, wherein said recombinant Listeria strain is administered to said human subject at a dose of 1 x 109 organisms.
8. The use of any of claims 1-4, wherein said recombinant Listeria strain is administered to said human subject at a dose of 3.31 x 10 organisms.
9. The use of any of claims 1-4, wherein said recombinant Listeria strain is a recombinant Listeria monocytogenes strain
10. The use of any of claims 1-4, wherein said recombinant Listeria strain has been passaged through an animal host.
11. The use of any of claims 1-4, wherein said recombinant polypeptide is expressed by said recombinant Listeria strain.
12. The use of any of claims 1-4, wherein said recombinant Listeria strain comprises a plasmid that encodes said recombinant polypeptide.
13. The use of claim 12, wherein said plasmid comprises a gene encoding a bacterial transcription factor. P-7771-PC3
14. The use of claim 12, wherein said plasmid comprises a gene encoding a metabolic enzyme.
15. The use of any of claims 1-4, wherein a second composition that comprises or directs expression of said E7 antigen is used in conjunction with said recombinant Listeria strain.
16. The use of any of claims 1 -4, wherein said recombinant Listeria strain has been stored in a frozen or lyophilized cell bank.
17. The use of any of claims 16, wherein said recombinant Listeria strain exhibits viability upon thawing or reconstitution of greater than 90%.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08726578A EP2134363A4 (en) | 2007-03-08 | 2008-03-07 | Compositions and methods for treatment of cervical cancer |
JP2009552749A JP5479918B2 (en) | 2007-03-08 | 2008-03-07 | Compositions and methods for the treatment of cervical cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/715,497 US8114414B2 (en) | 1994-11-08 | 2007-03-08 | Compositions and methods for treatment of cervical cancer |
US11/715,497 | 2007-03-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008109155A2 true WO2008109155A2 (en) | 2008-09-12 |
WO2008109155A3 WO2008109155A3 (en) | 2008-12-11 |
Family
ID=39738996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/003067 WO2008109155A2 (en) | 2007-03-08 | 2008-03-07 | Compositions and methods for treatment of cervical cancer |
Country Status (4)
Country | Link |
---|---|
US (1) | US8114414B2 (en) |
EP (1) | EP2134363A4 (en) |
JP (1) | JP5479918B2 (en) |
WO (1) | WO2008109155A2 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2288379A2 (en) * | 2008-05-19 | 2011-03-02 | Advaxis | Dual delivery system for heterologous antigens |
US8241636B2 (en) | 2006-08-15 | 2012-08-14 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
US8268326B2 (en) | 2006-08-15 | 2012-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9084747B2 (en) | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
US9226958B2 (en) | 2010-10-01 | 2016-01-05 | University Of Georgia Research Foundation, Inc. | Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
WO2016061182A1 (en) * | 2014-10-14 | 2016-04-21 | The Trustees Of The University Of Pennsylvania | Combination therapy for use in cancer therapy |
WO2017066706A1 (en) * | 2015-10-14 | 2017-04-20 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US9663557B2 (en) | 2012-12-27 | 2017-05-30 | Aduro Biotech, Inc. | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
US9919038B2 (en) | 2009-03-04 | 2018-03-20 | The Trustees Of The University Of Pennsylvania | Compositions comprising angiogenic factors and methods of use thereof |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
US10055540B2 (en) | 2015-12-16 | 2018-08-21 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
US10058599B2 (en) | 2012-03-12 | 2018-08-28 | Advaxis, Inc. | Suppressor cell function inhibition following Listeria vaccine treatment |
US10064898B2 (en) | 2011-03-11 | 2018-09-04 | Advaxis, Inc. | Listeria-based adjuvants |
US10143734B2 (en) | 2014-02-18 | 2018-12-04 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
US10258679B2 (en) | 2014-04-24 | 2019-04-16 | Advaxis, Inc. | Recombinant Listeria vaccine strains and methods of producing the same |
US10900044B2 (en) | 2015-03-03 | 2021-01-26 | Advaxis, Inc. | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
US11179339B2 (en) | 2017-09-19 | 2021-11-23 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
US11264117B2 (en) | 2017-10-10 | 2022-03-01 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
US11446369B2 (en) | 2007-05-10 | 2022-09-20 | Advaxis, Inc. | Compositions and methods comprising KLK3 or FOLH1 antigen |
US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
US11897927B2 (en) | 2016-11-30 | 2024-02-13 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
WO2004062597A2 (en) * | 2003-01-09 | 2004-07-29 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
DE102006035617A1 (en) * | 2006-07-31 | 2008-02-21 | Siemens Ag | Automatic determination of tumor burden |
US10702614B2 (en) | 2011-02-15 | 2020-07-07 | Albert Einstein College Of Medicine | Radiobacteria for therapy of cancer |
JP2021516972A (en) | 2018-03-09 | 2021-07-15 | アドバクシス, インコーポレイテッド | Compositions and Methods for Assessing Attenuation and Infectivity of Listeria Strains |
EP3785029A1 (en) | 2018-04-27 | 2021-03-03 | Advaxis, Inc. | Compositions and methods for evaluating potency of listeria-based immunotherapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
WO2004062597A2 (en) | 2003-01-09 | 2004-07-29 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
US20050118184A1 (en) | 2000-03-29 | 2005-06-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
WO2007061848A2 (en) | 2005-11-17 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Methods for producing, growing, and preserving listeria vaccine vectors |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567041A (en) * | 1977-12-08 | 1986-01-28 | Likhite Vilas V | Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent |
US4816253A (en) * | 1977-12-08 | 1989-03-28 | Likhite Vilas V | Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent |
CA1156953A (en) * | 1979-06-08 | 1983-11-15 | Michael A. Kessick | Lime addition to heavy crude oils prior to coking |
US5262177A (en) * | 1986-02-07 | 1993-11-16 | Oncogen | Recombinant viruses encoding the human melanoma-associated antigen |
US4777239A (en) * | 1986-07-10 | 1988-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic peptides of human papilloma virus |
JPS63173594A (en) | 1986-08-29 | 1988-07-18 | Medeisa Shinyaku Kk | Secretory protein induced by carcinogenic gene |
US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
WO1990014357A1 (en) * | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
US5830702A (en) * | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
WO1992021032A1 (en) * | 1991-05-24 | 1992-11-26 | The Regents Of The University Of California | Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients |
FR2686896B1 (en) | 1992-01-31 | 1995-01-06 | Pasteur Institut | MUTANT ATTENUE OF LISTERIA MONOCYTOGENES; RECOMBINANT STRAIN OF LISTERIA MONOCYTOGENES, USE AS HETEROLOGOUS VECTORS OF VACCINE ANTIGENS AND USE AS VACCINE OR DIAGNOSTIC COMPOSITION. |
US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
US5876735A (en) * | 1994-04-22 | 1999-03-02 | Corixa Corporation | Methods for enhancement of protective immune responses |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
US7794729B2 (en) * | 1994-11-08 | 2010-09-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for immunotherapy of cancer |
US8791237B2 (en) * | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US7662396B2 (en) | 2001-03-26 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
US7820180B2 (en) * | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
US5681570A (en) * | 1995-01-12 | 1997-10-28 | Connaught Laboratories Limited | Immunogenic conjugate molecules |
US5877159A (en) * | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
US5643599A (en) * | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
US5824538A (en) * | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
DE19541450C2 (en) * | 1995-11-07 | 1997-10-02 | Gsf Forschungszentrum Umwelt | Gene construct and its use |
US6479258B1 (en) * | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US5858682A (en) * | 1996-08-02 | 1999-01-12 | Pharmingen | E2A/pbx1 fusion protein specific monoclonal antibodies |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
DE69734605T2 (en) | 1997-04-18 | 2006-08-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Weakened salmonella, used as a vechicle for oral immunization |
US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
AU3710597A (en) | 1997-08-06 | 1999-03-01 | Laboratorio Medinfar-Produtos Farmaceuticos, Lda | Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system |
CA2268523C (en) | 1997-08-15 | 2007-01-30 | Unitika Ltd. | Mannose-containing feed and process for producing the same |
EP0902086A1 (en) | 1997-08-22 | 1999-03-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tuberculosis vaccine |
US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
US6306404B1 (en) * | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
US6818002B2 (en) * | 1999-02-02 | 2004-11-16 | Samuel Shiber | Vessel cleaner and barrier |
US6296734B1 (en) * | 1999-07-08 | 2001-10-02 | International Business Machines Corporation | Concentrated UV light curing of adhesive for pivot applications |
DE19949594A1 (en) | 1999-10-14 | 2001-04-26 | Deutsches Krebsforsch | Recombinant attenuated listeria for immunotherapy |
US6855320B2 (en) * | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
EP1195438A1 (en) * | 2000-10-06 | 2002-04-10 | Rijksuniversiteit te Groningen | Genetic immunisation against cervical carcinoma |
US7700344B2 (en) * | 2001-03-26 | 2010-04-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
EP1497654A4 (en) | 2001-08-13 | 2006-06-07 | Chen Swey Shen Alex | Immunoglobulin e vaccines and methods of use thereof |
JP2006502964A (en) * | 2002-02-06 | 2006-01-26 | ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン | Methods and compositions for targeting a systemic immune response against a specific organ or tissue |
US7425449B2 (en) | 2002-04-30 | 2008-09-16 | The Regents Of The University Of California | Site specific Listeria integration vectors and methods for using the same |
JP2005527240A (en) * | 2002-05-29 | 2005-09-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Attenuated Listeria species and how to use them |
US20050175625A1 (en) | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
KR101192652B1 (en) * | 2003-02-06 | 2012-10-19 | 앤저 테라퓨틱스 인코퍼레이티드 | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
EP1592442A2 (en) * | 2003-02-06 | 2005-11-09 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
ES2684749T3 (en) * | 2004-08-13 | 2018-10-04 | The Trustees Of The University Of Pennsylvania | Methods to build vaccines without antibiotic resistance |
EP1802338A4 (en) | 2004-10-18 | 2010-01-27 | Medimmune Inc | High cell density process for growth of listeria |
BRPI0518984A2 (en) * | 2004-12-10 | 2008-12-16 | Univ Emory | 2 'and 3' substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cell proliferation |
US20080124354A1 (en) * | 2006-07-10 | 2008-05-29 | Yvonne Paterson | Methods for administering tumor vaccines |
-
2007
- 2007-03-08 US US11/715,497 patent/US8114414B2/en not_active Expired - Fee Related
-
2008
- 2008-03-07 JP JP2009552749A patent/JP5479918B2/en not_active Expired - Fee Related
- 2008-03-07 EP EP08726578A patent/EP2134363A4/en not_active Ceased
- 2008-03-07 WO PCT/US2008/003067 patent/WO2008109155A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5663153A (en) | 1994-03-25 | 1997-09-02 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5723335A (en) | 1994-03-25 | 1998-03-03 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US20050118184A1 (en) | 2000-03-29 | 2005-06-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
WO2004062597A2 (en) | 2003-01-09 | 2004-07-29 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
WO2007061848A2 (en) | 2005-11-17 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Methods for producing, growing, and preserving listeria vaccine vectors |
Non-Patent Citations (16)
Title |
---|
"Molecular Cloning", 2001 |
BODANSZKY; BODANSZKY: "The Practice of Peptide Synthesis", 1984, SPRINGER-VERLAG |
CAUDY AA ET AL., GENES & DEVEL, vol. 16, pages 2491 - 96 |
DERBINSKI, J.; A. SCHULTE; B. KYEWSKI; L. KLEIN: "Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self", NAT IMMUNOL, vol. 2, 2001, pages 1032 |
GARAY-MALPARTIDA HM; OCCHIUCCI JM; ALVES J; BELIZARIO JE, BIOINFORMATICS, vol. 21, no. 1, June 2005 (2005-06-01), pages I169 - 76 |
IKONOMIDIS ET AL., J. EXP. MED., vol. 180, 1994, pages 2209 - 2218 |
KRIEG AM; YI AK; MATSON S; WALDSCHMIDT TJ; BISHOP GA; TEASDALE R; KORETZKY GA; KLINMAN DM, NATURE, vol. 374, pages 546 |
MICHAEL K. SCHUSTER; MARTIN GRABNER, AUSTRIAN NATIONAL EMBNET NODE |
NEILSEN PE, CURR OPIN STRUCT BIOL, vol. 9, pages 353 - 57 |
PURCHIO; G. C. FAREED, METHODS IN ENZYMOLOGY: METHODS FOR MOLECULAR CLONING IN EUKARYOTIC CELLS, 2003 |
RAZ NK ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 297, pages 1075 - 84 |
RECHSTEINER; ROGERS, TRENDS BIOCHEM. SCI., vol. 21, 1996, pages 267 - 271 |
See also references of EP2134363A4 |
SEWELL ET AL., ARCH. OTOLARYNGOL. HEAD NECK SURG., vol. 130, 2004, pages 92 - 97 |
STEWART ET AL.: "Solid Phase Peptide Synthesis", 1984, PIERCE CHEMICAL COMPANY |
WIRTH R ET AL., J BACTERIOL, vol. 165, 1986, pages 831 |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8241636B2 (en) | 2006-08-15 | 2012-08-14 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
US8268326B2 (en) | 2006-08-15 | 2012-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
US11446369B2 (en) | 2007-05-10 | 2022-09-20 | Advaxis, Inc. | Compositions and methods comprising KLK3 or FOLH1 antigen |
EP2288379A4 (en) * | 2008-05-19 | 2012-08-08 | Advaxis | Dual delivery system for heterologous antigens |
EP2853269A1 (en) * | 2008-05-19 | 2015-04-01 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US9644212B2 (en) | 2008-05-19 | 2017-05-09 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
EP2288379A2 (en) * | 2008-05-19 | 2011-03-02 | Advaxis | Dual delivery system for heterologous antigens |
US10695410B2 (en) | 2009-03-04 | 2020-06-30 | The Trustees Of The University Of Pennsylvania | Compositions comprising angiogenic factors and methods of use thereof |
US9919038B2 (en) | 2009-03-04 | 2018-03-20 | The Trustees Of The University Of Pennsylvania | Compositions comprising angiogenic factors and methods of use thereof |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
US9084747B2 (en) | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9226958B2 (en) | 2010-10-01 | 2016-01-05 | University Of Georgia Research Foundation, Inc. | Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
US9943590B2 (en) | 2010-10-01 | 2018-04-17 | The Trustees Of The University Of Pennsylvania | Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
US9463227B2 (en) | 2011-03-11 | 2016-10-11 | Advaxis, Inc. | Listeria-based adjuvants |
US10064898B2 (en) | 2011-03-11 | 2018-09-04 | Advaxis, Inc. | Listeria-based adjuvants |
US10058599B2 (en) | 2012-03-12 | 2018-08-28 | Advaxis, Inc. | Suppressor cell function inhibition following Listeria vaccine treatment |
US9663557B2 (en) | 2012-12-27 | 2017-05-30 | Aduro Biotech, Inc. | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
US10143734B2 (en) | 2014-02-18 | 2018-12-04 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
US10258679B2 (en) | 2014-04-24 | 2019-04-16 | Advaxis, Inc. | Recombinant Listeria vaccine strains and methods of producing the same |
EP3207142A4 (en) * | 2014-10-14 | 2018-07-04 | The Trustees Of The University Of Pennsylvania | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
EP3207162A4 (en) * | 2014-10-14 | 2018-07-04 | The Trustees Of The University Of Pennsylvania | Combination therapy for use in cancer therapy |
CN107429289A (en) * | 2014-10-14 | 2017-12-01 | 宾夕法尼亚大学理事会 | Conjoint therapy for treatment of cancer |
US20160228530A1 (en) * | 2014-10-14 | 2016-08-11 | The Trustees Of The University Of Pennsylvania | Combination therapy for use in cancer therapy |
WO2016061182A1 (en) * | 2014-10-14 | 2016-04-21 | The Trustees Of The University Of Pennsylvania | Combination therapy for use in cancer therapy |
US10900044B2 (en) | 2015-03-03 | 2021-01-26 | Advaxis, Inc. | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
US11702664B2 (en) | 2015-03-03 | 2023-07-18 | Advaxis, Inc. | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
WO2017066706A1 (en) * | 2015-10-14 | 2017-04-20 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
US10847252B2 (en) | 2015-12-16 | 2020-11-24 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
US11183286B2 (en) | 2015-12-16 | 2021-11-23 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
US10055540B2 (en) | 2015-12-16 | 2018-08-21 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
US10847253B2 (en) | 2015-12-16 | 2020-11-24 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
US11897927B2 (en) | 2016-11-30 | 2024-02-13 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
US11179339B2 (en) | 2017-09-19 | 2021-11-23 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
US11264117B2 (en) | 2017-10-10 | 2022-03-01 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
Also Published As
Publication number | Publication date |
---|---|
WO2008109155A3 (en) | 2008-12-11 |
US8114414B2 (en) | 2012-02-14 |
JP2010532313A (en) | 2010-10-07 |
EP2134363A4 (en) | 2010-09-08 |
EP2134363A2 (en) | 2009-12-23 |
US20090081250A1 (en) | 2009-03-26 |
JP5479918B2 (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2134363A2 (en) | Compositions and methods for treatment of cervical cancer | |
US8956621B2 (en) | Compositions and methods for treatment of cervical dysplasia | |
JP7300041B2 (en) | Recombinant Listeria Vaccine Strains and Methods of Producing The Same | |
US10010593B2 (en) | Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy | |
US20180265879A1 (en) | Manufacturing method of an immunotherapeutic formulation comprising a recombinant listeria strain | |
US20180280487A1 (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
US20160220652A1 (en) | Methods of using recombinant listeria vaccine strains in disease immunotherapy | |
US20070264279A1 (en) | Compositions and methods comprising a MAGE-b antigen | |
AU2016324170A1 (en) | Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08726578 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009552749 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008726578 Country of ref document: EP |